

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/31, C07K 14/315, 16/12, C12N 5/18, 1/21, A61K 39/09, C12Q 1/68, G01N 33/50</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 98/18930</b> <b>(43) International Publication Date:</b> 7 May 1998 (07.05.98)
<b>(21) International Application Number:</b> PCT/US97/19422 <b>(22) International Filing Date:</b> 30 October 1997 (30.10.97) <b>(30) Priority Data:</b> 60/029,960 31 October 1996 (31.10.96) US <b>(71) Applicant (for all designated States except US):</b> HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> KUNSCH, Charles, A. [US/US]; 2398B Dunwoody Crossing, Atlanta, GA 30338 (US). CHOI, Gil, H. [KR/US]; 11429 Potomac Oaks Drive, Rockville, MD 20850 (US). JOHNSON, L., Sydnor [US/US]; 13545 Ambassador Drive, Germantown, MD 20874 (US). HROMOCKYJ, Alex [US/US]; 10003 Sidney Road, Silver Spring, MD 20901 (US). <b>(74) Agents:</b> BROOKES, A., Anders et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> <i>STREPTOCOCCUS PNEUMONIAE</i> ANTIGENS AND VACCINES  <b>(57) Abstract</b>  The present invention relates to novel vaccines for the prevention or attenuation of infection by <i>Streptococcus pneumoniae</i> . The invention further relates to isolated nucleic acid molecules encoding antigenic polypeptides of <i>Streptococcus pneumoniae</i> . Antigenic polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention additionally relates to diagnostic methods for detecting <i>Streptococcus</i> nucleic acids, polypeptides and antibodies in a biological sample.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## *Streptococcus pneumoniae* Antigens and Vaccines

### *Field of the Invention*

5 The present invention relates to novel *Streptococcus pneumoniae* antigens for the detection of *Streptococcus* and for the prevention or attenuation of disease caused by *Streptococcus*. The invention further relates to isolated nucleic acid molecules encoding antigenic polypeptides of *S. pneumoniae*. Antigenic polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention additionally relates  
10 to diagnostic methods for detecting *Streptococcus* gene expression.

### *Background of the Invention*

*Streptococcus pneumoniae* has been one of the most extensively studied microorganisms since its first isolation in 1881. It was the object of many  
15 investigations that led to important scientific discoveries. In 1928, Griffith observed that when heat-killed encapsulated pneumococci and live strains constitutively lacking any capsule were concomitantly injected into mice, the nonencapsulated could be converted into encapsulated pneumococci with the same capsular type as the heat-killed strain. Years later, the nature of this  
20 "transforming principle," or carrier of genetic information, was shown to be DNA. (Avery, O.T., *et al.*, *J. Exp. Med.*, 79:137-157 (1944)).

In spite of the vast number of publications on *S. pneumoniae* many questions about its virulence are still unanswered, and this pathogen remains a major causative agent of serious human disease, especially community-acquired  
25 pneumonia. (Johnston, R.B., *et al.*, *Rev. Infect. Dis.* 13(Suppl. 6):S509-517 (1991)). In addition, in developing countries, the pneumococcus is responsible for the death of a large number of children under the age of 5 years from pneumococcal pneumonia. The incidence of pneumococcal disease is highest in infants under 2 years of age and in people over 60 years of age. Pneumococci  
30 are the second most frequent cause (after *Haemophilus influenzae* type b) of bacterial meningitis and otitis media in children. With the recent introduction of conjugate vaccines for *H. influenzae* type b, pneumococcal meningitis is likely to become increasingly prominent. *S. pneumoniae* is the most important etiologic agent of community-acquired pneumonia in adults and is the second  
35 most common cause of bacterial meningitis behind *Neisseria meningitidis*.

The antibiotic generally prescribed to treat *S. pneumoniae* is benzylpenicillin, although resistance to this and to other antibiotics is found occasionally. Pneumococcal resistance to penicillin results from mutations in its

penicillin-binding proteins. In uncomplicated pneumococcal pneumonia caused by a sensitive strain, treatment with penicillin is usually successful unless started too late. Erythromycin or clindamycin can be used to treat pneumonia in patients hypersensitive to penicillin, but resistant strains to these drugs exist. Broad spectrum antibiotics (e.g., the tetracyclines) may also be effective, although tetracycline-resistant strains are not rare. In spite of the availability of antibiotics, the mortality of pneumococcal bacteremia in the last four decades has remained stable between 25 and 29%. (Gillespie, S.H., *et al.*, *J. Med. Microbiol.* 28:237-248 (1989).

*S. pneumoniae* is carried in the upper respiratory tract by many healthy individuals. It has been suggested that attachment of pneumococci is mediated by a disaccharide receptor on fibronectin, present on human pharyngeal epithelial cells. (Anderson, B.J., *et al.*, *J. Immunol.* 142:2464-2468 (1989). The mechanisms by which pneumococci translocate from the nasopharynx to the lung, thereby causing pneumonia, or migrate to the blood, giving rise to bacteremia or septicemia, are poorly understood. (Johnston, R.B., *et al.*, *Rev. Infect. Dis.* 13(Suppl. 6):S509-517 (1991).

Various proteins have been suggested to be involved in the pathogenicity of *S. pneumoniae*, however, only a few of them have actually been confirmed as virulence factors. Pneumococci produce an IgA1 protease that might interfere with host defense at mucosal surfaces. (Kornfield, S.J., *et al.*, *Rev. Inf. Dis.* 3:521-534 (1981). *S. pneumoniae* also produces neuraminidase, an enzyme that may facilitate attachment to epithelial cells by cleaving sialic acid from the host glycolipids and gangliosides. Partially purified neuraminidase was observed to induce meningitis-like symptoms in mice; however, the reliability of this finding has been questioned because the neuraminidase preparations used were probably contaminated with cell wall products. Other pneumococcal proteins besides neuraminidase are involved in the adhesion of pneumococci to epithelial and endothelial cells. These pneumococcal proteins have as yet not been identified. Recently, Cundell *et al.*, reported that peptide permeases can modulate pneumococcal adherence to epithelial and endothelial cells. It was, however, unclear whether these permeases function directly as adhesions or whether they enhance adherence by modulating the expression of pneumococcal adhesions. (DeVelasco, E.A., *et al.*, *Micro. Rev.* 59:591-603 (1995). A better understanding of the virulence factors determining its pathogenicity will need to be developed to cope with the devastating effects of pneumococcal disease in humans.

Ironically, despite the prominent role of *S. pneumoniae* in the discovery of DNA, little is known about the molecular genetics of the organism. The *S. pneumoniae* genome consists of one circular, covalently closed, double-stranded DNA and a collection of so-called variable accessory elements, such as prophages, plasmids, transposons and the like. Most physical characteristics and almost all of the genes of *S. pneumoniae* are unknown. Among the few that have been identified, most have not been physically mapped or characterized in detail. Only a few genes of this organism have been sequenced. (See, for instance current versions of GENBANK and other nucleic acid databases, and references that relate to the genome of *S. pneumoniae* such as those set out elsewhere herein.) Identification of *in vivo*-expressed, and broadly protective, antigens of *S. pneumoniae* has remained elusive.

#### *Summary of the Invention*

The present invention provides isolated nucleic acid molecules comprising polynucleotides encoding the *S. pneumoniae* polypeptides described in Table 1 and having the amino acid sequences shown as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and so on through SEQ ID NO:226. Thus, one aspect of the invention provides isolated nucleic acid molecules comprising polynucleotides having a nucleotide sequence selected from the group consisting of: (a) a nucleotide sequence encoding any of the amino acid sequences of the polypeptides shown in Table 1; and (b) a nucleotide sequence complementary to any of the nucleotide sequences in (a).

Further embodiments of the invention include isolated nucleic acid molecules that comprise a polynucleotide having a nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98% or 99% identical, to any of the nucleotide sequences in (a) or (b) above, or a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide in (a) or (b) above. This polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues. Additional nucleic acid embodiments of the invention relate to isolated nucleic acid molecules comprising polynucleotides which encode the amino acid sequences of epitope-bearing portions of an *S. pneumoniae* polypeptide having an amino acid sequence in (a) above.

The present invention also relates to recombinant vectors, which include the isolated nucleic acid molecules of the present invention, and to host cells containing the recombinant vectors, as well as to methods of making such

vectors and host cells and for using these vectors for the production of *S. pneumoniae* polypeptides or peptides by recombinant techniques.

5 The invention further provides isolated *S. pneumoniae* polypeptides having an amino acid sequence selected from the group consisting of an amino acid sequence of any of the polypeptides described in Table 1.

10 The polypeptides of the present invention also include polypeptides having an amino acid sequence with at least 70% similarity, and more preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% similarity to those described in Table 1, as well as polypeptides having an amino acid sequence at least 70% identical, more preferably at least 75% identical, and still more preferably 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to those above; as well as isolated nucleic acid molecules encoding such polypeptides.

15 The present invention further provides a vaccine, preferably a multi-component vaccine comprising one or more of the *S. pneumoniae* polynucleotides or polypeptides described in Table 1, or fragments thereof, together with a pharmaceutically acceptable diluent, carrier, or excipient, wherein the *S. pneumoniae* polypeptide(s) are present in an amount effective to elicit an immune response to members of the *Streptococcus* genus in an animal.  
20 The *S. pneumoniae* polypeptides of the present invention may further be combined with one or more immunogens of one or more other streptococcal or non-streptococcal organisms to produce a multi-component vaccine intended to elicit an immunological response against members of the *Streptococcus* genus and, optionally, one or more non-streptococcal organisms.

25 The vaccines of the present invention can be administered in a DNA form, e.g., "naked" DNA, wherein the DNA encodes one or more streptococcal polypeptides and, optionally, one or more polypeptides of a non-streptococcal organism. The DNA encoding one or more polypeptides may be constructed such that these polypeptides are expressed fusion proteins.

30 The vaccines of the present invention may also be administered as a component of a genetically engineered organism. Thus, a genetically engineered organism which expresses one or more *S. pneumoniae* polypeptides may be administered to an animal. For example, such a genetically engineered organism may contain one or more *S. pneumoniae* polypeptides of the present  
35 invention intracellularly, on its cell surface, or in its periplasmic space. Further, such a genetically engineered organism may secrete one or more *S. pneumoniae* polypeptides.

The vaccines of the present invention may be co-administered to an animal with an immune system modulator (*e.g.*, CD86 and GM-CSF).

The invention also provides a method of inducing an immunological response in an animal to one or more members of the *Streptococcus* genus, preferably one or more isolates of the *S. pneumoniae* genus, comprising administering to the animal a vaccine as described above.

The invention further provides a method of inducing a protective immune response in an animal, sufficient to prevent or attenuate an infection by members of the *Streptococcus* genus, preferably at least *S. pneumoniae*, comprising administering to the animal a composition comprising one or more of the polynucleotides or polypeptides described in Table 1, or fragments thereof. Further, these polypeptides, or fragments thereof, may be conjugated to another immunogen and/or administered in admixture with an adjuvant.

The invention further relates to antibodies elicited in an animal by the administration of one or more *S. pneumoniae* polypeptides of the present invention and to methods for producing such antibodies.

The invention also provides diagnostic methods for detecting the expression of genes of members of the *Streptococcus* genus in an animal. One such method involves assaying for the expression of a gene encoding *S. pneumoniae* peptides in a sample from an animal. This expression may be assayed either directly (*e.g.*, by assaying polypeptide levels using antibodies elicited in response to amino acid sequences described in Table 1) or indirectly (*e.g.*, by assaying for antibodies having specificity for amino acid sequences described in Table 1). An example of such a method involves the use of the polymerase chain reaction (PCR) to amplify and detect *Streptococcus* nucleic acid sequences.

The present invention also relates to nucleic acid probes having all or part of a nucleotide sequence described in Table 1 (shown as SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and so on through SEQ ID NO:225) which are capable of hybridizing under stringent conditions to *Streptococcus* nucleic acids. The invention further relates to a method of detecting one or more *Streptococcus* nucleic acids in a biological sample obtained from an animal, said one or more nucleic acids encoding *Streptococcus* polypeptides, comprising: (a) contacting the sample with one or more of the above-described nucleic acid probes, under conditions such that hybridization occurs, and (b) detecting hybridization of said one or more probes to the *Streptococcus* nucleic acid present in the biological sample.

The invention also includes immunoassays, including an immunoassay for detecting *Streptococcus*, preferably at least isolates of the *S. pneumoniae* genus, comprising incubation of a sample (which is suspected of being infected with *Streptococcus*) with a probe antibody directed against an antigen/epitope of *S. pneumoniae*, to be detected under conditions allowing the formation of an antigen-antibody complex; and detecting the antigen-antibody complex which contains the probe antibody. An immunoassay for the detection of antibodies which are directed against a *Streptococcus* antigen comprising the incubation of a sample (containing antibodies from a mammal suspected of being infected with *Streptococcus*) with a probe polypeptide including an epitope of *S. pneumoniae*, under conditions that allow the formation of antigen-antibody complexes which contain the probe epitope containing antigen.

Some aspects of the invention pertaining to kits are those for: investigating samples for the presence of polynucleotides derived from *Streptococcus* which comprise a polynucleotide probe including a nucleotide sequence selected from Table 1 or a fragment thereof of approximately 15 or more nucleotides, in an appropriate container; analyzing the samples for the presence of antibodies directed against a *Streptococcus* antigen made up of a polypeptide which contains a *S. pneumoniae* epitope present in the polypeptide, in a suitable container; and analyzing samples for the presence of *Streptococcus* antigens made up of an anti-*S. pneumoniae* antibody, in a suitable container.

### **Detailed Description**

The present invention relates to recombinant antigenic *S. pneumoniae* polypeptides and fragments thereof. The invention also relates to methods for using these polypeptides to produce immunological responses and to confer immunological protection to disease caused by members of the genus *Streptococcus*, at least isolates of the *S. pneumoniae* genus. The invention further relates to nucleic acid sequences which encode antigenic *S. pneumoniae* polypeptides and to methods for detecting *S. pneumoniae* nucleic acids and polypeptides in biological samples. The invention also relates to *S. pneumoniae*-specific antibodies and methods for detecting such antibodies produced in a host animal.

### **Definitions**

The following definitions are provided to clarify the subject matter which the inventors consider to be the present invention.



As used herein, the phrase "pathogenic agent" means an agent which causes a disease state or affliction in an animal. Included within this definition, for examples, are bacteria, protozoans, fungi, viruses and metazoan parasites which either produce a disease state or render an animal infected with such an organism susceptible to a disease state (*e.g.*, a secondary infection). Further included are species and strains of the genus *Streptococcus* which produce disease states in animals.

As used herein, the term "organism" means any living biological system, including viruses, regardless of whether it is a pathogenic agent.

As used herein, the term "*Streptococcus*" means any species or strain of bacteria which is members of the genus *Streptococcus*. Such species and strains are known to those of skill in the art, and include those that are pathogenic and those that are not.

As used herein, the phrase "one or more *S. pneumoniae* polypeptides of the present invention" means polypeptides comprising the amino acid sequence of one or more of the *S. pneumoniae* polypeptides described in Table 1 and disclosed as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and so on through SEQ ID NO:226. These polypeptides may be expressed as fusion proteins wherein the *S. pneumoniae* polypeptides of the present invention are linked to additional amino acid sequences which may be of streptococcal or non-streptococcal origin. This phrase further includes polypeptide comprising fragments of the *S. pneumoniae* polypeptides of the present invention.

Additional definitions are provided throughout the specification.

#### ***Explanation of Table 1***

Table 1, below, provides information describing 113 open reading frames (ORFs) which encode potentially antigenic polypeptides of *S. pneumoniae* of the present invention. The table lists the ORF identifier which consists of the letters SP, which denote *S. pneumoniae*, followed immediately by a three digit numeric code, which arbitrarily number the potentially antigenic polypeptides of *S. pneumoniae* of the present invention and the nucleotide or amino acid sequence of each ORF and encoded polypeptide. The table further correlates the ORF identifier with a sequence identification number (SEQ ID NO:). The actual nucleotide or amino acid sequence of each ORF identifier is also shown in the Sequence Listing under the corresponding SEQ ID NO.

Thus, for example, the designation "SP126" refers to both the nucleotide and amino acid sequences of *S. pneumoniae* polypeptide number 126 of the present invention. Further, "SP126" correlates with the nucleotide

sequence shown as SEQ ID NO:223 and with the amino acid sequence shown as SEQ ID NO:224 as is described in Table 1.

The open reading frame within each "ORF" begins with the second nucleotide shown. Thus, the first codon for each nucleotide sequence shown is bases 2-4, the second 5-7, the third 8-10, and so on.

### *Explanation of Table 2*

Table 2 lists the antigenic epitopes present in each of the *S. pneumoniae* polypeptides described in Table 1 as predicted by the inventors. Each *S. pneumoniae* polypeptide shown in Table 1 has one or more antigenic epitopes described in Table 2. It will be appreciated that depending on the analytical criteria used to predict antigenic determinants, the exact address of the determinant may vary slightly. The exact location of the antigenic determinant may shift by about 1 to 5 residues, more likely 1 to 2 residues, depending on the criteria used. Thus, the first antigenic determinant described in Table 2, "Lys-1 to Ile-10" of SP001, represents a peptide comprising the lysine at position 1 in SEQ ID NO:2 through and including the isoleucine at position 10 in SEQ ID NO:2, but may include more or fewer residues than those 10. It will also be appreciated that, generally speaking, amino acids can be added to either terminus of a peptide or polypeptide containing an antigenic epitope without affecting its activity, whereas removing residues from a peptide or polypeptide containing only the antigenic determinant is much more likely to destroy activity. It will be appreciated that the residues and locations shown described in Table 2 correspond to the amino acid sequences for each ORF shown in Table 1 and in the Sequence Listing.

### *Explanation of Table 3*

Table 3 shows PCR primers designed by the inventors for the amplification of polynucleotides encoding polypeptides of the present invention according to the method of Example 1. PCR primer design is routine in the art and those shown in Table 3 are provided merely for the convenience of the skilled artisan. It will be appreciated that others can be used with equal success.

For each primer, the table lists the corresponding ORF designation from Table 1 followed by either an "A" or a "B". The "A" primers are the 5' primers and the "B" primers 3'. A restriction enzyme site was built into each primer to allow ease of cloning. The restriction enzyme which will recognize and cleave a sequence within each primer is shown in Table 3, as well, under the heading

"RE" for restriction enzyme. Finally the sequence identifier is shown in Table 3 for each primer for easy correlation with the Sequence Listing.

*Selection of Nucleic Acid Sequences Encoding Antigenic S. pneumoniae Polypeptides*

5 The present invention provides a select number of ORFs from those presented in the fragments of the *S. pneumoniae* genome which may prove useful for the generation of a protective immune response. The sequenced *S. pneumoniae* genomic DNA was obtained from a sub-cultured isolate of *S. pneumoniae* Strain 7/87 14.8.91, which has been deposited at the American Type Culture Collection, as a convenience to those of skill in the art. The *S. pneumoniae* isolate was deposited on October 10, 1996 at the ATCC, 12301 Park Lawn Drive, Rockville, Maryland 20852, and given accession number 55840. A genomic library constructed from DNA isolated from the *S. pneumoniae* isolate was also deposited at the ATCC on October 11, 1996 and given ATCC Deposit No. 97755. A more complete listing of the sequence obtained from the *S. pneumoniae* genome may be found in co-pending U.S. Provisional Application Serial No. 60/029,960, filed 10/31/96, incorporated herein by reference in its entirety. Some ORFs contained in the subset of fragments of the *S. pneumoniae* genome disclosed herein were derived through the use of a number of screening criteria detailed below.

The selected ORFs do not consist of complete ORFs. Although a polypeptide representing a complete ORF may be the closest approximation of a protein native to an organism, it is not always preferred to express a complete ORF in a heterologous system. It may be challenging to express and purify a highly hydrophobic protein by common laboratory methods. Thus, the polypeptide vaccine candidates described herein may have been modified slightly to simplify the production of recombinant protein. For example, nucleotide sequences which encode highly hydrophobic domains, such as those found at the amino terminal signal sequence, have been excluded from some constructs used for *in vitro* expression of the polypeptides. Furthermore, any highly hydrophobic amino acid sequences occurring at the carboxy terminus have also been excluded from the recombinant expression constructs. Thus, in one embodiment, a polypeptide which represents a truncated or modified ORF may be used as an antigen.

While numerous methods are known in the art for selecting potentially immunogenic polypeptides, many of the ORFs disclosed herein were selected

on the basis of screening all theoretical *S. pneumoniae* ORFs for several aspects of potential immunogenicity. One set of selection criteria are as follows:

5           1. *Type I signal sequence*: An amino terminal type I signal sequence generally directs a nascent protein across the plasma and outer membranes to the exterior of the bacterial cell. Experimental evidence obtained from studies with *Escherichia coli* suggests that the typical type I signal sequence consists of the following biochemical and physical attributes (Izard, J. W. and Kendall, D. A. *Mol. Microbiol.* **13**:765-773 (1994)). The length of the type I signal sequence is approximately 15 to 25 primarily hydrophobic amino acid residues with a net positive charge in the extreme amino terminus. In addition, the central region of the signal sequence adopts an alpha-helical conformation in a hydrophobic environment. Finally, the region surrounding the actual site of cleavage is ideally six residues long, with small side-chain amino acids in the -1 and -3 positions.

15           2. *Type IV signal sequence*: The type IV signal sequence is an example of the several types of functional signal sequences which exist in addition to the type I signal sequence detailed above. Although functionally related, the type IV signal sequence possesses a unique set of biochemical and physical attributes (Strom, M. S. and Lory, S., *J. Bacteriol.* **174**:7345-7351 (1992)). These are typically six to eight amino acids with a net basic charge followed by an additional sixteen to thirty primarily hydrophobic residues. The cleavage site of a type IV signal sequence is typically after the initial six to eight amino acids at the extreme amino terminus. In addition, type IV signal sequences generally contain a phenylalanine residue at the +1 site relative to the cleavage site.

25           3. *Lipoprotein*: Studies of the cleavage sites of twenty-six bacterial lipoprotein precursors has allowed the definition of a consensus amino acid sequence for lipoprotein cleavage. Nearly three-fourths of the bacterial lipoprotein precursors examined contained the sequence L-(A,S)-(G,A)-C at positions -3 to +1, relative to the point of cleavage (Hayashi, S. and Wu, H. C., *J. Bioenerg. Biomembr.* **22**:451-471 (1990)).

30           4. *LPXTG motif*: It has been experimentally determined that most anchored proteins found on the surface of gram-positive bacteria possess a highly conserved carboxy terminal sequence. More than fifty such proteins from organisms such as *S. pyogenes*, *S. mutans*, *E. faecalis*, *S. pneumoniae*, and others, have been identified based on their extracellular location and carboxy terminal amino acid sequence (Fischetti, V. A., *ASM News* **62**:405-410 (1996)). The conserved region consists of six charged amino acids at the extreme carboxy terminus coupled to 15-20 hydrophobic amino acids

presumed to function as a transmembrane domain. Immediately adjacent to the transmembrane domain is a six amino acid sequence conserved in nearly all proteins examined. The amino acid sequence of this region is L-P-X-T-G-X, where X is any amino acid.

5           An algorithm for selecting antigenic and immunogenic *S. pneumoniae* polypeptides including the foregoing criteria was developed. Use of the algorithm by the inventors to select immunologically useful *S. pneumoniae* polypeptides resulted in the selection of a number of the disclosed ORFs. Polypeptides comprising the polypeptides identified in this group may be  
10           produced by techniques standard in the art and as further described herein.

### ***Nucleic Acid Molecules***

          The present invention provides isolated nucleic acid molecules comprising polynucleotides encoding the *S. pneumoniae* polypeptides having  
15           the amino acid sequences described in Table 1 and shown as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and so on through SEQ ID NO:226, which were determined by sequencing the genome of *S. pneumoniae* and selected as putative immunogens.

          Unless otherwise indicated, all nucleotide sequences determined by  
20           sequencing a DNA molecule herein were determined using an automated DNA sequencer (such as the Model 373 from Applied Biosystems, Inc.), and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of DNA sequences determined as above. Therefore, as is known in the art for any DNA sequence determined by this  
25           automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other  
30           approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid  
35           sequence encoded by a determined nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

          Unless otherwise indicated, each "nucleotide sequence" set forth herein is presented as a sequence of deoxyribonucleotides (abbreviated A, G, C and

T). However, by "nucleotide sequence" of a nucleic acid molecule or polynucleotide is intended, for a DNA molecule or polynucleotide, a sequence of deoxyribonucleotides, and for an RNA molecule or polynucleotide, the corresponding sequence of ribonucleotides (A, G, C and U), where each thymidine deoxyribonucleotide (T) in the specified deoxyribonucleotide sequence is replaced by the ribonucleotide uridine (U). For instance, reference to an RNA molecule having a sequence described in Table 1 set forth using deoxyribonucleotide abbreviations is intended to indicate an RNA molecule having a sequence in which each deoxyribonucleotide A, G or C described in Table 1 has been replaced by the corresponding ribonucleotide A, G or C, and each deoxyribonucleotide T has been replaced by a ribonucleotide U.

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced synthetically. The DNA may be double-stranded or single-stranded. Single-stranded DNA or RNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

By "isolated" nucleic acid molecule(s) is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, recombinant DNA molecules contained in a vector are considered isolated for the purposes of the present invention. Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.

Isolated nucleic acid molecules of the present invention include DNA molecules comprising a nucleotide sequence described in Table 1 and shown as SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and so on through SEQ ID NO:225; DNA molecules comprising the coding sequences for the polypeptides described in Table 1 and shown as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and so on through SEQ ID NO:226; and DNA molecules which comprise sequences substantially different from those described above but which, due to the degeneracy of the genetic code, still encode the *S. pneumoniae* polypeptides described in Table 1. Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate such degenerate variants.

The invention also provides nucleic acid molecules having sequences complementary to any one of those described in Table 1. Such isolated molecules, particularly DNA molecules, are useful as probes for detecting expression of *Streptococcal* genes, for instance, by Northern blot analysis or the polymerase chain reaction (PCR).

The present invention is further directed to fragments of the isolated nucleic acid molecules described herein. By a fragment of an isolated nucleic acid molecule having a nucleotide sequence described in Table 1, is intended fragments at least about 15 nt, and more preferably at least about 17 nt, still more preferably at least about 20 nt, and even more preferably, at least about 25 nt in length which are useful as diagnostic probes and primers as discussed herein. Of course, larger fragments 50-100 nt in length are also useful according to the present invention as are fragments corresponding to most, if not all, of a nucleotide sequence described in Table 1. By a fragment at least 20 nt in length, for example, is intended fragments which include 20 or more contiguous bases of a nucleotide sequence as described in Table 1. Since the nucleotide sequences identified in Table 1 are provided as SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and so on through SEQ ID NO:225, generating such DNA fragments would be routine to the skilled artisan. For example, such fragments could be generated synthetically.

Preferred nucleic acid fragments of the present invention also include nucleic acid molecules comprising nucleotide sequences encoding epitope-bearing portions of the *S. pneumoniae* polypeptides identified in Table 1. Such nucleic acid fragments of the present invention include, for example, nucleotide sequences encoding polypeptide fragments comprising from about the amino terminal residue to about the carboxy terminal residue of each fragment shown in Table 2. The above referred to polypeptide fragments are antigenic regions of the *S. pneumoniae* polypeptides identified in Table 1.

In another aspect, the invention provides isolated nucleic acid molecules comprising polynucleotides which hybridize under stringent hybridization conditions to a portion of a polynucleotide in a nucleic acid molecule of the invention described above, for instance, a nucleic acid sequence identified in Table 1. By "stringent hybridization conditions" is intended overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.

By polynucleotides which hybridize to a "portion" of a polynucleotide is intended polynucleotides (either DNA or RNA) which hybridize to at least about 15 nucleotides (nt), and more preferably at least about 17 nt, still more preferably at least about 20 nt, and even more preferably about 25-70 nt of the reference polynucleotide. These are useful as diagnostic probes and primers as discussed above and in more detail below.

Of course, polynucleotides hybridizing to a larger portion of the reference polynucleotide, for instance, a portion 50-100 nt in length, or even to the entire length of the reference polynucleotide, are also useful as probes according to the present invention, as are polynucleotides corresponding to most, if not all, of a nucleotide sequence as identified in Table 1. By a portion of a polynucleotide of "at least 20 nt in length," for example, is intended 20 or more contiguous nucleotides from the nucleotide sequence of the reference polynucleotide (*e.g.*, a nucleotide sequences as described in Table 1). As noted above, such portions are useful diagnostically either as probes according to conventional DNA hybridization techniques or as primers for amplification of a target sequence by PCR, as described in the literature (for instance, in *Molecular Cloning, A Laboratory Manual*, 2nd. edition, Sambrook, J., Fritsch, E. F. and Maniatis, T., eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), the entire disclosure of which is hereby incorporated herein by reference).

Since nucleic acid sequences encoding the *S. pneumoniae* polypeptides of the present invention are identified in Table 1 and provided as SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and so on through SEQ ID NO:225, generating polynucleotides which hybridize to portions of these sequences would be routine to the skilled artisan. For example, the hybridizing polynucleotides of the present invention could be generated synthetically according to known techniques.

As indicated, nucleic acid molecules of the present invention which encode *S. pneumoniae* polypeptides of the present invention may include, but are not limited to those encoding the amino acid sequences of the polypeptides by themselves; and additional coding sequences which code for additional amino acids, such as those which provide additional functionalities. Thus, the sequences encoding these polypeptides may be fused to a marker sequence, such as a sequence encoding a peptide which facilitates purification of the fused polypeptide. In certain preferred embodiments of this aspect of the invention, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are



commercially available. As described by Gentz and colleagues (*Proc. Natl. Acad. Sci. USA* 86:821-824 (1989)), for instance, hexa-histidine provides for convenient purification of the resulting fusion protein.

Thus, the present invention also includes genetic fusions wherein the *S. pneumoniae* nucleic acid sequences coding sequences identified in Table 1 are linked to additional nucleic acid sequences to produce fusion proteins. These fusion proteins may include epitopes of streptococcal or non-streptococcal origin designed to produce proteins having enhanced immunogenicity. Further, the fusion proteins of the present invention may contain antigenic determinants known to provide helper T-cell stimulation, peptides encoding sites for post-translational modifications which enhance immunogenicity (*e.g.*, acylation), peptides which facilitate purification (*e.g.*, histidine "tag"), or amino acid sequences which target the fusion protein to a desired location (*e.g.*, a heterologous leader sequence).

In all cases of bacterial expression, an N-terminal methionine residues is added. In many cases, however, the N-terminal methionine residues is cleaved off post-translationally. Thus, the invention includes polypeptides shown in Table 1 with, and without an N-terminal methionine.

The present invention thus includes nucleic acid molecules and sequences which encode fusion proteins comprising one or more *S. pneumoniae* polypeptides of the present invention fused to an amino acid sequence which allows for post-translational modification to enhance immunogenicity. This post-translational modification may occur either *in vitro* or when the fusion protein is expressed *in vivo* in a host cell. An example of such a modification is the introduction of an amino acid sequence which results in the attachment of a lipid moiety.

Thus, as indicated above, the present invention includes genetic fusions wherein a *S. pneumoniae* nucleic acid sequence identified in Table 1 is linked to a nucleotide sequence encoding another amino acid sequence. These other amino acid sequences may be of streptococcal origin (*e.g.*, another sequence selected from Table 1) or non-streptococcal origin.

The present invention further relates to variants of the nucleic acid molecules of the present invention, which encode portions, analogs or derivatives of the *S. pneumoniae* polypeptides described in Table 1. Variants may occur naturally, such as a natural allelic variant. By an "allelic variant" is intended one of several alternate forms of a gene occupying a given locus on a chromosome of an organism (*Genes II*, Lewin, B., ed., John Wiley & Sons,

New York (1985)). Non-naturally occurring variants may be produced using art-known mutagenesis techniques.

Such variants include those produced by nucleotide substitutions, deletions or additions. The substitutions, deletions or additions may involve one or more nucleotides. These variants may be altered in coding regions, non-coding regions, or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the *S. pneumoniae* polypeptides disclosed herein or portions thereof. Silent substitution are most likely to be made in non-epitopic regions. Guidance regarding those regions containing epitopes is provided herein, for example, in Table 2. Also especially preferred in this regard are conservative substitutions.

Further embodiments of the invention include isolated nucleic acid molecules comprising a polynucleotide having a nucleotide sequence at least 90% identical, and more preferably at least 95%, 96%, 97%, 98% or 99% identical to: (a) a nucleotide sequence encoding any of the amino acid sequences of the polypeptides identified in Table 1; and (b) a nucleotide sequence complementary to any of the nucleotide sequences in (a) above.

By a polynucleotide having a nucleotide sequence at least, for example, 95% "identical" to a reference nucleotide sequence encoding a *S. pneumoniae* polypeptide described in Table 1, is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the subject *S. pneumoniae* polypeptide. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.

Certain nucleotides within some of the nucleic acid sequences shown in Table 1 were ambiguous upon sequencing. Completely unknown sequences are shown as an "N". Other unresolved nucleotides are known to be either a

purine, shown as "R", or a pyrimidine, shown as "Y". Accordingly, when determining identity between two nucleotide sequences, identity is met where any nucleotide, including an "R", "Y" or "N", is found in a test sequence and at the corresponding position in the reference sequence (from Table 1). Likewise, an A, G or "R" in a test sequence is identical to an "R" in the reference sequence; and a T, C or "Y" in a test sequence is identical to a "Y" in the reference sequence.

As a practical matter, whether any particular nucleic acid molecule is at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, a nucleotide sequence described in Table 1 can be determined conventionally using known computer programs such as the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). Bestfit uses the local homology algorithm of Smith and Waterman (*Advances in Applied Mathematics* 2:482-489 (1981)), to find the best segment of homology between two sequences. When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference nucleotide sequence and that gaps in homology of up to 5% of the total number of nucleotides in the reference sequence are allowed.

The present application is directed to nucleic acid molecules at least 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleic acid sequences described in Table 1. One of skill in the art would still know how to use the nucleic acid molecule, for instance, as a hybridization probe or a polymerase chain reaction (PCR) primer. Uses of the nucleic acid molecules of the present invention include, *inter alia*, (1) isolating *Streptococcal* genes or allelic variants thereof from either a genomic or cDNA library and (2) Northern Blot or PCR analysis for detecting *Streptococcal* mRNA expression.

Of course, due to the degeneracy of the genetic code, one of ordinary skill in the art will immediately recognize that a large number of nucleic acid molecules having a sequence at least 90%, 95%, 96%, 97%, 98%, or 99% identical to a nucleic acid sequence identified in Table 1 will encode the same polypeptide. In fact, since degenerate variants of these nucleotide sequences all encode the same polypeptide, this will be clear to the skilled artisan even without performing the above described comparison assay.

It will be further recognized in the art that, for such nucleic acid molecules that are not degenerate variants, a reasonable number will also encode

proteins having antigenic epitopes of the *S. pneumoniae* polypeptides of the present invention. This is because the skilled artisan is fully aware of amino acid substitutions that are either less likely or not likely to significantly effect the antigenicity of a polypeptide (*e.g.*, replacement of an amino acid in a region which is not believed to form an antigenic epitope). For example, since antigenic epitopes have been identified which contain as few as six amino acids (see Harlow, *et al.*, *Antibodies: A Laboratory Manual*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988), page 76), in instances where a polypeptide has multiple antigenic epitopes the alteration of several amino acid residues would often not be expected to eliminate all of the antigenic epitopes of that polypeptide. This is especially so when the alterations are in regions believed to not constitute antigenic epitopes.

### *Vectors and Host Cells*

The present invention also relates to vectors which include the isolated DNA molecules of the present invention, host cells which are genetically engineered with the recombinant vectors, and the production of *S. pneumoniae* polypeptides or fragments thereof by recombinant techniques.

Recombinant constructs may be introduced into host cells using well known techniques such as infection, transduction, transfection, transvection, electroporation and transformation. The vector may be, for example, a phage, plasmid, viral or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.

The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged *in vitro* using an appropriate packaging cell line and then transduced into host cells.

Preferred are vectors comprising *cis*-acting control regions to the polynucleotide of interest. Appropriate *trans*-acting factors may be supplied by the host, supplied by a complementing vector or supplied by the vector itself upon introduction into the host.

In certain preferred embodiments in this regard, the vectors provide for specific expression, which may be inducible and/or cell type-specific. Particularly preferred among such vectors are those inducible by environmental factors that are easy to manipulate, such as temperature and nutrient additives.

Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors, *e.g.*, vectors derived from bacterial plasmids, bacteriophage, yeast episomes, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as cosmids and phagemids.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli lac*, *trp* and *tac* promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating site at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase or neomycin resistance for eukaryotic cell culture and tetracycline or ampicillin resistance genes for culturing in *E. coli* and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium* cells; fungal cells, such as yeast cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A available from Stratagene; pET series of vectors available from Novagen; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Among known bacterial promoters suitable for use in the present invention include the *E. coli lacI* and *lacZ* promoters, the T3 and T7 promoters, the *gpt* promoter, the lambda PR and PL promoters and the *trp* promoter. Suitable eukaryotic promoters include the CMV immediate early promoter, the

HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus (RSV), and metallothionein promoters, such as the mouse metallothionein-I promoter.

5 Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection or other methods. Such methods are described in many standard laboratory manuals (for example, Davis, *et al.*, *Basic Methods In Molecular Biology* (1986)).

10 Transcription of DNA encoding the polypeptides of the present invention by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are *cis*-acting elements of DNA, usually about from 10 to 300 bp that act to increase transcriptional activity of a promoter in a given host cell-type. Examples of enhancers include the SV40 enhancer, which is located on the late side of the replication origin at bp 100 to 270, the  
15 cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

For secretion of the translated polypeptide into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the  
20 expressed polypeptide. The signals may be endogenous to the polypeptide or they may be heterologous signals.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals, but also additional heterologous functional regions. For instance, a region of additional amino  
25 acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification, or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide  
30 moieties to polypeptides to engender secretion or excretion, to improve stability and to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize proteins. For example, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion proteins comprising  
35 various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is thoroughly advantageous for use in therapy and diagnosis and thus results, for example, in improved pharmacokinetic properties (EP-A 0232 262).

On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified in the advantageous manner described. This is the case when Fc portion proves to be a hindrance to use in therapy and diagnosis, for example when the fusion protein is to be used as antigen for immunizations. In drug discovery, for example, human proteins, such as, hIL-5-receptor has been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. See Bennett, D. *et al.*, *J. Molec. Recogn.* 8:52-58 (1995) and Johanson, K. *et al.*, *J. Biol. Chem.* 270 (16):9459-9471 (1995).

The *S. pneumoniae* polypeptides can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography and high performance liquid chromatography ("HPLC") is employed for purification. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells.

### *Polypeptides and Fragments*

The invention further provides isolated polypeptides having the amino acid sequences described in Table I, and shown as SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and so on through SEQ ID NO:226, and peptides or polypeptides comprising portions of the above polypeptides. The terms "peptide" and "oligopeptide" are considered synonymous (as is commonly recognized) and each term can be used interchangeably as the context requires to indicate a chain of at least two amino acids coupled by peptidyl linkages. The word "polypeptide" is used herein for chains containing more than ten amino acid residues. All oligopeptide and polypeptide formulas or sequences herein are written from left to right and in the direction from amino terminus to carboxy terminus.

Some amino acid sequences of the *S. pneumoniae* polypeptides described in Table I can be varied without significantly effecting the antigenicity of the polypeptides. If such differences in sequence are contemplated, it should be remembered that there will be critical areas on the polypeptide which determine antigenicity. In general, it is possible to replace residues which do

not form part of an antigenic epitope without significantly effecting the antigenicity of a polypeptide. Guidance for such alterations is given in Table 2 wherein epitopes for each polypeptide is delineated.

5 The polypeptides of the present invention are preferably provided in an isolated form. By "isolated polypeptide" is intended a polypeptide removed from its native environment. Thus, a polypeptide produced and/or contained within a recombinant host cell is considered isolated for purposes of the present invention. Also intended as an "isolated polypeptide" is a polypeptide that has been purified, partially or substantially, from a recombinant host cell. For  
10 example, recombinantly produced versions of the *S. pneumoniae* polypeptides described in Table 1 can be substantially purified by the one-step method described by Smith and Johnson (*Gene* 67:31-40 (1988)).

The polypeptides of the present invention include: (a) an amino acid sequence of any of the polypeptides described in Table 1; and (b) an amino acid  
15 sequence of an epitope-bearing portion of any one of the polypeptides of (a); as well as polypeptides with at least 70% similarity, and more preferably at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% similarity to those described in (a) or (b) above, as well as polypeptides having an amino acid sequence at least 70% identical, more preferably at least 75% identical, and still  
20 more preferably 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to those above.

By "% similarity" for two polypeptides is intended a similarity score produced by comparing the amino acid sequences of the two polypeptides using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for  
25 Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711) and the default settings for determining similarity. Bestfit uses the local homology algorithm of Smith and Waterman (*Advances in Applied Mathematics* 2:482-489 (1981)) to find the best segment of similarity between two sequences.

30 By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a reference amino acid sequence of a *S. pneumoniae* polypeptide is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the  
35 reference amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to



5 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

The amino acid sequences shown in Table 1 may have on or more "X" residues. "X" represents unknown. Thus, for purposes of defining identity, if any amino acid is present at the same position in a reference amino acid sequence (shown in Table 1) where an X is shown, the two sequences are identical at that position.

15 As a practical matter, whether any particular polypeptide is at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to, for instance, an amino acid sequence shown in Table 1, can be determined conventionally using known computer programs such the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for instance, 95% identical to a reference sequence according to the present invention, the parameters are set, of course, such that the percentage of identity is calculated over the full length of the reference amino acid sequence and that gaps in homology of up to 5% of the total number of amino acid residues in the reference sequence are allowed.

25 As described below, the polypeptides of the present invention can also be used to raise polyclonal and monoclonal antibodies, which are useful in assays for detecting *Streptococcal* protein expression.

In another aspect, the invention provides peptides and polypeptides comprising epitope-bearing portions of the *S. pneumoniae* polypeptides of the invention. These epitopes are immunogenic or antigenic epitopes of the polypeptides of the invention. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein or polypeptide is the immunogen. These immunogenic epitopes are believed to be confined to a few loci on the molecule. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic determinant" or "antigenic epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes (Geysen, *et al.*, *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1983)). Predicted antigenic epitopes are shown in Table 2, below.

As to the selection of peptides or polypeptides bearing an antigenic epitope (*i.e.*, that contain a region of a protein molecule to which an antibody can bind), it is well known in that art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein (for instance, Sutcliffe, J., *et al.*, *Science* 219:660-666 (1983)). Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins (*i.e.*, immunogenic epitopes) nor to the amino or carboxyl terminals. Peptides that are extremely hydrophobic and those of six or fewer residues generally are ineffective at inducing antibodies that bind to the mimicked protein; longer, peptides, especially those containing proline residues, usually are effective (Sutcliffe, *et al.*, *supra*, p. 661). For instance, 18 of 20 peptides designed according to these guidelines, containing 8-39 residues covering 75% of the sequence of the influenza virus hemagglutinin HA1 polypeptide chain, induced antibodies that reacted with the HA1 protein or intact virus; and 12/12 peptides from the MuLV polymerase and 18/18 from the rabies glycoprotein induced antibodies that precipitated the respective proteins.

Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention. Thus, a high proportion of hybridomas obtained by fusion of spleen cells from donors immunized with an antigen epitope-bearing peptide generally secrete antibody reactive with the native protein (Sutcliffe, *et al.*, *supra*, p. 663). The antibodies raised by antigenic epitope-bearing peptides or polypeptides are useful to detect the mimicked protein, and antibodies to different peptides may be used for tracking the fate of various regions of a protein precursor which undergoes post-translational processing. The peptides and anti-peptide antibodies may be used in a variety of qualitative or quantitative assays for the mimicked protein, for instance in competition assays since it has been shown that even short peptides (*e.g.*, about 9 amino acids) can bind and displace the larger peptides in immunoprecipitation assays (for instance, Wilson, *et al.*, *Cell* 37:767-778 (1984) p. 777). The anti-peptide antibodies of the invention also are useful for purification of the mimicked protein, for instance, by adsorption chromatography using methods well known in the art.

Antigenic epitope-bearing peptides and polypeptides of the invention designed according to the above guidelines preferably contain a sequence of at

least seven, more preferably at least nine and most preferably between about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention. However, peptides or polypeptides comprising a larger portion of an amino acid sequence of a polypeptide of the invention, containing about 30 to about 50 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention, also are considered epitope-bearing peptides or polypeptides of the invention and also are useful for inducing antibodies that react with the mimicked protein. Preferably, the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (*i.e.*, the sequence includes relatively hydrophilic residues and highly hydrophobic sequences are preferably avoided); and sequences containing proline residues are particularly preferred.

Non-limiting examples of antigenic polypeptides or peptides that can be used to generate *Streptococcal*-specific antibodies include portions of the amino acid sequences identified in Table 1. More specifically, Table 2 discloses antigenic fragments of polypeptides of the present invention, which antigenic fragments comprise amino acid sequences from about the first amino acid residues indicated to about the last amino acid residue indicated for each fragment. The polypeptide fragments disclosed in Table 2 are believed to be antigenic regions of the *S. pneumoniae* polypeptides described in Table 1. Thus the invention further includes isolated peptides and polypeptides comprising an amino acid sequence of an epitope shown in Table 2 and polynucleotides encoding said polypeptides.

The epitope-bearing peptides and polypeptides of the invention may be produced by any conventional means for making peptides or polypeptides including recombinant means using nucleic acid molecules of the invention. For instance, an epitope-bearing amino acid sequence of the present invention may be fused to a larger polypeptide which acts as a carrier during recombinant production and purification, as well as during immunization to produce anti-peptide antibodies. Epitope-bearing peptides also may be synthesized using known methods of chemical synthesis. For instance, Houghten has described a simple method for synthesis of large numbers of peptides, such as 10-20 mg of 248 different 13 residue peptides representing single amino acid variants of a segment of the HA1 polypeptide which were prepared and characterized (by ELISA-type binding studies) in less than four weeks (Houghten, R. A. Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985)). This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten and coworkers (1986). In this procedure the individual

resins for the solid-phase synthesis of various peptides are contained in separate solvent-permeable packets, enabling the optimal use of the many identical repetitive steps involved in solid-phase methods. A completely manual procedure allows 500-1000 or more syntheses to be conducted simultaneously (Houghten, *et al.*, *supra*, p. 5134).

Epitope-bearing peptides and polypeptides of the invention are used to induce antibodies according to methods well known in the art (for instance, Sutcliffe, *et al.*, *supra*; Wilson, *et al.*, *supra*; Chow, M., *et al.*, *Proc. Natl. Acad. Sci. USA* 82:910-914; and Bittle, F. J., *et al.*, *J. Gen. Virol.* 66:2347-2354 (1985)). Generally, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling of the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine may be coupled to carrier using a linker such as m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carrier using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier-coupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 µg peptide or carrier protein and Freund's adjuvant. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

Immunogenic epitope-bearing peptides of the invention, *i.e.*, those parts of a protein that elicit an antibody response when the whole protein is the immunogen, are identified according to methods known in the art. For instance, Geysen, *et al.*, *supra*, discloses a procedure for rapid concurrent synthesis on solid supports of hundreds of peptides of sufficient purity to react in an enzyme-linked immunosorbent assay. Interaction of synthesized peptides with antibodies is then easily detected without removing them from the support. In this manner a peptide bearing an immunogenic epitope of a desired protein may be identified routinely by one of ordinary skill in the art. For instance, the immunologically important epitope in the coat protein of foot-and-mouth disease virus was located by Geysen *et al. supra* with a resolution of seven amino acids by synthesis of an overlapping set of all 208 possible hexapeptides covering the

entire 213 amino acid sequence of the protein. Then, a complete replacement set of peptides in which all 20 amino acids were substituted in turn at every position within the epitope were synthesized, and the particular amino acids conferring specificity for the reaction with antibody were determined. Thus, peptide  
5 analogs of the epitope-bearing peptides of the invention can be made routinely by this method. U.S. Patent No. 4,708,781 to Geysen (1987) further describes this method of identifying a peptide bearing an immunogenic epitope of a desired protein.

Further still, U.S. Patent No. 5,194,392, to Geysen (1990), describes a  
10 general method of detecting or determining the sequence of monomers (amino acids or other compounds) which is a topological equivalent of the epitope (*i.e.*, a "mimotope") which is complementary to a particular paratope (antigen binding site) of an antibody of interest. More generally, U.S. Patent No. 4,433,092, also to Geysen (1989), describes a method of detecting or determining a  
15 sequence of monomers which is a topographical equivalent of a ligand which is complementary to the ligand binding site of a particular receptor of interest. Similarly, U.S. Patent No. 5,480,971 to Houghten, R. A. *et al.* (1996) discloses linear C<sub>1</sub>-C<sub>7</sub>-alkyl peralkylated oligopeptides and sets and libraries of such peptides, as well as methods for using such oligopeptide sets and libraries  
20 for determining the sequence of a peralkylated oligopeptide that preferentially binds to an acceptor molecule of interest. Thus, non-peptide analogs of the epitope-bearing peptides of the invention also can be made routinely by these methods.

The entire disclosure of each document cited in this section on  
25 "Polypeptides and Fragments" is hereby incorporated herein by reference.

As one of skill in the art will appreciate, the polypeptides of the present invention and the epitope-bearing fragments thereof described above can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification  
30 and show an increased half-life *in vivo*. This has been shown, *e.g.*, for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins (EPA 0,394,827; Traunecker *et al.*, *Nature* 331:84-86 (1988)). Fusion proteins that have a disulfide-linked  
35 dimeric structure due to the IgG part can also be more efficient in binding and neutralizing other molecules than a monomeric *S. pneumoniae* polypeptide or

fragment thereof alone (Fountoulakis *et al.*, *J. Biochem.* 270:3958-3964 (1995)).

### *Diagnostic Assays*

5           The present invention further relates to a method for assaying for *Streptococcal* infection in an animal *via* detecting the expression of genes encoding *Streptococcal* polypeptides (*e.g.*, the polypeptides described Table 1). This method comprises analyzing tissue or body fluid from the animal for *Streptococcus*-specific antibodies or *Streptococcal* nucleic acids or proteins.  
10       Analysis of nucleic acid specific to *Streptococcus* can be done by PCR or hybridization techniques using nucleic acid sequences of the present invention as either hybridization probes or primers (*cf. Molecular Cloning: A Laboratory Manual, second edition*, edited by Sambrook, Fritsch, & Maniatis, Cold Spring Harbor Laboratory, 1989; Ereemeeva *et al.*, *J. Clin. Microbiol.* 32:803-810  
15       (1994) which describes differentiation among spotted fever group *Rickettsiae* species by analysis of restriction fragment length polymorphism of PCR-amplified DNA). Methods for detecting *B. burgdorferi* nucleic acids *via* PCR are described, for example, in Chen *et al.*, *J. Clin. Microbiol.* 32:589-595 (1994).

20       Where diagnosis of a disease state related to infection with *Streptococcus* has already been made, the present invention is useful for monitoring progression or regression of the disease state whereby patients exhibiting enhanced *Streptococcus* gene expression will experience a worse clinical outcome relative to patients expressing these gene(s) at a lower level.

25       By "assaying for *Streptococcal* infection in an animal *via* detection of genes encoding *Streptococcal* polypeptides" is intended qualitatively or quantitatively measuring or estimating the level of one or more *Streptococcus* polypeptides or the level of nucleic acid encoding *Streptococcus* polypeptides in a first biological sample either directly (*e.g.*, by determining or estimating  
30       absolute protein level or nucleic level) or relatively (*e.g.*, by comparing to the *Streptococcus* polypeptide level or mRNA level in a second biological sample). The *Streptococcus* polypeptide level or nucleic acid level in the second sample used for a relative comparison may be undetectable if obtained from an animal which is not infected with *Streptococcus*. When monitoring the progression or  
35       regression of a disease state, the *Streptococcus* polypeptide level or nucleic acid level may be compared to a second sample obtained from either an animal infected with *Streptococcus* or the same animal from which the first sample was obtained but taken from that animal at a different time than the first. As will be

appreciated in the art, once a standard *Streptococcus* polypeptide level or nucleic acid level which corresponds to a particular stage of a *Streptococcus* infection is known, it can be used repeatedly as a standard for comparison.

By "biological sample" is intended any biological sample obtained from an animal, cell line, tissue culture, or other source which contains *Streptococcus* polypeptide, mRNA, or DNA. Biological samples include body fluids (such as plasma and synovial fluid) which contain *Streptococcus* polypeptides, and muscle, skin, and cartilage tissues. Methods for obtaining tissue biopsies and body fluids are well known in the art.

The present invention is useful for detecting diseases related to *Streptococcus* infections in animals. Preferred animals include monkeys, apes, cats, dogs, cows, pigs, mice, horses, rabbits and humans. Particularly preferred are humans.

Total RNA can be isolated from a biological sample using any suitable technique such as the single-step guanidinium-thiocyanate-phenol-chloroform method described in Chomczynski and Sacchi, *Anal. Biochem.* 162:156-159 (1987). mRNA encoding *Streptococcus* polypeptides having sufficient homology to the nucleic acid sequences identified in Table 1 to allow for hybridization between complementary sequences are then assayed using any appropriate method. These include Northern blot analysis, S1 nuclease mapping, the polymerase chain reaction (PCR), reverse transcription in combination with the polymerase chain reaction (RT-PCR), and reverse transcription in combination with the ligase chain reaction (RT-LCR).

Northern blot analysis can be performed as described in Harada *et al.*, *Cell* 63:303-312 (1990). Briefly, total RNA is prepared from a biological sample as described above. For the Northern blot, the RNA is denatured in an appropriate buffer (such as glyoxal/dimethyl sulfoxide/sodium phosphate buffer), subjected to agarose gel electrophoresis, and transferred onto a nitrocellulose filter. After the RNAs have been linked to the filter by a UV linker, the filter is prehybridized in a solution containing formamide, SSC, Denhardt's solution, denatured salmon sperm, SDS, and sodium phosphate buffer. A *S. pneumoniae* polypeptide DNA sequence shown in Table 1 labeled according to any appropriate method (such as the <sup>32</sup>P-multiprimered DNA labeling system (Amersham)) is used as probe. After hybridization overnight, the filter is washed and exposed to x-ray film. DNA for use as probe according to the present invention is described in the sections above and will preferably at least 15 bp in length.

S1 mapping can be performed as described in Fujita *et al.*, *Cell* 49:357-367 (1987). To prepare probe DNA for use in S1 mapping, the sense strand of an above-described *S. pneumoniae* DNA sequence of the present invention is used as a template to synthesize labeled antisense DNA. The antisense DNA can then be digested using an appropriate restriction endonuclease to generate further DNA probes of a desired length. Such antisense probes are useful for visualizing protected bands corresponding to the target mRNA (*i.e.*, mRNA encoding *Streptococcus* polypeptides).

Preferably, levels of mRNA encoding *Streptococcus* polypeptides are assayed using the RT-PCR method described in Makino *et al.*, *Technique* 2:295-301 (1990). By this method, the radioactivities of the "amplicons" in the polyacrylamide gel bands are linearly related to the initial concentration of the target mRNA. Briefly, this method involves adding total RNA isolated from a biological sample in a reaction mixture containing a RT primer and appropriate buffer. After incubating for primer annealing, the mixture can be supplemented with a RT buffer, dNTPs, DTT, RNase inhibitor and reverse transcriptase. After incubation to achieve reverse transcription of the RNA, the RT products are then subject to PCR using labeled primers. Alternatively, rather than labeling the primers, a labeled dNTP can be included in the PCR reaction mixture. PCR amplification can be performed in a DNA thermal cycler according to conventional techniques. After a suitable number of rounds to achieve amplification, the PCR reaction mixture is electrophoresed on a polyacrylamide gel. After drying the gel, the radioactivity of the appropriate bands (corresponding to the mRNA encoding the *Streptococcus* polypeptides)) is quantified using an imaging analyzer. RT and PCR reaction ingredients and conditions, reagent and gel concentrations, and labeling methods are well known in the art. Variations on the RT-PCR method will be apparent to the skilled artisan.

Assaying *Streptococcus* polypeptide levels in a biological sample can occur using any art-known method. Preferred for assaying *Streptococcus* polypeptide levels in a biological sample are antibody-based techniques. For example, *Streptococcus* polypeptide expression in tissues can be studied with classical immunohistological methods. In these, the specific recognition is provided by the primary antibody (polyclonal or monoclonal) but the secondary detection system can utilize fluorescent, enzyme, or other conjugated secondary antibodies. As a result, an immunohistological staining of tissue section for pathological examination is obtained. Tissues can also be extracted, *e.g.*, with urea and neutral detergent, for the liberation of *Streptococcus* polypeptides for



Western-blot or dot/slot assay (Jalkanen, M., *et al.*, *J. Cell. Biol.* 101:976-985 (1985); Jalkanen, M., *et al.*, *J. Cell. Biol.* 105:3087-3096 (1987)). In this technique, which is based on the use of cationic solid phases, quantitation of a *Streptococcus* polypeptide can be accomplished using an isolated *Streptococcus* polypeptide as a standard. This technique can also be applied to body fluids.

Other antibody-based methods useful for detecting *Streptococcus* polypeptide gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). For example, a *Streptococcus* polypeptide-specific monoclonal antibodies can be used both as an immunoabsorbent and as an enzyme-labeled probe to detect and quantify a *Streptococcus* polypeptide. The amount of a *Streptococcus* polypeptide present in the sample can be calculated by reference to the amount present in a standard preparation using a linear regression computer algorithm. Such an ELISA for detecting a tumor antigen is described in Iacobelli *et al.*, *Breast Cancer Research and Treatment* 11:19-30 (1988). In another ELISA assay, two distinct specific monoclonal antibodies can be used to detect *Streptococcus* polypeptides in a body fluid. In this assay, one of the antibodies is used as the immunoabsorbent and the other as the enzyme-labeled probe.

The above techniques may be conducted essentially as a "one-step" or "two-step" assay. The "one-step" assay involves contacting the *Streptococcus* polypeptide with immobilized antibody and, without washing, contacting the mixture with the labeled antibody. The "two-step" assay involves washing before contacting the mixture with the labeled antibody. Other conventional methods may also be employed as suitable. It is usually desirable to immobilize one component of the assay system on a support, thereby allowing other components of the system to be brought into contact with the component and readily removed from the sample.

*Streptococcus* polypeptide-specific antibodies for use in the present invention can be raised against an intact *S. pneumoize* polypeptide of the present invention or fragment thereof. These polypeptides and fragments may be administered to an animal (*e.g.*, rabbit or mouse) either with a carrier protein (*e.g.*, albumin) or, if long enough (*e.g.*, at least about 25 amino acids), without a carrier.

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and F(ab')<sub>2</sub> fragments) which are capable of specifically binding to a *Streptococcus* polypeptide. Fab and F(ab')<sub>2</sub> fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may

have less non-specific tissue binding of an intact antibody (Wahl *et al.*, *J. Nucl. Med.* 24:316-325 (1983)). Thus, these fragments are preferred.

The antibodies of the present invention may be prepared by any of a variety of methods. For example, the *S. pneumoniae* polypeptides identified in Table 1, or fragments thereof, can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of a *S. pneumoniae* polypeptide of the present invention is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of high specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies. Such monoclonal antibodies can be prepared using hybridoma technology (Köhler *et al.*, *Nature* 256:495 (1975); Kohler *et al.*, *Eur. J. Immunol.* 6:511 (1976); Kohler *et al.*, *Eur. J. Immunol.* 6:292 (1976); Hammerling *et al.*, In: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., (1981) pp. 563-681 ). In general, such procedures involve immunizing an animal (preferably a mouse) with a *S. pneumoniae* polypeptide antigen of the present invention. Suitable cells can be recognized by their capacity to bind anti-*Streptococcus* polypeptide antibody. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP<sub>2</sub>O), available from the American Type Culture Collection, Rockville, Maryland. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al.* (*Gastroenterology* 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the *Streptococcus* polypeptide antigen administered to immunized animal.

Alternatively, additional antibodies capable of binding to *Streptococcus* polypeptide antigens may be produced in a two-step procedure through the use of anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and that, therefore, it is possible to obtain an antibody

which binds to a second antibody. In accordance with this method, *Streptococcus* polypeptide-specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the *Streptococcus* polypeptide-specific antibody can be blocked by a *Streptococcus* polypeptide antigen. Such antibodies comprise anti-idiotypic antibodies to the *Streptococcus* polypeptide-specific antibody and can be used to immunize an animal to induce formation of further *Streptococcus* polypeptide-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments). Alternatively, *Streptococcus* polypeptide-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

Of special interest to the present invention are antibodies to *Streptococcus* polypeptide antigens which are produced in humans, or are "humanized" (*i.e.*, non-immunogenic in a human) by recombinant or other technology. Humanized antibodies may be produced, for example by replacing an immunogenic portion of an antibody with a corresponding, but non-immunogenic portion (*i.e.*, chimeric antibodies) (Robinson, R.R. *et al.*, International Patent Publication PCT/US86/02269; Akira, K. *et al.*, European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison, S.L. *et al.*, European Patent Application 173,494; Neuberger, M.S. *et al.*, PCT Application WO 86/01533; Cabilly, S. *et al.*, European Patent Application 125,023; Better, M. *et al.*, *Science* 240:1041-1043 (1988); Liu, A.Y. *et al.*, *Proc. Natl. Acad. Sci. USA* 84:3439-3443 (1987); Liu, A.Y. *et al.*, *J. Immunol.* 139:3521-3526 (1987); Sun, L.K. *et al.*, *Proc. Natl. Acad. Sci. USA* 84:214-218 (1987); Nishimura, Y. *et al.*, *Canc. Res.* 47:999-1005 (1987); Wood, C.R. *et al.*, *Nature* 314:446-449 (1985); Shaw *et al.*, *J. Natl. Cancer Inst.* 80:1553-1559 (1988). General reviews of "humanized" chimeric antibodies are provided by Morrison, S.L. (*Science*, 229:1202-1207 (1985)) and by Oi, V.T. *et al.*, *BioTechniques* 4:214 (1986)). Suitable "humanized" antibodies can be alternatively produced by CDR or CEA substitution (Jones, P.T. *et al.*, *Nature* 321:552-525 (1986);

Verhoeyan *et al.*, *Science* 239:1534 (1988); Beidler, C.B. *et al.*, *J. Immunol.* 141:4053-4060 (1988)).

Suitable enzyme labels include, for example, those from the oxidase group, which catalyze the production of hydrogen peroxide by reacting with substrate. Glucose oxidase is particularly preferred as it has good stability and its substrate (glucose) is readily available. Activity of an oxidase label may be assayed by measuring the concentration of hydrogen peroxide formed by the enzyme-labeled antibody/substrate reaction. Besides enzymes, other suitable labels include radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulphur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

Further suitable labels for the *Streptococcus* polypeptide-specific antibodies of the present invention are provided below. Examples of suitable enzyme labels include malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast-alcohol dehydrogenase, alpha-glycerol phosphate dehydrogenase, triose phosphate isomerase, peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, and acetylcholine esterase.

Examples of suitable radioisotopic labels include  $^3\text{H}$ ,  $^{111}\text{In}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ ,  $^{51}\text{Cr}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$ ,  $^{75}\text{Se}$ ,  $^{152}\text{Eu}$ ,  $^{90}\text{Y}$ ,  $^{67}\text{Cu}$ ,  $^{217}\text{Bi}$ ,  $^{211}\text{At}$ ,  $^{212}\text{Pb}$ ,  $^{47}\text{Sc}$ ,  $^{109}\text{Pd}$ , etc.  $^{111}\text{In}$  is a preferred isotope where *in vivo* imaging is used since it avoids the problem of dehalogenation of the  $^{125}\text{I}$  or  $^{131}\text{I}$ -labeled monoclonal antibody by the liver. In addition, this radionuclide has a more favorable gamma emission energy for imaging (Perkins *et al.*, *Eur. J. Nucl. Med.* 10:296-301 (1985); Carasquillo *et al.*, *J. Nucl. Med.* 28:281-287 (1987)). For example,  $^{111}\text{In}$  coupled to monoclonal antibodies with 1-(P-isothiocyanatobenzyl)-DPTA has shown little uptake in non-tumorous tissues, particularly the liver, and therefore enhances specificity of tumor localization (Esteban *et al.*, *J. Nucl. Med.* 28:861-870 (1987)).

Examples of suitable non-radioactive isotopic labels include  $^{157}\text{Gd}$ ,  $^{55}\text{Mn}$ ,  $^{162}\text{Dy}$ ,  $^{52}\text{Tr}$ , and  $^{56}\text{Fe}$ .

Examples of suitable fluorescent labels include an  $^{152}\text{Eu}$  label, a fluorescein label, an isothiocyanate label, a rhodamine label, a phycoerythrin label, a phycocyanin label, an allophycocyanin label, an o-phthaldehyde label, and a fluorescamine label.

Examples of suitable toxin labels include diphtheria toxin, ricin, and cholera toxin.

Examples of chemiluminescent labels include a luminal label, an isoluminal label, an aromatic acridinium ester label, an imidazole label, an acridinium salt label, an oxalate ester label, a luciferin label, a luciferase label, and an aequorin label.

5           Examples of nuclear magnetic resonance contrasting agents include heavy metal nuclei such as Gd, Mn, and iron.

Typical techniques for binding the above-described labels to antibodies are provided by Kennedy *et al.*, *Clin. Chim. Acta* 70:1-31 (1976), and Schurs *et al.*, *Clin. Chim. Acta* 81:1-40 (1977). Coupling techniques mentioned in the  
10           latter are the glutaraldehyde method, the periodate method, the dimaleimide method, the m-maleimidobenzyl-N-hydroxy-succinimide ester method, all of which methods are incorporated by reference herein.

In a related aspect, the invention includes a diagnostic kit for use in screening serum containing antibodies specific against *S. pneumoniae*  
15           infection. Such a kit may include an isolated *S. pneumoniae* antigen comprising an epitope which is specifically immunoreactive with at least one anti-*S. pneumoniae* antibody. Such a kit also includes means for detecting the binding of said antibody to the antigen. In specific embodiments, the kit may include a recombinantly produced or chemically synthesized peptide or polypeptide  
20           antigen. The peptide or polypeptide antigen may be attached to a solid support.

In a more specific embodiment, the detecting means of the above-described kit includes a solid support to which said peptide or polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labelled anti-human antibody. In this embodiment, binding of the antibody to the *S.*  
25           *pneumoniae* antigen can be detected by binding of the reporter labelled antibody to the anti-*S. pneumoniae* antibody.

In a related aspect, the invention includes a method of detecting *S. pneumoniae* infection in a subject. This detection method includes reacting a body fluid, preferably serum, from the subject with an isolated *S. pneumoniae*  
30           antigen, and examining the antigen for the presence of bound antibody. In a specific embodiment, the method includes a polypeptide antigen attached to a solid support, and serum is reacted with the support. Subsequently, the support is reacted with a reporter-labelled anti-human antibody. The support is then examined for the presence of reporter-labelled antibody.

35           The solid surface reagent employed in the above assays and kits is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip sticks, 96-well plates or filter material. These attachment methods generally include non-specific adsorption of the

protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group. Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

5

### *Therapeutics and Modes of Administration*

The present invention also provides vaccines comprising one or more polypeptides of the present invention. Heterogeneity in the composition of a vaccine may be provided by combining *S. pneumoniae* polypeptides of the present invention. Multi-component vaccines of this type are desirable because they are likely to be more effective in eliciting protective immune responses against multiple species and strains of the *Streptococcus* genus than single polypeptide vaccines. Thus, as discussed in detail below, a multi-component vaccine of the present invention may contain one or more, preferably 2 to about 20, more preferably 2 to about 15, and most preferably 3 to about 8, of the *S. pneumoniae* polypeptides identified in Table 1, or fragments thereof.

Multi-component vaccines are known in the art to elicit antibody production to numerous immunogenic components. Decker, M. and Edwards, K., *J. Infect. Dis.* 174:S270-275 (1996). In addition, a hepatitis B, diphtheria, tetanus, pertussis tetravalent vaccine has recently been demonstrated to elicit protective levels of antibodies in human infants against all four pathogenic agents. Aristegui, J. *et al.*, *Vaccine* 15:7-9 (1997).

The present invention thus also includes multi-component vaccines. These vaccines comprise more than one polypeptide, immunogen or antigen. An example of such a multi-component vaccine would be a vaccine comprising more than one of the *S. pneumoniae* polypeptides described in Table 1. A second example is a vaccine comprising one or more, for example 2 to 10, of the *S. pneumoniae* polypeptides identified in Table 1 and one or more, for example 2 to 10, additional polypeptides of either streptococcal or non-streptococcal origin. Thus, a multi-component vaccine which confers protective immunity to both a Streptococcal infection and infection by another pathogenic agent is also within the scope of the invention.

As indicated above, the vaccines of the present invention are expected to elicit a protective immune response against infections caused by species and strains of *Streptococcus* other than strain of *S. pneumoniae* deposited with that ATCC.

Further within the scope of the invention are whole cell and whole viral vaccines. Such vaccines may be produced recombinantly and involve the

expression of one or more of the *S. pneumoniae* polypeptides described in Table 1. For example, the *S. pneumoniae* polypeptides of the present invention may be either secreted or localized intracellular, on the cell surface, or in the periplasmic space. Further, when a recombinant virus is used, the *S. pneumoniae* polypeptides of the present invention may, for example, be localized in the viral envelope, on the surface of the capsid, or internally within the capsid. Whole cells vaccines which employ cells expressing heterologous proteins are known in the art. See, e.g., Robinson, K. *et al.*, *Nature Biotech.* 15:653-657 (1997); Sirard, J. *et al.*, *Infect. Immun.* 65:2029-2033 (1997); Chabalgoity, J. *et al.*, *Infect. Immun.* 65:2402-2412 (1997). These cells may be administered live or may be killed prior to administration. Chabalgoity, J. *et al.*, *supra*, for example, report the successful use in mice of a live attenuated *Salmonella* vaccine strain which expresses a portion of a platyhelminth fatty acid-binding protein as a fusion protein on its cells surface.

A multi-component vaccine can also be prepared using techniques known in the art by combining one or more *S. pneumoniae* polypeptides of the present invention, or fragments thereof, with additional non-streptococcal components (e.g., diphtheria toxin or tetanus toxin, and/or other compounds known to elicit an immune response). Such vaccines are useful for eliciting protective immune responses to both members of the *Streptococcus* genus and non-streptococcal pathogenic agents.

The vaccines of the present invention also include DNA vaccines. DNA vaccines are currently being developed for a number of infectious diseases. Boyer, J *et al.*, *Nat. Med.* 3:526-532 (1997); reviewed in Spier, R., *Vaccine* 14:1285-1288 (1996). Such DNA vaccines contain a nucleotide sequence encoding one or more *S. pneumoniae* polypeptides of the present invention oriented in a manner that allows for expression of the subject polypeptide. The direct administration of plasmid DNA encoding *B. burgdorgeri* OspA has been shown to elicit protective immunity in mice against borrelial challenge. Luke, C. *et al.*, *J. Infect. Dis.* 175:91-97 (1997).

The present invention also relates to the administration of a vaccine which is co-administered with a molecule capable of modulating immune responses. Kim, J. *et al.*, *Nature Biotech.* 15:641-646 (1997), for example, report the enhancement of immune responses produced by DNA immunizations when DNA sequences encoding molecules which stimulate the immune response are co-administered. In a similar fashion, the vaccines of the present invention may be co-administered with either nucleic acids encoding immune modulators or the immune modulators themselves. These immune modulators

include granulocyte macrophage colony stimulating factor (GM-CSF) and CD86.

5 The vaccines of the present invention may be used to confer resistance to streptococcal infection by either passive or active immunization. When the vaccines of the present invention are used to confer resistance to streptococcal infection through active immunization, a vaccine of the present invention is administered to an animal to elicit a protective immune response which either prevents or attenuates a streptococcal infection. When the vaccines of the present invention are used to confer resistance to streptococcal infection through  
10 passive immunization, the vaccine is provided to a host animal (*e.g.*, human, dog, or mouse), and the antisera elicited by this antisera is recovered and directly provided to a recipient suspected of having an infection caused by a member of the *Streptococcus* genus.

15 The ability to label antibodies, or fragments of antibodies, with toxin molecules provides an additional method for treating streptococcal infections when passive immunization is conducted. In this embodiment, antibodies, or fragments of antibodies, capable of recognizing the *S. pneumoniae* polypeptides disclosed herein, or fragments thereof, as well as other *Streptococcus* proteins, are labeled with toxin molecules prior to their administration to the patient.  
20 When such toxin derivatized antibodies bind to *Streptococcus* cells, toxin moieties will be localized to these cells and will cause their death.

The present invention thus concerns and provides a means for preventing or attenuating a streptococcal infection resulting from organisms which have antigens that are recognized and bound by antisera produced in  
25 response to the polypeptides of the present invention. As used herein, a vaccine is said to prevent or attenuate a disease if its administration to an animal results either in the total or partial attenuation (*i.e.*, suppression) of a symptom or condition of the disease, or in the total or partial immunity of the animal to the disease.

30 The administration of the vaccine (or the antisera which it elicits) may be for either a "prophylactic" or "therapeutic" purpose. When provided prophylactically, the compound(s) are provided in advance of any symptoms of streptococcal infection. The prophylactic administration of the compound(s) serves to prevent or attenuate any subsequent infection. When provided  
35 therapeutically, the compound(s) is provided upon or after the detection of symptoms which indicate that an animal may be infected with a member of the *Streptococcus* genus. The therapeutic administration of the compound(s) serves to attenuate any actual infection. Thus, the *S. pneumoniae* polypeptides, and



fragments thereof, of the present invention may be provided either prior to the onset of infection (so as to prevent or attenuate an anticipated infection) or after the initiation of an actual infection.

5 The polypeptides of the invention, whether encoding a portion of a native protein or a functional derivative thereof, may be administered in pure form or may be coupled to a macromolecular carrier. Example of such carriers are proteins and carbohydrates. Suitable proteins which may act as macromolecular carrier for enhancing the immunogenicity of the polypeptides of the present invention include keyhole limpet hemacyanin (KLH) tetanus toxoid, 10 pertussis toxin, bovine serum albumin, and ovalbumin. Methods for coupling the polypeptides of the present invention to such macromolecular carriers are disclosed in Harlow *et al.*, *Antibodies: A Laboratory Manual, 2nd Ed.*; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988), the entire disclosure of which is incorporated by reference herein.

15 A composition is said to be "pharmacologically acceptable" if its administration can be tolerated by a recipient animal and is otherwise suitable for administration to that animal. Such an agent is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in a 20 detectable change in the physiology of a recipient patient.

While in all instances the vaccine of the present invention is administered as a pharmacologically acceptable compound, one skilled in the art would recognize that the composition of a pharmacologically acceptable compound varies with the animal to which it is administered. For example, a vaccine 25 intended for human use will generally not be co-administered with Freund's adjuvant. Further, the level of purity of the *S. pneumoniae* polypeptides of the present invention will normally be higher when administered to a human than when administered to a non-human animal.

30 As would be understood by one of ordinary skill in the art, when the vaccine of the present invention is provided to an animal, it may be in a composition which may contain salts, buffers, adjuvants, or other substances which are desirable for improving the efficacy of the composition. Adjuvants are substances that can be used to specifically augment a specific immune response. These substances generally perform two functions: (1) they protect 35 the antigen(s) from being rapidly catabolized after administration and (2) they nonspecifically stimulate immune responses.

Normally, the adjuvant and the composition are mixed prior to presentation to the immune system, or presented separately, but into the same

40

site of the animal being immunized. Adjuvants can be loosely divided into several groups based upon their composition. These groups include oil adjuvants (for example, Freund's complete and incomplete), mineral salts (for example,  $\text{AlK}(\text{SO}_4)_2$ ,  $\text{AlNa}(\text{SO}_4)_2$ ,  $\text{AlNH}_4(\text{SO}_4)$ , silica, kaolin, and carbon),  
5 polynucleotides (for example, poly IC and poly AU acids), and certain natural substances (for example, wax D from *Mycobacterium tuberculosis*, as well as substances found in *Corynebacterium parvum*, or *Bordetella pertussis*, and members of the genus *Brucella*. Other substances useful as adjuvants are the saponins such as, for example, Quil A. (Superfos A/S, Denmark). Preferred  
10 adjuvants for use in the present invention include aluminum salts, such as  $\text{AlK}(\text{SO}_4)_2$ ,  $\text{AlNa}(\text{SO}_4)_2$ , and  $\text{AlNH}_4(\text{SO}_4)$ . Examples of materials suitable for use in vaccine compositions are provided in *Remington's Pharmaceutical Sciences* (Osol, A, Ed, Mack Publishing Co, Easton, PA, pp. 1324-1341 (1980), which reference is incorporated herein by reference).

15 The therapeutic compositions of the present invention can be administered parenterally by injection, rapid infusion, nasopharyngeal absorption (intranasopharangeally), dermoabsorption, or orally. The compositions may alternatively be administered intramuscularly, or intravenously. Compositions for parenteral administration include sterile  
20 aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers or occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally  
25 comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water. Besides the inert diluents, such compositions can also include adjuvants, wetting agents, emulsifying and suspending agents, or sweetening, flavoring,  
30 or perfuming agents.

Therapeutic compositions of the present invention can also be administered in encapsulated form. For example, intranasal immunization of mice against *Bordetella pertussis* infection using vaccines encapsulated in biodegradable microsphere composed of poly(DL-lactide-co-glycolide) has been  
35 shown to stimulate protective immune responses. Shahin, R. *et al.*, *Infect. Immun.* 63:1195-1200 (1995). Similarly, orally administered encapsulated *Salmonella typhimurium* antigens have also been shown to elicit protective

immunity in mice. Allaoui-Attarki, K. *et al.*, *Infect. Immun.* 65:853-857 (1997). Encapsulated vaccines of the present invention can be administered by a variety of routes including those involving contacting the vaccine with mucous membranes (*e.g.*, intranasally, intracolonicly, intraduodenally).

5 Many different techniques exist for the timing of the immunizations when a multiple administration regimen is utilized. It is possible to use the compositions of the invention more than once to increase the levels and diversities of expression of the immunoglobulin repertoire expressed by the immunized animal. Typically, if multiple immunizations are given, they will be  
10 given one to two months apart.

According to the present invention, an "effective amount" of a therapeutic composition is one which is sufficient to achieve a desired biological effect. Generally, the dosage needed to provide an effective amount of the composition will vary depending upon such factors as the animal's or human's  
15 age, condition, sex, and extent of disease, if any, and other variables which can be adjusted by one of ordinary skill in the art.

The antigenic preparations of the invention can be administered by either single or multiple dosages of an effective amount. Effective amounts of the compositions of the invention can vary from 0.01-1,000  $\mu\text{g/ml}$  per dose, more  
20 preferably 0.1-500  $\mu\text{g/ml}$  per dose, and most preferably 10-300  $\mu\text{g/ml}$  per dose.

Having now generally described the invention, the same will be more readily understood through reference to the following example which is provided by way of illustration, and is not intended to be limiting of the present  
25 invention, unless specified.

### **Examples**

#### **Example 1: Expression and Purification of *S. pneumoniae* Polypeptides in *E. coli***

30 The bacterial expression vector pQE10 (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311) is used in this example for cloning of the nucleotide sequences shown in Table 1 and for expressing the polypeptides identified in Table 1. The components of the pQE10 plasmid are arranged such that the inserted DNA sequence encoding a polypeptide of the present invention expresses the polypeptide with the six His residues (*i.e.*, a "6 X His tag")  
35 covalently linked to the amino terminus.

The DNA sequences encoding the desired portions of the polypeptides of Table 1 are amplified using PCR oligonucleotide primers from either a DNA

library constructed from *S. pneumoniae*, such as the one deposited by the inventors at the ATCC for convenience, ATCC Deposit No. 97755, or from DNA isolated from the same organism such as the *S. pneumoniae* strain deposited with the ATCC as Deposit No. 55840. A list of PCR primers which can be used for this purpose is provided in Table 3, below. The PCR primers anneal to the nucleotide sequences encoding both the amino terminal and carboxy terminal amino acid sequences of the desired portion of the polypeptides of Table 1. Additional nucleotides containing restriction sites to facilitate cloning in the pQE10 vector were added to the 5' and 3' primer sequences, respectively. Such restriction sites are listed in Table 3 for each primer. In each case, the primer comprises, from the 5' end, 4 random nucleotides to prevent "breathing" during the annealing process, a restriction site (shown in Table 3), and approximately 15 nucleotides of *S. pneumoniae* ORF sequence (the complete sequence of each cloning primer is shown as SEQ ID NO:227 through SEQ ID NO:452).

For cloning the polypeptides of Table 1, the 5' and 3' primers were selected to amplify their respective nucleotide coding sequences. One of ordinary skill in the art would appreciate that the point in the protein coding sequence where the 5' primer begins may be varied to amplify a DNA segment encoding any desired portion of the complete amino acid sequences described in Table 1. Similarly, one of ordinary skill in the art would further appreciate that the point in the protein coding sequence where the 3' primer begins may also be varied to amplify a DNA segment encoding any desired portion of the complete amino acid sequences described in Table 1.

The amplified DNA fragment and the pQE10 vector are digested with the appropriate restriction enzyme(s) and the digested DNAs are then ligated together. The ligation mixture is transformed into competent *E. coli* cells using standard procedures such as those described in Sambrook *et al.*, *Molecular Cloning: a Laboratory Manual, 2nd Ed.*; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Transformants are identified by their ability to grow under selective pressure on LB plates. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing.

Clones containing the desired constructs are grown overnight ("O/N") in liquid culture under selection. The O/N culture is used to inoculate a large culture, at a dilution of approximately 1:25 to 1:250. The cells are grown to an optical density at 600 nm ("OD600") of between 0.4 and 0.6. Isopropyl-b-D-thiogalactopyranoside ("IPTG") is then added to a final concentration of 1 mM

to induce transcription from the *lac* repressor sensitive promoter, by inactivating the *lacI* repressor. Cells subsequently are incubated further for 3 to 4 hours. Cells are then harvested by centrifugation.

5 The cells are stirred for 3-4 hours at 4 C in 6M guanidine-HCl, pH 8. The cell debris is removed by centrifugation, and the supernatant containing the protein of interest is loaded onto a nickel-nitrilo-tri-acetic acid ("NiNTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6x His tag bind to the NI-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist, 1995, QIAGEN, Inc., *supra*).  
10 Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH8, then washed with 10 volumes of 6 M guanidine-HCl pH6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.0.

The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl.  
15 Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins can be eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH6 buffer plus 200 mM NaCl.  
20 The purified protein is stored at 4°C or frozen at -80°C.

The DNA sequences encoding the amino acid sequences of Table 1 may  
25 also be cloned and expressed as fusion proteins by a protocol similar to that described directly above, wherein the pET-32b(+) vector (Novagen, 601 Science Drive, Madison, WI 53711) is preferentially used in place of pQE10.

Each of the polynucleotides shown in Table 1, was successfully amplified and subcloned into pQE10 as described above using the PCR primers  
30 shown in Table 3. These pQE10 plasmids containing the DNAs of Table 1, except SP023, SP042, SP054, SP063, SP081, SP092, SP114, SP122, SP123, SP126, and SP127, were deposited with the ATCC as a pooled deposit as a convenience to those of skill in the art. This pooled deposit was desposited on October 16, 1997 and given ATCC Deposit No. 209369. Those of ordinary  
35 skill in the art appreciate that isolating an individual plasmid from the pooled deposit is trivial provided the information and reagents described herein. Each of the deposited clones is capable of expressing its encoded *S. pneumoniae* polypeptide.

## Example 2: Immunization and Detection of Immune Responses

### Methods

#### Growth of bacterial inoculum, immunization of Mice and Challenge with *S. pneumoniae*.

5            Propagation and storage of, and challenge by *S. pneumoniae* are preformed essentially as described in Aaberge, I.S. et al., Virulence of *Streptococcus pneumoniae* in mice: a standardized method for preparation and frozen storage of the experimental bacterial inoculum, *Microbial Pathogenesis*,  
10            18:141 (1995), incorporated herein by reference.

             Briefly, Todd Hewitt (TH) broth (Difco laboratories, Detroit, MI) with 17% FCS, and horse blood agar plates are used for culturing the bacteria. Both broth and blood plates are incubated at 37°C in a 5% CO<sub>2</sub> atmosphere. Blood plates are incubated for 18 hr. The culture broth is regularly 10-fold serially  
15            diluted in TH broth kept at room temperature and bacterial suspensions are kept at room temperature until challenge of mice.

             For active immunizations C3H/HeJ mice (The Jackson Laboratory, Bar Harbor, ME) are injected intraperitoneally (i.p.) at week 0 with 20 g of recombinant streptococcal protein, or phosphate-buffered saline (PBS),  
20            emulsified with complete Freund's adjuvant (CFA), given a similar booster immunization in incomplete Freund's adjuvant (IFA) at week 4, and challenged at week 6. For challenge *S. pneumoniae* are diluted in TH broth from exponentially-growing cultures and mice are injected subcutaneously (s.c.) at the base of the tail with 0.1 ml of these dilutions (serial dilutions are used to find  
25            medium infectious dose). Streptococci used for challenge are passaged fewer than six times *in vitro*. To assess infection, blood samples are obtained from the distal part of the lateral femoral vein into heparinized capillary tubes. A 25 ul blood sample is serially 10-fold diluted in TH broth, and 25 ul of diluted and undiluted blood is plated onto blood agar plates. The plates are incubated for 18  
30            hr. and colonies are counted.

             Other methods are known in the art, for example, see Langermann, S. et al., *J. Exp. Med.*, 180:2277 (1994), incorporated herein by reference.

### *Immunoassays*

Several immunoassay formats are used to quantify levels of streptococcal-specific antibodies (ELISA and immunoblot), and to evaluate the functional properties of these antibodies (growth inhibition assay). The ELISA and immunoblot assays are also used to detect and quantify antibodies elicited in response to streptococcal infection that react with specific streptococcal antigens. Where antibodies to certain streptococcal antigens are elicited by infection this is taken as evidence that the streptococcal proteins in question are expressed *in vivo*. Absence of infection-derived antibodies (seroconversion) following streptococcal challenge is evidence that infection is prevented or suppressed. The immunoblot assay is also used to ascertain whether antibodies raised against recombinant streptococcal antigens recognize a protein of similar size in extracts of whole streptococci. Where the natural protein is of similar, or identical, size in the immunoblot assay to the recombinant version of the same protein, this is taken as evidence that the recombinant protein is the product of a full-length clone of the respective gene.

### *Enzyme-Linked Immunosorbant Assay (ELISA).*

The ELISA is used to quantify levels of antibodies reactive with streptococcus antigens elicited in response to immunization with these streptococcal antigens. Wells of 96 well microtiter plates (Immunolon 4, Dynatech, Chantilly, Virginia, or equivalent) are coated with antigen by incubating 50  $\mu$ l of 1  $\mu$ g/ml protein antigen solution in a suitable buffer, typically 0.1 M sodium carbonate buffer at pH 9.6. After decanting unbound antigen, additional binding sites are blocked by incubating 100  $\mu$ l of 3% nonfat milk in wash buffer (PBS, 0.2% Tween 20, pH 7.4). After washing, duplicate serial two-fold dilutions of sera in PBS, Tween 20, 1% fetal bovine serum, are incubated for 1 hr, removed, wells are washed three times, and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG. After three washes, bound antibodies are detected with H<sub>2</sub>O<sub>2</sub> and 2,2'-azino-di-(3-ethylbenzthiazoline sulfonate) (Schwan, T.G., *et al.*, *Proc. Natl. Acad. Sci. USA* 92:2909-2913 (1985)) (ABTS®, Kirkegaard & Perry Labs., Gaithersburg, MD) and A405 is quantified with a Molecular Devices, Corp. (Menlo Park, California) Vmax™ plate reader. IgG levels twice the background level in serum from naive mice are assigned the minimum titer of 1:100.

***Sodiumdodecylsulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Immunoblotting***

Using a single well format, total streptococcal protein extracts or recombinant streptococcal antigen are boiled in SDS/2-ME sample buffer before electrophoresis through 3% acrylamide stacking gels, and resolving gels of higher acrylamide concentration, typically 10-15% acrylamide monomer. Gels are electro-blotted to nitrocellulose membranes and lanes are probed with dilutions of antibody to be tested for reactivity with specific streptococcal antigens, followed by the appropriate secondary antibody-enzyme (horseradish peroxidase) conjugate. When it is desirable to confirm that the protein had transferred following electro-blotting, membranes are stained with Ponceau S. Immunoblot signals from bound antibodies are detected on x-ray film as chemiluminescence using ECL™ reagents (Amersham Corp., Arlington Heights, Illinois).

***Example 3: Detection of Streptococcus mRNA expression***

Northern blot analysis is carried out using methods described by, among others, Sambrook *et al.*, *supra.* to detect the expression of the *S. pneumoniae* nucleotide sequences of the present invention in animal tissues. A cDNA probe containing an entire nucleotide sequence shown in Table 1 is labeled with <sup>32</sup>P using the *rediprime*™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using a CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to detect the expression of *Streptococcus* mRNA in an animal tissue sample.

Animal tissues, such as blood or spinal fluid, are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 C overnight, and films developed according to standard procedures.



It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples.

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

5

The entire disclosure of all publications (including patents, patent applications, journal articles, laboratory manuals, books, or other documents) cited herein are hereby incorporated by reference.

Table 1

**SP001 nucleotide (SEQ ID NO:1)**

TAAAATCTACGACAATAAAATCAACTCATTGCTGACTTGGGTTCTGAACGCCGCTCAATGCCCAAGC  
TAATGATATTCCACAGATTGGTTAAGGCAATCGTTTCTATCGAAGACCATCGCTTCTCGACCACAG  
GGGGATTGATACCATCCGTATCCTGGGAGCTTTCTTGCAGCAATCTGCAAAGCAATCCCTCCAAGGTGG  
ATCAACTCTCACCCAACAGTTGATTAAAGTTGACTTACTTTTCAACTTCGACTTCCGACCAGACTATTTT  
TCGTAAGGCTCAGGAAGCTTGGTTAGCGATTCAAGTTAGAACAAAAGCAACCAAGCAAGAAATCTTGAC  
CTACTATATAAAATAAGGTCTACATGTCTAATGGGAACATGGAATGCAGACAGCAGCTCAAACTACTA  
TGGTAAAGACCTCAATAATTAAAGTTTACCTCAGTTAGCCTTGCTGGCTGGAATGCCTCAGGCACCAAA  
CCAATATGACCCCTATTACATCCAGAAGCAGCCCAAGACCGCCGAACTTGGTCTTATCTGAAATGAA  
AAATCAAGGCTACATCTCTGCTGAACAGTATGAGAAAGCAGTCAATACACCAATTACTGATGGACTACA  
AAGTCTCAAATCAGCAAGTAATTACCCTGCTTACATGGATAATTACCTCAAGGAAGTCATCAATCAAGT  
TGAAGAAGAAAACAGGCTATAACCTACTCACAACTGGGATGGATGTCTACACAAATGTAGACCAAGAAGC  
TCAAAAACATCTGTGGGATATTTACAATACAGACGAATACGTTGCCATCCAGACGATGAATTGCAAGT  
CGCTTCTACCATTTGTTGATGTTTCTAACGGTAAAGTCATTGCCCAGCTAGGAGCAGCCATCAGTCAAG  
TAATGTTTCTTCCGGAATTAACCAAGCAGTAGAAACAAACCGGACTGGGGATCAACTATGAAACCGAT  
CACAGACTATGCTCCTGCTTGGAGTACGGTGTCTACGATTCAACTGCTACTATCGTTACAGTACGCC  
CTATAACTACCCTGGGACAAATACTCCTGTTTATACTGGGATAGGGGCTACTTTGGCAACATCACCTT  
GCAATACGCCCTGCAACAATCGCGAAACGTCACCGCTGGAACTCTAAACAAGGTCGGACTCAACCG  
CGCCAAGACTTTCTAAATGGTCTAGGAATCGACTACCCAAGTATTCCTACTCAAATGCCATTTCAAG  
TAACACAACCGAATCAGACAAAAAATATGGAGCAAGTAGTGAAGAGATGGCTGCTGCTTACGCTGCCTT  
TGCAATGGTGGAACTTACTATAAACCAATGTATATCCATAAAGTCGCTTTAGTGATGGGAGTGAAAA  
AGAGTTCTCTAATGTGGAACCTCGTGCCATGAAGGAAACGACAGCCTATATGATGACCGACATGATGAA  
AACAGTCTTGACTTATGGAACCTGGACGAAATGCCTATCTTGCTTGGCTCCCTCAGGCTGGTAAACAGG  
AACCTCTAACTATACAGACGAGGAAATTGAAAACCATCAAGACCTCTCAATTTGTAGCACCTGATGA  
ACTATTTGCTGGCTATACGCGTAAATATTCAATGGCTGTATGGACAGGCTATTCTAACCGTCTGACACC  
ACTTGTAGGCAATGGCCTTACGGTCGCTGCCAAAGTTTACCGCTCTATGATGACCTACCTGTCTGAAGG  
AAGCAATCCAGAAGATTGGAATATACCAGAGGGGCTCTACAGAAATGGAGAATTCGTATTTAAAAATGG  
TGCTCGTTCTACGTGGAACCTACCTGCTCCACAACAACCCCATCAACTGAAAGTTCAAGCTCATCATC  
AGATAGTTCAACTTCACAGTCTAGCTCAACCACTCCAAGCACAAATAATAGTACGACTACCAATCCTAA  
CAATAATACGCAACAATCAAATACAACCCCTGATCAACAAAATCAGAATCCTCAACCAGCACAAACA

**SP001 AMINO ACID (SEQ ID NO:2)**

KIYDNKNQLIADLGSERRVNAQANDIPTDLVKAIVSIEDHRFFDHRGIDTIRILGAFLRNLSNSLQGG  
STLTQQLIKLTYFSTSDQTI SRKAQEAWLAIQLEQKATKQEI LTYI INKVYMSNGNYGMQTAAQNY  
GKDLNLSLPQLALLAGMPQAPNQYDPYSHPEAAQDRRLVLSEMKNGYISAEQYKAVNTPITDGLQ  
SLKSASNPAYMDNYLKEVINQVEEETGYNLLTGMDEVYTNVDQEAQKHLWDIYNTDEYVAYPDDELQV  
ASTIVDVSNQKVIQQLGARHQSSNVSGINQAVETNRDWGSTMKPI TDYAPALEYGVYDSTATIVHDEP  
YNYPGTNTPVYNWDRGYFGNITLQYALQQSRNVPVAVETLNKVLNRAKTFNLGLGIDYPSIHYSNAISS  
NTTESDKKYGASSEKMAAAYAAFANGGTYKPMYIHKVVFSDGSEKEFSNVGTRAMKETTA YMMTDMMK  
TVLTYGTGRNAYLAWLPQAGKTGTSNYTDEEIE NHIKTSQFVAPDELFAGYTRKYSMAVWVTGYSNRLTP  
LVGNGLTVAAKVYRSMMTYLSEGSNPEDWNIPEGLYRNGEFVFKNGARSTWNSPAPQPPSTESSSSSS  
DSSTSQSSSTTPSTNNSTTTNPNNTQQSNTT PDQONQNPQPAQP

**SP004 nucleotide (SEQ ID NO:3)**

AAATTACAATACGACTATGAATTGACCTCTGGAGAAAAATTACCTCTTCTAAAGAGATTTTCAGGTTA  
CACTTATATTGGATATATCAAAGAGGAAAAACGACTTCTGAGTCTGAAGTAAGTAATCAAAGAGTTT  
AGTTGCCACTCCTACAAAAACAACAAAGGTGGATTATAATGTTACACCGAATTTTGTAGACCATCCATC  
AACAGTACAAGCTATTCAGGAACAAACACCTGTTTCTTCAACTAAGCCGACAGAAGTTCAAGTAGTTGA  
AAAACCTTTCTCTACTGAATTAATCAATCCAAGAAAAGAAGAGAAACAATCTTCAGATTCTCAAGAACA  
ATTAGCCGAACATAAGAATCTAGAAACGAAGAAAGAGGAGAAGATTTCTCCAAAAGAAAAGACTGGGGT  
AAATACATTAAATCCACAGGATGAAGTTTTATCAGGTCAATTGAACAAACCTGAACCTTATATCGTGA  
GGAACTATGGAGACAAAAATAGATTTTCAAGAAGAAATTCAGAAAATCCTGATTAGCTGAAGGAAC  
TGTAAGAGTAAAACAAGAAGGTAAATTAGGTAAAGAAAGTTGAAATCGTCAGAATATTCTCTGTAAACAA  
GGAAGAAGTTTCGCGAGAAATTGTTTCAACTTCAACGACTGCGCCTAGTCCAAGATAGTCGAAAAAGG  
TACTAAAAAACTCAAGTTATAAAGGAACAACCTGAGACTGGTGTAGAACATAAGGACGTACAGTCTGG  
AGCTATTGTTGAACCCGCAATTCAGCCTGAGTTGCCCGAAGCTGTAGTAAGTGACAAAGGCGAACCA  
AGTTCAACCTACATTACCCGAAGCAGTTGTGACCGACAAAGGTGAGACTGAGGTTCAACCAGAGTCGCC  
AGATACTGTGGTAAGTGATAAAGGTGAACCAGAGCAGGTAGCACCGCTTCCAGAATATAAGGGTAATAT

Table 1

49

TGAGCAAGTAAAACCTGAAACTCCGGTTGAGAAGACCAAAGAACAAGGTCCAGAAAAAACTGAAGAAGT  
TCCAGTAAAACCAACAGAAGAAACACCAGTAAATCCAAATGAAGGTACTACAGAAGGAACCTCAATTCA  
AGAAGCAGAAAAATCCAGTTCAACCTGCAGAAGAATCAACAACGAATTCAGAGAAAGTATCACCAGATAC  
ATCTAGCAAAAATACTGGGGAAGTGTCAGTAATCCTAGTGATTTCGACAACCTCAGTTGGAGAATCAAA  
TAAACCAGAACATAATGACTCTAAAAATGAAAAATTCAGAAAAAACTGTAGAAGAAGTTCAGTAAATCC  
AAATGAAGGCACAGTAGAAGGTACCTCAAATCAAGAAACAGAAAAACCAGTTCAACCTGCAGAAGAAAC  
ACAAACAACTCTGGGAAAAATAGCTAACGAAAAATCTGGAGAAGTATCCAATAAACCTAGTGATTCAAA  
ACCACCAAGTTGAAGAATCAAATCAACCAGAAAAAACGGAAGTCAACAAAAACCAGAAAAATTCAGGTAA  
TACAACATCAGAGAATGGACAAACAGAACCAACCATCAACGGAATTCAGTGAAGATGTTTCAAC  
CGAATCAAAACATCCCAATTCAAATGGAAACGAAGAAATTAACAAGAAAAATGAAGTACACCTGATAA  
AAAGGTAGAAGAACCAGAGAAAACTTGAAATTAAGAAATGTTTCCGACCTAGAGTTA

**SP004 amino acid (SEQ ID NO:4)**

NYNTDYELTSGEKLPLPKEISGYTYIGYIKEGKTTSESEVSNQKSSVATPTKQKQVDYNVTPNFVDHPS  
TVQAIQEQTTPVSSTKPTVEVQVVEKPFSTELINPRKEEKQSSDSQEQLAEHKNLETKKEEKISPEKKTGV  
NTLNPQDEVLSGQLNKPELLYREETMETKIDFQEEIQENPDLAEGTVRVKQEGKLGKKVEIVRIFSUNK  
EEVSREIVSTSTTAPSPRIVEKGTKKTQVIKEQPETGVEHKDVQSGAIVEPAIQPELPEAVVSDKGEPE  
VQPTLPEAVVTDKGETEVQPEPDTVVSVDKGEPEQVAPLPEYKGNIEQVKPETPVEKTKEQGEKTEEV  
PVKPTTEETPVNPNEGTTEGTSIQEAENPVQPAEESTTNSEKVSPTSSKNTGEVSSNPSDSTTSVGESN  
KPEHNSKENSEKTVEEVPVNPNEGTVEGTSNQETEKVPQPAEETQTN SGKIANENTGEVSNKPSDSK  
PPVEESNQPEKNGTATKPENSGNTTSENGQTEPEPSNGNSTEDVSTESNTSNSNGNEEIKQENELDPDK  
KVEEPEKTLRLNVSDELEL

**SP006 nucleotide (SEQ ID NO:5)**

TGAGAATCAAGCTACACCCAAAGAGACTAGCGCTCAAAAGACAATCGTCCTTGCTACAGCTGGCGACGT  
GCCACCATTGACTACGAAGACAAGGGCAATCTGACAGGCTTTGATATCGAAGTTTAAAGGCAGTAGA  
TGAAAACTCAGCGACTACGAGATTCAATTCCAAGAACCCTGGGAGAGCATCTTCCAGGACTTGA  
TTCTGGTCACTATCAGGCTGCGGCCAATACTTGAGTTACACAAAAGAGCGTGCTGAAAAATACCTTTA  
CTCGCTTCCAATTTCCAACAATCCCTCGTCCTTGTGACGCAACAAGAAAAATCCTTTGACTTCTCTTGA  
CCAGATCGCTGGTAAAAACAACAAGAGGATACCGGAACCTTCAACGCTCAATTCATCAATAACTGGAA  
TCAGAAACACACTGATAATCCCGCTACAATTAATTTTCTGGTGAGGATATTGGTAAACGAATCCTAGA  
CCTTGCTAACGGAGAGTTTGATTTCCTAGTTTGTGACAAGGTATCCGTTCAAAGATTATCAAGGACCG  
TGGTTTAGACCTCTCAGTCGTTGATTACCTTCTGCAGATAGCCCCAGCAATTATATCATTTTCTCAAG  
CGACCAAAAAGAGTTTAAAGAGCAATTGATAAAGCGCTCAAAGAACTCTATCAAGACGGAACCTTGA  
AAACTCAGCAATACCTATCTAGGTGGTTCTTACCTCCAGATCAATCTCAGTTACAA

**SP006 amino acid (SEQ ID NO:6)**

ENQATPKETSAQKTIVLATAGDVPPFDYEDKGNLTGFDIEVLKAVDEKLSDYIEIQFORTAWESIFPGLD  
SGHYQAAANNLSYTKERAKEYLYSLPISNNPLVLVSNKKNPLTSLDQIAGKTTQEDTGTSAQFINNWN  
QKHTDNPATINFSGEDIGKRILDLANGEFDLFLVDKVSQKIIKDRGLDLSVVDLPSADSPSNYIIFSS  
DQKEFKEQFDKALKELYQDGTLEKLSNTYLGGSYLPDQSQLQ

**SP007 nucleotide (SEQ ID NO:7)**

TGGTAACCGCTCTTCTCGTAACGCAGCTTCATCTTCTGATGTGAAGACAAAAGCAGCAATCGTCACTGA  
TACTGGTGGTGTGATGACAAATCATTCACCAATCAGCTTGGGAAGGTTTGCAGGCTTGGGGTAAAGA  
ACACAATCTTTCAAAGATAACGGTTTCACTTACTTCCAATCAACAAGTGAAGCTGACTACGCTAACAA  
CTTGCAACAAGCGGCTGGAAGTTACAACCTAATCTTCGGTGTGGTTTGGCCCTTAATAATGCAGTTAA  
AGATGCAGCAAAAAGAACACACTGACTTGAACATATGCTTGTGATTGATGATGTGATTAAAGACCAAAAGAA  
TGTTGCGAGCGTAACCTTTCGCTGATAATGAGTCAGGTACCTTACCTGCAGGTGTGGCTGCAGCAAAAACAAC  
TAAGACAAAACAAGTTGGTTTTGTAGGTGGTATCGAATCTGAAGTTATCTCTCGTTTGAAGCAGGATT  
CAAGGCTGGTGTGCGTCAGTAGACCCATCTATCAAAGTCCAAGTTGACTACGCTGGTTTCAATTTGGTGA  
TGCGGCTAAAGGTAAAAACAATTGCAGCCGCACAATACGCAGCCGGTGCAGATATTGTTTACCAAGTAGC  
TGTTGGTACAGGTGCAGGTGTCTTTCAGAGGCAAAATCTCTCAACGAAAGCCGCTCTGAAAATGAAAA  
AGTTTGGGTTATCGGTGTGATCGTGACCAAGAAGCAGAAGGTAAATACACTTCTAAAGATGGCAAAGA  
ATCAAACCTTTGTTCTGTATCTACTTTGAAACAAGTTGGTACAACCTGTAAGATATTTCTAACAAGGC  
AGAAAGAGGAGAAATCCCTGGCGGTCAAGTGATCGTTTACTCATTTGAAGGATAAAGGGTTGACTTGGC  
AGTAACAAACCTTTCAGAAGAAGGTAAAAAGCTGTGCAAGATGCAAAAGCTAAATCCTTGATGGAAG  
CGTAAAGTTCTCTGAAAAA

Table 1

50

**SP007 amino acid (SEQ ID NO:8)**

GNRSSRNAASSSDVKTAAIVTDTGGVDDKSFNQSAWEGLQAWGKEHNLSKDNFTYFQSTSEADYANN  
LQQAAGSYNLIFGVGFALNNVAKDAAKEHTDLNLYVLIDDVIKDQKNVASVTFADNESGYLAGVAAAKTT  
KTKQVGVFVGGIESEVISRFEAGFKAGVASVDPSIKVQVDYAGSFGDAAKGKTIAAAQYAAGADIVYQVA  
GGTGAGVFAEAKSLNESRPENKVVWVIGVDRDQEAEGKYTSKDGKESNFVLVSTLKVQVGTTVKDISNKA  
ERGEFPGGQVIVYSLKDKGVDLAVTNLSEEGKKAVEDAKAKILDGSVKVPEK

**SP008 nucleotide (SEQ ID NO:9)**

TGTGGAAATTTGACAGGTAACAGCAAAAAAGCTGCTGATTGAGGTGACAAACCTGTTATCAAAATGTAC  
CAAATCGGTGACAAACCAGACAACCTTGGATGAATTGTTAGCAAATGCCAACAAAATCATTGAAGAAAAA  
GTTGGTGCCAAATTGGATATCCAATACCTTGGCTGGGGTGACTATGGTAAGAAAATGTCAGTTATCACA  
TCATCTGGTGAAAACATATGATATTGCCTTTGCAGATAACTATATTGTAAATGCTCAAAAAGGTGCTTAC  
GCTGACTTGACAGAATTGTACAAAAAGAAGGTAAAGACCTTTACAAAGCACTTGACCCAGCTTACATC  
AAGGGTAATACTGTAAATGGTAAGATTTACGCTGTTCCAGTTGCAGCCAACGTTGCATCATCTCAAAAC  
TTTGCCCTCAACGGAACCTCTCCTTGCTAAATATGGTATCGATATTTTCAGGTGTTACTTCTTACGAAACT  
CTTGAGCCAGTCTTGAAACAAATCAAAGAAAAAGCTCCAGACGTAGTACCATTGCTATTGGTAAAGTT  
TTCATCCCATCTGATAATTTTGACTACCCAGTAGCAACGGTCTTCCATTTCGTTATCGACCTTGAAGGC  
GATACTACTAAAGTTGTAAACCGTTACGAAGTGCCTCGTTTCAAAGAACACTTGAAGACTCTTCACAAA  
TTCATGAAGCTGGCTACATTCCAAAAGACGTGCGCAACAGCGATACTTCCTTTGACCTTCAACAAGT  
ACTTGGTTTCGTTTCGTGAAGAAACAGTAGGACAGCTGACTACGGTAACAGCTTGCTTTACAGTGTGGC  
AACAAGATATCCAAATCAAACCAATTACTAATTCATCAAGNAAAACCAAACAACAGTTGCTAAC  
TTTGTCATCTCAAAACAACCTCTAAGAACAAGAAAAATCAATGGAAATCTTGAACCTCTTGAATACGAAC  
CCAGAACCTTGAACGGTCTTGTTTACGGTCCAGAAGGCAAGAACTGGGAAAAAATTGAAGGTAAAGAA  
AACCCTGTTTCGCGTCTTGTATGGCTACAAAGGAAACACTCACATGGGTGGATGGAACACTGGTAAACAAC  
TGGATCCTTTACATCAACGAAAACGTTACAGACCAACAAATCGAAAATTTCTAAGAAAGAATTGGCAGAA  
GCTAAAGAACTCCAGCGCTTGGATTTATCTTCAATACTGACAATGTGAAATCTGAAATCTCAGCTATT  
GCTAACACAATGCAACAATTTGATACAGCTATCAACACTGGTACTGTAGACCCAGATAAAGCGATTCCA  
GAATTGATGGAAAAATTGAAATCTGAAGGTGCCTACGAAAAAGTATTGAACGAAATGCAAAAACAATAC  
GATGAATTCCTGAAAAACAAAAA

**SP008 amino acid (SEQ ID NO:10)**

CGNLTGNSKKAADSGDKPVIKMYQIGDKPDNLDELLANANKIIEEKVGAKLDIQYLGWGDYGGKMSVIT  
SSGENYDIAFADNYIVNAQKGAYADLTELYKKEGKDLKALDPAYIKGNTVNGKIYAVPVAANVASSQN  
FAGNFLLAKYGIDISGVTSEYETLEPVLKQIKEKAPDVVPFAIGKVFIPSDNFDYPVANGLPFVIDLEG  
DTTKVNVNRYEVPRFKEHLKTLHKFYEAGYIPKDVATSDTSFDLQQDTWVREETVGPADYGNLSLRVA  
NKDIQIKPITNFIXNQTTQVANFVISNNSKNKEKSMELNLLNTNPELLNGLVYGPEGKNWEKIEGKE  
NRVRVLDGYKGNTHMGGWNTGNNWILYINENVTDQDIENSKKELAEAKESPALGFIFNTDNVKSEISAI  
ANTMQQFDTAINTGTVPDKAIPELMEKLKSEGAYEVLNEMQKQYDEFLNKK

**SP009 nucleotide (SEQ ID NO:11)**

TGGTCAAGGAACCTGCTTCTAAAGACAACAAAGAGGCAGAACTTAAGAAGGTTGACTTTATCCTAGACTG  
GACACCAAATACCAACCACACAGGGCTTTATGTTGCCAAGGAAAAAGGTTATTTCAAAGAAGCTGGAGT  
GGATGTTGATTTGAAATTGCCACCAGAAGAAAGTTCTTCTGACTTGGTTATCAACGGAAAGGCACCATT  
TGCAGTGTATTTCCAAGACTACATGGCTAAGAAATTGGAAAAAGGAGCAGGAATCACTGCCGTTGCAGC  
TATTGTTGAACACAATACATCAGGAATCATCTCTCGTAAATCTGATAATGTAAGCAGTCCAAAAGACTT  
GGTTGGTAAGAAATATGGGACATGGAATGACCCAACCTGAACTTGCTATGTTGAAAACCTTGGTAGAATC  
TCAAGGTGGAGACTTTGAGAAGGTTGAAAAAGTACCAAATAACGACTCAAATCAATCACACCGATTGC  
CAATGGCGTCTTTGATACTGCTTGGATTACTACGGTTGGGATGGTATCCTTGCTAAATCTCAAGGTGT  
AGATGCTAACTTCATGTACTTGAAAGACTATGTCAAGGAGTTTGACTACTATTACCAGGTATCATCTGC  
AAACAACGACTATCTGAAAGATAACAAAGAAGCTCGCAAAGTCATCCAAGCCATCAAAAAGGGCTA  
CCAATATGCCATGGAACATCCAGAAGAAGCTGCAGATATTCTCATCAAGAATGCACCTGAACTCAAGGA  
AAAACGTGACTTTGTCATCGAATCTCAAAAATACTTGTCAAAAAGAAATACGCAAGCGACAAGGAAAAATG  
GGGTCAATTTGACGCAGCTCGCTGGAATGCTTTCTACAAATGGGATAAAGAAAAATGGTATCCTTAAAGA  
AGACTTGACAGACAAAGGCTTCACCAACGAATTTGTGAAA

**SP009 amino acid (SEQ ID NO:12)**

Table 1

51

GQGTASKDNKEAELKKVDFILDWTPNTNHTGLYVAKEKGYFKEAGVDVDLKLPPPESSSDLVINGKAPF  
AVYFQDYMAKKLEKAGITAVAAIVEHNTSGIISRKSDNVSSPKDLVGKKYGTWNPTELAMKLTLVES  
QGGDFEKVEKVPNNDSNSITPIANGVFDTAWIYYGWDGILAKSQGVDFANFMYLKDYVKEFDYYSPIVIA  
NNDYLDKNKEEARKVIAIKKGYQYAMEHPPEEAADILIKNAPELKEKRDFVIESQKYLKEYASDKEKW  
GQFDAARWNAFYKWDKENGILKEDLTDKGFNEFVK

**SP010 nucleotide (SEQ ID NO:13)**

TAGCTCAGGTGGAACGCTGGTTCATCCTCTGGAACAACTGCCAAAGCTCGCACTATCGATGAAAT  
CAAAAAAGCGGTGAAC TCGGAATCGCCGTGTTTGGAGATAAAAAACCGTTGGCTACGTTGACAATGA  
TGGTTCACCAAGGTACGCTACGATATTGAACTAGGGAACCACTAGCTCAAGACCTTGGTGTCAAGGT  
TAAATACATTTTCAAGTCGATGCTGCCAACCGTGGGAATACTTGATTTCAAACAAGGTAGATATTACTCT  
TGCTAACTTTACAGTAAC TACGAACGTAAGAAACAAGTTGATTTTGCCCTTCCATATATGAAAGTTTC  
TCTGGGTGTCGTATCACCTAAGACTGGTCTCATTACAGACGTCAAACAACCTTGAAGGTAAACCTTAAT  
TGTCACAAAAGGAACGACTGCTGAGACTTATTTTGAAGAAGTATCCAGAAATCAAACCTCCAAAAATA  
CGACCAATACAGTGACTCTTACCAAGCTCTTCTTGACGGACGTGGAGATGCCTTTTCACTGACAATAC  
GGAAGTTCTAGCTTGGGCGCTTGAATAAAGGATTGGAAGTAGGAATTACTTCCCTCGGTGATCCCGA  
TACCATTGCGGCAGCAGTTCAAAAAGGCAACCAAGAATTGCTAGACTTCATCAATAAAGATATTGAAAA  
ATTAGGCAAGGAAAACCTTCTTCCACAAGGCCTATGAAAAGACACTTCACCCAACCTACGGTGACGCTGC  
TAAAGCAGATGACCTGGTTGTTGAAGGTGGAAGAAGTTGAT

**SP010 amino acid (SEQ ID NO:14)**

SSGGNAGSSSGKTTAKARTIDEIKKSGELRIAVFGDKPFGYVDNDGSTKVRDYDIELGNQLAQDLGVKV  
KYISVDAANRAEYLI SNKVDITLANFTVTDERKKQVDFALPYMKVSLGVVSPKTGLITDVKQLEGKTLI  
VTKGTTAETTYFEKNHPEIKLQKYDQYSDSYQALLDGRGDAFSTDNTEVLAWALENKGFVEGITS LGDPD  
TIAAAVQKGNQELLD FINKDIEKLGENFFHKAYEKT LHPTYGDAAKADDLVVEGGKVD

**SP011 nucleotide (SEQ ID NO:15)**

CTCCAAC TATGGTAAATCTGCGGATGGCACAGTGACCATCGAGTATTTCAACCAGAAAAAGAAATGAC  
CAAAACCTTGGAAAGAAATCACTCGTGATTTTGAAGAGGAAAACCTAAGATCAAGGTCAAAGTCGTCAA  
TGTACCAAATGCTGGTGAAGTATTGAAGACACGCGTTCTCGCAGGAGATGTGCCTGATGTGGTCAATAT  
TTACCCACAGTCCATCGAACTGCAAGAATGGGCAAAAGCAGGTGTTTTTGAAGATTGAGCAACAAAGA  
CTACCTGAAACGCGTGAAAAATGGCTACGCTGAAAAATATGCTGTAAACGAAAAAGTTTACAACGTTCC  
TTTTACAGCTAATGCTTATGGAATTTACTACAACAAAGATAAATTCTGAAGAACTGGGCTTGAAGGTTC  
TGAAACCTGGGATGAATTTGAACAGTTAGTCAAAAGATATCGTTGCTAAAGGACAAACACCATTTGGAAT  
TGCAGGTGCAGATGCTTGGACACTCAATGGTTACAATCAATAGCCTTTGCGACAGCAACAGGTGGAGG  
AAAAGAAGCAAATCAATACCTTCGTTATTCTCAACCAATGCCATTAAATTGTCGGATCCGATTATGAA  
AGATGATATCAAGGTCATGGACATCCTTCGCATCAATGGATCTAAGCAAAAGAACTGGGAAGGTGCTGG  
CTATACCGATGTTATCGGAGCCTTCGCACGTGGGGATGTCTCATGACACCAATGGGTCTTGGGCGAT  
CACAGCGATTAAATGAACAAAAACCGAACTTTAAGATTGGGACCTTCATGATTCAGGAAAAGAAAAAGG  
ACAAAGCTTAACCGTTGGTGCAGGAGACTTGGCATGGTCTATCTCAGCCACCACCAAAACATCCAAAAGA  
AGCCAATGCCTTTGTGGAATATATGACCCGTCCAGAAGTCATGCAAAAATACTACGATGTGGACGGATC  
TCCAACAGCGATCGAAGGGGTCAAACAAGCAGGAGAAGATTACCGCTTGCTGGTATGACCGAATATGC  
CTTTACGGATCGTCACTTGGTCTGGTTGCAACAATACTGGACCAGTGAAGCAGACTTCCATACCTTGAC  
CATGAACTATGTCTTGACCGGTGATAACAAGGCATGGTCAATGATTTGAATGCCTTCTTTAACCCGAT  
GAAAGCGGATGTGGAT

**SP011 amino acid (SEQ ID NO:16)**

SNYGSADGTVTIEYFNQKKEMTKTLEEITRDFEKENPKIKVKVNVNPNAGEVLKTRVLAGDVPDVVNI  
YPQSIELQEWAKAGVFEDLSNKDYLRVKNGYAEKYAVNEKVYNVPFTANAYGIYNNKDKFEELGLKVP  
ETWDEFQQLVKDIVARGQTPFGIAGADAWTLNGYNQLAFATATGGGKEANQYLRYSQPNAILKSDPIMK  
DDIKVMDILRINGSKQKNWEGAGYTDVIGAFARGDVLMTPNGSWAITAINEQPNFKIGTFMIPGKEKG  
QSLTVGAGDLAWSISATTKHPKEANAFVEYMTREVMQKYVDVGSPTAIEGVKQAGEDSPLAGMTEYA  
FTDRHLVWLQQYWTSEADFHTLTMNYVLTDGKQGMVNDLNAFFNPMKADVD

**SP012 nucleotide (SEQ ID NO:17)**

TGGGAAAAATTCTAGCGAACTAGTGGAGATAATTGGTCAAAGTACCAGTCTAACAAGTCTATTACTAT  
TGGATTTGATAGTACTTTTGTTCGAATGGGATTGCTCAGAAAGATGGTCTTATGCAGGATTTGATAT  
TGATTTAGCTACAGCTGTTTTTGAATAATACGGAATCACGGTAAATTGGCAACCGATTGATTGGGATTT

Table 1

52

GAAAGAAGCTGAATTGACAAAAGGAACGATTGATCTGATTGGAATGGCTATTCCGCTACAGACGAACG  
CCGTGAAAAGGTGGCTTTCAGTAACATCATATGAAGAATGAGCAGGTATTGGTTACGAAGAAATCATC  
TGGTATCACGACTGCAAAGGATATGACTGGAAAAGACATTAGGAGCTCAAGCTGGTTCATCTGGTTATGC  
GGACTTTGAAGCAAATCCAGAAATTTGAAGAATATTGTCGCTAATAAGGAAGCGAATCAATACCAAAC  
CTTTAATGAAGCCTTGATTGATTGAAAAACGATCGAATTGATGGTCTATTGATTGACCGTGCTATGC  
AACTATTATTTAGAAGCAGAAGGTGTTTTAAACGATTATAATGTCTTTACAGTTGGACTAGAAACAGA  
AGCTTTTGCGGTGGAGCCCGTAAGGAAGATACAACTTGGTTAAGAAGATAAATGAAGCTTTTTCTAG  
TCTTTACAAGGACGGCAAGTTCCAAGAAATCAGCCAAAATGGTTTGGAGAAGATGTAGCAACCAAAGA  
AGTAAAAGAAGGACAG

**SP012 nucleotide (SEQ ID NO:18)**

GKNSSETSGDNWSKYQSNKSITIGFDSTFVPMGFAQKDGSYAGFDIDLATAVFEKYGITVNWQPIDWDL  
KEAELTKGTIDLIWNGYSATDERREKVAFSNSYMKNEQVLVTKSSGITTAKDMTGKTLGAQAGSSGYA  
DFEANPEILKNIVANKEANQYQTFNEALIDLKNDRIDGLLIDRVYANYYLEAEGVLNDYNVFTVGLETE  
AFAVGARKEDTNLVKKINEAFSSLYKDGKFQEISQKWFGEDEVATKEVKEGQ

**SP013 nucleotide (SEQ ID NO:19)**

TGCTAGCGGAAAAAAGATACAACTTCTGGTCAAAAACTAAAAGTTGTTGCTACAACTCAATCATCGC  
TGATATTACTAAAAATATTGCTGGTGACAAAATTGACCTTCATAGTATCGTTCGGATTGGGCAAGACCC  
ACACGAATACGAACCACTTCCTGAAGACGTTAAGAAAACCTCTGAGGCTAATTTGATTTTCTATAACGG  
TATCAACCTTGAAACAGGTGGCAATGCTTGGTTTACAAAATTGGTAGAAAATGCCAAGAAAACCTGAAAA  
CAAAGACTACTTCGCAGTCAGCGACGGCGTTGATGTTATCTACCTTGAAGGTCAAAATGAAAAAGGAAA  
AGAAGACCCACACGCTTGGCTTAACCTTGAACCGGTATTATTTTTGCTAAAAATATCGCCAAACAATT  
GAGCGCCAAAAGACCCCTAACAATAAAGAATTCTATGAAAAAATCTCAAAGAAATATACTGATAAGTTAGA  
CAAACCTTGATAAAGAAAGTAAGGATAAAATTTAATAAGATCCCTGCTGAAAAGAACTCATTTGAACCAG  
CGAAGGAGCATTCAAATACTTCTCTAAAGCCTATGGTGTCCCAAGTGCTTACATCTGGGAAATCAATAC  
TGAAGAAGAAGGAACCTCTGAACAAATCAAGACCTTGGTTGAAAACCTTCGCCAAACAAAAGTTCCATC  
ACTCTTTGTAGAAATCAAGTGTGGATGACCGTCCAATGAAAACCTGTTTCTCAAGACACAAACATCCCAAT  
CTACGCTCAAATCTTTACTGACTCTATCGCAGAACAGGTAAAGAAGGCGACAGCTACTACAGCATGAT  
GAAATACAACCTTGACAAGATTGCTGAAGGATTGGCAAAA

**SP013 amino acid (SEQ ID NO:20)**

ASGKKDTSQGQKLKVATNSIIADITKNIAGDKIDLHSIVPIGQDPHEYEPLPEDVKKTSEANLIFYNG  
INLETGGNAWFTKLVENAKKTENKDYFAVSDGVDVIYLEGQNEKGKEDPHAWNLNLENGIIFAKNIAKQL  
SAKDPNNKEFYEKNLKEYTDKLDKDKESKDKFNKIPAEKKLIVTSEGAFKYFSKAYGVPSAYIWEINT  
EEEGTPEQIKTLVEKLRQTKVPSLFVSSVDDRPMTVSQDTNIPYIAQIFTDSIAEQGKEGDSYYSMM  
KYNLDKIAEGLAK

**SP014 nucleotide (SEQ ID NO:21)**

TGGCTCAAAAAATACAGCTTCAAGTCCAGATTATAAGTTGGAAGGTGTAACATTCCCGCTTCAAGAAAA  
GAAAACATTGAAGTTTATGACAGCCAGTTCACCGTTATCTCCTAAAGACCCAAATGAAAAGTTAATTTT  
GCAACGTTTGGAGAAGGAACTGGCGTTCATATTGACTGGACCAACTACCAATCCGACTTTGCAGAAAA  
ACGTAACCTTGGATATTCTAGTGGTGATTTACCAGATGCTATCCACAACGACGGAGCTTCAGATGTGGA  
CTTGATGAACTGGGCTAAAAAAGGTGTTATTATTCCAGTTGAAGATTGATTGATAAATACATGCCAAA  
TCTTAAGAAAATTTGGATGAGAAACCAGAGTACAAGGCCTTGATGACAGCACCTGATGGGCACATTTA  
CTCATTTCCATGGATTGAAGAGCTTGGAGATGGTAAAGAGTCTATTACAGTGTCAACGATATGGCTTG  
GATTAACAAAGATTGGCTTAAGAACTTGGTCTTGAAATGCCAAAACTACTGATGATTGATTAAAGT  
CCTAGAAGCTTTCAAAAACGGGGATCCAAATGGAATGGAGAGGCTGATGAAATTCATTTTCAATTTAT  
TAGTGGTAACGGAACGAAGATTTTAAATTCCTATTTGCTGCATTTGGTATAGGGGATAACGATGATCA  
TTTAGTAGTAGGAAATGATGGCAAAGTTGACTTCACAGCAGATAACGATAACTATAAAGAAGGTGTCAA  
ATTTATCCGTC AATTGCAAGAAAAAGGCTGATTGATGATAAAGAAGCTTTTCAACATGATTGGAATAGTTA  
CATTGCTATAAGGTCATGATCAGAAATTTGGTGTGTTACTTTACATGGGATAAGAATAATGTTACTGGAAG  
TAACGAAAGTTATGATGTTTTACCAGTACTTGCTGGACCAAGTGGTCAAAAACACGTAGCTCGTACAAA  
CGGTATGGGATTTGCACGTGACAAGATGGTTATTACCAGTGTAACAAAAACCTAGAATTGACAGCTAA  
ATGGATTGATGCACAATACGCTCCACTCCAATCTGTGCAAAATAACTGGGGAACCTACGGAGATGACAA  
ACAACAAAAACATCTTTGAATTGGATCAAGCGTCAATAGTCTAAAAACCTTACCCTAAACGGAAGTGC  
ACCAGCAGAACTTCGTCAAAAGACTGAAGTAGGAGGACCACTAGCTATCCTAGATTCACTATGGTAA  
AGTAACAACCATGCCTGATGATGCCAAATGGCGTTTGGATCTTATCAAAGAATATTATGTTCTTACAT

Table 1

GAGCAATGTCAATAACTATCCAAGAGTCTTTATGACACAGGAAGATTTGGACAAGATTGCCCATATCGA  
AGCAGATATGAATGACTATATCTACCGTAAACGTGCTGAATGGATTGTAAATGGCAATATTGATACTGA  
GTGGGATGATTACAAGAAAGAACTTGAAAAATACGGACTTTCTGATTACCTCGCTATTAAACAAAAATA  
CTACGACCAATACCAAGCAAACAAAAAC

**SP014 amino acid (SEQ ID NO:22)**

GSKNTASSPDYKLEGVTFPLQEKTKLFMTASSPLSPKDPNEKLILQRLKETGVHIDWTNYQSDFAEK  
RNLDISSGDLPAIHNDGASDVLNWNWAKKGVIIIPVEDLIDKYPNLKKILDEKPEYKALMTAPDGHY  
SFPWIEELGDGKESIHSVNDMAWINKDWLKKLGLEMPKTTDDLIKVLEAFKNGDPNGNGEADIIPFSFI  
SGNGNEDFKFLFAAFGIGDNDHLLVVGNDGKVDFTADNDNYKEGVKFIQRLQEKGLIDKEAFEHDWNSY  
IAKGHDQKFGVYFTWDKNNVTGSNESYDVLVPLAGPSGQKHVARTNGMGFARDKMVITSVNKNLELTAK  
WIDAQYAPLQSVQNNWGTGDDKQONIFELDQASNSLKHLPNGTAPAE LRQKTEVGGPLAILD SYYGK  
VTTMPDDAKWRDLIKEYYVPYMSNVNYP RVFMTQEDLDKIAHIEADMNDYIYRKRAEWIVNGNIDTE  
WDDYKKELEKYGLSDYLAIKQKYDQYQANKN

**SP015 nucleotide (SEQ ID NO:23)**

TAGTACAAACTCAAGCACTAGTCAGACAGAGACCAGTAGCTCTGCTCCAACAGAGGTAACCATTTAAAG  
TTCCTGACGAGGTCAAACCTTCCAAAGTTCTGAAAAGATTGTGACCTTTGACCTCGGCGCTGCCGA  
TACTATTGCGCTTTAGGATTTGAAAAAATATCGTCGGAATGCCTACAAAACCTGTTCCGACTTATCT  
AAAAGACCTAGTGGGAAGTGTCAAAAATGTTGGTTCTATGAAAGAACCTGATTAGAAAGCTATCGCCGC  
CCTTGAGCCTGATTGATTATCGCTTCGCCACGTACACAAAATTCGTAGACAAATTCAAAGAAATCGC  
CCCAACCGTTCTCTCCAAGCAAGCAAGGACGACTACTGGACTTCTACCAAGGCTAATATCGAATCCTT  
AGCAAGTGCCTTCGCGCAAACTGGTACACAGAAAGCCAAAGGAAGATTGACCAAGCTAGACAAGAGCAT  
CCAAGAAGTCGCTACTAAAAATGAAAGCTCTGACAAAAAGCCCTTGCGATCCTCCTTAATGAAGGAAA  
AATGGCAGCCTTTGGTGCCAAATCTCGTTCTCTTCTTGTACCAAACCTTGAAATTCAAACCAACTGA  
TACAAAATTTGAAGACTCACGCCACGGACAAGAAGTCAGCTTTGAAAGTGTCAAAGAAATCAACCCTGA  
CATCCTCTTTGTCAATCAACCGTACCCTTGCCATCGGTGGGACAACCTTAGCAACGACGGTGTCCCTAGA  
AAATGCCCTTATCGCTGAAACACCTGCTGCTAAAAATGGTAAGATTATCCAACCTAACACACGACCTCTG  
GTATCTAAGCGGAGCGGACTTGAATCAACAAACTCATGATTGAAGACATACAAAAAGCTTTGAAA

**SP015 amino acid (SEQ ID NO:24)**

STNSSTSQTETSSSAPTEVTIKSSLDEVKLSKVPEKIVTFDLGAADTIRALGFENIVGMPTKTVPTYL  
KDLVGTVKNVGSMEKPDLEAIAALEPDLIIASPRTQKFVDKFKEIAPTIVLFQASKDDYWTSTKANIESL  
ASAFGETGTQKAKEELTKLDKSIQEVATKNESDDKKALAILLNEGKMAAFGAKSRSFSLYQTLKFKPTD  
TKFEDSRHQEVSFESVKEINPDILFVINRTLAIGGDNSSNDGVLENALIAETPAKNGKIIQLTPDLW  
YLSGGGLESTKLMIEDIQKALK

**SP016 nucleotide (SEQ ID NO:25)**

TGGCAATTCTGGCGAAGTAAAGATGCTGCCAAATCAGGTGGTGACGGTGCCAAAACAGAAATCACTTG  
GTGGGCATTCCCAGTATTTACCCAAGAAAAAACTGGTGACGGTGTGGAACCTTATGAAAAATCAATCAT  
CGAAGCGTTTGAAAAAGCAAAACCCAGATATAAAAAGTGAAATTGGAAACCATCGACTTCAAGTCAGGTCC  
TGAAAAAATCACACAGCCATCGAAGCAGGAACAGCTCCAGACGTACTCTTTGATGCACCAGGACGTAT  
CATCCAATACGGTAAAAACGGTAAATTTGGCTGAGTTGAATGACCTCTTCACAGATGAATTTGTTAAAGA  
TGTCACAATGAAAACATCGTACAAGCAAGTAAAGCTGGAGACAAGGCTTATATGTATCCGATTAGTTC  
TGCCCCATTCTACATGGCAATGAACAAGAAAATGTTAGAAGATGCTGGAGTAGCAACCTTGTAAGA  
AGGTTGGACAACCTGATGATTTTGAAAAAGTATTGAAAGCACTTAAAGACAAGGGTTACACACCAGGTTC  
ATTGTTCAAGTTCTGGTCAAGGGGGAGACCAAGGAACACGTGCCTTTATCTCTAACCTTTATAGCGGTTC  
TGTAACAGATGAAAAAGTTAGCAAATATACAACTGATGATCCTAAATTCGTCAAAGGTCTTGAAAAAGC  
AACTAGCTGGATTAAAGACAATTTGATCAATAATGGTTCACAATTTGACGGTGGGGCAGATATCCAAAA  
CTTTGCCAACGGTCAAACATCTTACACAATCCTTTGGGCACCAGCTCAAAATGGTATCCAAGCTAAACT  
TTTAGAAGCAAGTAAGGTAGAAGTGGTAGAAGTACCATTCCCATCAGACGAAGGTAAGCCAGCTCTTGA  
GTACCTTGTAACGGGTTTGACAGTATTCAACAATAAAGACGACAAGAAAGTCGCTGCATCTAAGAAATT  
CATCCAGTTTATCGCAGATGACAAGGAGTGGGACCTAAAGACGTAGTTCGTACAGGTGCTTTCCAGT  
CCGTACTTCATTTGGAAAACCTTTATGAAGACAAAACGATGGAACAATCAGCGGTGGACTGCAATACTA  
CTCACCATACTACAACACTATTGATGGATTGCTGAAATGAGAACACTTTGGTTCCCAATGTTGCAATC  
TGTATCAAATGGTGACGAAAAACAGCAGATGCTTTGAAAGCCTTCACTGAAAAAGCGAACGAAACAAT  
CAAAAAAGCTATGAAACAA

Table 1

**SP016 amino acid (SEQ ID NO:26)**

GNSGGSKDAAKSGGDGAKEITWWAFPVFTQKEKTDGTVGTYEKSIIIEAFEKANPDIKVKLETIDFKSGP  
EKITTAIEAGTAPDVLFDAPGRRIIQYGKNGKLAELNDLFTDEFVKDVNNENIVQASKAGDKAYMYPIS  
APFYMAMNKKMLEDAGVANLVKEGWTTDDFEKVLKALKDKGYTPGSLFSSGQGGDQGTAFISNLYSGS  
VTDEKVSKEYTTDDPKFVKGLEKATSWIKDNLINNGSQFDGGADIQNFANGQTSYITLWAPAQNGIQAKL  
LEASKVEVVEVFPFSDGKPALEYLVNGFAVFNKDDKKVAASKKFIQFIADDEKWEKPKDVVRTGAFPV  
RTSFGKLYEDKRMETISGWTQYYSPYYNTIDGFAEMRTLWFPMLQSVSNGDEKPADALKAFTEKANETI  
KKAMKQ

**SP017 nucleotide (SEQ ID NO:27)**

TTCACAAGAAAAACAAAAATGAAGATGGAGAACTAAGACAGAACAGACAGCCAAAGCTGATGGAAC  
AGTCGGTAGTAAGTCTCAAGGAGCTGCCCAGAGAAAGCAGAAGTGGTCAATAAAGGTGATTACTACAG  
CATTCAAGGGAAATACGATGAAATCATCGTAGCCAACAACTATCCATTGTCTAAAGACTATAATCC  
AGGGGAAAATCCAACAGCCAAGGCAGAGTTGGTCAAACCTCATCAAGCGATGCAAGAGGCAGGTTTCCC  
TATTAGTGATCATTACAGTGGTTTTAGAAGTTATGAAACTCAGACCAAGCTCTATCAAGATTATGTCAA  
CCAAGATGGAAAGGCAGCAGCTGACCGTTACTCTGCCCGTCCCTGGCTATAGCGAACACCAGACAGGCTT  
GGCCTTTGATGTGATTGGGACTGATGGTGATTGTTGGTGACAGAAGAAAAAGCAGCCCAATGGCTCTTGGA  
TCATGCAGCTGATTATGGCTTTGTTGTCCGTTATCTCAAAGGCAAGGAAAAGGAAACAGGCTATATGGC  
TGAAGAATGGCACCTGCGTTATGTAGGAAAAGAAGCTAAAGAAATTGCTGCAAGTGGTCTCAGTTTGGA  
AGAATACTATGGCTTTGAAGGCGGAGACTACGTCGAT

**SP017 amino acid (SEQ ID NO:28)**

SQEKTKNEDGETKTEQTAKADGTVGSKSQGAAQKAEVVNKGDYYSIQGKYDEIIIVANKHYPLSKDYNP  
GENPTAKAELVKLIKAMQEAGFPISDHYSGFRSYETQTKLYQDYVNQDGKAAADRYSPGYSEHQGL  
AFDVIQDGDLDVTEEKAAQWLLDHAADYGFVVRYLKGKEKETGYMAEEWHLRYVGKEAKEIAASGLSLE  
EYYGFEGGDYVD

**SP019 nucleotide (SEQ ID NO:29)**

GAAAGGTCTGTGGTCAAATAATCTTACCTGCGGTTATGATGAAAAATAATCTTGGAATAATAAATAT  
AAAAATACCTGAAGAAAAATATCAGTTATTATTGGGTCAAATGGTTGTGGGAAATCAACACTCATTAA  
AACCTTGTCTCGACTTATAAAGCCATTAGAGGGAGAAAGTATTGCTTGATAATAAATCAATTAATTCTTA  
TAAAGAAAAAGATTTAGCAAACACATAGCTATATTACCTCAATCTCCAATAATCCCTGAATCAATAAC  
AGTAGCTGATCTTGTAAGCCGTGGTCGTTTTCCCTACAGAAAGCCTTTTAAGAGTCTTGGAAGATGA  
CCTTGAAATAATAACAGATCAATGGTTAAGGCCAATGTTGAAGATCTAGCAAATAACCTAGTTGAAGA  
ACTTTCTGGGGGTCAAAGGCAAAGAGTATGGATAGCTCTAGCCCTAGCCCAAGATACAAGTATCCTACT  
TTTAGATGAGCCAACTACTTACTTGGATATCTCATATCAAATAGAACTATTAGACCTCTTGACTGATCT  
AAACCAAAAAATATAAGACAACCATTTGCATGATTTTGACGATATAAATCTAACAGCAAGATACGCTGA  
TTACCTATTTGCAATTAAAGAAGGTAAACTTGTTCAGAGGGAAAGCCTGAAGATATACTAAATGATAA  
ACTAGTTAAAGATATCTTTAATCTTGAAGCAAAAATATACGTGACCCTATTTCCAATTGCGCTCTAAT  
GATTCCTATTGGCAAGCACCATGTTAACTCT

**SP019 amino acid (SEQ ID NO:30)**

KGLWSNNLTCGYDEKIILENINIKIPEEKISVIIGSNGCGKSTLIKTLRSLIKPLEGEVLLDNKSINSY  
KEKDLAKHIAILPQSPPIIPESITVADLVSRGRFPYRKPFKSLGKDDLEIINRSMVKANVEDLANNLVEE  
LSGGQRQRVWIALALAQDTSILLLDDEPTTYLDISYQIELLDLLDLNQKYKTTICMILHDINLTARYAD  
YLFAIKEGKLVAEGKPEDILNDKLVKDIFNLEAKIIRDPISNSPLMIPIGKHHVS

**SP020 nucleotide (SEQ ID NO:31)**

AAACTCAGAAAAGAAAGCAGACAATGCAACAACCTATCAAAATCGCAACTGTTAACCGTAGCGGTTCTGA  
AGAAAAACGTTGGGACAAAATCCAAGAATTGGTTAAAAAAGACGGAATTACCTTGGAATTTACAGAGTT  
CACAGACTACTCACAACCAACAAAGCAACTGCTGATGGCGAAGTAGATTGAACGCTTTCCAACACTA  
TAACTTCTTGAACAACCTGGAACAAAGAAAACGGAAAAGACCTTGTAGCGATTGCAGATACTTACATCTC  
TCCAATCCGCCCTTTACTCAGGTTGAATGGAAGTGCCAACAAGTACACTAAAGTAGAAGACATCCCAGC  
AAACGGAGAAAATCGCTGTACCGAATGACGCTACAAACGAAAGCCGTGCGCTTTATTTGCTTCAATCAGC  
TGGCTTGATTAAATTTGGATGTTTCTGGAAGTCTGCTTGAACAGTTGCCAACATCAAAGAAAAATCCAAA  
GAACTTGAAAAATCACTGAATTGGACGCTAGCCAAACAGCTCGTTTCAATGTCATCAGTTGACGCTGCCGT  
TGTAACAATACCTTCGTTACAGAAGCAAAATTTGGACTACAAGAAATCACTTTTCAAAGAACAAAGCTGA  
TGAAACTCAAAACAATGGTACAACATCATTGTTGCAAAAAAGATTGGGAAACATCACCTAAGGCTGA



Table 1

55

TGCTATCAAGAAAGTAATCGCAGCTTACCACACAGATGACGTGAAAAAAGTTATCGAAGAATCATCAGA  
TGGTTTGGATCAACCAGTTTGG

**SP020 amino acid (SEQ ID NO:32)**

NSEKKADNATTIKIATVNRSGSEKRWDKIQELVKKDGITLEFTEFTDYSQPNKATADGEVDLNAFQHY  
NFLNNWNKENGKDLVAIADTYISPIRLYSGLNGSANKYTKVEDIPANGEIAPNDATNESRALYLLQSA  
GLIKLDVSGTALATVANIKENPKNLKITELDASQTARSLSSVDAAVVNNTFVTEAKLDYKKSFLKEQAD  
ENSKQWYNIIVAKKDWETSPKADAIAKKVIAAYHTDDVKKVIEESSDGLDQPVW

**SP021 nucleotide (SEQ ID NO:33)**

TTCGAAAGGGTCAGAAGGTGCAGACCTTATCAGCATGAAAGGGGATGTCATTACAGAACATCAATTTTA  
TGAGCAAGTGAAAAGCAACCCTTCAGCCCAACAAGTCTTGTTAAATATGACCATCCAAAAAGTTTGTGA  
AAAACAATATGGCTCAGAGCTTGATGATAAAGAGGTTGATGATACTATTGCCGAAGAAAAAACAATA  
TGGCGAAAACCTACCAACGTGTCTTGTCAAGCAGGTATGACTCTTGAAACACGTAAAGCTCAAATTCG  
TACAAGTAAATTAGTTGAGTTGGCAGTTAAGAAGGTAGCAGAAGCTGAATTGACAGATGAAGCCTATAA  
GAAAGCCTTTGATGAGTACACTCCAGATGTAACGGCTCAAATCATCCGCTCTTAATAATGAAGATAAGGC  
CAAAGAAAGTTCTCGAAAAGCCAAGGCAGAAGGTGCTGATTTTGCTCAATTAGCCAAAGATAATTCAAC  
TGATGAAAAAACAAGAAATGGTGGAGAAATTACCTTGATTCTGCTTCAACAGAAGTACCTGGAGC  
AAGTCCAAAAAGCCGCTTTTCGCTTTTAGATGTGGGATGGTGTTCGATGTGGATTACAGCAACTG  
GGGCACACCAAGCCTACAG

**SP021 amino acid (SEQ ID NO:34)**

SKGSEGADLISMKGDVITEHQFYEQVSNPSAQQVLLNMTIQKVFQYSELDDKEVDDTIAEKKQY  
GENYQRVLSQAGMTLETRKAQIRTSKLVELAVKKVAEAELEDEAYKKAFDEYTPDVTAQIIRLNNEKA  
KEVLEKAKAEGADFAQLAKDNSTDEKTKENGGEITFDSASTEVPGASPKPLFAFRCGMVFLDVDSNW  
GTPSLQ

**SP022 nucleotide (SEQ ID NO:35)**

GGGGATGGCAGCTTTTAAAAATCCTAACAATCAATACAAAGCTATTACAATTGCTCAAACCTCTAGGTGA  
TGATGCTTCTTCAGAGGAATTGGCTGGTAGATATGGTTCTGCTGTTTCAGTGACAGAAGTGACTGCCTC  
AAACCTTTCAACAGTTAAACTAAAGCTACGGTTGTAGAAAAACCACTGAAAGATTTTAGAGCGTCTAC  
GTCTGATCAGTCTGGTTGGGTGGAATCTAATGGTAAATGGTATTTCTATGAGTCTGGTGATGTGAAGAC  
AGGTTGGGTGAAAACAGATGGTAAATGGTACTATTTGAATGACTTAGGTGTCATGCAGACTGGATTGTG  
AAAATTTTCTGGTAGCTGGTATTACTTGAGCAATTCAGGTGCTATGTTTACAGGCTGGGGAACAGATGG  
TAGCAGATGGTTCTACTTTGACGGCTCAGGAGCTATGAAGACAGGCTGGTACAAGGAAAATGGCACTTG  
GTATTACCTTGACGAAGCAGGTATCATGAAGACAGGTTGGTTTAAAGTCGGACCACACTGGTACTATGC  
CTACGGTTACGGAGCTTTGGCTGTGAGCACAAACACCAGATGGTTACCGTGTAATGGTAATGGTGA  
ATGGGTAAAC

**SP022 amino acid (SEQ ID NO:36)**

GMAAFKNPNNOYKAITIAQTLGDDASSEELAGRYGSAVQCTEVTASNLSVTKATVVEKPLKDFRST  
SDQSGWVESNGKWYFYESGDVKTGWVKTDGKWYLLNDLGVMTQGFVKFSGSWYLLNSNGAMFTGWGTDG  
SRWFYFDGSGAMKTGWYKENGWYLLDEAGIMKTGWFKVPHWYAYGSGALAVSTTTPDGYRVNGNGE  
WVN

**SP023 nucleotide (SEQ ID NO:37)**

AGACGAGCAAAAAATTAAGCAAGCAGAAGCGGAAGTTGAGAGTAAACAAGCTGAGGCTACAAGGTAA  
AAAAATCAAGACAGATCGTGAAGAAGCAGAAGAAGCTAAACGAAGAGCAGATGCTAAAGAGCAAGG  
TAAACCAAAGGGGCGGGCAAAACGAGGAGTTCCCTGGAGAGCTAGCAACACCTGATAAAAAAGAAAATGA  
TGCGAAGTCTTCAGATTCTAGCGTAGGTGAAGAACTCTTCCAAGCCATCCCTGAAACCAGAAAAAA  
GGTAGCAGAAGCTGAGAAGAAGGTTGAAGAAGCTAAGAAAAAGCCGAGGATCAAAAAGAAGAAGATCG  
CCGTAACCTACCCAACCAATACTTACAAAACGCTTGAACCTGAAATTGCTGAGTCCGATGTGGAAGTTAA  
AAAAGCGGAGCTTGAAC TAGTAAAAGAGGAAGCTAAGGAACCTCGAAACGAGGAAAAAGTTAAGCAAGC  
AAAAGCGGAAGTTGAGAGTAAAAGAGCTGAGGCTACAAGGTTAGAAAAATCAAGACAGATCGTAAAA  
AGCAGAAGAGAAGCTAAACGAAAAGCAGCAGAAGAAGATAAAGTTAAAGAAAAACCAGCTGAACAACC  
ACAACCAGCGCCGGCTCCAAAAGCAGAAAAACCAGCTCCAGCTCCAAAACCAGAGAATCCAGCTGAACA  
ACCAAAAGCAGAAAAACCAGCTGATCAACAAGCTGAAGAAGACTATGCTCGTAGATCAGAAGAAGAATA  
TAATCGCTTGACTCAACAGCAACCGCCAAAAACTGAAAAACCAGCACACCATCTACTCCAAAAACAGG

Table 1

56

CTGGAAACAAGAAAACGGTATGTGGTACTTCTACAATACTGATGGTTCAATGGCGACAGGATGGCTCCA  
AAACAATGGCTCATGGTACTACCTCAACAGCAATGGCGCTATGGCGACAGGATGGCTCCAAAACAATGG  
TTCATGGTACTATCTAAACGCTAATGGTTCAATGGCAACAGGATGGCTCCAAAACAATGGTTTCATGGTA  
CTACCTAAACGCTAATGGTTCAATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTACTACCTAAA  
CGCTAATGGTTCAATGGCGACAGGATGGCTCCAATACAATGGCTCATGGTACTACCTAAACGCTAATGG  
TGATATGGCGACAGGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAA  
AGCAAGCCAATGGTTCAAAGTATCAGATAAATGGTACTATGTCAATGGCTCAGGTGCCCTTGCAAGTCAA  
CACAACTGTAGATGGCTATGGAGTCAATGCCAATGGTGAATGGGTAAAC

**SP023 amino acid (SEQ ID NO:38)**

DEQKIKQAEAEVESKQAEATRLKKIKTDREEAEAEAKRRADAKEQGKPKGRAKRGVPGELATPDKKEND  
AKSSDSSVGEETLPSPSLKPEKKVAEAEKKVEEAKKKAEDQKEEDRRNYPTNTYKLTLELEIAESDVEVK  
KALELVKEEAEKEPRNEEKVKQAKAEVESKKAETRLKIKTDRKKAEEAEAKRKAEEEDKVKEKPAEQP  
QPAPAPKAEPAPAPKPENPAEQPKAEKPADQQAEEYARRSEEEYNRLTQQQPPKTEKPAQPSTPKTG  
WKQENGMMWYFYNTDGSMTGWLQNNNGSWYYLNSNGAMATGWLQNNNGSWYYLNANGSMATGWLQNNNGSWY  
YLNANGSMATGWLQYNGSWYYLNANGSMATGWLQYNGSWYYLNANGDMATGWVKDGDWYYLEASGAMK  
ASQWFKVSDKWYYVNGSGALAVNTTVDGYGVNANGEWVN

**SP025 nucleotide (SEQ ID NO:39)**

CTGTGGTGAGGAAGAACTAAAAAGACTCAAGCAGCACAAACAGCCAAAACAACAAACGACTGTACAACA  
AATTGCTGTTGGAAGATGCTCCAGACTTCACATTGCAATCCATGGATGGCAAAGAAGTTAAGTTATC  
TGATTTTAAGGGTAAAAAGGTTTACTTGAAGTTTTGGGCTTCATGGTGTGGTCCATGCAAGAAAAGTAT  
GCCAGAGTTGATGGAAGTAGCGGCGAAACCAGATCGTGATTTGCAAAATCTTACTGTCAATGCACCAGG  
AATTCAAGGTGAAAAAACTGTTGAGCAATCCCAATGGTTCCAGGAACAAGGATATAAGGATATCCC  
AGTTCTTTATGATACCAAAGCAACCACTTCCAAGCTTATCAAATTCGAAGCATTCCTACAGAATATT

**SP025 amino acid (SEQ ID NO:40)**

CGEEETKKTKQAAQPKQQTTVQQIAVGKDAPDFTLQSMGKEVKLSDFKGGKVYLKFWASWCGPCKKSM  
PELMELAAKPDRDFEILTVAIPGIQGEKTVEQFPQWFQEQGYKDI PVLYDTKATTSKLIKFEAFLQNI

**SP028 nucleotide (SEQ ID NO:41)**

GACTTTTAACAATAAACTATTGAAGAGTTGCACAATCTCCTTGTCTCTAAGGAAATTTCTGCAACAGA  
ATTGACCCAAGCAACACTTGAAAATATCAAGTCTCGTGAGGAAGCCCTCAATTCATTTGTCAACCATCGC  
TGAGGAGCAAGCTCTTGTTCAGCTAAAGCCATTGATGAAGCTGGAATTGATGCTGACAATGTCCTTTC  
AGGAATTCCACTTGCTGTTAAGGATAACATCTCTACAGACGGTATTCTCACAACGCTGCCTCAAAAAT  
GCTCTACAACATATGAGCCAATCTTTGATGCGACagCTgTTGCCAATGCAAAAACCAAGGGCATGATTGT  
CGTTGGAAGACCAACATGGACGAATTTGCTATGGGTGGTTCAAGGTGAAACTTCACACTACGGAGCAAC  
TAAAAACGCTTGGAACCACAGCAAGGTTCTGCTGGGTGCATCAAGTGGTTCTGCCGCACTGTAGCCTC  
AGGACAAGTTTCGCTTGCTACTTGGTTCTGATACTGGTGGTTCCATCCGCCAACCTGCTGCCTTCAACGG  
AATCGTTGGTCTCAAACCAACCTACGGAACAGTTTACGTTTCGGTCTCATTGCCTTTGGTAGCTCATT  
AGACCAGATTGGACCTTTTGCTCCTACTGTTAAGGAAAATGCCCTCTTGCTCAACGCTATTGCCAGCGA  
AGATGCTAAAGACTCTACTTCTGCTCCTGTCCGCATCGCCGACTTTACTTCAAAAATCGGCCAAGACAT  
CAAGGGTATGAAAATCGCTTTGCCTAAGGAATACCTAGGCGAAGGAATTGATCCAGAGGTTAAGGAAAC  
AATCTTAAACGCGGCCAAACACTTTGAAAAATTGGGTGCTATCGTCAAGAAGTCAGCCTTCCTCACTC  
TAAATACGGTGTTGCCGTTTATTACATCATCGCTTCATCAGAAGCTTCATCAAACCTGCAACGCTTCGA  
CGGTATCCGTTACGGCTATCGCGCAGAAGATGCAACCAACCTTGATGAAAATCTATGTAACACGCCGAAG  
CCAAGGTTTGGTGAAGAGGTAAACAGTCGTATCATGCTGGGTACTTTTCACTCTTTTCACTAGGTTACTA  
TGATGCCTACTACAAAAGGCTGGTCAAGTCCGTACCCTCATCATTCAAGATTTGAAAAAGTCTTCGC  
GGATTACGATTTGATTTTGGGTCCAACCTGCTCCAAGTGTGCTTATGACTTGGATTCTCTCAACCATGA  
CCCAGTTGCCATGTACTTAGCCGACCTATTGACCATACCTGTAAACTTGGCAGGACTGCCTGGAATTTTC  
GATTCCTGCTGGATTCTCTCAAGGTCTACCTGTGCGACTCCAATTGATTGGTCCCAAGTACTCTGAGGA  
AACCATTTACCAAGCTGCTGCTGCTTTTGAAGCAACAACAGACTACCACAAAACAACACCCGTGATTTT  
TGGAGGTGACAAC

**SP028 amino acid (SEQ ID NO:42)**

TFNNKTI EELHNLVSKEISATELTQATLENIKSREEALNSFVTIAEEQALVQAKAIDEAGIDADNVLS  
GIPLAVKDNISTDGILTTAASKMLYNYEIPFATAVANAKTKGMIVVGKTNMDEFAMGGSGSETSHYGAT  
KNAWNHSKVPGGSSSGSAAAVASGQVRLSLGSDTGGSI RQPAAFNGIVGLKPTYGTVSRFGLI AFGSSL

Table 1

57

DQIGFPAPT VKENALLLNIA SEDAKDSTSAPVRIADFTSKIGQDIKGMKIALPKEYLGEGIDPEVKET  
ILNAAKHFEKLG AIVEEVSLPHSKYGVAVYIIASSEASSNLQRFDGIRYGYRAEDATNLDEIYVNSRS  
QGFGEEVKRRIMLGTFSLSSGYDAYYKKAGQVRLIIQDFEKFADYDLILGPTAPSVAYDLDLSLNHD  
PVAMYLADLLTIPVNLAGLPGISIPAGFSQGLPVGLQLIGPKYSEETIYQAAAAFEATTDYHKQQPVI  
GGDN

**SP030 nucleotide (SEQ ID NO:43)**

CTTTACAGGTAAACA ACTACAAGTCGGCGACAAGGCGCTTGATTTTCTCTTACTACAACAGATCTTTC  
TAAAAAATCTCTGGCTGATTTTGATGGCAAGAAAAAGTCTTGAGTGTCTGCTTCCTTCTATCGATACAGG  
CATCTGCTCAACTCAAACACGTCGTTTTAATGAAGAATTGGCTGGACTGGACAACACGGTCGTATTGAC  
TGTTTTCAATGGACCTACCTTTTGCTCAAAAACGTTGGTGCGGTGCTGAAGGCCTTGACAATGCCATTAT  
GCTTTTCAGACTACTTTGACCATCTTTTCGGGCGCGGATTATGCCCTCTTGATCAACGAATGGCACCTATT  
AGCACGCGCAGTCTTTGTCTCGATACTGACAATACGATTGCTACGTTGAATACGTGGATAATATCAA  
TTCTGAGCCAAACTTCGAA

**SP030 amino acid (SEQ ID NO:44)**

FTGKQLQVGDKALDFSLTTTDL SKKSLADFDGKKVLSVVP SIDTGICSTQTRRFNEELAGLDNTVVL  
VSMDLPFAQKRWCGAEGLDNAIMLSDYFDHSFGRDYALLINEWHLLARAVFVLDTDNTRYVEYVDNIN  
SEPNFE

**SP031 nucleotide (SEQ ID NO:45)**

CCAGGCTGATACAAGTATCGCAGACATTCAAAAAAGAGGCGAAGTGGTTGTCTGGTGTCAAACAAGACGT  
TCCCAATTTTGGTTACAAGATCCCAAGACCGGTACTTATTCTGGTATCGAAACCGACTTGGCCAAGAT  
GGTAGCTGATGAAGTCAAGGTCAAGATTCGCTATGTCCGGTTACAGCACAAACCCGCGCCCCCTTCT  
AGACAATGAACAGGTGCGATATGGATATCGCGACCTTTACCATCACGGACGAACGCAAAAACTCTACAA  
CTTTACCAGTCCCTACTACACAGACGCTTCTGGATTTTGGTCAATAAATCTGCCAAATCAAAAAGAT  
TGAGGACCTAAACGGCAAAACCATCGGAGTCGCCCAAGGTTCTATCACCCAACGCCTGATTACTGAAGT  
GGGTAAAAAGAAAGGTCTGAAGTTTAAATTCGTCGAAGTGGTTCTTACCCAGAATTGATTACTTCCCT  
GCACGCTCATCGTATCGATACCTTTCCGTTGACCGCTCTATTCTATCTGGCTACACTAGTAAACGGAC  
AGCACTACTAGATGATAGTTTCAAGCCATCTGACTACGGTATTGTTACCAAGAAATCAAAATACAGAGCT  
CAACGACTATCTTGATAACTTGGTTACTAAATGGAGCAAGGATGGTAGTTTGCAGAACTTTATGACCG  
TTACAAGCTCAAACCATCTAGCCATACTGCAGAT

**SP031 amino acid (SEQ ID NO:46)**

QADTSIADIQRGELVVGKQDVPNFGYXDPKTGTYSIGIETDLAKMVADELKVKIRYVPVTAQTRGPLL  
DNEQVDMDIATFTITDERKKLYNFTSPYYTDASGFLVNKSAIKKIEDLNGKTIGVAQGSITQRLITEL  
GKKKGLKFKFVELGSYPELITSLHAHRIDTFSVDRSILSGYTSKRTALLDDSFKPSDYGIVTKKSNTEL  
NDYLDNLVTKWSKDGSLQKLYDRYKLPSSHTAD

**SP032 nucleotide (SEQ ID NO:47)**

GTCTGTATCATTGAAAACAAAGAAACAAACCGTGGTGTCTTgACTTTCACTATCTCTCAAGACCAAAT  
CAAACAGAAATTGGACCGTGTCTTCAAGtCAGTGAAGAAATCTCTTAATGTTCCAGGTTTCCGTAAAGG  
TCACCTTCCACGCCCTATCTTCGACCAAAAAATTTGGTGAAGAAGCTCTTTATCAAGATGCAATGAACGC  
ACTTTTGCCAAACGCTTATGAAGCAGCTGTAAAAGAAGCTGGTCTTGAAGTGGTTGCCCAACCAAAAAT  
TGACGTAACCTCAATGGAAGAGGTCAAGACTGGGTTATCACTGCTGAAGTCGTTACAAAACCTGAAGT  
AAAATTGGGTGACTACAAAACCTTGAAGTATCAGTTGATGTAGAAAAAGTAAGTACGCTGATGT  
CGAAGAGCGTATCGAACGCGAACGCAACAACCTGGCTGAATTGGTTATCAAGGAAGCTGCTGCTGAAAA  
CGGCGACACTGTTGTGATCGACTTCGTTGGTTCTATCGACGGTGTGAAATTTGACGGTGGAAAAGGTGA  
AACTTCTCACTTGGACTTGGTTCAAGTCAATTCATCCCTGGTTTCGAAGACCAATTGGTAGGTCACCTC  
AGCTGGCGAAACCGTTGATGTTATCGTAACATTCACGAGAAGACTACCAAGCAGAAGACCTTGCAGGTAA  
AGAAGCTAAATTCGTGACAACCTATCCACGAAGTAAAGCTAAAGAAGTCCGGCTCTTGACGATGAAGT  
TGCAAAAGACATTGATGAAGAAGTTGAAACACTTGCTGACTTGAAAGAAAAATACAGCAAGAATTTGGC  
TGCTGCTAAAGAAGAAGCTTACAAAGATGCAGTTGAAGGTGCAGCAATTGATACAGCTGTAGAAAATGC  
TGAAATCGTAGAACTTCCAGAAGAAATGATCCATGAAGAAGTTCACCGTTTCAGTAAATGAATTCCTTGG  
GAATTTGCAACGTCAAGGGATCAACCTGACATGTACTTCAAATCACTGGAACCTACTCAAGAAGACCT  
TCACAACCAATACCAAGCAGAAGCTGAGTCACGTACTAAGACTAACCTTGTATCGAAGCAGTTGCCAA  
AGCTGAAGGATTTGATGCTTCAGAAGAAGAAATCCAAAAAGAAGTTGAGCAATTGGCAGCAGACTACAA

Table 1

58

CATGGAAGTTGCACAAGTTCAAACTTGCTTTCAGCTGACATGTTGAAACATGATATCACTATCAAAAA  
AGCTGTTGAATTGATCACAAGCACAGCAACAGTAAAA

**SP032 amino acid (SEQ ID NO:48)**

SVSFENKETNRGVLFTTISQDQIKPELDRVFKSVKSLNVPGFGRKGLPRPIFDQKFGEEALYQDAMNA  
LLPNAYEAAVKEAGLEVVAQPKIDVTSMEKGQDWVITAENVTKPEVKLGDKNLEVSVDVEKEVTDADV  
EERIERERNLAEVLVKEAAAENGDTVVIDFVGSIDGVEFDGGKGENFSLGLSGSQFIPGFEDQLVGH  
AGETVDVIVTFPEDYQAEFLAGKEAKFVTTIHEVKAKEVPALDDELAKDIDEEVETLADLKEKYSKELA  
AAKEEAYKDAVEGAIDTAVENAEIVELPEEMIHEEVHRSVNEFLGNLQROGINPDMYFQITGTTQEDL  
HNQYQAEAESRTKTNLVIEAVAKAEGFDASEEIQKEVEQLAADYNMEVAQVQNLLSADMLKHDITIKK  
AVELITSTATVK

**SP033 nucleotide (SEQ ID NO:49)**

TGGTCAAAAAGGAAAGTCAGACAGGAAAGGGGATGAAAATTGTGACCAGTTTTTATCCTATCTACGCTAT  
GGTTAAGGAAGTATCTGGTGACTTGAATGATGTTCCGGATGATTCAAGTAGTGGTATTCACTCCTT  
TGAACCTTCGGCAAATGATATCGCAGCCATCTATGATGCAGATGTCTTTGTTTACCATTCTCATACACT  
CGAATCTTGGGCAGGAAGTCTGGATCCAAATCTAAAAAATCCAAAGTGAAGGTCTTAGAGGCTTCTGA  
GGGAATGACCTTGAACGTGTCCCTGGACTAGAGGATGTGGAAGCAGGGGATGGAGTTGATGAAAAAC  
GCTCTATGACCCCTCACACATGGCTAGATCCTGAAAAGCTGGAGAAGAAGCCCAAATTATCGCTGATAA  
ACTTTCAGAGGTGGATAGTGAGCATAAAGAGACTTATCAAAAAATGCGCAACCTTTATCAAAAAAGCT  
CAGGAAT

**SP033 amino acid (SEQ ID NO:50)**

GQKESQTGKGMKIVTSFYPIYAMVKEVSGDLNDRMIQSSSGIHSFEPSANDIAAIYDADFVYHSHTL  
ESWAGSLDPNLKSKYKVLASEGMTLERVPGLEDVEAGDGVDEKTLYPDHTWLDPEKAGEEAQIIADK  
LSEVDSEHKETYQKNAQPLSKLRN

**SP034 nucleotide (SEQ ID NO:51)**

GAAGGATAGATATATTTTAGCATTTGAGACATCCTGTGATGAGACCAGTGTGCGCGTCTTGAAAAACGA  
CGATGAGCTCTTGTCATATGTCATTGCTAGTCAAATTGAGAGTCACAAACGTTTGGTGGCGTAGTGCC  
CGAAGTAGCCAGTCGTCACCATGTGCGAGGTCAATACAGCCTGTATCGAGGAGCATTTGGCAGAAGCAGG  
GATTACCGAAGAGGACGTGACAGCTGTTGCGGTTACCTACGGACCAGGCTTGGTCGGAGCCTTGCTAGT  
TGGTTTTGTCAGCTGCCAAGGCCTTTGCTTGGGCTCACGGACTTCCACTGATTCTGTTAATCACATGGC  
TGGGCACCTCATGGCAGCTCAGAGTGTGGAGCCTTTGGAGTTTCCCTTGCTAGCCCTCTTGCTCAGCGG  
CGGACACACAGAGTTGGTTTATGTTTTCGGAGGCAGGAGATTATAAGATTGTTGGGGAAACCCGTGATGA  
TGCGGTTGGTGAGGCTTATGATAAGGTCGGCCGTGTCATGGGCTTGACCTATCCTGCAGGTCGTGAGAT  
TGACGAGCTGGCTCATCAGGGCAGGATATTTATGATTTCCCCCGTGCCATGATTAAGGAAGATAATCT  
GGAGTTCTCCTTCTCAGGTTTGAAATCTGCCTTTATCAATCTTCATCACAATGCCGAGCAAAAGGGAGA  
AAGCCTGTCTACAGAAGATTTGTGTGCTTCCCTTCAAGCAGCAGTTATGGACATTCTCATGGCAAAAC  
CAAGAAGGCTTTGGAGAAATATCCTGTTAAATCCTAGTTGTGGCAGGTGGTGTGGCAGCCAATAAAGG  
TCTCAGAGAACGCCCTAGCAGCCGAAATCACAGATGTCAAGGTTATCATCCCCCTCTGCGACTCTGCGG  
AGACAATGCAGGTATGATTGCCATATGCCAGCGTCAGCNAGTGAACAAAGAAAACCTTCGCAGGCTGGGA  
CCTCAATGCCAAACCAAGTCTTGCCCTTGATACCATGGAA

**SP034 amino acid (SEQ ID NO:52)**

KDRYILAFETSCDETSVAVLKNDELLENVIAEQIESHKRFGGVVPEVASRHHVEVITACIEEALAEAG  
ITEEDVTAVAVTYGPGVLVGLVLSAAKFAWAHGLPLIPVNHMAGHLMAAQSVPELEFLLALLVSG  
GHTELVVYSEAGDYKIVGETRDDAVGEAYDKVGRVMGLTYPAGREIDELAHQGQDIYDFPRAMIKEDNL  
EFSFSGLSAFINLHHNAEQKGESLSTEDLCASFQAAVMDILMAKTKKALEKYPVKILVAGGVAANKG  
LRERLAAEITDVKVIIPPLRLCGDNAGMIAYASVSXWNKENFAGWDLNAKPSLAFDTME

**SP035 nucleotide (SEQ ID NO:53)**

GGTAGTTAAAGTTGGTATTAACGGTTTCGGACGTATCGGTCGTCTTGCTTTCGGTCGTATCCAAAACGT  
AGAAGGTGTTGAAGTTACACGCATCAACGACCTTACAGATCCAGTTATGCTTGACACTTGTGAAATA  
CGACACAACCTCAAGGTCGTTTCGACGGTACTGTTGAAGTTAAAGAAGGTGGATTTGAAGTTAACGGTAA  
ATTCATCAAAGTTTCTGCTGAACGTGATCCAGAACAAATCGACTGGGCTACTGACGGTGTAGAAATCGT  
TCTTGAAGCTACTGGTTTCTTTGCTAAGAAAGAAGCAGCTGAAAAACACCTTAAAGGTGGAGCTAAAAA

Table 1

59

AGTTGTTATCACTGCTCCTGGTGAAACGACGTTAAACAGTTGTATTCAACACTAACCACGACGTTCT  
TGACGGTACTGAAACAGTTATCTCAGGTGCTTCATGTACTACAACTGCTTGGCTCCAATGGCTAAAGC  
TCTTCAAGACAACCTTGGTGTGTTGAAGGATTGATGACTACTATCCACGCTTACACTGGTGACCAAAT  
GATCCTTGACGGACCACACCGTGGTGGTGACCTTCGCCGTGCTCGCGCTGGTGCTGCAAAACATCGTTCC  
TAACCTCAACTGGTGCTGCAAAAGCTATCGGTCTTGTAAATCCCAGAAATGAATGGTAAACTTGACGGATC  
TGCACAACCGCTTCCAACCTCCAACCTGGATCAGTTACTGAATTGGTAGCAGTTCTTGAAAAGAAGCTTAC  
TGTTGATGAAGTGAACGCAGCTATGAAAGCAGCTTCAAACGAATCATAACGGTTACACAGAAGATCCAAT  
CGTATCTTCAGATATCGTAGGTATGTCTTACGGTTCATTGTTTGACGCAACTCAAACATAAGTTCTTGA  
CGTTGACGGTAAACAATTGGTTAAAGTTGTATCATGGTACGACAACGAAATGTCATACACTGCACAAC  
TGTTTCGTACTCTTGAATACTTCGCAAAAATTGC

**SP035 amino acid (SEQ ID NO:54)**

VVKVINGFGRIGRLAFRRIQNVEGVETRINDLTPVMLAHLKLYDTTQGRFDGTVEVKEGGFEVNGK  
FIKVSERDEPEQIDWATDGVIEVLEATGFFAKKEAAEKHLKGGAKKVITAPGNDVKTVPFNTNHDVL  
DGTETVISGASCTTNCLAPMAKALQDNFVVEGLMTTIIHAYTGDQMLDGPHRGGDLRRARAGANIVP  
NSTGAAKAIGLVIPELNGKLDGSAQRVPTPTGSVTELVAVLEKNVTVDEVNAAMKAASNESYGYTEDPI  
VSSDIVGMSYGLFDTATQTKVLDVDGKQLVKVVSWDNEMSYTAQLVRTLGLIRKNC

**SP036 nucleotide (SEQ ID NO:55)**

TTCTTACGAGTTGGGACTGTATCAAGCTAGAACGGTTAAGGAAAAATAATCGTGTTCCTATATAGATGG  
AAAACAAGCGACGCAAAAAACGGAGAATTTGACTCCTGATGAGGTAGCAAGCGTGAAGGAATCAATGC  
TGAGCAAATCGTCATCAAGATAACAGACCAAGGCTATGTCACTTCACATGGCGACCACCTATCATTATTA  
CAATGGTAAGGTTCTTATGACGCTATCATCAGTGAAGAATTACTCATGAAAGATCCAACTATAAGCT  
AAAAGATGAGGATATTGTTAATGAGGTCAAGGGTGGATATGTTATCAAGGTAGATGGAAAACTATATGT  
TTACCTTAAGGATGCTGCCACGCGGATAACGTCGTACAAAAGAGGAAATCAATCGACAAAAACAAGA  
GCATAGTCAACATCGTGAAGGTGGAACCTCAAAGAACGATGGTGTCTTGCCTTGGCACGTTTCGCAAGG  
ACGCTATACTACAGATGATGGTTATATCTTTAATGCTTCTGATATCATAGAGGATACTGGTGATGCTTA  
TATCGTTCCTCATGGAGATCATTACCATTACATTCCTAAGAATGAGTTATCAGCTAGCGAGTTGGCTGC  
TGCAGAAGCCTTCCTATCTGGTCGAGGAAATCTGTCAAATTCAGAACCCTATCGCCGACAAAAATAGCGA  
TAACACTTCAAGAACAACTGGGTACCTTCTGTAAGCAATCCAGGAACTACAAATCAACACAAGCAAA  
CAACAGCAACACTAACAGTCAAGCAAGTCAAAGTAATGACATTGATAGTCTCTTGAACAGCTTACAA  
ACTGCCTTTGAGTCAACGACATGTAGAATCTGATGGCCTTGTCTTTGATCCAGCACAAATCACAAGTCG  
AACAGCTAGAGGTGTTGCACTGCCACACGGAGATCATTACCCTTCAATCCCTTACTCTCAATGTCTGA  
ATTGGAAGAACGAATCGCTCGTATTATTCCTTTCGTTATCGTTCAAACCATTTGGGTACCAGATTCAAG  
GCCAGAACAACCAAGTCCACAACCGACTCCGGAACCTAGTCCAGGCCCGCAACCTGCACCAATCTTAA  
AATAGACTCAAATCTTCTTTGGTTAGTCAGCTGGTACGAAAAGTTGGGAAGGATATGTATTCGAAGA  
AAAGGGCATCTCTCGTTATGTCTTTGCGAAAGATTTACCATCTGAAACTGTTAAAAATCTTGAAAGCAA  
GTTATCAAAACAAGAGAGTGTTCACACACTTTAAGTCTGCTAAAAAGAAAATGTTGCTCCTCGTGACCA  
AGAATTTTATGATAAAGCATATAATCTGTTAACTGAGGCTCATAAAGCCTTGTTTGNAAATAAGGGTCG  
TAATTCGTGATTTCCAAGCCTTAGACAAATTATTAGAAGCCTTGAATGATGAATCGACTAATAAGAAAA  
ATTGGTAGATGATTTATTGGCATTCTTAGCACCAATTACCCATCCAGAGCGACTTGGCAAACCAATTC  
TCAAATTGAGTATACTGAAGACGAAGTTCGTATTGCTCAATTAGCTGATAAGTATACAACGTCAGATGG  
TTACATTTTTTGATGAACATGATATAATCAGTGATGAAGGAGATGCATATGTAACGCCTCATATGGGCCA  
TAGTCACTGGATTGGAAAAGATAGCCTTTCTGATAAGGAAAAGTTGCAGCTCAAGCCTATACATAAAGA  
AAAAGGTATCCTACCTCCATCTCCAGACGCAGATGTTAAAGCAAATCCAAGTGGAGATAGTGACGAGC  
TATTTACAATCTGTGAAAGGGGAAAAACGAATTCCTACTCGTTGACTTCCATATATGGTTGAGCATAAC  
AGTTGAGGTTAAAAACGGTAATTTGATTATTCTCTCATAAGGATCATTACCATAATATTAAATTTGCTTG  
GTTTGATGATCACACATACAAAGCTCCAAATGGCTATACCTTGAAGATTTGTTTGCGACGATTAAGTA  
CTACGTAGAACACCCCTGACGAACGTCCACATTCTAATGATGGATGGGGCAATGCCAGTGAGCATGTGTT  
AGGCAAGAAAGACCACAGTGAAGATCCAAATAAGAACTTCAAAGCGGATGAAGAGCCAGTAGAGGAAAC  
ACCTGCTGAGCCAGAAGTCCCTCAAGTAGAGACTGAAAAAGTAGAAGCCCAACTCAAAGAAGCAGAAGT  
TTTGCTTGCGAAAGTAACGGATTCTAGTCTGAAAGCCAATGCAACAGAACTCTAGCTGGTTTACGAAA  
TAATTTGACTCTTCAAATTATGGATAACAATAGTATCATGGCAGAAGCAGAAAAATTACTTGCCTTGTT  
AAAAGGAAGTAATCCTTCATCTGTAAGTAAGGAAAAATAAAC

**SP036 amino acid (SEQ ID NO:56)**

SYELGLYQARTVKENNRVSYIDGKQATQKTENLTPDEVSKREGINAEQIVIKITDQGYVTSBGDHYHY  
NGKVPYDAIISEELMKDPNYKLKDEDIVNEVKGGYVIKVDGKYVYVYKDAHADNVRTKEEINRQKQE

Table 1

60

HSQHREGGTPRNDGAVALARSQGRYTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKNELSASELAA  
AEAFLSGRGNLSNSRTYRRQNSDNTSRTNWVPSVSNPGTTNTNTSNNSNTNSQASQSNIDISLLKQLYK  
LPLSQRHVESDGLVFDPAQITSRTARGVAVPHGDHYHFIPYSQMSELEERIARIIPLYRSNHWPDSR  
PEQPSPQPTPEPSPGPQPAPNLKIDSNSSLVSQLVRKVGEGYVFEEKGISRYVFAKDLPSETVKNLESK  
LSKQESVSHTLTAKKENVAPRDQEFYDKAYNLLTEAHKALFXNKGRNSDFQALDKLLERLNDESTNKEK  
LVDDLLAFLAPITHPERLGKPN SQIEYTEDEVRIAQLADKYTTSDGYIFDEHDIISDEGDAYVTPHMGH  
SHWIGKDSLSDEKVAQAAYTKEKGILPPSPDADVKANPTGDSAAIYNRVKGEKRIPLVRLPYMVEHT  
VEVKNGNLIIPH KDHYHNIKFAWFDDHTYKAPNGYTTLEDLFATIKYVVEHPDERPHSNDGWGNASEHVL  
GKKDHSEDPNKNFKADEEPVEETPAEPEVPQVETEKVEAQLKEAEVLLAKVTDSSSLKANATETLAGLRN  
NLTLQIMDNNSIMAEAEKLLALLKGSNPSSVSKEKIN

**SP038 nucleotide (SEQ ID NO:57)**

TACTGAGATGCATCATAATCTAGGAGCTGAAAAGCGTTCAGCAGTGGCTACTACTATCGATAGTTTAA  
GGAGCGAAGTCAAAAAGTCAGAGCACTATCTGATCCAAATGTGCGTTTTGTTCCCTTCTTTGGCTCTAG  
TGAATGGCTTCGTTTTGACGGTGCTCATTCTGCGGTATTAGCTGAGAAATACAATCGTTCCTACCGTCC  
TTATCTTTTAGGACAGGGGGGAGCTGCATCGCTTAACCAATATTTTGGAAATGCAACAGATGTTACCACA  
GCTGGAGAAATAACAAGTTGTGTATGTTATCTCACCTCAGTGGTTCAGTAAAAATGGCTATGATCCAGC  
AGCCTTCCAGCAGTATTTTAATGGAGACCAGTTGACTAGTTTTCTGAAACATCAATCTGGGGATCAGGC  
TAGTCAATATGCAGCGACTCGCTTACTGCAACAGTTCCTCAACGTAGCTATGAAGGACCTGGTTCAGAA  
GTTGGCAAGTAAAGAAGAAATTGTCGACAGCAGACAATGAAATGATTGAATTATTGGCTCGTTTTAATGA  
ACGCCAAGCTTCCTTTTTTGGTCAGTTTTTCGGTTAGAGGCTATGTTAACTACGATAAGCATGTAGCTAA  
GTATTTAAAAATCTTGCCAGACCAGTTTTCTTATCAGGCAATAGAAGATGTTGTCAAAGCAGATGCTGA  
AAAAAATACCTCCAATAATGAGATGGGAATGGAATAATTTCTATAATGAGCAGATCAAGAAGGATTT  
GAAGAAATTAAGGATTCTCAGAAAAGCTTTACCTATCTCAAGTCGCCAGAGTATAATGNNTTGCGAGTT  
GGTTTTAACACAGTTTTCTAAATCTAAGGTAAACCGGATTTTTATCATTCACCTGTTAATAAAAAATG  
GATGNACTATGCTGGTCTACGAGAGGATATGTACCAACAAACGGTGCAGAAAGATTGCTACCAGTTAGA  
AAGTCAAGGTTTTACCAATATAGCAGATTTTTCTAAGGACGGCGGGGAGCCTTTCTTTATGAAGGACAC  
CATTCACCTTGGTTGGTTGGTTGGTTGGCTTTTGACAAGGCAGTTGATCCTTTCTATCCAATCCCAC  
ACCAGCTCCGACTTACCATCTGAATGAGCGCTTTTTCAGCAAAGATTGGGCGACTTATGATGGAGATGT  
CAAAGAA

**SP038 amino acid (SEQ ID NO:58)**

TEMHNLGAEKRSVAVATTIDSFKERSQKVRALSDPNVRFVPPFGSSEWLRFDAHSAVLAEKYNRSYRP  
YLLGQGAASLNQYFGMQMLPQLENKQVVYVISPQWFSKNGYDPAAFQYFNGDQLTSFLKHQSGDQA  
SQYAATRLQQFPNVAMKDLVQKLASKEELSTADNEMIELLARFNERQASFFGFQFSVRGVYNYDKHVAK  
YLKILPDQFSYQAIEDVVKADAENKTSNNEMGMENYFYNEQIKKDLKKLKDSQKSFTYLSPEYNXLQL  
VLTQFSKSKVNPIFIIPVNVKWMXYAGLREDMYQQTQKIRYQLESQGFNIADF SKDGGEPPFMKDT  
IHLGWLGLAFDKAVDPFLSNPTPAPTYHLNERFFSKDWATYDGDVKE

**SP039 nucleotide (SEQ ID NO:59)**

GGTTTTGAGAAAGTATTTGCAGGGGGCCCTGATTGAGTCGATTGAGCAAGTGGAATGACCGTATTGT  
GGAAATTACAGTTTCCAATAAAAACGAGATTGGAGACCATATCCAGGCTACCTTGATTATCGAAATTAT  
GGGGAACACAGTAATATTCTACTGGTCGATAAAAGCAGTCATAAAATCCTCGAAGTTATCAACACGT  
CGGCTTTTACAAAATAGCTACCGCACCTTACTTCCAGGATCGACCTATATCGCTCCGCCAAGTACAAA  
ATCTCTCAATCTTTTACTATCAAGGATGAAAAGCTTTTGAAATCCTGCAAAACCAAGAACTAACAGC  
AAAAAATCTTCAAGCCCTCTTTCAAGGTCTGGGACGCGATACGGCAAATGAATTGGAAAGGATACGGT  
TAGTGAAAAACTTTCCGCTTTCCGAAATTTTTTCAATCAAGAAACCAAGCCATGCTTGACTGAGACTTC  
CTTCAGTCCAGTTCCTTTTGCAAATCAGGTGGGAGAGCCTTTTGCAAATCTTTCTGATTTGTTGGACAC  
CTACTATAAGGATAAGGCTGAGCGCGACCGCTCAAACAGCAGGCCAGTGAAGTATTCGTCGTGTTGA  
AAATGAAGTTTCAGAAAAACCGACACAACTCAAAAAACAGGAAAAAGAGTTACTGGCGACAGACAACGC  
TGAAGAATTTCTGCAAAAAGGAGAATTGCTGACAACCTTCTCCACCAAGTGCTTAACGACCAAGACCA  
GGTTATCCTAGACAACTACTATACCAACCAACCTATCATGATTGCGCTTGATAAGGCTCTGACTCCCAA  
CCAGAATGCCCAACGCTATTTTAAACGGTATCAGAACTCAAAGAAGCTGTCAAATACTTGACTGATTT  
GATTGAAGAAACCAAGCCACTATTTCTATCTGAAAGGTAGAAACCGTCTCAACCAAGCTGGACT  
GGAAGAAATCGCTGAAATCCGTGAAGAAATGATTCAAACAGGTTTTATCCGCAGAAAGACAACGGGAGAA  
AATCCAGAAACGCAAAAACTAGAACATATCTAGCAAGCGATGGCAAAACCATCATCTATGTCGGACG  
AAACAATCTTCAAAATGAGGAATTGACCTTTAAAAATGGCCCGCAAGGAGGAACCTTTGGTTCCATGCTAA  
GGACATTCTTGGAAGCCATGTTGTCTATCTCAGGAAATCTTGACCCATCTGATGCAGTCAAGACAGACGC

Table 1

61

AGCAGAGTTAGCTGCCTACTTCTCTCAAGGGCGCCTGTGCAATCTGGTGCAGGTAGATATGATTGAAGT  
CAAAAAACTCAATAAACCAACTGGTGGAACCCGGCTTTGTCACTTACACAGGACAAAAGACCCTCCG  
CGTCACACCAGACTCCAAAAAATTGCATCCATGAAAAAATCC

**SP039 amino acid (SEQ ID NO:60)**

VLRKYLQGALIESIEQVENDRIVEITVSNKNEIGDHIQATLIIEMGKHSNILLVDKSSHKILEVIKHV  
GFSQNSYRTLLPGSTYIAPPSTKSLNPFTIKDEKLFEILQTQELTAKNLQSLFQGLGRDTANELERILV  
SEKLSAFRNFFNQETKPCLTETSFSPVPFANQVGEFFANLSDLLDTYYKDKAERDRVKQQASELIRRV  
NELQKNRHKLKKQEKELLATDNAEEFRQKGELLTFLHQVPNDQDQVILDNYITNQPIALDKALTPN  
QNAQRYFKRYQKLKEAVKYLTDLIEETKATILYLESVETVLNQAGLEEIAEIREELIQTGFIRRRQREK  
IQKRKKLEQYLASDGKTIIVYGRNNLQNEELTFKMARKEELWFHAKDIPGSHVVISGNLDPDAVKTD  
AELAAYSQGRSLNLVQVDMIEVKLNKPTGGKPGFVTTYTGQKTLRVTPDSKKIASMKKS

**SP040 nucleotide (SEQ ID NO:61)**

GACAACATTTACTATCCATACAGTAGAGTCAGCACCAGCAGAAGTGAAAGAAATCTTGAAACAGTAGA  
AAAAGACAACAATGGCTATATTCCTAACCTAATCGGTCTCTTGGCCAATGCCCGACTGTTTGTAGAAGC  
CTACCAAAATGTCTCATCTATCCACCGTCGCAACAGCCTGACACCGTTGAGCGTGAAGTGGTGCAAAT  
CACGGCAGCCGTGACCAATGGTTGTGCCTTCTGTGTCGAGGTACACAGCCTTTTCCATCAAAACAAAT  
CCAGATGAATGATGACTTGATTCAAGCTCTTCGCAATCGTACTCCAATTGAAACAGATCCTAAATTGGA  
TACCCTAGCTAAGTTTACCTTGGCAGTTATCAATACCAAGGGTCGTGTAGGAGATGAAGCCTTGTCTGA  
GTTTTTGAAGCTGGCTACACTCAACAAATGCCTTGGATGTGGTTTTTGGTGTGAGCCTAGCAATCCT  
CTGTAATATGCCAACAACTTAGCTAATACCAATTAATCCAGAATTGCAACCTTATGCC

**SP040 amino acid (SEQ ID NO:62)**

TTFTIHTVESAPAEVKEILETVKEDNNGYIPNLIGLLANAPTIVLEAYQIVSSIHRNLSLTPVEREVVQI  
TAAVTNGCAFCVAGHTAFSIKQIQMDDLIQALRNRTPIETDPKLDTLAKFTLAVINTKGRVGDALSE  
FLEAGYTQQNALDVVFGVSLAILCNYANNLANTPINPELQPYA

**SP041 nucleotide (SEQ ID NO:63)**

GGCTAAGGAAAGAGTGGATGTACTAGCTTATAAACAGGGGTTGTTTGAACGAGAGAGCAGGCCAAGCG  
AGGTGTGATGGCTGGCTAGTCGTAGCAGTCCTTAATGGAGAACGGTTTGACAAGCCAGGAGAGAAAAT  
TCCAGATGACACCGAATTAAACTCAAGGGGGAGAACTCAAGTATGTCAGCCGTGGTGGTTTGAACCT  
GGAAAGGCCTTGAGGTCTTTGATTTGTCGGTGGATGGCGGACTACGATTGATATCGGGGCTCTAC  
TGGAGGTTTTACCGATGTCATGCTACAGAATAGTGCCAAGTTGGTCTTGCAGTCGATGTTGGTACCAA  
TCAGTTGGCTTGAAATTACGCCAAGACCCACGAGTTGTCAGCATGGAGCAGTTCAATTTCCGCTATGC  
TGAAAGACTGATTTGAGCAGGAGCCGAGCTTTGCCAGTATTGATGTGAGTTTCATTTCCCTTAGTCT  
GATTTTGCCAGCCTTGACCGTGTCTTGGCTGATCAAGGTGAGGTGGTAGCACTTGTCAAACCTCAGTT  
TGAGGCAGGACGTGAGCAGATTGGGAAAAATGGAATTATTCGAGATGCTAAGGTTATCAGAAATGTCCT  
TGAATCTGTAACAGCTATGGCAGTAGAGGTAGGTTTTTCAGTCCTTGGCTTGGACTTTTCTCCCATCCA  
AGGTGGACATGGAAATATTGAATTTTAGCGTATTGAAAAAAGAAAAGTCAGCAAGCAATCAGATTCT  
TGCTGAGATTAAAGAAGCAGTAGAGAGGGCGCATAGTCAATTTAAAAATGAA

**SP041 amino acid (SEQ ID NO:64)**

AKERVDVLAYKQGLFETREQAKRGVMAGLVAVLNGERFDKPGEKIPDDTELKLGKELKYVSRGGLKL  
EKALQVFDLSVDGATTIDIGASTGGFTDVMLQNSAKLVFAVDVGTNQLAWKLQDPRVVSMEQFNFRYA  
EKTDFEQEPSFASIDVSFISLSLILPALHRVLADQGVVALVKPQFEAGREQIGKNGIIRDAKVHQNVL  
ESVTAMAVEVGFVGLGLDFSPIQGGHGNIEFLAYLKKESASNQILAEIKEAVERAHSQFKNE

**SP042 nucleotide (SEQ ID NO:65)**

TTGTTCCATGAACTTGGTCGTCACCAAGCTGGTCAGGTTAAGAAAGAGTCTAATCGAGTTTCTTATAT  
AGATGGTGATCAGGCTGGTCAAAAGGCAGAAAACCTTGACACCAGATGAAGTCAGTAAGAGGGAGGGGAT  
CAACGCCGAACAAATNGTNATCAAGATTACGGATCAAGGTTATGTGACCTCTCATGGAGACCATTATCA  
TTACTATAATGGCAAGGTTCCCTTATGATGCCATCATCAGTGAAGAGCTCCTCATGAAAGATCCGAATTA  
TCAGTTGAAGGATTACAGACATTGTCAATGAAATCAAGGGTGGTTATGTCAATTAAGGTAAACGGTAAATA  
CTATGNTTACCTTAAGGATGCAGCTCATGCGGATAATATTCGGACAAAAGAAGAGATTAAACGTCAGAA  
GCAGGAACGCAGTCATAATCATAACTCAAGAGCAGATAATGCTGTTGCTGCAGCCAGAGCCCAAGGACG  
TTATACAACGGATGATGGGTATATCTTCAATGCATCTGATATCATTGAGGACACGGGTGATGCTTATAT  
CGTTCCTCACGGCGACCATTACCATACATTCCCTAAGAAATGAGTTATCAGCTAGCAGGTTAGCTGCTGC

Table 1

62

AGAAGCCTATTGGAATGGGAAGCAGGGATCTCGTCTTCTTCAAGTTCTAGTTATAATGCAAATCCAGC  
TCAACCAAGATTGTCAGAGAACCACAATCTGACTGTCACTCCAACCTTATCATCAAAATCAAGGGGAAAA  
CATTTCAGCCTTTTACGTGAATTGTATGCTAAACCCCTTATCAGAACGCCATGTGGAATCTGATGGCCT  
TATTTTCGACCCAGCGCAAATCACAAGTCGAACCGCCAGAGGTGTAGCTGTCCCTCATGGTAACCATTA  
CCACTTTTATCCCTTATGAACAAATGCTCTGAATTGGAACCAAGTATGCTCGTATTATCCCTTCGTTA  
TCGTTCAAACCATTTGGGTACCAGATTCAAGACCAGAACAACCAAGTCCACAATCGACTCCGGAACCTAG  
TCCAAGTCCGCAACCTGCACCAAATCCTCAACCAGCTCCAAGCAATCCAATTGATGAGAAATTGGTCAA  
AGAAGCTGTTTCAAAAAGTAGGCGATGGTTATGTCTTTGAGGAGAATGGAGTTTCTCGTTATATCCCAGC  
CAAGGATCTTTTCAAGCAAAACAGCAGCAGGCATTGATAGCAAACCTGGCCAAGCAGGAAAGTTTATCTCA  
TAAGCTAGGAGCTAAGAAAACCTGACCTCCCATCTAGTGATCGAGAATTTTACAATAAGGCTTATGACTT  
ACTAGCAAGAATTCACCAAGATTTACTTGATAATAAAGGTCGACAAGTTGATTTTGAGGCTTTGGATAA  
CCTGTTGGAACGACTCAAGGATGTCNCAAGTGATAAAGTCAAGTTAGTGGANGATATCTTTCCTTCTT  
AGCTCCGATTTCGTATCCAGAACGTTTAGGAAAACCAAAATGCGCAAATTACCTACACTGATGATGAGAT  
TCAAGTAGCCAAGTTGGCAGGCAAGTACACAACAGAAGACGGTTATATCTTTGATCCTCGTGATATAAC  
CAGTGATGAGGGGGATGCCATGTAACTCCACATATGACCCATAGCCACTGGATTAAAAAAGATAGTTT  
GTCTGAAGCTGAGAGAGCGGCAGCCAGGCTTATGCTAAAGAGAAAGGTTTGACCCCTCCTTCGACAGA  
CCATCAGGATTCAGGAAATACTGAGGCAAAAGGAGCAGAAGCTATCTACAACCGGTGAAAGCAGCTAA  
GAAGGTGCCACTTGATCGTATGCCCTTACAATCTTCAATATACTGTAGAAGTCAAAACGGTAGTTTAAT  
CATACCTCATTATGACCATTAACATAACATCAAATTTGAGTGGTTTGACGAAGGCTTTTATGAGGCACC  
TAAGGGGTATACTCTTGAGGATCTTTTGGCGACTGCTCAAGTACTATGTCGAACATCCAAACGAACGTC  
GCATTCAGATAATGGTTTGGTAAACGCTAGCGACCATGTTCAAAGAAACAAAATGGTCAAGCTGATAC  
CAATCAAACGGAACCAAGCGAGGAGAAACCTCAGACAGAAAAACCTGAGGAAGAAACCCCTCGAGA  
AGAGAAACCGCAAAGCGAGAAACAGAGTCTCCAAACCAACAGAGGAACCAGAAGATCACCAGAGGA  
ATCAGAAGAACCTCAGGTCGAGACTGAAAAGGTTGAAGAAAACTGAGAGAGGCTGAAGATTTACTTGG  
AAAAATCCAGGAT

**SP042 amino acid (SEQ ID NO:66)**

CSYELGRHQAGQVKESNRVSYIDGDQAGQKAENLTPDEVSKREGINAEQXVIKITDQGYVTSBGDHYH  
YYNGKVPYDAIISEELMKDPNYQLKDSDIVNEIKGGYVIKVNKYYVYLKDAHADNIRTKKEIKRQK  
QERSHNHNSRADNAVAARAQGRYTTDDGYIFNASDIEDTGDAYIVPHGDHYHYIPKNELSA SELAAA  
EAYWNGKQGSRPSSSSSYNANPAQPLRSENHNLTVPTYHQNGENISSLLRELYAKPLSERHVESDGL  
IFDPAQITSRARGVAVPHGNHYHFIPYEQMSELEKRIARIIPLYRSNHWVPDSRPEQSPQSTPEPS  
PSPQAPNPQAPSNPIDELVKEAVRKVG DYVFEEENGVSRYIPAKDLAETAAGIDSKLAKQESLSH  
KLGAKKTDLPSSDREFYNKAYDLLARIHQDLLDNKGRQVDFEALDNLLERLKDVXSDKVLVXDILAF  
APIRHPERLGKPNQITYTDEIQVAKLAGKYTTEDGYIFDPRDITSDEGDAYVTPHMTSHWIKKDSL  
SEAERAAAQAYAKEKGLTPSTDHQDSGNTEAKGAEAIYNRVKAAKKVPLDRMPYNLQYTVVEVKNGLI  
IPHYDHYHNIKFEWFDEGLYEAPKGYTLEDLLATVKYYVEHPNERPHSDNGFGNASDHVQRNKGQADT  
NQTEKPSSEKQTEKPEETPREKQSEKPEPKTEPEESPEESEEPQVETEKVEEKLREAEDLLG  
KIQD

**SP043 nucleotide (SEQ ID NO:67)**

TTATAAGGGTGAATTAGAAAAAGGATACCAATTTGATGGTTGGGAAATTTCTGGTTTCGAAGGTAAAAA  
AGACGCTGGCTATGTTATTAATCTATCAAAAGATACCTTTATAAAACCTGTATTCAAGAAAATAGAGGA  
GAAAAAGGAGGAAGAAAATAAACCTACTTTTGATGTATCGAAAAAGAAAGATAACCCACAAGTAAACCA  
TAGTCAATTAAATGAAAGTCACAGAAAAGAGGATTTACAAAGAGAAGAGCATTACAAAAATCTGATTC  
AACTAAGGATGTTACAGCTACAGTTCTTGATAAAAACAATATCAGTAGTAAATCAACTACTAACAATCC  
TAATAAG

**SP043 amino acid (SEQ ID NO:68)**

YKGELEKGYQFDGWEISGFEGKKDAGYVINLSKDTFIKPVFKKIEEKKEENKPTFDVSKKKDNPOVNH  
SQLNESHKEDLQREEHSQKSDSTKDVTTATVLDKNNISSKSTNNPNK

**SP044 nucleotide (SEQ ID NO:69)**

GAATGTTTCAGGCTCAAGAAAGTTCAGGAAATAAAATCCACTTTATCAATGTTCAAGAAGGTGGCAGTGA  
TGCGATTATTTCTTGAAAGCAATGGACATTTTGCCATGGTGGATACAGGAGAAGATTATGATTTCCGAGA  
TGGAAGTGATTTCTCGCTATCCATGGAGAGAAGGAATTGAAACGCTTATAAGCATGTTCTTAACAGACCG  
TGTCTTTCTGCTTTGAAGGAATTGGGTGTCCAAAACTTGATTTTATTTTGGTGACCCATACCCACAG  
TGATCATATTGGAATGTTGATGAATTACTGTCTACCTATCCAGTTGACCGAGTCTATCTTAAGAAATA



Table 1

63

TAGTGATAGTCGTATTACTAATTCTGAACGTCTATGGGATAATCTGTATGGCTATGATAAGGTTTTACA  
GACTGCTGCAGAAAAAGGTGTTTCAGTTATTCAAATATCACACAAGGGGATGCTCATTTTCAGTTTGG  
GGACATGGATATTCAGCTCTATAATTATGAAATGAAACTGATTTCATCGGGTGAATTAAAGAAAAATTG  
GGATGACAAATCCAATTCCTTGATTAGCGTGGTGAAAGTCAATGGCAAGAAAAATTACCTTGGGGCCGA  
TTTAGATAATGTTTCATGGAGCAGAAGACAAGTATGGTCCTCTCATTTGAAAAAGTTGATTGATGAAGTT  
TAATCATCACCATGATACCAACAAATCAAATACCAAGGATTTTCATTAATAAATTTGAGTCCGAGTTTGAT  
TGTTCAAACCTTCGGATAGTCTACCTTGGAAAAATGGTGTGATAGTGAGTATGTTAATTGGCTCAAAGA  
ACGAGGAATTGAGAGAATCAACGCAGCCAGCAAAGACTATGATGCAACAGTTTTTGATATTCGAAAAGA  
CGGTTTTGTCAATATTTCAACATCCTACAAGCCGATTCCAAGTTTTCAAGCTGGTTGGCATAAGAGTGC  
ATATGGGAACCTGGTGGTATCAAGCGCCTGATTCTACAGGAGAGTATGCTGTCGGTTGGAATGAAATCGA  
AGGTGAATGGTATTACTTTAACCACAAACGGGTATCTTGTTACAGAATCAATGGAAAAATGGAACAATCA  
TTGGTTCTATTTGACAGACTCTGGTGTCTCTGCTAAAAATTTGGAAGAAAAATCGCTGGAATCTGGTATTA  
TTTTAACAAAGAAAACAGATGAAAATTTGGTTGGATTCAAGATAAAGAGCAGTGGTATTATTTGGATGT  
TGATGGTTCTATGAAGACAGGATGGCTTCAATATATGGGGCAATGGTATTACTTTGCTCCATCAGGGGA  
A

**SP044 amino acid (SEQ ID NO:70)**

INVQAQESSGNKIHFINVQEGGSDAIILESNHFMVDTGEDYDFPDGSDSRYPWREGIETSYKHLVLTDR  
VFRRLKELGVQKLDLDFILVTHTHSDHIGNVDELLSTYFVDRVYLKKYSDSRITNSERLWDNLYGYDKVLQ  
TAAEKGVSVIQNITQGDHAFQFGDMDIQLYNYENETDSSGELKKIWDDNSNSLISVVKVNGKKIYVLGGD  
LDNVHGAEDKYGPLIGKVDLMKFNHHDNTKSNKDFIKNLSPLIVQTSDSLWPKNGVDSEYVNWNLKE  
RGIERINAASKDYDATVFDIRKDGFEVNIISTYKPIPSFQAGWHKSAYGNWYQAPDSTGEYAVGWNEIE  
GEWYYFNQTGILLQNWKKWNHWFYLTDSGASAKNWKKIAGIWIYYFNKENQMEIGWIQDKEQWYLDV  
DGSMTGTWLQYMGQWYFAPSGE

**SP045 nucleotide (SEQ ID NO:71)**

CTTGGGTGTAACCCATATCCAGCTCCTTCCAGTCTTGTCTTACTACTTTGTCAATGAATTGAAAAACCA  
TGAACGCTTGTCTGACTACGCTTCAAGCAACAGCAACTACAACCTGGGGATATGACCCTCAAACCTACTT  
CTCCTTGACTGGTATGTACTCAAGCGATCCTAAGAATCCAGAAAAACGAATCGCAGAATTTAAAAACCT  
CATCAACGAAATCCACAAACGTGGTATGGGAGCTATCCTAGATGTCGTTTATAACCACACAGCCAAAGT  
CGATCTCTTTGAAGATTTGGAACCAACTACTACCATTATGGATGCCGATGGCACACCTCGAAGTATG  
CTTTGGTGGTGGACGCTTGGGGACAACCCACCATATGACCAAAACGGCTCCTAATTGACTCTATCAAATA  
CCTAGTTGATACCTACAAAGTGATGGCTTCCGTTTCGATATGATGGGAGACCATGACGCCGCTTCTAT  
CGAAGAAGCTTACAAGGCTGCACGCGCCCTCAATCCAAACCTCATCATGCTTGGTGAAGGTTGGAGAAC  
CTATGCCGGTGATGAAAACATGCCTACTAAAGCTGCTGACCAAGATTGGATGAAACATACCGATACTGT  
CGCTGTCCTTTTCAGATGACATCCGTAACAACCTCAAATCTGGTTATCCAAACGAAGGTCAACCTGCCTT  
TATCACAGGTGGCAAGCGTGATGTCAACACCATCTTTAAAAATCTCATTTGCTCAACCAACTAACTTTGA  
AGCTGACAGCCCTGGAGATGTCATCCAATACATCGCAGCCCATGATAACTTGACCCTCTTTGACATCAT  
TGCCCAGTCTATCAAAAAAGACCCAAAGCAAGGCTGAGAACTATGCTGAAATCCACCGTCTGTTTACGACT  
TGGAATCTCATGGTCTTGACAGCTCAAGGAACCTCATTATCCACTCCGGTCAGGAATATGGACGTAC  
TAAACAATTCCTGACCCAGCCTACAAGACTCCAGTAGCAGAGGATAAGGTTCCAAACAAATCTCACTT  
GTTGCGTGATAAGGACGGCAACCCATTTGACTATCCTTACTTCATCCATGACTCTTACGATTCTAGTGA  
TGCAGTCAACAAGTTTGACTGGACTAAGGCTACAGATGGTAAAGCTTATCCTGAAAAATGTCAAGAGCCG  
TGACTATATGAAAGGTTTGATTGCCCTTCGTCAATCTACAGATGCCTTCCGACTTAAGAGTCTTCAAGA  
TATCAAAGACCGTGTCCACCTCATCACTGTCCAGGCCAAAAATGGTGTGGAAAAAGAGGATGTAGTGAT  
TGGCTACCAAATCACTGCTCCAAACGGCGATATCTACGCAGTCTTTGTCAATGCGGATGAAAAAGCTCG  
CGAATTTAATTTGGGAACCTGCCTTTGCACATCTAAGAAATGCGGAAGTTTGGCAGATGAAAAACCAAGC  
AGGACCAGTCGGAATTGCCAACCCGAAAGGACTTGAATGGACTGAAAAAGGCTTGAAATGGAATGCCCT  
TACAGCTACTGTTCTTCGAGTCTCTCAAATGGAAGTACCATGAGTCAACTGCAGAAAGAGAAACCAGA  
CTCAACCCCTTCCAAGCTGAACATCAAATGAAGCTTCTACCCCTGCACATCAAGACCCAGCTCCAGA  
AGCTAGACCTGATTCTACTAAACAGATGCCAAAGTAGCTGATGCGGAAAAATAAACCTAGCCAAGCTAC  
AGCTGATTCAACAAGCTGAACAACAGCACAAGAAGCACAAGCATCATCTGTAAAAAGACGGGTTGAAA  
CGAATCGGTAGAAAACTCTAGCAAGGAAAAATATACCTGCAACCCAGATAAACAAAGCTGAA

**SP045 nucleotide (SEQ ID NO:72)**

LGVTHIQLLPVLSYYFVNELKNHERLSDYASSNSNYNWGYDPQNYFSLTGMYSDDPKNPEKRIAEPKLN  
INEIHKRGMGAILDVVYNHTAKVDLFEDLEPNYYHFMDADGTPRTSFGGGRLGTTTHMTKRLLIDSIKY  
LVDITYKVDGFRFDMMDHDAASIEEAYKAARALNPNLIMLGEGWRTYAGDENMPTKAADQDWMKHTDTV

Table 1

AVFSDDIRNNLKSYPNEGQPAFITGGKRDVNTIFKNLIAQPTNFEADSPGDVIQYIAAHNLTFLFDII  
AQSIKKDPSKAENYAEIHRRLRLGNLMVLTAQGTPIHSGQEYGRTKQFRDPAYKTPVAEDKVPNKS  
LRDKDGNPFDPYFYIHDSYDSSDAVNKFDWTKATDGKAYPENVKSRDYMKGILALRQSTDAFRLKSLQD  
IKDRVHLITVPGQNGVEKEDVIGYQITAPNGDIYAVFVNADEKAREFNLGTAFAHLRNAEVLADENQA  
GPVGIANPKGLEWTEKGLKLNALTATVLRVSQNGTSHESTAEKPDSTPSKPEHQNEASHPAHQDPAPE  
ARPDSTKPKDAKVADAENKPSQATADSQAEQPAQEAQASSVKEAVRNESVENSSKENIPATPKQAE

**SP046 nucleotide (SEQ ID NO:73)**

TAGTGATGGTACTTGGCAAGGAAAACAGTATCTGAAAGAAGATGGCAGTCAAGCAGCAAATGAGTGGGT  
TTTNGATACTCATTATCAATCTTGGTCTATATAAAAGCAGATGCTAACTATGCTGAAAATGAATGGCT  
AAAGCAAGGTGACGACTATTTTTACCTCAAATCTGGTGGCTATATGGCCAAATCAGAATGGGTAGAAGA  
CAAGGGAGCCTTTTATATCTTGACCAAGATGGAAAGATGAAAAGAAATGCTTGGGTAGGAACCTTCCTA  
TGTTGGTGCAACAGGTGCCAAAGTAATAGAAGACTGGGTCTATGATTCTCAATACGATGCTTGGTTTTA  
TATCAAAGCAGATGGACAGCACGCAGAGAAAAGAAATGGCTCCAAATTAAAGGGAAGGACTATTATTTCAA  
ATCCGGTGGTTATCTACTGACAAGTCAGTGGATTAATCAAGCTTATGTGAATGCTAGTGGTGCCAAAGT  
ACAGCAAGGTGGCTTTTGGACAAACAATACCAATCTTGGTTTTACATCAAAGAAAATGGAACTATGC  
TGATAAAGAATGGATTTTCGAGAATGGTCACTATTATTATCTAAAATCCGGTGGCTACATGGCAGCCAA  
TGAATGAAATTTGGGATAAGGAATCTTGGTTTTATCTCAAATTTGATGGGAAAATGGCTGAAAAGAATG  
GGTCTACGATTCTCATAGTCAAGCTTGGTACTACTTCAAATCCGGTGGTTACATGACAGCCAATGAATG  
GATTTGGGATAAGGAATCTTGGTTTTACCTCAAATCTGATGGGAAAATAGCTGAAAAGAATGGGTCTA  
CGATTCTCATAGTCAAGCTTGGTACTACTTCAAATCTGGTGGCTACATGGCGAAAATGAGACAGTAGA  
TGGTTATCAGCTTGGAAAGCGATGGTAAATGGCTTGGAGGAAAACTACAAATGAAAATGCTGCTTACTA  
TCAAGTAGTGCTTACAGCCAATGTTTATGATTTCAGATGGTGAAAAGCTTTCCTATATATCGCAAGG  
TAGTGTCGTATGGCTAGATAAGGATAGAAAAAGTGATGACAAGCGCTTGGCTATTACTATTTCTGGTTT  
GTCAGGCTATATGAAACAGAAGATTTACAAGCGCTAGATGCTAGTAAGGACTTTATCCCTTATTATGA  
GAGTGATGGCCACCGTTTTTATCACTATGTGGCTCAGAAATGCTAGTATCCCAGTAGCTTCTCATCTTTC  
TGATATGGAAGTAGGCAAGAAATATTATTCGGCAGATGGCTGCATTTTGATGGTTTTAAGCTTGAGAA  
TCCCTTCCCTTTTCAAAGATTTAACAAGAGGCTACAACTACAGTGTGAAGAATTGGATAAGGTATTTAG  
TTTGCTAAACATTAAACAATAGCCTTTTGGAGAACAAGGGCGCTACTTTAAGGAAGCCGAAGAACATTA  
CCATATCAATGCTCTTTATCTCTTGGCCATAGTGCCCTAGAAAAGTAACTGGGGAAGAAGTAAATTTGC  
CAAAGATAAGAATAAATTTCTTTGGCATTACAGCCATGATGATACGACCCCTTACCTTTCTGCTAAGACAT  
TGATGATGTGGATAAGGAATTTTAGGTGCAACCAAGTGGATTAAGGAAAATTTATTCGATAGGGGAAG  
AACTTTCCTTGGAAACAAGGCTTCTGGTATGAATGTGGAATATGCTTCAGACCCCTTATTGGGGCGAAAA  
AATTGCTAGTGTGATGATGAAAATCAATGAGAAGCTAGGTGGCAAAGAT

**SP046 amino acid (SEQ ID NO:74)**

SDGTWQGGKQYLKEDGSQAANEVVDTHYQSWFYIKADANYAENEWLKQGGDDYFYLKSGGYMAKSEWVED  
KGAFFYLDQDGKMKRNAWVGTSYVGATGAKVIEDWVYDSQYDAWFYIKADGQHAKEWLQIKGKDYYFK  
SGGYLLTSQWINQAYVNASGAKVQGGWLFQKQYQSWFYIKENGYADKEWIFENGHYFYLKSGGYMAAN  
EWIWDKESWFLKFDGKMAEKWVYDSHSQAWYFYKSGGYMTANEWIWDKESWFLKSDGKIAEKWVY  
DSHSQAWYFYKSGGYMAKNETVDGYQLGSDGKWLGGKTTNENAAYYQVVPVTANVYDSDGEKLSYISQ  
SVVWLDKDRKSDDKRLAITISGLSGYMKTEDLQALDASKDFIPYYESDGHRYFYHYVAQNASIPVASHLS  
DMEVGKKYYSADGLHFDGFKLENPFLLFKDLTEATNYSAEELDKVFSLLNINNSLLENKGATFKEAEHY  
HINALYLLAHSALSNWGRS KIAKDKNNFFGITAYDTPYLSAKTFDDVDKGILGATKWKIENYIDRGR  
TFLGNKASGMNVEYASDPYWGKIASVMMKINEKLGGKD

**SP048 nucleotide (SEQ ID NO:75)**

TGGGATTCAATATGTCAGAGATGATACTAGAGATAAAGAAGAGGGAATAGAGTATGATGACGCTGACAA  
TGGGGATATTATTGTAAAAGTAGCGACTAAACCTAAGGTAGTAACCAAGAAAATTTCAAGTACGCGAAT  
TCGTTATGAAAAAGATGAAACAAAAGACCGTAGTGAAAACTCTGTTACAATTGATGGAGAGGATGGCTA  
TGTAACACGACAAGGACCTACGATGTTAATCCAGAGACTGGTTATGTTACCGAACAGGTTACTGTTGA  
TAGAAAAGAAGCCACGATACAGTTATCAAAGTTCAGCTAAAAGCAAGGTTGAAGAAGTTCTTGTTC  
ATTGCTACTAAATATGAAGCAGACAATGACCTTTCTGCAGGACAGGAGCAAGAGATTACTCTAGGAAA  
GAATGGGAAAACAGTTACAACGATAACTTATAATGTAGATGGAAAGAGTGGACAAGTAAGTGAAGTAC  
TTTAAGTCAAAAAAAGACTCTCAAACAAGAGTTGTTAAAAAAGAACCArKCCCCAAGTTCTTGTCCA  
AGAAATTCGAATCGAAACAGAATATCTCGATGGCCCACTCTTGATAAAAGTCAAGAAAGTAGAAGAAGT  
AGGAGAAATTTGGTAAATTAATCTTACTACAATCTATACTGGTAGATGAACGTGATGGAAACAATTTGAAGA  
AACTACTTCTCGTCAAATTAATTAAGAGATGGTAAAAAGACGTATAAGGAGAGGGACGAGAGAACCTGA

65

SP051 nucleotide (SEQ ID NO:81)

Table 1

ATCTGTAGTTTATGCGGATGAAACACTTATTACTCATACTGCTGAGAAACCTAAAGAGGAAAAAATGAT  
AGTAGAAGAAAAGGCTGATAAAGCTTTGGAACTAAAAATATAGTTGAAAGGACAGAACAAAGTGAACC  
TAGTTCAACTGAGGCTATTGCATCTGAGNAGAAAGAAGATGAAGCCGTAACCCAAAAGAGGAAAAAGT  
GTCTGCTAAACCGGAAGAAAAAGCTCCAAGGATAGAATCACAAGCTTCAAATCAAGAAAAACCGCTCAA  
GGAAGATGCTAAAGCTGTAACAAATGAAGAAGTGAATCAAATGATTGAAGACAGGAAAGTGGATTTTAA  
TCAAAATTGGTACTTTAACTCAATGCAAAATTCTAAGGAAGCCATTAAACCTGATGCAGACGTATCTAC  
GTGGAAAAAATTAGATTTACCGTATGACTGGAGTATCTTTAACGATTTTCGATCATGAATCTCCTGCACA  
AAATGAAGGTGGACAGCTCAACGGTGGGGAAGCTTGGTATCGCAAGACTTTCAAACCTAGATGAAAAAGA  
CCTCAAGAAAAATGTTTCGCCTTACTTTTGTATGGCGTCTACATGGATTCTCAAGTTTATGTCAATGGTCA  
GTTAGTGGGGCATTATCCAAATGGTTATAACCAGTTCTCATATGATATCACCAAATACCTTCAAAAAGA  
TGGTCGTGAGAATGTGATTGCTGTCCATGCAGTCAACAAACAGCCAAGTAGCCGTTGGTATTTCAGGAAG  
TGGTATCTATCGTGATGTGACTTTACAAGTGACAGATAAGGTGCATGTTGAGAAAAATGGGACAACCTAT  
TTTAACACCAAACTTGAAGAACAACAATGGCAAGGTTGAAACTCATGTGACCAGCAAAATCGTCAA  
TACGGACGACAAAGACCATGAACCTGTAGCCGAATATCAAATCGTTGAACGAGGTGGTTCATGCTGTAAC  
AGGCTTAGTTTCGTACAGCGAGTCTGACCTTAAAAGCACATGAATCAACAAGCCTAGATGCGATTTTAGA  
AGTTGAAAGACCAAACTCTGGACTGTTTAAATGACAAACCTGCCTTGTACGAATTGATTACGCGTGT  
TTACCGTGACGGTCAATTGGTTGATGCTAAGAAGGATTTGTTTGGTTACCGTTACTATCACTGGACTCC  
AAATGAAGGTTTCTCTTTGAATGGTGAACGTATTAAATTCATGGAGTATCCTTGCACCACGACCATGG  
GGCGCTTGGAGCAGAAGAAAACCTATAAAGCAGAATTTCGCCCTCTCAAAACAAATGAAGGAGATGGGAGT  
TAACCTCCATCCGTACAACCCACAACCCCTGCTAGTAGCAAAACCTTGCAAAATCGCAGCAAACTAGGTTT  
ACTCGTTTCAAGGAAGAGGCTTTGATACGTGGTATGGTGGCAAGAAACCTTATGACTATGGACGTTTCTTT  
TGAAAAAGATGCCACTCACCCAGAAGCTCGAAAAGGTGAAAAATGGTCTGATTTTGACCTACGTACCAT  
GGTCGAAAGAGGCAAAACAACCCCTGCTATCTTCATGTGGTCAATTGGTAATGAAATAGGTGAAGCTAA  
TGGTGATGCCCCACTCTTTAGCAACTGTTAAACGTTTGGTTAAGGTTATCAAGGATGTTGATAAGACTCG  
CTATGTTACCATGGGAGCAGATAAAATCCGTTTTCGGTAATGGTAGCGGAGGGCATGAGAAAAATTGCTGA  
TGAACCTCGATGCTGTTGGATTTAACTATTCTGAAGATAATTACAAAGCCCTTAGAGCTAAGCATCCAAA  
ATGGTTGATTTATGGATCAGAAACATCTTCAGCTACCCGTACACGTGGAAGTTACTATCGCCCTGAACG  
TGAATTGAAACATAGCAATGGACCTGAGCGTAATTATGAACAGTCAGATTATGGAAATGATCGTGTGGG  
TTGGGGGAAAACAGCAACCCGCTTCATGGACTTTTGACCGTGACAACGCTGGCTATGCTGGACAGTTTAT  
CTGGACAGGTACGGACTATATTGGTGAACCTACACCATGGCACAACCAAAATCAAACCTCTGTTAAGAG  
CTCTTACTTTGGTATCGTAGATACAGCCGGCATCCAAAACATGACTTCTATCTCTACCAAAGC

## SP051 amino acid (SEQ ID NO:82)

SVVYADETLITHAEKPKEEKMIVEEKADKALETKNIVERTEQSEPSSTEAIASEXKEDEAVTPKEEKV  
SAKPEEKAPRIESQASNQEKPLKEDAKAVTNEEVNQMIEDRKVDNFQNWYFKLNANSKEAIKPDADVST  
WKKLDLPYDWSIFNDFHESPAQNEGGQLNGGEAWYRKTFKLDEKDLKKNVRLTFDGVYMDSQVYVNGQ  
LVGHYPNGYNQFSYDITKYLQKDGRENVIHAVHNKQPSRWYSGSGIYRDVTLQVTDKVHVEKNGTTI  
LTPKLEEQQHGVETHVTSKIVNTDDKDELVAEQIVERGGHAVTGLVRTASRTLKAHESTSLDAILE  
VERPKLWTVLNDKPALYELITRVYRDGQLVDAKKDLFGYRYHWPNEGFSLNGERIKFHGVSLHHDHG  
ALGAENYKAERYRLKQMKEMGVNSIRTTNHPASEQTLQIAAELGLLVQEEAFDTWYGGKKPYDYGRFF  
EKDATHPEARKGEKWSDFDLRTMVERGKNNPAIFMWSIGNEIGEANGDAHSLATVKRLVKVIKDVKTR  
YVTMGADKFRFGNGSGGHEKIADELDAVGFNYSYEDNYKALRAKHPKWLIIYGSETSSATRTRGSYYRPER  
ELKHSNGPERNYEQSDYGNDRVWGKTATASWTFDRDNAGYAGQFIWTGTDYIGEPTPWHNQNPQTPVKSS  
SYFGIVDTAGIPKHDFYLYQS

## SP052 nucleotide (SEQ ID NO:83)

TTACTTTGGTATCGTAGATACAGCCGGCATTCAAAACATGACTTCTATCTCTACCAAAGCCAATGGGT  
TTCTGTTAAGAAGAAACCGATGGTACACCTTCTTCTCACTGGAAGTGGGAAAACAAAGAATTAGCATC  
CAAAGTAGCTGACTCAGAAGGTAAGATTCCAGTTCGTGCTTATTTCGAATGCTTCTAGTGATAGAAATGTT  
CTTGAATGGAAAATCTCTTGGTCTTAAGACTTTCAATAAAAAACAAACCAGCGATGGGCGGACTTACCA  
AGAAGGTGCAAAATGCTAATGAACCTTATCTTGAATGGAAAGTTGCCTATCAACCAGGTACCTTGGAAGC  
AATTGCTCGTGATGAATCTGGCAAGGAAATGCTCGAGATAAGATTACGACTGCTGGTAAGCCAGCGGC  
AGTTCGCTCTTATTAAGGAAGACCATGCGATTGCAGCAGATGGAAAAGACTTGACTTACATCTACTATGA  
AATTGTTGACAGCCAGGGGAATGTGGTTCCAACCTGCTAATAATCTGGTTCGCTTCCAATTGCATGGCCA  
AGGTCAACTGGTGGTGTAGATAACGGGAGAACAGCCAGCCGTGAACGCTATAAGGCGCAAGCAGATGG  
TTCTTGGATTTCGTAAAGCATTTAATGGTAAAGGTGTTGCCATTGTCAAATCAACTGAACAAGCAGGGAA  
ATTCAACCTGACTGCCCCTCTGATCTCTTGAATCGAACCAAGTCACTGTCTTTACTGGTAAGAAAGA  
AGGACAAGAGAAGACTGTTTTGGGGACAGAAGTGCCAAAAGTACAGACCATTATTGGAGAGGCACCTGA

Table 1

67

AATGCCTACCACTGTTCCGTTTGTATACAGTGATGGTAGCCGTGCAGAACGTCCTGTAACCTGGTCTTC  
AGTAGATGTGAGCAAGCCTGGTATTGTAACGGTGAAAGGTATGGCTGACGGACGAGAAGTAGAAGCTCG  
TGTAAGAGTGATTGCTCTTAAATCAGAGCTACCAGTTGTGAAACGTATTGCTCCAAATACTGACTTGAA  
TTCTGTAGACAAATCTGTTTCCTATGTTTGGATTGATGGAAGTGTGAAGAGTATGAAGTGGACAAGTG  
GGAGATTGCCGAAGAAGATAAAGCTAAGTTAGCAATTCAGGTTCTCGTATTCAAGCGACCGGTTATTT  
AGAAGGTCAACCAATTCATGCAACCCCTGTGGTAGAAGAAGGCAATCCTGCGGCACCTGCAGTACCAAC  
TGTAACGGTTGGTGGTGAGGCAGTAACAGGTCTTACTAGTCAAAAACCAATGCAATACCGCACTCTTGC  
TTATGGAGCTAAGTTGCCAGAAGTCACAGCAAGTCTAAAAATGCAGCTGTTACAGTTCTTCAAGCAAG  
CGCAGCAAACGGCATGCGTGCGAGCATCTTTATTTCAGCCTAAAGATGGTGGCCCTCTTCAAACCTATGC  
AATTCATTCCTTGAAGAAGCGCCAAAAATTGCTCACTTGAGCTTGCAAGTGGAAAAAGCTGACAGTCT  
CAAAGAAGACCAAACCTGTCAAATTGTCGGTTCGAGCTCACTATCAAGATGGAACGCAAGCTGTATTACC  
AGCTGATAAAGTAACCTTCTCTACAAGTGGTGAAGGGGAAGTCGCAATTCGTAAAGGAATGCTTGAGTT  
GCATAAGCCAGGAGCAGTCACTCTGAACGCTGAATATGAGGGAGCTAAAGACCAAGTTGAACTCACTAT  
CCAAGCCAATACTGAGAAGAAGATTGCGCAATCCATCCGTCCTGTAAATGTAGTGACAGATTGTCATCA  
GGAACCAAGTCTTCCAGCAACAGTAACAGTTGAGTATGACAAAGGTTTCCCTAAAACCTATAAAGTCAC  
TTGGCAAGCTATTCCGAAAGAAAACTAGACTCCTATCAAACATTGAAAGTACTAGGTAAAGTTGAAGG  
AATTGACCTTGAAGCGCGTGCAAAAGTCTCTGTAGAAGGTATCGTTTCAGTTGAAGAAGTCAGTGTGAC  
AATCCAATCGCAGAAGCACCACAATTACCAGAAAGTGTTCGGACATATGATTCAAATGGTCACGTTTC  
ATCAGCTAAGGTTGCATGGGATGCGATTTCGTCCAGAGCAATACGCTAAGGAAGGTGCTTTACAGTTAA  
TGGTCGCTTAGAAGGTACGCAATTAACA

## SP052 amino acid (SEQ ID NO:84)

YFGIVDTAGIPKHDFYLYQSQWVSVKKKPMVHLLPHWNWENKELASKVADSEGKIPVRAYSNAASSVELF  
LNGKSLGLKTFNKKQTS DGRTYQEGANANELYLEWKVAYQPGTLEAIARDESGKEIARDKITTAGKPAA  
VRLIKEDHAIADGKDLTYIYYEIVDSQGNVPTANNLVRFLHGGQQLVGVNDNGEQASRERYKAQADG  
SWIRKAFNGKGVAIKSTEQAGKFTLTAHSDLLKSNQVTVFTGKKEGQEKTVLGTVEVPKVQTIIGEAP  
MPTTVPFVYSDGSRAERPVTWSSVDVSKPGIVTVKGMADGREVEARVEVIALKSELVVKRIAPNTDLN  
SVDKSVSYVLIDGSVEEYEVDKWEIAEEDKAKLAI PGSRIQATGYLEGQPIHATLVVEEGNPAAPAVPT  
VTVGGEAVTGLTSQKPMQYRTLAYGAKLPEVTASAKNAAVTVLQASAANGMRASIFIQPKDGGPLQTYA  
IQFLEEAPKIAHLSLQVEKADSLKEDQTVKLSVRAHYQDGTQAVLPADKVTFSTSGEGEVAIRKGMLEL  
HKPGAVTLNAEYEGAKDQVELTIQANTEKKIAQSIRPVNVVTDLHQEPSLPATVTEYDKGFPKTHKVT  
WQAIPEKLDYSYQTFEVLGKVEGIDLEARAKVSEVIGVSVEEVSVTTPIAEAPQLPESVRTYDSNGHVS  
SAKVAWDAIRPEQYAKEGVFTVNGRLEGTQLT

## SP053 nucleotide (SEQ ID NO:85)

AGCTAAGGTTGCATGGGATGCGATTTCGTCCAGAGCAATACGCTAAGGAAGGTGTCTTTACAGTTAATGG  
TCGCTTAGAAGGTACGCAATTAACAATAAATTCATGTTTCGCGTATCTGCTCAAACCTGAGCAAGGTGC  
AAACATTTCTGACCAATGGACCGGTTCCAGAAATGCCACTTGCCCTTTGCTTCAGACTCAAATCCAAGCGA  
CCCAGTTTCAAATGTTAATGACAAGCTCATTTCTACAATAACCAACCAGCCAATCGTTGGACAAACTG  
GAATCGTACTAATCCAGAAGCTTCAGTCCGGTGTCTGTTTGGAGATTGAGGTATCTTGAGCAAACGCTC  
CGTTGATAATCTAAGTGTTCGATTCCATGAAGACCATGGAGTTGGTGTACCGAAGTCTTATGTGATTGA  
GTATTATGTTGGTAAGACTGTCCCAACAGCTCTTAAAAACCCCTAGTTTGTGGTAATGAGGACCATGT  
CTTTAATGATTCTGCCAACTGGAAACAGTTACTAATCTAAAAGCCCCCTGCTCAACTCAAGGCTGGAGA  
AATGAACCACTTTAGCTTTGATAAAGTTGAAACCTATGCTGTTTCGTATTTCGCATGGTTAAAGCAGATAA  
CAAGCGTGGAACGTTATACAGAGGTACAAATCTTTGCGAAACAAGTTGCGGCAGCCCAAGCAAGGACA  
AACAAGAATCCAAGTTGACGGCAAGACTTAGCAAACTTCAACCTGATTTGACAGACTACTACCTTGA  
GTCTGTAGATGGAAAAGTTCCGGCAGTCACAGCAAGTGTAGCAACAATGGTCTCGCTACCGTCGTTCC  
AAGCGTTTCGTGAAGGTGAGCCAGTTTCGTGTATCGCGAAAGCTGAAAATGGCGACATCTTAGGAGAATA  
CCGCTGCACTTCACTAAGGATAAGAGCTTACTTTCTCATAAACCAAGTTGCTGCGGTTAAACAAGCTCG  
CTTGCTACAAGTAGGTCAAGCACTTGAATTGCGGACTAAGGTTCCAGTTTACTTCACAGGTAAAGACGG  
CTACGAAACAAAAGACCTGACAGTTGAATGGGAAGAAGTTCCAGCGGAAAATCTGACAAAAGCAGGTCA  
ATTTACTGTTTCGAGGCCGTGTCCTTGGTAGTAACCTTGTGCTGAGATCACTGTACGAGTGACAGACAA  
ACTTGGTGAGACTCTTTCAGATAACCCCTAATATGATGAAAACAGTAACCAGGCCCTTTGCTTCAGCAAC  
CAATGATATTGACAAAACTCTCATGACCGCGTTGACTATCTCAATGACGGAGATCATTCAGAAAATCG  
TCGTTGGACAACTGGTCACCAACACCATCTTCTAATCCAGAAGTATCAGCGGGTGTGATTTTCCGTGA  
AATGGTAAGATTGTAGAACGGACTGTTACACAAGGAAAAGTTCAGTTCTTTGCGATAGTGGTACGGA  
TGCACCATCTAACTCGTTTTAGAACGCTATGTCGGTCCAGAGTTTGAAGTGCCAACTACTATTCAAA  
CTACCAAGCCTACGACGCAGACCATCCATTCAACAATCCAGAAAATTTGGGAAGCTGTTCTTATCGTGC

Table 1

68

GGATAAAGACATTGCAGCTGGTGATGAAATCAACGTAACATTTAAAGCTATCAAAGCCAAAGCTATGAG  
ATGGCGTATGGAGCGTAAAGCAGATAAGAGCGGTGTTGCGATGATTGAGATGACCTTCCTTGCACCAAG  
TGAATTGCCTCAAGAAAGCACTCAATCAAAGATTCTTGTAGATGGAAGAAGCTTGCTGATTTTCGCTGA  
AAATCGTCAAGACTATCAAATTACCTATAAAGGTCAACGGCCAAAAGTCTCAGTTGAAGAAAACAATCA  
AGTAGCTTCAACTGTGGTAGATAGTGGAGAAGATAGCTTCCAGTACTTGTTCGCCTCGTTTCAGAAAG  
TGGAAAACAAGTCAAGGAATACCGTATCCACTTGACTAAGGAAAAACCAGTTCTGAGAAGACAGTTGC  
TGCTGTATAAGAAGATCTTCCAAAAATCGAATTTGTTGAAAAAGATTGCGCATACAAGACAGTTGAGAA  
AAAAGATTCAACACTGTATCTAGGTGAAACTCGTGTAGAACAAGAAGGAAAAGTTGAAAAAGAAGCTAT  
CTTTACAGCGATTAACTCTGTATGGAAGTAAGGAAGAAAACTCCGTGAAGTGGTAGAAGTTCCGACAGA  
CCGCATCGTCTTGGTTGGAACCAAACAGTAGCTCAAGAAGCTAAAAAACACAAGTGTCAAGAAAAGC  
AGATACAAAACCAATTGATTCAAGTGAAGCTAGTCAAACATAATAAGCCAG

**SP053 amino acid (SEQ ID NO:86)**

AKVAWDAIRPEQYAKEGVFTVNGRLEGTQLTKLHVRVSAQTEQGANISDQWTGSELPLAFASDSNPDS  
PVSNNVDKLISSYNNQPANRWTNWNRTNPEASVGVLFGDSGILSKRSVDNLSVGFHEDHGVGVPKSYVIE  
YYVGKTVPTAPKNPSFVGNEDHVFNDNSANWKPVNTLKAPAQLKAGEMNHFSFDKIVETVAVRIRMVKADN  
KRGTSITEVQIFAKQVAAAQGGQTRIQVDGKDLANFNPDLDYVLESVDGKVPVAVTASVSNGLATVVP  
SVREGFPVRVIAKAENGDI LGEYRLHFTKDKSLLSHKPVAAVKQARLLQVGQALELPTKVPVYFTGKDG  
YETKDLTVEEVPAENLTAKAQFTVRGRVLGSNLVAEITVRVTDKLGTELSDNPNYDENSNOAFASAT  
NDIDKNSHDRVLDYLDGDHSENRRWTNWSPTPSSNPEVSAGVIFRENGKIVERTVTQGVQFFADSGTD  
APSKLVLERVVGPEFEVPTYYSNYQAYDADHPFNPNPENWEAVPYRADKDIAAGDEINVTFKAIKAKAMR  
WRMERKADKSGVAMIEMTFLAPSELQESTQSKILVDGKELADFAENRQDYQITYKGQRPKVSVEENNQ  
VASTVVDSGEDSFPVLRVLVSESGKQVKEYRIHLTKEKPVSEKTVAAVQEDLPKIEFEVKDLAYKTVEK  
KDSTLYLGETRVEQEGKVGKERIFTAINPDGSKEEKLREVVEVPTDRIVLVGTPVAQEAKKPQVSEKA  
DTKPIDSSEASQTNKAQ

**SP054 nucleotide (SEQ ID NO:87)**

CTATCACTATGTAAATAAAGAGATTATTTACAAGAAGCTAAAGATTTAATTCAGACAGGAAAGCCTGA  
CAGGAATGAAGTTGTATATGGTTTGGTGTATCAAAAAGATCAGTTGCCTCAAACAGGGACAGAA

**SP054 amino acid (SEQ ID NO:88)**

YHYVNKEIISQEAQDLIQTKPDRNEVVYGLVYQKDQLPQTGTE

**SP055 nucleotide (SEQ ID NO:89)**

TGAGACTCCTCAATCAATAACAAATCAGGAGCAAGCTAGGACAGAAAACCAAGTAGTAGAGACAGAGGA  
AGCTCCAAAAGAAGAAGCACCTAAAACAGAGAAGAAAGTCCAAAGGAAGAACCAAAATCGGAGGTAAAACC  
TACTGACGACACCCCTTCTAAAGTAGAAGAGGGGAAAGAAGATTACAGCAGAACCAGCTCCAGTTGAAGA  
AGTAGGTGGAGAAGTTGAGTCAAAACCAGAGGAAAAAGTAGCAGTTAAGCCAGAAAGTCAACCATCAGA  
CAAACCAGCTGAGGAATCAAAAGTTGAACAAGCAGGTGAACCAGTCGCGCCAAGAGAAGACGAAAAGGC  
ACCAGTCGAGCCAGAAAAGCAACCAGAAGCTCCTGAAGAAGAGAAGGCTGTAGAGGAAACACCGAAAACA  
AGAAGAGTCAACTCCAGATACCAAGGCTGAAGAACTGTAGAACCAAAAGAGGAGACTGTTAATCAATC  
TATTGAACAACCAAAAGTTGAAACGCCTGCTGTAGAAAAACAAACAGAACCAACAGAGGAACCAAAAGT  
TGAACAAGCAGGTGAACCAGTCGCGCCAAGAGAAGACGAAACAGGCACCAACGGCACCAGTTGAGCCAGA  
AAAGCAACCAGAAGTTCTGAAGAAGAGAAGGCTGTAGAGGAAACACCGAAACCAGAAGATAAAATAAA  
GGGTATTGGTACTAAAGAACCAGTTGATAAAAGTGAGTTAAATAATCAAATTGATAAAGCTAGTTTCACT  
TTCTCCTACTGATTAT

**SP055 amino acid (SEQ ID NO:90)**

ETPQSITNQEQARTENQVVETEEAPKEEAPKTEESPKEEPKSEVKPTDDTLPKVEEGKEDSAEPAPVEE  
VGGEVESKPEEKVAVKPESQPSDKPAEESKVEQAGEPVAPREDEKAPVEPEKQPEAPEEEKAVEETPKQ  
EESTPDTKAEETVEPEKETVNSIEQPKVETPAVEKQTEPTEEPKVEQAGEPVAPREDEQAPTAPVEPE  
KQPEVPREEKAVEETPKPEDKIKGIGTKPEVDKSELNNQIDKASSVSPTDY

**SP056 nucleotide (SEQ ID NO:91)**

GGATGCTCAAGAACTGCGGGAGTTCACTATAAATATGTGGCAGATTACAGAGCTATCATCAGAAGAAAA  
GAAGCAGCTTGCTATGATATTCGACATACGTGGAGAATGATGATGAACTTATTATCTTGTATTATAA  
GTTAAATTCTCAAAATCAACTGGCGGAATTGCCAAATACTGGAAGCAAGAAATGAGAGGCAA

Table 1

**SP056 amino acid (SEQ ID NO:92)**

DAQETAGVHYKYVADSELSSEEKKQLVYDIPTYVENDDETYLVYKLNSQNQLAELPNTGSKNERQ

**SP057 nucleotide (SEQ ID NO:93)**

CGACAAAGGTGAGACTGAGGTTCAACCAGAGTCGCCAGATACTGTGGTAAGTGATAAAGGTGAACCAGA  
GCAGGTAGTACCGCTTCCAGAATATAAGGGTAATATTGAGCAAGTAAAACCTGAAACTCCGGTTGAGAA  
GACCAAAGAACAAGGTCCAGAAAAAACTGAAGAAGTTCCAGTAAAACCAACAGAAGAAACACCACTAAA  
TCCAAATGAAGGTACTACAGAAGGAACCTCAATTCAAGAAGCAGAAAAATCCAGTTCAACCTGCAGAAGA  
ATCAACAACGAATTCAGAGAAAGTATCACCAGATACATCTAGCAAAAATACTGGGGAAGTGTCCAGTAA  
TCCTAGTGATTTCGACAACCTCAGTTGGAGAATCAAATAAACAGAACATAATGACTCTAAAAATGAAAA  
TTCAGAAAAAACTGTAGAAGAAGTTCCAGTAAATCCAAATGAAGGCACAGTAGAAGGTACCTCAAATCA  
AGAAACAGAAAAACCAAGTTCAACCTGCAGAAGAAACACAAACAACTCTGGGAAAATAGCTAACGAAAA  
TACTGGAGAAGTATCCAATAAACCTAGTGATTCAAACCAACCAAGTTGAAGAATCAAATCAACCAGAAAA  
AAACGGAACCTGCAACAAAACAGAAAAATTCAGGTAATACAACATCAGAGAAATGGACAAACAGAACCA  
ACCATCAAACGGAATTCAACTGAGGATGTTTCAACCGAATCAAACACATCCAATTCAAATGGAAACGA  
AGAAATTAACAAGAAAAATGAAGTAGACCCTGATAAAAAGGTAGAAGAACCAGAGAAAAACCTTGAATT  
AAGAAAT

**SP057 amino acid (SEQ ID NO:94)**DKGETEVQPESPDTVVSDKGEPEQVAPLPEYKGNIEQVKPETPVEKTKEQGPEKTEEVVVKPTEETPVN  
PNEGTTGTSIQEAENPVQPAEESTTNSEKVSPTSSKNTGEVSSNPSTTSVSGESNKPEHNDSKNEN  
SEKTVEEVVNPNEGTVEGTSNQETEKVPQPAEETQTN SGKIANENTGEVSNKPSDSKPPVEESNQPEK  
NGTATKPENSGNTTSENGQTEPEPSNGNSTEDVSTESNTSNSNGNEEIKQENELDPDKKVEEPEKTLEL  
RN**SP058 nucleotide (SEQ ID NO:95)**

AAATCAATTGGTAGCACAGATCCAAAAGCACAGATAGCACTAACTGACTGCTGAAAAATCAACTGT  
TAAAGCACCTGCTCAAAGAGTAGATGTAAGATATAACTCATTTAACAGATGAAGAAAAAGTTAAGGT  
TGCTATTTTACAAGCAAATGGTTCAGCATTAGACGGAGCGACAATCAATGTAGCTGGAGATGGTACAGC  
AACAAATCACATTTCCAGATGGTTCAGTAGTGACGATTCTAGGAAAAGATACAGTTCAACAATCTGCGAA  
AGGTGAATCTGTAACCAAGAAGCTACACCAGAGTATAAGCTAGAAAAATACACCAGGTGGAGATAAGGG  
AGGCAATACTGGAAGCTCAGATGCTAATGCGAATGAAGGCGGTGGTAGCCAGGCGGTGGATCAGCTCA  
CACAGGTTACAAAACTCAGCTCAATCACAAGCTTCTAAGCAATTAGCTACTGAAAAAGAATCAGCTAA  
AAATGCCATTGAAAAAGCAGCCAAGGACAAGCAGGATGAAATCAAAGGCGCACCGCTTTCTGTATAAGA  
AAAAGCAGAACTTTTAGCAAGAGTGGAAGCAGAAAAACAAGCAGCTCTCAAAGAGATTGAAATGCGAA  
AACTATGGAAGATGTGAAGGAAGCAGAAACGATTGGAGTGCAAGCCATTGCCATGGTTACAGTTCTTAA  
GAGACCAGTGGCTCCTAAT

**SP058 amino acid (SEQ ID NO:96)**NQLVAQDPKAQDSTKLTAEKSTVKAPAQRVDVKDITHLTDEEKVKVAILQANGSALDGATINVAGDGT  
TITFPDGSVVTILGKDTVQQSAGGESVTQEATPEYKLENTPGGDKGGNTGSSDANANEGGGSQAGGSAH  
TGSQNSAQSQASKQLATEKESAKNAIEKAAKDKQDEIKGAPLSDKEKAELLARVEAEKQAALKEIENAK  
TMEDVKEAETIGVQAIAMVTVPKRPVAPN**SP059 nucleotide (SEQ ID NO:97)**

CAACAGTCAGTTCAGGAACGATTGAGGTGATTTACAGAGAAAATGGCTCTGGGACACGGGGTGCCTT  
CACAGAAATCACAGGGATTCTCAAAAAAGACGGTGATAAAAAAATTGACAACACTGCCAAAACAGCTGT  
GATTCAAAATAGTACAGAAGGTGTCTCTCAGCAGTTCAAGGGAATGCTAATGCTATCGGCTACATCTC  
CTTGGGATCTTTAACGAAATCTGTCAAGGCTTTAGAGATTGATGGTGTCAAGGCTAGTCGAGACACAGT  
TTTAGATGGTGAATACCTCTTCAACGTCCCTTCAACATTGTTTGGTCTTCTAATCTTTCCAAGCTAGG  
TCAAGATTTTATCAGCTTTATCCACTCCAAACAAGGTCAACAAGTGGTCACAGATAATAAATTTATTGA  
AGCTAAAACCGAAACCGGAATATACAAGCCAACACTTATCAGGCAAGTTGTCTGTTGTAGGTTCCAC  
TTCAGTATCTTCTTAATGGAATAATAGCAGAAGCTTATAAAAAAGAAAATCCAGAAGTTACGATTGA  
TATTACCTCTAATGGGTCTTTCAGCAGGTATTACCGCTGTTAAGGAGAAAACCGCTGATATTGGTATGGT  
TTCTAGGGAATTAACCTCTGAAGAAGGTAAGAGTCTACCCATGATGCTATTGCTTTAGACGGTATTGC  
TGTGTGGTCAATAATGACAATAAGCCAAGCAAGTCAGTATGGCTGAAGTTCAGACGTTTTTAGTGG  
CAAAATTAACCACTGGGACAAGATTAAA

Table 1

**SP059 amino acid (SEQ ID NO:98)**

KQSASGTIEVISRENGSGTRGAFTEITGILKKDGGKKIDNTAKTAVIQNSTEGVLSAVQGNANAIGYIS  
LGSITKSVKALEIDGVKASRDTVLDGEYPLQRPFNIVWSSNLSKLGQDFISFIHSKQGGQVVDNKFIE  
AKTETTEYTSQHLGKLSVVGSTSVSSLMEKLA EAYKKENPEVTIDITSNGSSAGITAVKEKTADIGMV  
SRELTPEEGKSLTHDAIALDGIADVNNNDNKASQVSMELADVFSGKLTTWDKIK

**SP060 nucleotide (SEQ ID NO:99)**

ATTGATGATGCGGATGAAAAGATGACCCGTGATGAAATTGCCTATATGCTGACAAATAGTGAAGAAAC  
ATTGGATGCTGATGAGATTGAGATGCTACAAGGTGTCTTTTCGCTCGATGAAGTATGGCAGGAGAGGT  
TATGGTTCTCTGAACGGATGCCTTTATGGTGGATATTCAGGATGATAGTCAAGCCATTATCCAAAGTAT  
TTTAAACAAAATTATTCTCGTATCCCGGTTTATGATGGGGATAAGGACAATGTAATTGGAATCATTCA  
CACCAAGAGTCTCCTTAAGGCAGGCTTTGTGGACGGTTTTGACAATATTGTTTGAAGAGAATTTTACA  
AGATCCACTTTTTGTACCTGAAACTATTTTTGTGGATGACTTGTAAAAGAACTGCGAAATACCCAAAG  
ACAAATG

**SP060 amino acid (SEQ ID NO:100)**

FDDADEKMTTRDEIAYMLTNSEETLDADEIEMLQGVFSLDELMAREVMVPRTD AFMVDIQDDSQAI IQSI  
LKQNYSRIPVYDGDKNVIGIIHTKSLKAGFVDGFDNIVWKRI LQDPLFVPETIFVDDLKELRNTQR  
QM

**SP062 nucleotide (SEQ ID NO:101)**

GGAGAGTCGATCAAAAAGTAGATGAAGCTGTGTCTAAGTTTGAAAAGGACTCATCTTCTTCGTCAAGTTC  
AGACTCTTCCACTAAACCGGAAGCTTCAGATACAGCGAAGCCAAACAAGCCGACAGAACCCAGGAGAAAA  
GGTAGCAGAAGCTAAGAAGAAGGTTGAAGAAGCTGAGAAAAAGCCAAGGATCAAAAAGAAGAAGATCG  
TCGTAAC TACCCAACATTACTTACAAAACGCTTGAACTTGAAATTGCTGAGTCCGATGTGGAAGTTAA  
AAAAGCGGAGCTTGAAGTAGTAAAAGTGAAGCTAACGAACCTCGAGACGAGCAA

**SP062 amino acid (SEQ ID NO:102)**

ESRSKVDEAVSKFEKDSSSSSSSDSSTKPEASDTAKPNKPTEPGEKVAEAKKKVEEA EKKAKDQKEEDR  
RNYPTITYKTLELEIAESDVEVKKAELELVKVKANEP RDEQ

**SP063 nucleotide (SEQ ID NO:103)**

ATGGACAACAGGAACTGGGACGAGGTTATATCTGGTAAGATTGACAAGTACAAAGATCCAGATATTCC  
AACAGTTGAATCACAAGAAGTTACGTGAGACTCTAGTGATAAAGAAATAACGGTAAGGTATGACCGTTT  
ATCAACACCAGAAAAACCAATCCCAACCAAAATCCAGAGCATCCAAGTGTTCCGACACCAAAACCCAGA  
ACTACCAAATCAAGAGACTCCAACACCAGATAAAACCAACTCCAGAACCAGGTACTCCAAAACTGAAAC  
TCCAGTGAATCCAGACCCAGAAGTTCGGACTTATGAGACAGGTAAGAGAGAGGAATTGCCAAACACAGG  
TACAGAAGCTAAT

**SP063 amino acid (SEQ ID NO:104)**

WTTGNWDEVISGKIDKYKDPDIPTVESQEVTS DSSDKEITVRYDRLSTPEKPIQP NPEHPSVPTPNPE  
LPNQETPTPKPTPEPGTPKTETPVNPDPEVPTYETGKREELPNTGTEAN

**SP064 nucleotide (SEQ ID NO:105)**

CGATGGGCTCAATCCAACCCAGGTCAAGTCTTACCTGAAGAGACATCGGGAACGAAAGAGGGTGACTT  
ATCAGAAAAACCAGGAGACACCGTTCTCACTCAAGCGAAACCTGAGGGCGTTACTGGAAATACGAATTC  
ACTTCCGACACCTACAGAAAGAACTGAAGTGAGCGAGGAAACAAGCCCTTCTAGTCTGGATACACTTTT  
TGAAAAAGATGAAGAAGCTCAAAAAAATCCAGAGCTAACAGATGTCTTAAAAGAAAAGTGTAGATACAGC  
TGATGTGGATGGGACACAAGCAAGTCCAGCAGAACTACTCCTGAACAAGTAAAAGGTGGAGTGAAAGA  
AAATACAAAAGACAGCATCGATGTTCTGCTGCTTATCTTGAAAAAGCTGAAGGGAAAGGTCCTTTTAC  
TGCCGGTGTAACCAAGTAATTCCTTATGAACTATTCGCTGGTGATGGTATGTTAACTCGTCTATTACT  
AAAAGCTTCGGATAATGCTCCTTGGTCTGACAATGGTACTGCTAAAAATCCTGCTTTACCTCCTCTTGA  
AGGATTAACAAAAGGGAAATACTTCTATGAAGTAGACTTAAATGGCAATACTGTTGGTAAACAAGGTCA  
AGCTTTAATTGATCAACTTCGCGCTAATGGTACTCAAACCTATAAAGCTACTGTTAAAGTTTACGGAAA  
TAAAGACGGTAAAGCTGACTTGACTAATCTAGTTGCTACTAAAAATGTAGACATCAACATCAATGGATT  
AGTTGCTAAAGAAACAGTTCAAAAAGCCGTTGCAGACAACGTTAAAGACAGTATCGATGTTCCAGCAGC  
CTACCTAGAAAAAGCCAAGGGTGAAGGTCCATTACAGCAGGTGTCAACCATGTGATTCCATACGAAC T  
CTTCGAGGTGATGGCATGTTGACTCGTCTCTTGCTCAAGGCATCTGACAAGGCACCATGGTCAGATAA



Table 1

71

CGGCGACGCTAAAAACCCAGCCCTATCTCCACTAGGCGAAAAACGTGAAGACCAAAGGTCAATACTTCTA  
TCAANTAGCCTTGGACGGAAATGTAGCTGGCAAAGAAAAACAAGCGCTCATTGACCAGTTCCGAGCAAA  
NGGTACTCAAACCTTACAGCGCTACAGTCAATGTCTATGGTAACAAAGACGGTAACCAGACTTGGACAA  
CATCGTAGCAACTAAAAAAGTCACTATTAACATAAACGGTTTAATTTCTAAAGAAACAGTTCAAAAAGC  
CGTTGCAGACAACGTTAANGACAGTATCGATGTTCCAGCAGCCTACCTAGAAAAAGCCAAGGGTGAAGG  
TCCATTACAGCAGGTGTCAACCATGTGATTCATACGAACTCTTCGACGGTGATGGTATGTTGACTCG  
TCTCTTGCTCAAGGCATCTGACAAGGCACCATGGTCAGATAACGGNGACGCTAAAAACCCAGCNCATC  
TCCACTAGGTGAAAACGTGAAGACCAAAGGTCAATACTTCTATCAANTAGCCTTGGACGGAAATGTAGC  
TGGCAAAGAAAAACAAGCGCTCATTGACCAGTTCCGAGCAAACGGTACTCAAACCTTACAGCGCTACAGT  
CAATGTCTATGGTAACAAAGACGGTAAACCAGACTTGGACAACATCGTAGCAACTAAAAAAGTCACTAT  
TAAGATAAATGTTAAAGAAACATCAGACACAGCAAATGGTTCATTATCACCTTCTAACTCTGGTTCTGG  
CGTGACTIONCGATGAATCACAATCATGCTACAGGTACTACAGATAGCATGCCTGCTGACACCATGACAAG  
TTCTACCAACACGATGGCAGGTGAAAACATGGCTGCTTCTGCTAACAAGATGTCTGATACGATGATGTC  
AGAGGATAAAGCTATG

**SP064 amino acid (SEQ ID NO:106)**

DGLNPTPGQVLPEETSGTKEGDLSEKPGDTVLTQAKPEGVTGNTNSLPTPTERTVSEETSPSSLDTLF  
EKDEEAQKNPELTDVLKETVDTADVDTQASPAETTPQVKGKVKENTKDSIDVPAAYLEKAEKGKPF  
AGVNQVIPYELFAGDGMRLRLLLKASDNAPWSDNGTAKNPALPPLGLTKGKYFYFVDLNGNTVKGQGO  
ALIDQLRANGTQTYKATVKVYGNKDGKADLTNLVATKNVDININGLVAKETVQKAVADNVKDSIDVPA  
YLEKAKGEGPFTAGVNHVIPYELFAGDGMRLRLLLKASDKAPWSDNGDAKNPALSPLGENVTKGQYFY  
QXALDGNVAGKEKQALIDQFRAXGTQTYSATVNVYGNKDGKPDLDNIVATKKVTININGLISKETVQKA  
VADNVXDSIDVPAAYLEKAKGEGPFTAGVNHVIPYELFAGDGMRLRLLLKASDKAPWSDNGDAKNPALS  
PLGENVTKGQYFYQXALDGNVAGKEKQALIDQFRANGTQTYSATVNVYGNKDGKPDLDNIVATKKVTI  
KINVKETSDTANGSLSPNSGSGVTPMNNHATGTTDSMPADTMTSSTNTMAGENMAASANKMSDTMMS  
EDKAM

**SP065 nucleotide (SEQ ID NO:107)**

TTCCAATCAAAAACAGGCAGATGGTAAACTCAATATCGTGACAACCTTTTACCCTGTCTATGATTTTAC  
CAAGCAAGTCGCAGGAGATACGGCTAATGTAGAACTCCTAATCGGTGCTGGGACAGAACCTCATGAATA  
CGAACCATCTGCCAAGGCAGTTGCCAAAATCCAAGATGCAGATACCTTCGTTTATGAAAATGAAAACAT  
GGAAACATGGGTACCTAAATTGCTAGATACCTTGGATAAGAAAAAGTGAAGAACCATCAAGGCGACAGG  
CGATATGTTGCTCTTGCCAGGTGGCGAGGAAGAAGAGGGAGACCATGACCATGGAGAAGAAGGTCATCA  
CCATGAGTTTGACCCCCATGTTTGGTTATCACCAGTTCGTGCCATCAAACCTAGTAGAGCACCATCCGCG  
ACACTTGTGACGAGATTATCCTGATAAAAAAGAGACCTTTGAGAAGAATGCAGCTGCCTATATCGAAAA  
ATTGCAAGCCTTGGATAAGGCTTACGCAGAAGGTTTGTCTCAAGCAAAACAAAAGAGCTTTGTGACTCA  
ACACGCAGCCTTTAACTATCTTGCTTGGACTATGGGACTC

**SP065 amino acid (SEQ ID NO:108)**

SNQKQADGKLNIVTTFYPVYEFTKQVAGDTANVELLIGAGTEPHEYEPSAKAVAKIQDADTFVYENEM  
ETWVPKLLDLDKKKVKTIKATGDMLLLPGGEEEEGDHGHGEEGHHHEFDPHVWLSPVRAIKLVEHHR  
HLSADYPDKKETFEKNAAAYIEKLQALDKAYAEGLSQAKQKSFVTQHAAFNYLALDYG

**SP067 nucleotide (SEQ ID NO:109)**

TATCAGAGATCGAACGGTAAGACAACCACAACGACTATGATTGGGGAAGTTTGTACTGCTGCTGGCCA  
ACATGGTCTTTTATCAGGGAATATCGGCTATCCAGCTAGTCAGGTTGCTCAAATAGCATCAGATAAGGA  
CACGCTTGTTATGGAACCTTCTTCTTCCAACTCATGGGTGTTCAAGAATTCATCCAGAGATTGCGGT  
TATTACCAACCTCATGCCAACTCATATCGACTACCATGGGTCAATTTTCGGAATATGTAGCAGCCAAGTG  
GAATATCCAGAACAAGATGACAGCAGCTGATTTCTTGTCTTGAACCTTAACTCAAGACTTGGCAAAGA  
CTTGACTTCCAAGACAGAAGCCACTGTTGTACCATTTCACAACTTGAAAAGGTTGATGGAGCTTATCT  
GGAAGATGGTCAACTCTACTTCCGTGGTGAAGTAGTCATGGCAGCGAATGAAATCGGTGTTCCAGGTAG  
CCACAATGTGGAATAATGCCCTTGCGACTATTGCTGTAGCCAAGCTTCGTGATGTGGACAATCAAACCAT  
CAAGGAAACTCTTTCAGCCTTCGGTGGTGTCAAACACCGTCTCCAGTTTGTGGATGACATCAAGGGTGT  
TAAATCTATAACGACAGTAAATCAACTAATATCTTGGCTACTCAAAAAGCCTTGTGAGGATTGACAA  
CAGCAAGGTCGTCTTGATTGCAAGTGGTTTGGACCGTGGCAATGAGTTTGACGAATTGGTGCCAGACAT  
TACTGGACTCAAGAAGATGGTCATCTGGGTCAATCTGCAGAACGTGTCAAACGGGCAGCAGACAAGGC  
TGGTGTGCTTATGTGGAGGCGACAGATATTGCAGATGCGACCCGCAAGGCCTATGAGCTTGGGACTCA

Table 1

AGGAGATGTGGTTCTTCTTAGTCCTGCCAATGCTAGCTGGGATATGTATGCTAACTTTGAAGTACGTGG  
CGACCTCTTTATCGACACAGTAGCGGAGTTAAAGAA

**SP067 amino acid (SEQ ID NO:110)**

GITGSNGKTTTTTMMIGEVLTAAGQHGLLSGNIGYPASQVAQIASDKDTLVMELSSFQLMGVQEFHPEIA  
VITNLMPTHIDYHGSFSEYVAAKWNIONKMTAADFLVLNFNQDLAKDLTSKTEATVVPFSTLEKVDGAY  
LEDGQLYFRGEVMAANEIGVPGSHNVENALATIIVAKLRDVDNQTIKETLSAFGGVKHRLQFVDDIKG  
VKFYNDKSTNILATQKALSGFDNSKVLIAGGLDRGNEFDELVPDITGLKKMVLIGQSAERVKRAADK  
AGVAYVEATDIADATRKAYELATQGDVVLLSPANASWDMYANFEVRGDLFIDTVaelKE

**SP068 nucleotide (SEQ ID NO:111)**

AAGTTCATCGAAGATGGTTGGGAAGTCCACTATATCGGGGACAAGTGTGGTATCGAACACCAAGAAATC  
CTTAAGTCAGGTTTGGATGTCACCTTCCATTCTATTGCGACTGGAAAATTGCGTCGCTATTTCTCTTGG  
CAAAATATGCTGGACGCTTCAAAGTTGGTTGGGGAATTGTCCAATCGCTCTTTATCATGTTGCGACTG  
CGTCCACAGACCCCTTTTTCAAAGGGGGGCTTTGTCTCAGTACCGCCTGTTATCGCTGCGCGTGTGTCA  
GGAGTGCCCTGTCTTTATTCACGAATCTGACCTGTCTATGGGCTTGGCCAATAAAATCGCCTATAAATT  
CGGACTAAGATGTATTCAACCTTTGAACAAGCTTCGAGTTTGGCTAAGGTTGAGCATGTGGGAGCGG

**SP068 amino acid (SEQ ID NO:112)**

SSSKMVGKSTISGTSVVSNTKKSLSQVWMSPIILLRENCVAISLGKICWTSSKLVGELSNRSLSCDC  
VHRPFFQRGALSQYRLSLRVCQECLSLFTNLTLWAWPIKSPINLRLRCIQPLNKLRLVWRLSMWER

**SP069 nucleotide (SEQ ID NO:113)**

ATCGCTAGCTAGTGAAATGCAAGAAAGTACACGTAAATTCAAGGTTACTGCTGACCTAACAGATGCCGG  
TGTGGAACGATTGAAGTTCCTTTGAGCATTGAAGATTTACCCAATGGGCTGACCGCTGTGGCGACTCC  
GCAAAAAATTACAGTCAAGATTGGTAAGAAGGCTCAGAAGGATAAGGTAAAGATTGTACCAGAGATTGA  
CCCTAGTCAAATTGATAGTCGGGTACAAATTGAAAATGTCATGGTGTCAGATAAAGAAGTGTCTATTAC  
GAGTGACCAAGAGACATTGGATAGAATTGATAAGATTATCGCTGTTTTGCCAATAGCGAACGTATAAC  
AGGTAATTACAGTGGTTCAGTACCTTTGCAGGCAATCGACCGCAATGGTGTTGCTTTACCGGCAGTTAT  
CACTCCGTTTTGATACAATAATGAAGGTGACTACAAAACCAAGTAGCACCAAGTTCAAGCACATCAAATTC  
AAGTACAAGCAGTTCATCGGAGACATCTTCGTCAACGAAAGCAACTAGTTCAAAAACGAAT

**SP069 amino acid (SEQ ID NO:114)**

SLASEMQESTRKFKVTADLTDAGVGTIEVPLSIEDLPNGLTAVATPQKITVKIGKKAQKDKVKIVPEID  
PSQIDSRVQIENVMVSDKEVSITSDQETLDRIDKIIAVLPTSERITGNYSVPLQIDRNGVVLP  
TPFDTIMKVTTKPVAPSSSTSNSSTSSSETSSSTKATSSKTN

**SP070 nucleotide (SEQ ID NO:115)**

GCACCAGATGGGGCACAAAGGTTCAAGGATCAGATGTTGAAAAGTACTACTTTACCCAACGCGGTCTTGA  
GCAGGCAGGAATTACCATTCCTTCTTTTATGAAAAAATCTAGACGGTGATATGGAAATTATCGCTGG  
AAATGCCTTTTCGTCCAGATAACAACGTCGAAATTGCCTATGCGGACCAAAATGGTATCAGCTACAAACG  
TTACCATGAGTTTCTAGGTAGCTTTATGCGTGACTTTGTTAGCATGGGAGTAGCAGGAGCACATGGAAA  
AACTTCAACGACAGGTATGTTGTCTCATGTCTTGTCTCACATTACAGATACCAGCTTCTTGATTGGAGA  
TGGGACAGGTCGTGGTTTCGGCCAATGCCAAATATTTTGTCTTTGAATCTGACGAATATGAGCGTCACTT  
CATGCCTTACCACCCAGAATACTCTATTATCACCAACATTGACTTTGACCATCCAGATTATTTACAAAG  
TCTCGAGGATGTTTTTAATGCCTTTAACGACTATGCCAAACAAATCACCAAGGGTCTTTTTGTCTATGG  
TGAAGATGCTGAATTGCGTAAGATTACGCTGATGCACCAATTTATTATTATGGTTTTGAAGCTGAAGG  
CAATGACTTTGTAGCTAGTGATCTTCTTCGTTCAATAACTGGTTCAACCTTCACCGTTCAATTTCCGTGG  
ACAAAACCTTGGGGCAATTCCACATTCCAACCTTTGGTCGTCACAAATATCATGAATGCGACAGCCGTTAT  
TGGTCTTCTTTACACAGCAGGATTTGATTTGAACTTGGTGCGTGAGCACTTGAAAACATTTGCCCGGTGT  
TAAACGTCGTTTCACTGAGAAAATTGTCAATGATACAGTGATTATCGATGACTTTGCCCAACCATCCAAC  
AGAAATTATTGCGACCTTGGATGCGGCTCGTCAGAAATACCCAAGCAAGGAAATTGTAGCAGTCTTTCA  
ACCGCATACCTTTACAAGAACCATTGCCTTGTGAGCAGCTTTGCCCATGCTTTAAACCAAGCAGATGC  
TGTTTATCTAGCGCAAATTTATGGCTCGGCTCGTGAAAGTAGATCATGGTGACGTTAAGGTAGAAGACCT  
AGCCAACAAAATCAACAAAAAACCAAGTGATTACTGTTGAAAATGTTTCTCCACTCCTAGACCATGA  
CAATGCTGTTTACGTCTTTATGGGAGCAGGAGACATCCAAACCTATGAATACTCATTTGAGCGTCTCTT  
GTCTAACTTGACAAGCAATGTTCAA

Table 1

## SP070 amino acid (SEQ ID NO:116)

HQMGHKVQGS DVEKYFTQ RGLEQAGITILPFDEKNLDGDM EIIAGNAFRPDNNVEIAYADQNGISYKR  
YHEFLGSFMRDFVSMGVAGAHGKTSTTGMLSHVLSHITDTSFLIGDGTGRGSANAKYFVFESDEYERHF  
MPYHPEYSIIITNIDFDHPDYFTSLEDVFNAFNDYAKQITKGLFVYGEDAELRKITS DAPIYYYGF EAEG  
NDFVASDLLRSITGSTFTVHFRGQNLQGFHIPTFGRHNIMNATAVIGLLYTAGFDLNLVREHLKTFAGV  
KRRFTEKIVNDTVIIDFAHHPTEIIATLDAARQKYP SKEIVAVFQPHFTFTRTIALLDFFAHALNQADA  
VYLAQIYGSAREVDHGDVKVEDLANKINKKHQVITVENVSPLLDH DNAVYVFMGAGDIQTYEYSFERLL  
SNLTSNVQ

## SP071 nucleotide (SEQ ID NO:117)

TTTAAACCCAACTGTTGGTACTTTCTTTTACTGCAGGATTGAGCTTGTAGTTTTATTGGTTTCTAA  
AAGGGAAAATGGAAAGAAACGACTTGTTCATTTTCTGCTGTTGACTAGCATGGGAGTTCAATGTGTGCC  
GGCCAGTGCTTTTGGGTTGACCAGCCAGATTTTATCTGCCTATAATAGTCAGCTTTCTATCGGAGTCGG  
GGAACATTTACCAGAGCCTCTGAAAATCGAAGGTTATCAATATATTGGTTATATCAAACTAAGAAACA  
GGATAATACAGAGCTTTCAAGGACAGTTGATGGGAAATACTCTGCTCAAAGAGATAGTCAACCAAACTC  
TACAAAAACATCAGATGTAGTTCATTCAGCTGATTTAGAATGGAACCAAGGACAGGGGAAGGTTAGTTT  
ACAAGGTGAAGCATCAGGGGATGATGGACTTTCAGAAAAATCTTCTATAGCAGCAGACAATCTATCTTC  
TAATGATTCATTCGCAAGTCAAGTTGAGCAGAATCCGGATCACAAAGGAGAATCTGTAGTTCGACCAAC  
AGTGCCAGAACAAAGGAAATCCTGTGTCTGCTACAACCGGTGCAGAGTGCCGAAGAGGAAGTATTGGCGAC  
GACAAATGATCGACCAGAGTATAAACTTCCATTGGAAACCAAGGCACGCAAGAACCCGGTCATGAGGG  
TGAAGCCGCGAGTCCGTGAAGACTTACCAGTCTACACTAAGCCACTAGAAACCAAGGTACACAAGGACC  
CGGACATGAAGGTGAAGCTGCAGTTCGCGAGGAAGAACCAGCTTACACAGAACCGTTAGCAACGAAAGG  
CACGCAAGAGCCAGGTCATGAGGGCAAAGCTACAGTCCGCGAAGAGACTCTAGAGTACACGGAACCGGT  
AGCGACAAAAGGCACACAAGAACCCGAACATGAGGGCGAaCGGsCAGTAGAAGAAGAATCTCCGGCTTT  
AGAGGTCACTACACGAAATAGAACGGAAATCCAGAAATATTCCTTATACAACAGAAGAAATTCAGGATCC  
AACACTTCTGAAAAATCGTCTGTAAGATTGAACGACAAGGGCAAGCAGGGACACGTACAATTCAATATGA  
AGACTACATCGTAAATGGTAATGTCGTAGAACTAAAGAAGTGTCACGAACTGAAGTAGCTCCGGTCAA  
CGAAGTCGTTAAAGTAGGAACACTTGTGAAAGTTAAACCTACAGTAGAAATTACAACTTAACAAAAGT  
TGAGAACAATAAACTCTATAACTGTAAGTTATAACTTAATAGACACTACCTCAGCATAGTTTCTGCAAA  
AACCGAAGTTTTCATGGAGACAAGCTAGTTAAAGAGGTGGATATAGAAAATCCTGCCAAAGAGCAAGT  
AATATCAGGTTTACTACTACACCGTATACAGTTAAACACACCTAACTTATAATTTGGGTGAAAA  
TAATGAGGAAAATACTGAAACATCAACTCAAGATTTCCAATTAGAGTATAAGAAAATAGAGATTAAAGA  
TATTGATTACAGTAGAATTATACGGTAAAGAAAATGATCGTTATCGTAGATATTTAAGTCTAAGTGAAGC  
GCCGACTGATACGGCTAAATACTTTGTAAAAGTGAAATCAGATCGCTTCAAAGAAATGTACCTACCTGT  
AAAATCTATTACAGAAAATACGGATGGAACGTATAAAGTGACGGTAGCCGTTGATCAACTTGTGCAAGA  
AGGTACAGACGGTTACAAAGATGATTACACATTTACTGTAGCTAAATCTAAAGCAGAGCAACCAGGAGT  
TTACACATCCTTTAAACAGCTGGTAACAGCCATGCAAAGCAATCTGTCTGGTGTCTATACATTGGCTTC  
AGATATGACCGCAGATGAGGTGAGCTTAGGCGATAAGCAGACAAGTTATCTCACAGGTGCATTTACAGG  
GAGCTTGATCGGTTCTGATGGAACAAAATCGTATGCCATTTATGATTTGAAGAAACCATTTTGTATAC  
ATTAAATGGTGTACAGTTAGAGATTTGGATATTTAAACTGTTTCTGCTGATAGTAAAGAAAATGTCCG  
AGCGCTGGCGAAGGCAGCGAATAGCGCGAATATTAATAATGTTGCAGTAGAAGGAAAAATCTCAGGTGC  
GAAATCTGTTGCGGGATTAGTAGCGAGCGCAACAAATACAGTGATAGAAAACAGCTCGTTTACAGGGAA  
ACTTATCGCAAAATCACCAGGACAGTAATAAAAAATGATACTGGAGGAATAGTAGGTAATAACAGGAAA  
TAGTTTCGAGAGTTAATAAAGTTAGGGTAGATGCCCTTAATCTCTACTAATGCACGCAATAATAACCAAAC  
AGCTGGAGGGATAGTAGGTAGATTAGAAAATGGTGCATTGATATCTAATTCGGTTGCTACTGGAGAAAT  
ACGAAATGGTCAAGGATATTCTAGAGTCGGAGGAATAGTAGGATCTACGTGGCAAAACGGTCGAGTAAA  
TAATGTTGTGAGTAACGTAGATGTTGGAGATGGTTATGTTATCACCGGTGATCAATACGCAGCAGCAGA  
TGTGAAAAATGCAAGTACATCAGTTGATAATAGAAAAGCAGACAGATTGCTACAAAATTATCAAAAAGA  
CCAAATAGACGCGAAAGTTGCTGATTATGGAATCACAGTAACCTTTGATGATACTGGGCAAGATTTAAA  
ACGTAATCTAAGAGAAGTTGATTATACAAGACTAAATAAAGCAGAAGCTGAAAGAAAAGTAGCTTATAG  
CAACATAGAAAACTGATGCCATTCTACAATAAAGACCTAGTAGTTCACTATGGTAACAAAGTAGCGAC  
AACAGATAAACTTTACACTACAGAAATTGTTAGATGTTGTGCCGATGAAAGATGATGAAGTAGTAACGGA  
TATTAATAATAAGAAAAATTCATAAAATAAAGTTATGTTACATTTCAAAGATAATACAGTAGAATACCT  
AGATGTAACATTCAAAAGAAAACCTCATAAACAGTCAAGTAATCGAATACAATGTTACAGGAAAAGAATA  
TATATTACACCCAGAAGCATTGTTTCAGACTATACAGCGATAACGAATAACGTACTAAGCGACTTGCA  
AAATGTAACACTTAAC

## SP071 amino acid (SEQ ID NO:118)

Table 1

FNPTVGTFLFTAGLSLLVLLVSKRENGKKRLVHFLLLTSMGVQLLPASAFGLTSQILSAYNSQLSIGVG  
EHLPEPLKIEGYQYIGYIKTKKQDNTELSTVDGKYSQQRDSQPNSTKTSADVHSADLEWNQGGQKVS  
QGEASGDDGLSEKSSIAADNLSSNDSFASQVEQNPDKGESVVRPTVPEQGNPVSATTVQSAEEEEVLAT  
TNDRPEYKLPLETGKTQEPGHEGEAAVREDLPVYTKPLETKGTQGPGEHEGEAAVREEEPAYTEPLATKG  
TQEPGHEGKATVREETLEYTEPVATKGTQEPHEGERXVEEELPALEVTTRNRTEIQNIPTYTEEIQDP  
TLLKNRRKIERQGGAGTRTIQYEDYIVNGNVVETKEVSRTEVAPVNEVVKVGTLVKVKPTVEITNLTKV  
ENKKSITVSYNLIDTTSAYVSAKTQVFHGDKLVEVDIENPAKEQVISGLDYYTPYTVKTHLTYNLGEN  
NEENTETSTQDFQLEYKKIEIKDIDSVELYKENDRYRRYLSLSEAPTD TAKYFVKVKSDFKEMYLPV  
KSITENTDGTYKVTVAVDQLVEEGTDGYKDDYFTVAKSKAEQPGVYTSFKQLVTAMQSNLSGVYTLAS  
DMTADDEVSLGDKQTSYLTGAFTGSLIGSDGTSYAIYDLKKPLFDTLNGATVRDLDIKTVSADSKENVA  
ALAKAANSANINNVAVEGKISGAKSVAGLVSATNTVIENSSFTGKLIANHQDSKNKNDTGGIVGNITGN  
SSRVNKVRVDALISTNARNNNQTAGGIVGRLENGALISNSVATGEIRNGQGYSRVGGIVGSTWQNGRVN  
NVVSNVDVGDGYVITGDQYAAADVKNASTVDNRKADRFATKLSKDQIDAKVADYGITVTLDDTGQDLK  
RNLREVDYTRLNKAEARKVAYSNIEKLMFPYFNKDLVHYGNKVATTDKLYTTELLDVVPMKDDEVVTD  
INNKKNSINKVMLHFKDNTVEYLDVTFKENFINSQVIEYNVTGKEYIFTPEAFVSDYTAITNNVLSDLQ  
NVTNLN

**SP072 nucleotide (SEQ ID NO:119)**

TTTAAACCCAACTGTTGGTACTTTTCCTTTTACTGCAAGGATTGAGCTTGTTAGTTTTATTGGTTTCTTAA  
AAGGGAAAATGGAAAGAAACGACTTGTTCATTTTCTGCTGTTGACTAGCATGGGAGTTCAATTGTTGCC  
GGCCAGTGCTTTTGGGTTGACCAGCCAGATTTTATCTGCCTATAATAGTCAGCTTTCATCGGAGTCGG  
GGAACATTTACCAGAGCCTCTGAAAATCGAAGGTTATCAATATATTGGTTATATCAAACTAAGAAACA  
GGATAATACAGAGCTTCAAGGACAGTTGATGGGAAATACTCTGCTCAAAGAGATAGTCAACCAAACCTC  
TACAAAAACATCAGATGTAGTTCATTCAGCTGATTTAGAATGGAACCAAGGACAGGGGAAGGTTAGTTT  
ACAAGGTGAAGCATCAGGGGATGATGGACTTTCAGAAAAATCTTCTATAGCAGCAGACAATCTATCTTC  
TAATGATTTCATTTCGCAAGTCAAGTTGAGCAGAAATCCGGATCACAAAGGAGAATCTGTAGTTCGACCAAC  
AGTGCCAGAACCAAGGAAATCCTGTGTCTGCTACAACGGTGCAGAGTGCGGAAGAGGAAGTATTGGCGAC  
GACAAATGATCGACCAGAGTATAAACTTCCATTGGAACCAAAGGCACGCAAGAACCCGGTCATGAGGG  
TGAAGCCGCAGTCCGTGAAGACTTACCAGTCTACACTAAGCCACTAGAAACCAAAGGTACACAAGGACC  
CGGACATGAAGGTGAAGCTGCAGTTCGCGAGGAAGAACCAGCTTACACAGAACCGTTAGCAACGAAAGG  
CACGCAAGAGCCAGGTCATGAGGGCAAAGCTACAGTCCGCGAAGAGACTCTAGAGTACACGGAACCGGT  
AGCGACAAAAGGCACACAAGAACCAGCAATGAGGGCGAaCGGsCAGTAGAAGAAGAACTTCCGGCTTT  
AGAGGTCACCTACACGAAATAGAACGGAATCCAGAATATTCTTATACAACAGAAGAAATTCAGGATCC  
AACACTTCTGAAAAATCGTCGTAAGATTGAACGACAAGGGCAAGCAGGGACACGTACAATTCATATGA  
AGACTACATCGTAAATGGTAATGTCTGTAAGAACTAAAGAAGTGTACGAACTGAAGTAGCTCCGGTCAA  
CGAAGTCGTTAAAGTAGGAACACTTGTGAAAGTTAAACCTACAGTAGAAATTACAACTTAACAAAAGT  
TGAGAACAAAAATCTATACTGTAAGTTATACTTAATAGACACTACCTCAGCATATGTTTCTGCAAA  
AACGCAAGTTTTCCATGGAGACAAGCTAGTTAAAGAGGTGGATATAGAAAATCCTGCCAAAGAGCAAGT  
AATATCAGGTTTATGATTACTACACACCGTATACAGTTAAACACACCTAACTTATAATTGGGTGAAAA  
TAATGAGGAAAATACTGAAACATCAACTCAAGATTTCCAATTAGAGTATAAGAAAATAGAGATTAAAGA  
TATTGATTTCAGTAGAATTATACGGTAAAGAAAATGATCGTTATCGTAGA

**SP072 amino acid (SEQ ID NO:120)**

FNPTVGTFLFTAGLSLLVLLVSKRENGKKRLVHFLLLTSMGVQLLPASAFGLTSQILSAYNSQLSIGVG  
EHLPEPLKIEGYQYIGYIKTKKQDNTELSTVDGKYSQQRDSQPNSTKTSADVHSADLEWNQGGQKVS  
QGEASGDDGLSEKSSIAADNLSSNDSFASQVEQNPDKGESVVRPTVPEQGNPVSATTVQSAEEEEVLAT  
TNDRPEYKLPLETGKTQEPGHEGEAAVREDLPVYTKPLETKGTQGPGEHEGEAAVREEEPAYTEPLATKG  
TQEPGHEGKATVREETLEYTEPVATKGTQEPHEGERXVEEELPALEVTTRNRTEIQNIPTYTEEIQDP  
TLLKNRRKIERQGGAGTRTIQYEDYIVNGNVVETKEVSRTEVAPVNEVVKVGTLVKVKPTVEITNLTKV  
ENKKSITVSYNLIDTTSAYVSAKTQVFHGDKLVEVDIENPAKEQVISGLDYYTPYTVKTHLTYNLGEN  
NEENTETSTQDFQLEYKKIEIKDIDSVELYKENDRYRR

**SP073 nucleotide (SEQ ID NO:121)**

TCGTAGATATTTAAGTCTAAGTGAAGCGCCGACTGATACGGCTAAATACTTTGTAAAAGTGAAATCAGA  
TCGCTTCAAAGAAATGTACCTACCTGTAAATCTATTACAGAAAATACGGATGGAACGTATAAAGTGAC  
GGTAGCCGTTGATCAACTTGTCTGAAGAAGGTACAGACGGTTACAAAGATGATTACACATTTACTGTAGC  
TAAATCTAAAGCAGAGCAACCAGGAGTTTACACATCCTTTAAACAGCTGGTAACAGCCATGCAAAGCAA  
TCTGTCTGGTGTCTATACATTGGCTTCAGATATGACCGCAGATGAGGTGAGCTTAGCGGATAAGCAGAC

Table 1

75

AAGTTATCTCACAGGTGCATTTACAGGGAGCTTGATCGGTTCTGATGGAACAAAATCGTATGCCATTTA  
TGATTTGAAGAAACCATTATTTGATACATTAAATGGTGCTACAGTTAGAGATTTGGATATTTAAACTGT  
TTCTGCTGATAGTAAAGAAAATGTCGCAGCGCTGGCGAAGGCAGCGAATAGCGCGAATATTAATAATGT  
TGCAGTAGAAGGAAAAATCTCAGGTGCGAAAATCTGTTGCGGGATTAGTAGCGAGCGCAACAAATACAGT  
GATAGAAAACAGCTCGTTTACAGGGAACTTATCGCAAATCACCAGGACAGTAATAAAAAATGATACTGG  
AGGAATAGTAGGTAATATAACAGGAAATAGTTTCGAGAGTTAATAAAGTTAGGGTAGATGCCTTAATCTC  
TACTAATGCACGCAATAATAACCAACAGCTGGAGGGATAGTAGGTAGATTAGAAAATGGTGCATTGAT  
ATCTAATTCGGTTGCTACTGGAGAAATACGAAATGGTCAAGGATATTTCTAGAGTCGGAGGAATAGTAGG  
ATCTACGTGGCAAACGGTCGAGTAAATAATGTTGTGAGTAACGTAGATGTTGGAGATGGTTATGTTAT  
CACCGGTGATCAATACGCAGCAGCAGATGTGAAAAATGCAAGTACATCAGTTGATAATAGAAAAGCAGA  
CAGATTCGCTACAAAATTATCAAAAGACCAAATAGACGCGAAAAGTTGCTGATTATGGAATCACAGTAAC  
TCTTGATGATACTGGGCAAGATTTAAACGTAATCTAAGAGAAGTTGATTATACAAGACTAAATAAAGC  
AGAAGCTGAAAGAAAAGTAGCTTATAGCAACATAGAAAACTGATGCCATTTCTACAATAAGACCTAGT  
AGTTCATATGGTAAACAAAGTAGCGACAACAGATAAACTTTACACTACAGAATTGTTAGATGTTGTGCC  
GATGAAAGATGATGAAGTAGTAACGGATATTAATAATAAGAAAAATTCATAAAATAAGTTATGTTACA  
TTTCAAAGATAATACAGTAGAATACCTAGATGTAACATTCAAAGAAAACCTTCATAAACAGTCAAGTAAT  
CGAATACAATGTTACAGGAAAAGAATATATATTACACCAGAAGCATTGTTTCAGACTATACAGCGAT  
AACGAATAACGTACTAAGCGACTTGCAAAATGTAACACTTAAC

**SP073 amino acid (SEQ ID NO:122)**

RRYLSLSEAPDTAKYFVKVKSDFKEMYL PVKSITENTDGYKVTVAVDQLVEEGTDGYKDDYTFTVA  
KSKAEQPGVYTSFKQLVTAMQSNLSGVYTLASDMTAEVSLGDKQTSYLTGAFTGSLIGSDGTSYAIY  
DLKKPLFDTLNGATVRDLDIKTVSADSKENVAALAKAANSANINNVAVEGKISGAKSVAGLVASATNTV  
IENSSTGKLIANHQDSNKNDDGGIVGNITGNSSRVNVKVRVDALISTNARNNNQTAGGIVGRLENGALI  
SNSVATGEIRNGQGYSRVGGIVGISTWQNGRVNVVSNVDVGDGYVITGDQYAAADVKNASTSVDNRKAD  
RFATKLSKDQIDAKVADYGITVTLDDTGQDLKRNLRVVDYTRLNKAERKVAYSNIKLMFPYFNKDLV  
VHYGNKVATTDKLYTTELLDVVPMKDDEVVTDINNKKNSINKVMLHFKDNTVEYLDVTFKENFINSQVI  
EYNVTGKEYIFTPEAFVSDYTAITNNVLSLDLQNVTLN

**SP074 nucleotide (SEQ ID NO:123)**

CTTTGGTTTTGAAGGAAGTAAGCGTGGACAATTTGCTGTAGAGGAATCAATCAACTTCGTGAGCATGT  
AGACACTCTATTGATTATCTCAAACAACAATTTGCTTGAAATTGTTGATAAGAAAACACCGCTTTTGGA  
GGCTCTTAGCGAAGCGGATAACGTTCTTCGTCAAGGTGTTCAAGGGATTACCGATTTGATTACCAATCC  
AGGATTGATTAACTTTGACTTTGCCGATGTGAAAACGGTAATGGCAAACAAAGGGAATGCTCTTATGGG  
TATTGGTATCGGTAGTGGAGAAGAACGTGTGGTAGAAGCGGCACGTAAGGCAATCTATTCACTACTCT  
TGAAACAACATATTGACGGTGTGAGGATGTTATCGTCAACGTTACTGGTGGTCTTGACTTAACCTTGAT  
TGAGGCAGAAGAGGCTTCACAAATTGTGAACCAGGCAGCAGGTCAAGGAGTGAACATCTGGCTCGGTAC  
TTCAATTGATGAAAGTATGCGTGATGAAATTCGTGTAACAGTTGTTGCAACGGGTGTTGCTCAAGACCG  
CGTAGAAAAGGTTGTGGCTCCACAAGCTAGATCTGCTACTAACTACCGTGAGACAGTGAAACCAGCTCA  
TTCACATGGCTTTGATCGTCATTTTGATATGGCAGAAACAGTTGAATTGCCAAAACAAAATCCACGTCG  
TTTGAACCAACTCAGGCATCTGCTTTTGGTGATTGGGATCTTCGCCGTGAATCGATTGTTTCGTACAAC  
AGATTCACTCGTTTCTCCAGTCGAGCGCTTTGAAGCCCCAATTTACAAGATGAAGATGAATTGGATAC  
ACCTCCATTTTCAAAAATCGT

**SP074 amino acid (SEQ ID NO:124)**

FGFEGSKRGQFAVEGINQLREHVDTLIIISNNNLEIVDKKTPLEALSEADNVLRQGVQGITDLITNP  
GLINLDFADVKTVMANKGNALMGIGIGSGEERVVEAARKAIYSPLETTIDGAEDVIVNVTGGLDLTLI  
EAEASQIVNQAGQGVNIWLGTSIDESMRDEIRVTVVATGVRQDRVEKVVPQARSATNYRETVKPAH  
SHGFDRHFDMAETVELPKQNPRLRLEPTQASAFGDWDLRRESIVRTTDSVVSVERFEAPISQDEDELDT  
PPFFKNR

**SP075 nucleotide (SEQ ID NO:125)**

CTACTACCTCTCGAGAGAAAGTGACCTAGAGGTGACCGTTTTTGACCATGAGCAAGGTCAAGCCACCAA  
GGCCGCAGCAGGAATTATCAGTCCTTGGTTTTCCAAACGCCGTAATAAAGCCTGGTACAAGATGGCGCG  
CTTGGGGGCTGATTTTTATGTGGATTTATTAGCTGATTTAGAGAAAATCAGGACAAGAAAATCGACTTTTA  
CCAGCGTTCGGGAGTCTTTCTCTTGAAAAAGGATGAATCCAATTTGGAAGAATTTATCAACTGGCCCT  
CCAGCGCAGAGAAGAATCTCCCTTGATAGGGCAATTAGCCATTCTGAACCAAGCCTCAGCTAATGAATT  
ATTCCCTGGTTGACAGGGATTGACCGCCTGCTCTATGCTTCTGGTGGAGCGAGAGTAGATGGCCAAT

Table 1

TTTAGTGACTCGTTTGCTGGAAGTCAGTCATGTCAAGCTGGTCAAAGAAAAAGTGACTCTGACACCGTT  
AGCATCAGGCTACCAGATTGGTGAAGAGGAGTTTGAGCAGGTTATTTTGGCGACGGGAGCTTGGTTGGG  
GGACATGTTAGAGCCTTTAGGTTATGAAGTGGATGTCCGTCCTCAAAAAGGACAACACTACGAGATTATCA  
GCTTGCCCAAGACATGGAAGATTACCTGTGTGTCATGCCAGAAGGGGAGTGGGATTTGATTCCCTTTGC  
AGGTGGGAAATTATCCTTAGGCGCTACCCACGAAAATGACATGGGATTTGATTTGACGGTAGATGAAAC  
CTTGCTCCAACAAATGGAGGAGGCCACCTTGACTCACTATCTGATTTTGGCTGAAGCTACTTCAAAATC  
TGAGCGTGTGGAAATCCGTGCCTACACCAGTGATTTCTCTCTTTCTTTGGGCAGGTGCCTGACTTAAC  
TGGTGTCTATGCAGCCAGTGGACTAGGTTTCATCAGGCTCACAACCTGGTCTTATCATTGGTTACCATCT  
AGCCCAACTGATCCAAGACAAGGAGTTGACCTTGGACCTCTAAATTACCCAATTGAAAACATATGTCAA  
ACGAGTAAAAAGCGAA

**SP075 amino acid (SEQ ID NO:126)**

YYLSRESDLVTVFDHEQGQATKAAAGIISPWFSKRRNKAWYKMARLGADFYVDLLADLEKSGQEIDFY  
QRSGVFLKKDESNLEELYQLALQRREESPLIGQLAILNQASANELFPGLQGFDRLLYASGGARVDGQL  
LVTRLLEVSHVKLVKEKVTLTPLASGYQIGEEFEQVILATGAWLGDMLEPLGYEVDVRPQKGQLRDYQ  
LAQDMEDYPVVMPEGEWDLIPFAGGKLSLGATHENDMGFDLTVDLTLQMEELTHYLILAEATSKS  
ERVGIRAYTSDFSPPFGQVPLDTGVYAASGLSSGLTTGPIIGYHLAQLIQDKELTLDPLNYPNIENVK  
RVKSE

**SP076 nucleotide (SEQ ID NO:127)**

TAAGGTCAAAGTCAGACCGCTAAGAAAGTGCTAGAAAAGATTGGAGCTGACTCGGTTATCTCGCCAGA  
GTATGAAATGGGGCAGTCTCTAGCACAGACCATTCTTTCCATAATAGTGTGATGTCTTTCAGTTGGA  
TAAAAATGTGTCTATCGTGGAGATGAAAATTCCTCAGTCTTGGGCAGGTCAAAGTCTGAGTAAATTAGA  
CCTCCGTGGCAAATACAATCTGAATATTTGGGGTTCCGAGAGCAGGAAAATCCCCATTGGATGTTGA  
ATTTGGACCAGATGACCTCTTGAAAGCAGATACCTATATTTTGGCAGTCATCAACAACAGTATTTGGA  
TACCCTA

**SP076 amino acid (SEQ ID NO:128)**

KVKSQTAKKVLEKIGADSVISPEYEMQSLAQTLFHNSVDVFQLDKNVSIVEMKIPQSWAGQSLSKLD  
LRGKYNLNLGFRQENSPLDVEFGPDDLKADTYILAVINNQYLDL

**SP077 nucleotide (SEQ ID NO:129)**

TGACGGGTCTCAGGATCAGACTCAGGAAATCGCTGAGTGTCTAGCTAGCAAGTATCCTAATATCGTTAG  
AGCCATCTATCAGGAAAATAAATGCCATGGCGGTGCGGTCAATCGTGGCTTGGTAGAGGCTTCTGGGCG  
CTATTTTAAAGTAGTTGACAGTGATGACTGGGTGGATCCTCGTGCCTACTTGAAAATTCTTGAAACTTG  
CAGGAACCTTGAGAGCAAAGGTCAAGAGGTGGATGTCTTTG

**SP077 amino acid (SEQ ID NO:130)**

DGSQDQTQEIACLASKYPNIVRAIYQENKCHGGAVNRLVEASGRYFKVVDSDDWDPRAYLKILETC  
RNLRAKVKRWMSL

**SP078 nucleotide (SEQ ID NO:131)**

TAGAGGCTTTGCCAAATGGTGGGAAGGGCACGAGCGTCGAAAAGAGGAACGCTTTGTCAAACAAGAAGA  
AAAAGCTCGCCAAAAGGCTGAGAAAAGAGGTAGATTAGAACAAGAAGAGACTGAAAAAGCCTTACTCGA  
TTTGCCTCCTGTTGATATGGAACGGGTGAAATCTGACAGAGGAAGCTGTTCAAATCTTCCACCTAT  
TCCAGAAGAAAAGTGGGTGGAACAGAAATCATCTGCCTCAAGCTGAACCTTAAATCCCTGAACAGGA  
AGATGACTCAGATGACGAAGATGTTTCAGGTTCGATTTTTAGCCAAAGAAGCCCTTGAATACAACTTCC  
AAGCTTACAACCTTTGCACCAGATAAACCAAAAGATCAGTCTAAAGAGAAGAAAATGTGACAGAGAAA  
TATCAAATCTTAGAAGCAACCTTTGCTAGCTTTGGTATTAAGGTAACAGTTGAACGGGCCGAAATTGG  
GCCATCAGTGACCAAGTATGAAGTCAAGCCGCTGTTGGTGAAGGGTCAACCGCATTTCCAATCTATC  
AGATGACCTCGCTCTAGCCTTGGCTGCCAAAGATGTCCGGATTGAAGCACCAATCCCTGGGAAATCCCT  
AATCGGAATTGAAGTGCCCAACTCCGATATTGCCACTGTATCTTTCCGAGAATATGGAACAATCGCA  
AACGAAAGCAGAAAATTTCTTGGAATTCCTTTAGGGAAGGCTGTTAATGGAACCGCAAGAGCTTTTGA  
CCTTTCTAAATGCCCCACTTGCTAGTTGCAGGTTCAACGGGTTCAAGGAAGTCAGTAGCAGTTAACGG  
CATTATTGCTAGCATTCTCATGAAGGCGAGACCAGATCAAGTTAAATTTATGATGGTCGATCCCAAGAT  
GGTTGAGTTATCTGTTTACAATGATATTCGCCACCTCTTGATTCCAGTCGTGACCAATCCACGCAAAGC  
CAGCAAGGCTCTGAAAAGGTTGTGGATGAAATGGAACCGTTATGAACTCTTTGCCAAGGTGGGAGT  
TCGGAATATTGCAGGTTTAAATGCCAAGGTAGAAGAGTTCAATTCACAGTCTGAGTACAAGCAAATTC

Table 1

77

GCTACCATTTCATTGTCGTGATTGTGGATGAGTTGGCTGACCTCATGATGGTGGCCAGCAAGGAAGTGA  
AGATGCTATCATCCGTTCTTGGGCAGAAGGCGCGTGCAGGTATCCACATGATTCTTGAACCTACGG  
TCCATCTGTTGATGTCTCTGGTTTGATTAAGGCCAATGTTCCATCTCGTGTAGCATTTCGCGTTTC  
ATCAGGAACAGACTCCCGTACGATTTTGGATGAAAATGGAGCAGAAAACTTCTTGGTCGAGGAGACAT  
GCTCTTTAAACCGATTGATGAAAATCATCCAGTTCGTCTCCAAGGCTCCTTTATCTCGGATGACGATGT  
TGAGCGCATTGTGAACCTCATCAAGACTCAGGCAGATGCAGACTACGATGAGAGTTTTGATCCAGGTGA  
GGTTTCTGAAAATGAAGGAGAATTTTCGGATGGAGATGCTGGTGGTGATCCGCTTTTTGAAGAAGCTAA  
GTCTTTGGTTATCGAAACACAGAAAGCCAGTGCCTCTATGATTCAGCGTCGTTTATCAGTTGGATTAA  
CCGTGCGACCCGTCTCATGGAAGAACTGGAGATAGCAGGTGTCATCGGTCCAGCTGAAGGTACCAACC  
TCGAAAAGTGTTACAACAA

**SP078 amino acid (SEQ ID NO:132)**

RGFAKWEGHERRKEERFVKQEEKARQKAEKEARLEQEETEKALLDLPPVDMETGEILTEEAVQNLPP  
PEEKWVEPEIILPQAEKLFPEQEDDSDDEDVQVDFSAKEALEYKLPQLFAPDKPKDQSKKKIVREN  
IKILEATFASFGIKVTERAEIGPSVTKYEVKPAVGVRVNRISNLSDDLALALAAKDVRIEAPIPGKSL  
IGIEVPNSDIATVSFRELWEQSQTAEFLEIPLGKAVNGTARAFDLKMPHLLVAGSTGSGKSVAVNG  
IIASILMKARPDQVKFMMVDPKMWELSVNDIPHLIPVVTNPRKASKALQKVVDENENRYELFAKVG  
RNIAGFNAKVEEFNSQSEYKQIPLPFIVIVDELADLMVASKEVEDAIRLGQKARAAGIHMILATQR  
PSVDVISGLIKANVPSRVFAVSSGTDSTRTILDENGAEKLLGRGDMFLFKPIDENHPVRLQGSFISDDDV  
ERIVNFIKTQADADYDESFDPGEVSENEGEFSGDAGGDPLFEEAKSLVIETQKASASMIQRRLSVGFN  
RATRLMEELEIAGVIGPAEGTKPRKVLQ

**SP079 nucleotide (SEQ ID NO:133)**

TCAAAAAGAGAAGGAAAACCTTGGTTATTGCTGGGAAAATAGGTCCAGAACCAGAAAATTTGGCCAATAT  
GTATAAGTTGCTGATTGAAGAAAATACCAGCATGACTGCGACTGTTAAACCGAATTTTGGGAAGACAAG  
CTTCCTTTATGAAGCTCTGAAAAAAGGCGATATTGACATCTATCCTGAATTTACTGGTACGGTGACTGA  
AAGTTTGCTTCAACCATCACCAAGGTGAGTCATGAACCAGAACAGGTTTATCAGGTGGCGCGTGATGG  
CATTGCTAAGCAGGATCATCTAGCCTATCTCAAAACCATGTCTTATCAAAACACCTATGCTGTAGCTGT  
TCCGAAAAAGATTGCTCAAGAATATGGCTTGAAGACCATTTAGACTTGAAAAAAGTGGAAGGGCAGTT  
GAAGGCAGGTTTTACACTCGAGTTTAACGACCGTGAAAGATGGAATAAGGGCTTGCAATCAATGTATGG  
TCTCAATCTCAATGTAGCGACCATTTAGCCAGCCCTTCGCTATCAGGCTATTCAGTCAGGGGATATTCA  
AATCACGGATGCCTATTGACTGATGCGGAATTGGAGCGTTATGATTACAGGTCTTGGAAGATGACAA  
GCAACTCTTCCACCTTATCAAGGGGCTCCACTCATGAAAGAAGCTCTTCTCAAGAAACACCCAGAGTT  
GGAAAGAGTTCTTAATACATTGGCTGGTAAGATTACAGAAAGCCAGATGAGCCAGCTCAACTACCAAGT  
CGGTGTTGAAGGCAAGTCAGCAAAGCAAGTAGCCAAGGAGTTTCTCCAAGAACAAGGTTTGTGTAAGAA  
A

**SP079 amino acid (SEQ ID NO:134)**

QKEKENLVIAGKIGPEPEILANMYKLLIEENTSMTATVKPNFGKTSFLYEALKKGDIDIPEFTGTVTE  
SLLQSPKVSHEPEQVYQVARDGIAKQDHLAYLKPMYSQNTYAVAVPKKIAQEYGLKTIIDLKKVEGQL  
KAGFTLEFNDREDGNKGLQSMYGLNLNVATIEPALRYQAIQSGDIQITDAYSTDAELERYDLQVLEDDK  
QLFPPYQGAPLMKEALLKKHPELRLVNTLAGKITESQMSQLNYQVGVGKSAKQVAKEFLQEQLLKK

**SP080 nucleotide (SEQ ID NO:135)**

ACGTTCTATTGAGGACCACTTTGATTCAAACCTCGAATTGGAATATAACCTCAAAGAAAAAGGGAAAAC  
AGATCTTTTGAAGCTAGTTGATAAAACAACGACATGCGTCTGCATTTTATCCGCCAAACTCATCCACG  
CGGTCTCGGAGATGCTGTTTTGCAAGCCAAGGCTTTCGTGCGAAATGAACCTTTTGTGCTTATGCTTGG  
TGATGACTTGATGGATATCACAGACGAAAAGGCTGTTCCACTTACCAAACAACCTCATGGATGACTACGA  
GCGTACCCACGCGTCTACTATCGCTGTCTGCGAGTCCCTCATGACGAAGTATCTGCTTACGGGGTTAT  
TGCTCCGCAAGGCGAAGGAAAAGATGGTCTTTACAGTGTGAAACCTTTGTTGAAAAACCAGCTCCAGA  
GGACGCTCCTAGCGACCTTGCTATTATCGGACGCTACCTCCTCACGCCTGAAATTTTGTGATTCTCGA  
AAAGCAAGCTCCAGGTGCAGGAAAATGAAATTCAGCTGACAGATGCAATCGACACCCCTCAATAAAACACA  
ACGTGTATTTGCTCGTGAGTTCAAAGGGGCTCGTTACGATGTCGGAGACAAGTTTGGCTTCATGAAAAC  
ATCCATCGACTACGCCCTCAAACACCCACAAGTCAAAGATGATTTGAAGAATTACCTCATCCAACCTTG  
AAAAGAATTGACTGAGAAGGAA

Table 1

**SP080 amino acid (SEQ ID NO:136)**

RSIEDHFDNSFELEYNLKEKGKTDLLKLVDKTTDMRLHFIRQTHPRGLGDAVLQAKAFVGNPEFVVMGLG  
DDLMDITDEKAVPLTKQLMDDYERTHASTIAVMPVPHDEVSAYGVIAPQGEGKDGLYSVETFVEKPAPE  
DAPSDLAIGRYLLTPEIFEILEKQAPGAGNEIQLTDAIDTLNKTQRVFAREFKGARYDVGDKFGFMKT  
SIDYALKHPQVKDDLKNYLIQLGKELTEKE

**SP081 nucleotide (SEQ ID NO:137)**

CGCTCAAAAATACCAGAGGTGTTCTAGCTAATCGAGCACGTTTCTCCTCAAATGTTGAAAGCCCCAATTGGA  
GAGTGTCTTTTCTGATATTCCACCTCAGGCTGTAAAACTGGAATGTTGGCTACTACTGAAATCATGGA  
AATCATCCAACCCCTATCTTAAAAAACTGGATTGTCCTTATGTCTTGATCCTGTTATGGTTGCTACAAG  
TGGAGATGCCCTTGATTGACTCAAATGCTAGAGACTATCTCAAAACAACTTACTACCTCTAGCAACTAT  
TATTACGCCAAATCTTCCTGAAGCAGAAGAGATTGTTGGTTTTTCAATCCATGACCCCGAAGACATGCA  
GCGTGTGGTGCCTGATTTTAAAAGAATTTGGTCTCAGTCTGTGGTTATCAAAGGCGGACATCTCAA  
AGGTGGTGTAAAGATTTCTCTTTACCAAGAATGAACAATTTGTCTGGGAAAGCCACGAATTCAAAC  
CTGTACACCCCATGGTACT

**SP081 amino acid (SEQ ID NO:138)**

AQNTGRGVQLIEHVSPQMLKAQLESVFS DIPPAVKTGMLATTEIMEIIQPYLKKLDCPYVLDPVMVATS  
GDALIDSNARDYLKTNLLPLATIIITPNLPEAEIIVGFSIHDPEDMQRAGRLILKEFGPQSVVIKGGHLK  
GGAKDFLFTKNEQFVWESPRIQTCHTHGT

**SP082 nucleotide (SEQ ID NO:139)**

AATTGTACAATTAGAAAAAGATAGCAAATCAGACAAAGAACAAGTTGATAAACTATTTGAATCATTTGA  
TGCATCTTCAGATGAATCTATTTCTAAATTTAAAGAACTATCTGAAACTTCACTTAAAACCGATGCAGG  
TAAAGACTATCTTAATAACAAAGTCAAAGAATCATCTAAAGCAATTGTAGATTTTCATTTGCAAAAAGG  
TTTGGCTTATGATGTTAAAGATTGATGACAAATTTAAAGATAAAGCAACTCTTGAAACAAATGTAAA  
AGAAATTACAAAACAAATTGATTTTATCAAAAAAGTTGATGAAACTTTTAAACAAGAGAATTGGGAAGA  
AACTCTTAAATCTCTAAATGATCTTGTGATAAATATCAAAAACAAATCGAACTTTTGAAGAAAGAAGA  
AGAAAAAGCTGCTGAAAAAGCTGCTGAAAAAGCAAAGGAATCTTCTAGTCAAAGTAATTTCTTCTGGTAG  
TGCTTCTAATGAGTCTTATAATGGATCTTCCAATTCAAATGTAGATTATAGTTTCATCTGAACAACTAA  
TGGATATTCAAATAATTATGGCGGTCAAGATTATTCTGGTTCAGGAGATAGTTCAACAAATGGTGGATC  
ATCAGAACAATATTATCTAGCAATTCAAACAGCGGAGCAAATAATGTCTACAGATATAAAGGCACTGG  
TGCTGACGGCTATCAAAGATACTACTACAAAGATCATAATAATGGAGATGTGTATGATGACGATGGAAA  
TTACCTTGGGAACCTTTGGTGGCGGCATTGCAGAACCTAGTCAACGC

**SP082 amino acid (SEQ ID NO:140)**

IVQLEKDSKSDKEQVDKLFESFDASSDESISKLKELSETSLKTDAGKDYLNNKVKESSKAIVDFHLQKG  
LAYDVKDSDDKFKDKATLETNVKEITKQIDFIKKVDETFKQENLEETLKSNDLVDKYQKQIELLKKEE  
EKAAEKAAEKAKESSQSNSSGSASNESYNGSSNSNVDYSSSEQTNGYSNNYGGQDYS GSGDSSTNGGS  
SEQYSSSNSNSGANNVYRYKGTGADGYQRYYYKDHNGVDVYDDDDGNLGNFGGGIAEPSQR

**SP083 nucleotide (SEQ ID NO:141)**

TCTGACCAAGCAAAAAGAAGCAGTCAATGACAAAGGAAAAGCAGCTGTTGTTAAGGTGGTGGAAAGCCA  
GGCAGAACTTTATAGCTTAGAAAAGAAATGAAGATGCTAGCCTAAGAAAGTTACAAGCAGATGGACGCAT  
CACGGAAGAACAGGCTAAAGCTTATAAAGAATACAATGATAAAAATGGAGGAGCAAATCGTAAAGTCAA  
TGAT

**SP083 amino acid (SEQ ID NO:142)**

LTKQKEAVNDKGKAAVVKVVESQAELYSLEKNEDASLRKLQADGRITEEQAKAYKEYNDKNGGANRKVN  
D

**SP084 nucleotide (SEQ ID NO:143)**

GTCCGGCTCTGTCCAGTCCACTTTTTCTAGCGGTAGAGGAACAGATTTTCTTTATGGAGTTTGAAGAACT  
CTATCGGGAAACCAAAAACGCAGTGTAGCCAGTCAGCAAAAGACTAGTCTGAACTTAGATGGGCAGAC  
GCTTAGCAATGGCAGTCAAAAGTTGCCAGTCCCTAAAGGAATTCAGGCCCATCAGGCCAAAGTATTAC  
ATTTGACCGAGCTGGGGGCAATTCGTCCCTGGCTAAGGTTGAATTTAGACCAGTAAAGGAGCGATTTCG  
CTATCAATTATATCTAGGAAATGGAAAAATTAAACGCATTAAGGAAACAAAAAT



Table 1

79

**SP084 amino acid (SEQ ID NO:144)**

SGSVQSTFSAVEEQIFFMEFEELYRETQKRVSASQQKTSNLNDGQTLNNGSQKLFPVKGIQAPSGQSIT  
FDRAGGNSSLAKVEFQTSKGAIRYQLYLGNGKIKRIKETKN

**SP085 nucleotide (SEQ ID NO:145)**

GGGACAAATTCAAAAAATAGGCAAGAGGAAGCAAAAACTTGCAAAAGGAAGAAGTCTTGAGGGTAGC  
TAAGATGGCCCTGCAGACGGGGCAAAATCAGGTAAGCATCAACGGAGTTGAGATTTCAGGTATTTCTAG  
TGAAAAAGGATTGGAGGTCTACCATGGTTCAGAACAGTTGTTGGCAATCAAAGAGCCA

**SP085 amino acid (SEQ ID NO:146)**

GQIQKNRQEEAKILQKEEVLRLVAKMALQTGQNQVSINGVEIQVFSSEKGLEVYHGSEQLLAIKEP

**SP086 nucleotide (SEQ ID NO:147)**

TCGCTACCAGCAACAAAGCGAGCAAAAGGAGTGGCTCTTGTGTTGTGGACCAACTTGAGGTAGAAATTAGA  
CCGTTTCGCAGTTTCGAAAAAGTAGAAGGCAATCGCCTATACATGAAGCAAGATGGCAAGGACATCGCCAT  
CGGTAAGTCAAAGTCAGATGATTTCCGTAAACGAATGCTCGTGGTCGAGGTTATCAGCCTATGGTTTA  
TGGACTCAAATCTGTACGGATTACAGAGGACAATCAACTGGTTCGCTTTCATTTCCAGTTCCAAAAAGG  
CTTAGAAAGGGAGTTCATCTATCGTGTGGAAAAAGAAAAAAGT

**SP086 amino acid (SEQ ID NO:148)**

RYQQQSEQKEWLLFVDQLEVELDRSQFEKVEGNRLYMKQDGKDIAIGKSKSDDFRKTNARGRGYQPMVY  
GLKSVRITEDNQLVRFHFQFQKGLEREFYRVEKEKS

**SP087 nucleotide (SEQ ID NO:149)**

GAACCGACAAGTCGCCCACTATCAAGACTATGCTTTGAATAAAGAAAAATTGGTTGCTTTTGCTATGGC  
TAAACGAACCAAGATAAGGTTGAGCAAGAAAGTGGGGAACAGTTTTTAACTTAGGTCAGGTAAGCTA  
TCAAAACAAGAAACTGGCTTAGTGACGAGGGTTCGTACGGATAAGAGCCAATATGAGTTCTGTTTCC  
TTCAGTCAAATCAAAGAAGAGAAAAAGAGATAAAAAGGAAGAGGTAGCGACCGATTCAAGCGAAAAAGT  
GGAGAAGAAAAAATCAGAAGAGAAGCCTGAAAAGAAAGAGAATTCA

**SP087 amino acid (SEQ ID NO:150)**

NRQVAHYQDYALNKEKLVAFAAMAKRTKDKVEQESGEQFFNLQVSYQNKKTLGVTRVRTDKSQYEFLFP  
SVKIKEEKRDKKEEVATDSSEKVEKKKSEEKPEKKENS

**SP088 nucleotide (SEQ ID NO:151)**

GGTTGTGGGCTGGCAATATATCCCGTTTCCATCTAAAGGTAGTACAATTGGTCCTTACCCAAATGGTAT  
CAGATTAGAAGGTTTTCCAAAGTCAGAGTGGTACTACTTCGATAAAAAATGGAGTGCTACAAGAGTTTGT  
TGGTTGGAACCAATTAGAGATTAAGAACTAAAGACAGTGTGGAAGAAAGTACGGGGAAAAACGTGAAGA  
TTCAGAAGATAAAGAAGAGAAGCGTTATTATACGAACTATTACTTTAATCAAAATCATTCTTTAGAGAC  
AGGTTGGCTTTATGATCAGTCTAACTGGTATTATCTAGCTAAGACGGAAATTAATGGAGAAAACTACCT  
TGGTGGTGAAAGACGTGCGGGGTGGATAAACGATGATTTCGACTTGGTACTACCTACCTAGATCCAACAACCTGG  
TATTATGCAAAACAGGTTGGCAATATCTAGGTAATAAGTGGTACTACCTCCGTTCCTCAGGAGCAATGGC  
CACTGGCTGGTATCAGGAAGGTACCACTTGGTATTATTAGACCACCCAAATGGCGATATGAAAACAGG  
TTGGCAAAACCTTGGGAACAAATGGTACTATCTCCGTTTCATCAGGAGCTATGGCAACTGGTTGGTATCA  
AGATGGTTCAACTTGGTACTACCTAAATGCAGGTAATGGAGACATGAAGACAGGTTGGTTCCAGGTCAA  
TGGCAACTGGTACTATGCTTATAGCTCAGGTGCTTTGGCAGTGAATACGACCGTAGATGGCTATTCTGT  
CAACTATAATGGCGAATGGGTTCCG

**SP088 amino acid (SEQ ID NO:152)**

VVGWQYIPFPSKSTIGPYPNGIRLEGFPKSEWYFDKNGVLQEFVGWKTLEIKTKDSVGRKYGEKRED  
SEDKEEKRYYTNYFYNQNHSLGTWLYDQSNWYLLAKTEINGENYLGGERAGWINDDSTWYLYLDPPTG  
IMQTGWQYLGKWKYYLRSSGAMATGWYQEGTTWYLYLDHPNGDMKTGWQNLGNKWKYYLRSSGAMATGWYQ  
DGSTWYLYLNAGNGDMKTGWLFQVNGNWKYYAYSSGALAVNTTVDGYSVNYNGEWVR

**SP089 nucleotide (SEQ ID NO:153)**

GGCCAAATCAGAAATGGGTAGAAAGACAAGGGAGCCTTTTATTATCTTGACCAAGATGGAAAGATGAAAAG  
AAATGCTTGGGTAGGAACCTCCTATGTTGGTGCAACAGGTGCCAAAGTAATAGAAGACTGGGTCTATGA  
TTCTCAATACGATGCTTGGTTTTATATCAAAGCAGATGGACAGCACGCAGAGAAAGAAATGGCTCCAAAT

Table 1

80

TAAAGGGAAGGACTATTATTTCAAATCCGGTGGTTATCTACTGACAAGTCAGTGGATTAATCAAGCTTA  
TGTGAATGCTAGTGGTGCCAAAGTACAGCAAGGTTGGCTTTTGGACAAACAATACCAATCTTGGTTTTA  
CATCAAAGAAAATGGAACTATGCTGATAAAGAATGGATTTTCGAGAATGGTCACTATTATTATCTAAA  
ATCCGGTGGCTACATGGCAGCCAATGAATGGATTTGGGATAAGGAATCTTGGTTTTATCTCAAATTTGA  
TGGGAAAATGGCTGAAAAAGAATGGGTCTACGATTCTCATAGTCAAGCTTGGTACTACTTCAAATCCGG  
TGGTTACATGACAGCCAATGAATGGATTTGGGATAAGGAATCTTGGTTTTATCTCAAATCTGATGGGAA  
AATAGCTGAAAAAGAATGGGTCTACGATTCTCATAGTCAAGCTTGGTACTACTTCAAATCCGGTGGTTA  
CATGACAGCCAATGAATGGATTTGGGATAAGGAATCTTGGTTTTACCTCAAATCTGATGGGAAAATAGC  
TGAAAAAGAATGGGTCTACGATTCTCATAGTCAAGCTTGGTACTACTTCAAATCTGGTGGCTACATGGC  
GAAAAATGAGACAGTAGATGGTTATCAGCTTGGGAAGCGATGGTAAATGGCTTGGAGGAAAAACTACAAA  
TGAAAAATGCTGCTTACTATCAAGTAGTGCTGTACAGCCAATGTTTATGATTAGATGGTGAAGGCT  
TTCTATATATCGCAAGGTAGTGTGCTATGGCTAGATAAGGATAGAAAAAGTATGACAAGCGCTTGGC  
TATTACTATTTCTGGTTTGTGTCAGGCTATATGAAAACAGAAGATTTACAAGCGCTAGATGCTAGTAAGGA  
CTTTATCCCTTATTATGAGAGTGATGGCCACCGTTTTTACTACTATGTGGCTCAGAATGCTAGTATCCC  
AGTAGCTTCTCATCTTTCTGATATGGAAGTAGGCAAGAAATATTATTTCGGCAGATGGCCTGCATTTTGA  
TGGTTTTAAGCTTGAGAATCCCTTCTTTTCAAAGATTTAAACAGAGGCTACAACTACAGTGCTGAAGA  
ATTGGATAAGGTATTTAGTTTGTCTAAACATTAACAATAGCCTTTTGGAGAACAAGGCGCTACTTTTAA  
GGAAGCCGAAGAACATTACCATATCAATGCTCTTTATCTCCTTGGCCATAGTGCCCTAGAAAAGTAAGTG  
GGGAAGAAGTAAATTGCCAAAGATAAGAATAATTTCTTTGGCATTACAGCCTATGATACGACCCCTTA  
CCTTCTGCTAAGACATTTGATGATGTGGATAAGGGAATTTTAGGTGCAACCAAGTGGATTAAGGAAAA  
TTATATCGATAGGGGAAGAACTTTCTTGGAAACAAGGCTTCTGGTATGAATGTGGAATATGCTTCAGA  
CCCTTATTGGGGCGAAAAATTGCTAGTGTGATGATGAAAATCAATGAGAAG

**SP089 amino acid (SEQ ID NO:154)**

AKSEWVEDKGAFFYLLDQDGKMKRNAWVGTSYVGATGAKVIEDWVYDSQYDAWFYIKADGQHAKEKEWLQI  
KGDYFFKSGGYLLTSQWINQAYVNASGAKVQQGWLFDKQYQSWFYIKENGNYADKEWIFENGHYYYLK  
SGGYMAANEWIWDKESWFLKFDGKMAEKWVYDSHSQAWYFFKSGGYMTANEWIWDKESWFLKSDGK  
IAEKWVYDSHSQAWYFFKSGGYMTANEWIWDKESWFLKSDGKIAEKWVYDSHSQAWYFFKSGGYMA  
KNETVDGYQLGSDGKWLGKTTNENAAYYQVVPVTANVYDSDEKLSYISQGSVWVLDKDRKSDDKRLA  
ITISGLSGYMKTEDLQALDASKDFIPYYESDGRFHYHYVAQNASIPVASHLSMEVGKKYYSADGLHFD  
GFKLENPFLFKDLTEATNYSAEELDKVFSLLNINNSLLENKGATFKEAEHYHINALYLLAHSALSNW  
GRSKIAKDKNFFGITAYDTPYLSAKTFDDVDKGILGATKWIKENYIDRGRFTLGNKASGMNVEYASD  
PYWGEKIASVMMKINEK

**SP090 nucleotide (SEQ ID NO:155)**

ATTTGCAGATGATTCTGAAGGATGGCAGTTTGTCCAAGAAAATGGTAGAACCTACTACAAAAAGGGGA  
TCTAAAAGAAACCTACTGGAGAGTGATAGATGGGAAGTACTATTATTTTGATCCTTTATCCGGAGAGAT  
GGTTGTCGGCTGGCAATATATACCTGCTCCACACAAGGGGGTTACGATTGGTCTTCTCCAAGAATAGA  
GATTGCTCTTAGACCAGATTGGTTTTATTTTGGTCAAGATGGTGTATTACAAGAATTTGTTGGCAAGCA  
AGTTTTAGAAAGCAAAAACCTGCTACGAATACCAACAAACATCATGGGGAAGAATATGATAGCCAAGCAGA  
GAAACGAGTCTATTATTTTGAAGATCAGCGTAGTTATCATACTTTAAAAAAGTGGTTGGATTTATGAAGA  
GGGTCAATTGGTATTATTTTACAGAAGGATGGTGGCTTTGATTGCGCGCATCAACAGATTGACGGTTGGAGA  
GCTAGCACGTGGTTGGGTTAAGGATTACCCTCTTACGTATGATGAAGAGAAGCTAAAAGCAGCTCCATG  
GTACTATCTAAATCCAGCAACTGGCATTATGCAAACAGGTTGGCAATATCTAGGTAATAGATGGTACTA  
CCTCCATTGCTCAGGAGCTATGGCAACTGGCTGGTATAAGGAAGGCTCAACTTGGTACTATCTAGATGC  
TGAAAATGGTGATATGAGAACTGGCTGGCAAAACCTTGGGAACAAATGGTACTATCTCCGTTTCATCAGG  
AGCTATGGCAACTGGTTGGTATCAGGAAAGTTCGACTTGGTACTATCTAAATGCAAGTAATGGAGATAT  
GAAAACAGGCTGGTTCCAAGTCAATGGTAAGTGGTACTATGCCTATGATTACAGGTGCTTTAGCTGTTAA  
TACCACAGTAGGTGGTTACTACTTAACTATAATGGTGAATGGGTTAAG

**SP090 amino acid (SEQ ID NO:156)**

VFADDSEGWFQVQENGRYYKKGDLKETVWRVIDGKYFFDPLSGEMVVGWQYIPAPHKGVITIGPSPRI  
EIALRPDWFYFGQDGVLFQFVGKQVLEAKTATNTNKHGEEYDSQAEKRVYFFEDQRSYHTLKTGWIYE  
EGHWYYLQKDGDFDSRINRLTVGELARGWVKDYPLTYDEEKLKAAPWYYLNPATGIMQTGWQYLGNRWY  
YLHSSGAMATGWYKEGSTWYYLDAENGDMRTGWQNLGNKWYYLRSSGAMATGWYQESSWYYLNASNGD  
MKTGWQVNGNWYYAYDSGALAVNTTVGGYYLNYNGEWVK

Table 1

**SP091 nucleotide (SEQ ID NO:157)**

TGTCGCTGCAAATGAACTGAAGTAGCAAAAACCTCGCAGGATACAACGACAGCTTCAAGTAGTTCAGAGCAAAAATCAGTCTTCTAATAAAACGCAACGAGCGCAGAAAGTACAGACTAATGCTGCTGCCACTGGGATGGGGATTATTATGTAAAGGATGATGGTTCTAAAGCTCAAAGTGAATGGATTTTGTGACAACACTATAAAGCTTGGTTTTATATTAATTCAGATGGTCGTTACTCGCAGAATGAATGGCATGGAAAATTACTACCTGAAATCAGGTGGATATATGGCCCAAAACGAGTGGATCTATGACAGTAATTACAAGAGTTGGTTTTATCTCAAATCAGATGGGGCTTATGCTCATCAAGAATGGCAATTGATTGGAAATAAGTGGTACTACTTCAAGAAAGTGGGTTACATGGCTAAAAGCCAATGGCAAGGAAGTTATTTCTTGAATGGTCAAGGAGCTATGATGCAAAAATGAATGGCTSCTATGATCCAGCCTATTCTGCTTATTTTTATCTAAAATCCGATGGAACCTTATGCTAACC AAGAGTGGCAAAAAGTGGGCGGCAATGGTACTATTTCAAGAAGTGGGGCTATATGGCTCGGAATGAGTGGCAAGGCAACTACTATTTGACTGGAAGTGGTGGCCATGGCGACTGACGAAGTATTATGGATGGTACTC GCTATATCTTTGCGGCCCTCTGGTGAGCTCAAAGAAAAAAGATTTGAATGTCGGCTGGGTTACAGAGATGGTAAGCGCTATTTCTTTAATAATAGAGAAGAACAAGTGGGAACCGAATGCTAAGAAAGTCATTG ATATTAGTGAGCACAATGGTCGTATCAATGATTGGAAAAAGGTTATTGATGAGAACGAAGTGGATGGTGTCATTGTTTCGTCTAGGTTATAGCGGTAAAGAAGACAAGGAATTGGCGCATAACATTAAGGAGTTAAACC GTCTGGGAATTCCTTATGGTGTCTATCTCTATACCTATGCTGAAAATGAGACCGATGCTGAGAGTGACGCTAAACAGACCATTGAACCTTATAAAGAAATACAATTAAGAACCTGTCTTACCCTATCTATTATGATGTTG AGAATTTGGGAATATGTAAATAAGAGCAAGAGAGCTCCAAGTGATACAGGCACCTTGGGTTAAATCATCAACAAGTACATGGACACGATGAAGCAGGCGGGTTATCAAAATGTGTATGCTCTATAGCTATCTGTAGTTTAT TACAGACGCGTTTAAACACCCAGATATTTTAAACATGTAAACTGGGTAGCGGCCTATACGAATGCTTTAGAAATGGGAAAACCTCATTATTCAGGAAAAAAGGTTGGCAATATACCTCTTCTGAATACATGAAAG GAATCCAAGGGCGCGTAGATGTCAGCGTTTGGTAT

**SP091 amino acid (SEQ ID NO:158)**

VAANETEVAKTSQDTTASSSSSEQNQSSNKTQTSAEVQTNAAHWDGDYVVKDDGSKAQSEWIFDNYYK AWFYINSDGRYSQNEWHGNYLKSQGYMAQNEWIYDSNYKSWFYLKSDGAYAHQEWQLIGNKWYFFKKW GYMAKSQWQGSYFLNGQGAMQNEWLYDPAYSAYFYLKSDGTYANQEWQKVGKWWYFFKKWGYMARNEW QGNYLYLTGSGAMATDEVIMDTRYIFAASGELKEKKDLNVGWVHRDGRYFFNNREEQVGEHAKKVID ISEHNKRINDWKVIDENEVDGVIVRLGYSGKEDKELAHNIKELNRLGIPYGVLYLYTAEENETDAESDA KQTIELIKYNMNLSPYIYDVENWEYVNVKSKRAPSDTGTWVKIINKYMDTMKQAGYQNVVYYSYRSL QTRLKHPDILKHVNWVAAYTNALEWENPHYSGKKGWQYTSSEYMKGIQGRVDVSVWY

**SP092 nucleotide (SEQ ID NO:159)**

TACGCTCAGCCTACTTTTGTAAAGAGCAGAAGAATCTCCACAAGTTGTCGAAAAATCTTCATTAGAGAA GAAATATGAGGAAGCAAAAGCAAAAGCTGATACTGCCAAGAAAGATTACGAAACGGCTAAAAAGAAAGC AGAAGACGCTCAGAAAAAGTATGAAGATGATCAGAAGAGAAGTGAAGGAGAAAGCTCGAAAAAGAGCAGA AGCATCTCAAAAATTGAATGATGTGGCGCTTGTGTTTCAAAATGCATATAAAGAGTACCGAGAAGTTCA AAATCAACGTAGTAAATATAAATCTGACGCTGAATATCAGAAAAAATTAACAGAGGTGCGACTCTAAAT AGAGAAGGCTAGGAAAGAGCAACAGGACTTGCAAAATAAATTTAATGAAGTAAGAGCAGTTGTAGTTCC TGAACCAAATGCGTTGGCTGAGACTAAGAAAAAAGCAGAAGAAGCTAAAGCAGAAGAAAAAGTAGCTAA GAGAAAAATATGATTATGCAACTCTAAAGGTAGCACTAGCGAAGAAAGAGTAGAGGCTAAGGAACTTGA AATTGAAAAAATTTCAATATGAAATTTCTACTTTGGAACAAGAAGTTGCTACTGTCAACATCAAGTAGA TAATTTGAAAAAATCTTCTGCTGGTGGCGATCCTGATGATGGCACAGAAGTTATAGAAGCTAAAATTAAA AAAAGGAGAAGCTGAGCTAAACGCTAAACAAGCTGAGTTAGCAAAAAAACAACAGAAGCTGAAAAAATCT TCTTGACAGCCTTGATCCTGAAGGTAAGACTCAGGATGAATTAGATAAAGAGCAGAAGAAGCTGAGTT GGATAAAAAAGCTGATGAACCTCAAAATAAAGTTGCTGATTTAGAAAAAGAAATTAGTAACCTTGAAAT ATTACTTGGAGGGGCTGATNCTGAAGATGATACTGCTGCTCTTCAAAATAAATTAGCTACTAAAAAAGC TGAATTGGAAAAAATCAAAAAGAATTAGATGCAGCTCTTAATGAGTTAGGCCCTGATGGAGATGAAGA AGAACTCCAGCGCCGCTCCTCAACCAGAGCAACCAGCTCCTGCACCAAAACCAGAGCAACCAGCTCC AGCTCCAAAACCAGAGCAACCAGCTCCTGCACCAAAACCAGAGCAACCAGCTCCAGCTCCAAAACCAGA GCAACCAGCTCCAGCTCCAAAACCAGAGCAACCAGCTAAGCCGGAGAAACCAGCTGAAGAGCCTACTCA ACCAGAAAAACCAGCCACTCCAAAACAGGCTGGAACAAGAAACGGTATGTGGTATTTCTACAATAC TGATGGTTCAATGGCAATAGGTTGGCTCCAAAACAACGGTTTATGGTACTACCTAAACGCTAACGGCGC TATGGCAACAGGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGCATCAGGTGCTATGAAAGC AAGCCAATGGTTCAAAGTATCAGATAAATGGTACTATGTCAACAGCAATGGCGCTATGGCGACAGGCTG GCTCCAATACAATGGCTCATGGTACTACCTCAACGCTAATGGTGATATGGCGACAGGATGGCTCCAATA CAACGGTTCATGGTATTACCTCAACGCTAATGGTGATATGGCGACAGGATGGGCTAAAGTCAACGGTTCATGGTACTA ATGGTACTACCTAAACGCTAACGGTGCTATGGCTACAGGTTGGGCTAAAGTCAACGGTTCATGGTACTA

Table 1

CCTAAACGCTAACGGTTCAATGGCAACAGGTTGGGTGAAAGATGGAGATACCTGGTACTATCTTGAAGC  
ATCAGGTGCTATGAAAGCAAGCCAATGGTTCAAAGTATCAGATAAATGGTACTATGTCAATGGCTTAGG  
TGCCCTTGCACTAACACAACCTGTAGATGGCTATAAAGTCAATGCCAATGGTGAATGGGTT

**SP092 amino acid (SEQ ID NO:160)**

TSQPTFVRAEESPVVEKSSLEKKYEEAKAKADTAKKDYETAKKKAEDAQKKYEDDQKRTEEKARKEAE  
ASQKLNDAVALVQNAKEYREVQNRSKYKSDAEYQKKLTEVDSKIEKARKEQDLQNKFNVRVAVVP  
EPNALAETKKKAEKAEKVAKRKYDYATLKVLAKEVEAKELEIEKLQYEISTLEQEVATAQHQVD  
NLKKLLAGADPDDGTEVIEAKLKKGEAELNAKQAEAKKQTELEKLLDSLDPGKTQDELKEAEAEEL  
DKKADELQNKVADLEKEISNLEILLGGADXEDDTAALQNKLATKKAELEKTQKELDAALNELGPDGDEE  
ETPAPAPQPEQPAPAPKPEQPAPAPKPEQPAPAPKPEQPAPAPKPEQPAPAPKPEQPAKPEKPAEPTQ  
PEKPATPKTGWKQENGWYFYNTDGSMAIGWLQNGSWYYLNANGAMATGWVKDGDWYYLEASGAMKA  
SQWFKVSDKWYYVNSNGAMATGWLQYNGSWYYLNANGDMATGWLQYNGSWYYLNANGDMATGWAKVNGS  
WYYLNANGAMATGWAKVNGSWYYLNANGSMATGWVKDGDWYYLEASGAMKASQWFKVSDKWYYVNLG  
ALAVNTTVDGYKVNANGEW

**P093 nucleotide (SEQ ID NO:161)**

TGGACAGGTGAAAGTTCATGCTACATTTGTGAAATCCATGACAACGTAAATGTACCAAGAACAACAGAA  
CCATTCTCTCGCCTACAATCAACGCTTGGNTTCGCAAAATCGCATTGTAGATCCTTTTTTGGCGGAGGG  
ATATGAGGTCAATTACCAAGTGTCTGACGACCCTGATGCAGTCTATGGTTACTTGTCTATTCCAAGTTT  
GGAAATCATGGAGCCGTTTATTTGGGAGCAGATTATCATCATTTAGGGATGGGCTTGGCTCATGTGGA  
TGGTACACCGCTGCCTCTGGATGGTACAGGGATTGCTCAGTGATTGCTGGGCACCGTGCAGAGCCAAG  
CCATGTCTTTTTCCGCCATTTGGATCAGCTAAAAGTTGGAGATGCTCTTTATTATGATAATGGCCAGGA  
AATTGTAGAATATCAGATGATGGACACAGAGATTATTTACCGTCGGAATGGGAAAAATTAGAATCGGT  
TAGCTCTAAAAATATCATGACCTTGATAACCTGCGATCCGATTCTACCTTTAATAAACGCTTATTAGT  
GAATTTTGAACGAGTCGCTGTTTATCAAAAATCAGATCCACAAACAGCTGCAGTTGCGAGGGTTGCTTT  
TACGAAAGAAGGACAATCTGTATCGCGTGTGCAACCTCTCAATGGTTG

**SP093 amino acid (SEQ ID NO:162)**

GQVKGHATFVKSMTTEMYQEQQNHSLAYNQRLXSQNRIVDPFLAEGYEVNYQVSDDPDAVYGYLSIPSL  
EIMEPVYLGADYHHLGMGLAHVDGTPPLDGTGIRSVIAGHRAEPSHVFFRHLQDKVGDALYYDNGQE  
IVEYQMMDEIILPSEWEKLESVSSKNIMTLITCDPIPTFNKRLLVNFERVAVYQKSDPQTAARVAVF  
TKEGQSVSRVATSQWL

**SP094 nucleotide (SEQ ID NO:163)**

GATTGCTCCTTTGAAGGATTTGAGAGAAACCATGTTGGAAATTGCTTCTGGTGCTCAAAATCTTCGTGC  
CAAGGAAGTTGGTGCCTATGAAGTGAAGTAAGTACGCAATTTAATGCTATGTTGGATCAGATTGA  
TCAGTTGATGGTAGCTATTCGTAGCCAGGAAGAAACGACCCGTCAGTACCAACTTCAAGCCCTTTTCGAG  
CCAGATTAATCCACATTTCTCTATAACACTTTGGACACCATCATCTGGATGGCTGAATTTTCATGATAG  
TCAGCGAGTGGTGCAGGTGACCAAGTCTTTGGCAACCTATTTCCGCTTGGCGCTCAATCAAGGCAAGGA  
CTTGATTTGTCTCTCTGACGAAATCAATCATGTCCGCCAGTATCTCTTTATCCAGAAACAACGCTATGG  
AGATAAGCTGGAATACGAAATTAATGAAATGTTGCCTTTGATAATTTAGTCTTACCCAAGCTGGTCTT  
ACAACCCCTTGTAGAAAATGCTCTTTACCATGGCATTAAGGAAAAGGAAGGTCAGGGCCATATTAACCT  
TTCTGTCCAGAAACAGGATTCGGGATTGGTCATCCGTATTGAGGATGATGGCGTTGGCTTCCAAGATGC  
TGGTGATAGTAGTCAAAGTCAAACGTCGAGGAGTTGGTCTTCAAATGTCCGATCAACGGCTCAA  
ACTTCATTTTGGAGCCAATTACCATATGAAGATTGATTCTAGACCCCAAAAAGGACGAAAGTTGAAAT  
ATATATAAATAGAAATAGAACTAGC

**SP094 amino acid (SEQ ID NO:164)**

IAPLKDLRETMLEIASGAQNLRAKEVGAYELREVTRQFNAMLDQIDQLMVAIRSQEETTRQYQLQALSS  
QINPHFLYNTLDIIWMAEFHDSQRVVQVTKSLATYFRLALNQKDLICLSDEINHVRQYLFIQKQRYG  
DKLEYEINENVAFDNLVLPKLVLPVENALYHGIKEKEGQGHIKLSVQKQDSGLVIRIEDDGVGFQDA  
GDSSQSQLKRGVGLQNVQRLKLHFGANYHMKIDSRPQKGTKEIYINRIETS

**SP095 nucleotide (SEQ ID NO:165)**

TAGGTCATATGGGACTTTTTTCTACAACAAAATAGGCTCCATAATATCTATAAGGGATTTACCCACTA  
CAATATTATAGAGCCGAAAATTCACATCTAATATATGCAGACTACTTTGAAATGAAATTAATAAATTT  
ATTAAAGGATGACACAAAAGTTTTTGAATACTACATTCAAATTTGTAGAAGGATATAAATATACCT

Table 1

GACAGAATCTAAAGAATCTGGAATTAAACAAATGGACAATGTCATAAAATATTTTGAGTTTATTGAATC  
TAAAGTATTGCTTTATATTTTCAAAAACGATTAAATGAGCTGATAGAT

**SP095 amino acid (SEQ ID NO:166)**

RSYGTFFLQQNRLHNIYKGFTHYKYRAENSHLIYADYFEMKLKLLKDDTKVFEKSTFKFVEGYKIYL  
TESKESGIKQMDNVIKYFEFIESKSIALYFQKRLNELID

**SP096 nucleotide (SEQ ID NO:167)**

CAACGTTGAGAATTATTTGCGAATGTGTTTGGATAGCATTTCAGAAATCAGACGTATCAAAATTTTGAGTG  
TTTATTAATCAATGATGGCTCTCCAGATCATTCATCCAAAATATGTGAAGAATTTGTAGAGAAAGATTC  
TCGTTTCAAATATTTTGAGAAAGCAAACGGCGGTCTTTCATCAGCTCGTAACCTAGGTATTGAATGTTT  
GGGGGGGGCGTACATTACTTTTGTAGACTC

**SP096 amino acid (SEQ ID NO:168)**

NVENYLRMCCLDSIQNTYQNFECLLINDGSPDHSSKICEEFVEKDSRFKYFEKANGGLSSARNLGI ECS  
GGGVHYFCRL

**SP097 nucleotide (SEQ ID NO:169)**

CTACTATCAATCAAGTTCTTCAGCCATTGAGGCCACCATTGAGGGCAACAGCCAAACGACCATCAGCCA  
GACTAGCCACTTTATTTCAGTCTTATATCAAAAACTAGAAACCACCTCGACTGGTTTGACCCAGCAGAC  
GGATGTTCTGGCCTATGCTGAGAATCCCAGTCAAGACAAGGTCGAGGGAATCCGAGATTGTTTTTGAC  
CATCTTGAAGTCAGATAAGGACTTGAAAACGTGTGTGCTGGTGACCAAATCTGGTCAGGTCATTTCTAC  
AGATGACAGTGTGCAGATGAAAACCTCCTCTGATATGATGGCTGAGGATTGGTACCAAAGGCCATTCA  
TCAGGGAGCTATGCCTGTTTTGACTCCAGCTCGTAAATCAGATAGTCAGTGGGTCATTTCTGTCACTCA  
AGAAGTTGTTGATGCAAGGGAGCCAATCTGGTGTGCTTCGTTTGGATATTCTTATGAAACTCTGGA  
AGCCTATCTCAATCAACTCCAGTTGGGGCAGCAGGGCTTTCCTTCATTATCAATGAAAACCTGAATT  
TGTCTACCATCTCAACACACAGTTTATAGTTCGTCTAGCAAAATGGAGGCTATGAAACCTTACATCGA  
TACAGGTCAGGGTTATACTCCTGGTCACAAATCCTACGTCAGTCAAGAGAAGATTGCAGGAAGTATTG  
GACGGTGTCTGGCGTGTATCATTGGAAAAGTTAGACCAGGTTTCGGAGTCAG

**SP097 amino acid (SEQ ID NO:170)**

YYQSSSSAIEATIEGNSQTTISQTSHFQSYIKKLETTSTGLTQQTDVLAYAENPSQDKVEGIRDLEFLT  
ILKSKDLKTVVLVTKSGQVISTDDSVQMKTSDDMAEDWYQKAIHQAMPVLT PARKSDSQWVISVTO  
ELVDAKGANLGVRLDISYETLEAYLNQLQLGQQGFAP IINENHEFVYHPQHTVYSSSSKMEAMKPYID  
TGQGYTPGHKSYVSQEKIAGTDWTVLGVSSLEKLDQVRSQ

**SP098 nucleotide (SEQ ID NO:171)**

GACAAAAACATTAAACGTCCTGAGGTTTTATCACCTGCAGGGACTTTAGAGAAGCTAAAGGTAGCTGT  
TCAGTATGGAGCAGATGCTGTCTTTATCGGTGGTCAGGCCTATGGTCTTCGTAGCCGTGCGGGAACTT  
TACTTTTCAACAGATGGAAGAAGCGGTGCAGTTTGCGGCCAAGTATGGTGCCAAGGTCTATGTAGCGGC  
TAATATGGTTATGCACGAAGGAAATGAAGCTGGTGTGGTGAGTGGTTCCGTAAACTGCGTGATATCGG  
GATTGCAGCAGTTATCGTATCTGACCCAGCCTTGATTATGATTGCAGTGACTGAAGCACCAGGCCTTGA  
AATCCACCTTTCTACCCAAGCCAGTGCCACTAATATGAAACCCCTTGAGTCTGGAAGAGCTAGGCTT  
GACTCGTGTGTTTTAGCGCGTGAGGTTTCAATGGAAGAATTAGCTGAGATCCGCAAACGTACAGATGT  
TGAAATTGAAGCCTTTGTCCATGGAGCTATGTGTATTTTCACTACTCTGGACGTTGTACTCTTTCAAACCA  
CATGAGTATGCGTGATGCCAACCGTGGTGGATGTTCTCAGTCATGCCGTTGGAAATACGACCTTTACGA  
TATGCCATTTGGGAAAGAACGTAAGAGTTTGCAGGGTGAGATTCCAGAAGAATTTTCAATGTCAGCCGT  
TGACATGTCTATGATTGACCANATTCAGATATGATTGAAAATGGTGTGGACAGTCTAAAAATCGAAGG  
ACGTATGNAGTCTATTTACTANGTATCAACAGTAACCACTGCTACAAGGCGGCTGTGGATGCCTATCT  
TGAAAGTCCCTGAAAAGTTTGAAGCTATCAAACAAGACTTGGTGGACGAGATGTGGAAGGTTGCCCAACG  
TGAAGTGGCTACAGGATTTTACTATGGTACACCATCTGAAAATGAGCAGTTGTTTGGTGTCTCGTCGTAA  
AATCCCTGAGTACAAGTTTGTCTGCTGAAGTGGTTTCTTATGATGATGCCGCACAAACAGCAACTATTCTG  
TCAACGAAACGTCATTAACGAAGGGGACCAAGTTGAGTTTTATGGTCCAGGTTTCCGTCATTTTGAAAC  
CTATATTGAAGATTTGCATGATGCTAAAGGCAATAAAATCGACCGCGCTCCAAATCCAATGGAAGTATT  
GACTATTAAAGTCCCAACCTGTTCAATCAGGAGACATGGTTCGAGCTCTTAAAGAGGGGCTTATCAA  
TCTTTATAAGGAAGATGGAACCAGCGTCACAGTTCGTGCT

Table 1

**SP098 amino acid (SEQ ID NO:172)**

TKTLKRPEVLSPAGTLEKLKQVAVQYGADAVFIGGQAYGLRSRAGNFTFEQMEEGVQFAAKYGAKVYVAA  
NMVMHEGNEAGAGGEWFRKLRDIGIAAVIVSDPALIMIAVTEAPGLEIHLSTQASATNYETLEFWKELGL  
TRVVLAREVSMELAEIRKRTDVEIEAFVHGAMCISYSGRCTLNHSMSMRDANRGCCSQSCRWKYDLYD  
MPFGKERKSLQGEIPEEFSMSAVDMSMIDXIPDMIENGVDLSKIEGRMXSIHXVSTVTNICYKAAVDAYL  
ESPEKFEAIKQDLVDEMVKVAQRELATGFYYGTPSENEQLFGARRKIPEYKFVAEVVSYDDAAQTATIR  
QRNVINEGDQVEFYGPGFRHFETYIEDLHDAKGNKIDRAPNPMELLTIKVPQPVQSGDMVRALKEGLIN  
LYKEDGTSVTVRA

**SP099 nucleotide (SEQ ID NO:173)**

TTCTCAGGAGACCTTTAAAAATATCACCAATAGCTTCTCCATGCAAATCAATCGTCGCGTCAACCAAGG  
AACGCCTCGTGGTGTCTGGGAATATCAAGGGTGAAGACATCAAAAAATCACCGAAAAACAAGGCCATTGA  
GTCTTATGTCAAACGTATCAACGCTATCGGAGATTGACTGGATATGACCTGATTGAAACGCCAGAAAC  
CAAGAAGAACTCTACTGCTGATCGTGCCAAAGCGTTTTGGAAGTAGCTTGATGATTACAGGTGTCAATGA  
CTCCTCTAAAGAAGACAAGTTTGTCTCTGTTTCTTATAAACTAGTCGAAGGAGAGCACTTAACCAACGA  
CGACAAGGATAAAATCCTCTTGCACAAGGACTTGGCAGCCAAACACGGCTGGAAAGTAGGGGACAAGGT  
TAAACTGGACTCTAATATCTACGATGCAGATAATGAAAAAGGAGCCAAGGAAACAGTTGAAGTGACAAT  
CAAGGGACTCTTTGATGGTCATAATAAGTCAGCAGTAACCTACTCACAAGAACTTTACGAAAACACAGC  
TATTACAGACATTACACTGCTGCAAAACTTTATGGATACACAGAAGACACAGCCATTTATGGGGACGC  
AACCTTCTTTGTAACAGCAGACAAGAACTTGGATGATGTTATGAAAGAGTTGAATGGCATCAGTGGTAT  
CAACTGGAAGAGCTACACACTCGTCAAGAGCTCCTCTAACTACCCAGCTCTTGAGCAATCTATCTCTGG  
TATGTACAAGATGGCCAAC

**SP099 amino acid (SEQ ID NO:174)**

SQETFKNITNSFSMQINRRVNQGTTPRGAGNIKEDIKKITENKAIESYVKRINAIGDLTGYDLIETPET  
KKNLTADRAKRFSGSSLMITGVNDSSKEDKFVSGSYKLVGEHLEHTNDDKDKILLHKDLAAKHGKVGDKV  
KLDSDNIYDADNEKGAKETVEVTIKGLFDGHNKSAVTYSQELYENTAITDIHTAAKLYGYTEDTAIYGDA  
TFFVTADKNLDDVMKELNGISGINWKSYYTLVKSSSNYPALQSIISGMKMAN

**SP100 nucleotide (SEQ ID NO:175)**

AGTAAATGCGCAATCAAATTCATTAATATTAATAGATGAACCTGAAATCTCACTTCATCCGAGTGCAAT  
CTATAAATTTAAAGAGTTTTTACTTCAAGAGTGTTTTAAATAAAAAACATCAAATTATTATCACTACACA  
TTCTACACAACCTATAAAAGATTTTCTAGAGAAGCCGTGAAACTTTTAGTGAAAAACGGAGAAAAGGT  
AGATGTTATTGAAAAATTTGATTATCAGGATGCATTTTTTGAATTAGGTGATGTGTATCATTCTAGGAA  
GATGATTTATGTTGAAGATAGACTAGCTAAATATATTCTAGAGTTTGTTATCACTCATTACAGGTAGTGA  
GAATCTTAAACAGAAATTTAGTAGTGAGATATATTCTCTGGTGAGCAAATCAAATAATTTGTAATAATAT  
TTTAAACTCATCGTATTTAGATTCCGATAACCATTATTTTGGCTTGATGGAGATCAAAACACTAATGT  
TAGTGAATCAAATAATTTAATGAATATCTTGAAAATGGTGTTGTTATATCAGATAAAATTCCTGAATC  
AGATAATAAAATCTTGATGATATTATAAAATTGATAANGGATGTCCAATTAATTTAATGTTTCAGG  
TAATAAAGGGCAAAAAATAATATTGAATTAATTGCGAAACAAAGAAGCTTTATAGATTATTGGGCTAA  
ATAC

**SP100 amino acid (SEQ ID NO:176)**

VNAQNSNLILIDEPEISLHPSAIYKFKEFLQECNLKHKQIIITTHSTQLIKDFPREAVKLLVKNGEKV  
DVNIENIDYQDAFFELGDVYHSRKMIYVEDRLAKYILEFVITHSGSENKQNLVVRIYIPGGANQIIICNNI  
LNSSYLDSDNHFWLDGDQNTNVSESNNLMNYLENGVVISDKIPESDNKNLDDIIKLIXGCPKIFNVSG  
NKGQKNNIELIAKQRSFIDYWAKY

**SP101 nucleotide (SEQ ID NO:177)**

TTACCGCGTTCATCAAGATGTCAAACAAGTCATGACCTATCAACCCATGGTGCGAGAAATATTGAGTGA  
ACAAGACACCCCAGCAAACGAAGAGCTTGTGCTTGCTATGATTTATACTGAAACAAAAGGAAAAGAAGG  
CGATGTTATGCAGTCTAGTGAGTCTGCAAGTGGTTCCACCAACACCATCAATGATAATGCCTCTAGCAT  
TCGGAAGGCATTCAAACCTCTGACAGGCAATCTCTATCTGGCGCAGAAGAAGGGGGTAGATATCTGGAC  
AGCTGTTCAAGCCTATAATTTTGGACCTGCCTATATCGATTTTATCGCCCAAAATGGCAAGGAAAATAC  
CCTGGCTCTAGCCAAACAGTACTCTCGTGAGACTGTTGCCCCCTTGCTTGGAATAGGACTGGAAAGAC  
TTATAGTTATATTACCCCATTTCCATTTTTCACGGTGTGAACTCTATGTAATGGAGGAAACTATTA  
TTATTCTAGACAGGTACGACTTAACCTTTACATCATCAAATGTTTCACTCTCTTTTCAACATCTGGC

Table 1

85

**SP101 amino acid (SEQ ID NO:178)**

YRVHQDVQVMTYQPMVREILSEQDTPANEELVLAMIYTTETKGKEGDMQSSSESASGSTNTINDNASSI  
RQGIQTLTGNLYLAQKKGVDIWTAQAYNFGPAYIDFIAQNGKENTLALAKQYSRETVPALLGNRTGKT  
YSYIHPISIFHGAELYVNGGNYYYSRQVRLNLYIICFTLFSTSG

**SP102 nucleotide (SEQ ID NO:179)**

GTGGATGGGCTTTAACTATCTTCGTATTCGCCGTGCGGCTAAAATTGTGGACAATGAGGAGTTTGAAGC  
CTTGATTCGTACGGGTCAATTGATTGATTTCGCGCAGCCAGCAGAATTCCACAGAAAACATATCCTTGG  
TGCACGCAATATTCCTTCAAGTCAGTTGAAAAGTAGTCTTCGAGCCCTTCGTAAAGATAAACCTGTCTT  
TCTCTACGAAAACCAACGTGCGCAACGAGTTACAAATGCAGCTCTTACTTGAAAAACAAGGTTTTTC  
TGAGATTTATATCCTTTCTTATGGCTTGGATTCTTGGAAAGGGAAGTGAAGACTAGC

**SP102 amino acid (SEQ ID NO:180)**

WMGFNYLRIRRAAKIVDNEEFELIRTGQLIDLRDPAEFHRKHILGARNIPSSQLKTSLAALRKDKPVL  
LYENQRAQRVTNAAALYLKKQGFSEIYILSYGLDSWKGVKTS

**SP103 nucleotide (SEQ ID NO:181)**

ACTAAACCAGCATCGTTTCGAGGAAAATAAGGACAATAATCGTGTCTCTTATGTGGATGGCAGCCAGTC  
AAGTCAGAAAAGTGAAAACCTTGACACCAGACCAGGTTAGCCAGAAAAGAAGGAATTCAGGCTGAGCAAAT  
TGTAATCAAAATTACAGATCAGGGCTATGTAACGTCACACGGTGACCACTATCATTACTATAATGGGAA  
AGTTCCTTATGATGCCCTCTTTAGTGAAGAACTCTTGATGAAGGATCCAAACTATCAACTTAAAGACGC  
TGATATTGTCAATGAAGTCAAGGGTGGTTATATCATCAAGGTCGATGGAAAATATTATGTCTACCTGAA  
AGATGCAGCTCATGCTGATAATGTTTGAAGTAAAGATGAAATCAATCGTCAAAAACAAGAATATGTCAA  
AGATAATGAGAAGGTTAACTCTAATGTTGCTGTAGCAAGGTCCTCAGGGACGATATACGACAAATGATGG  
TTATGTCTTTAATCCAGCTGATATTATCGAAGATACGGGTAATGCTTATATCGTTCTCATGGAGGTCA  
CTATCACTACATTCCCAAAAGCGATTTATCTGCTAGTGAATTAGCAGCAGCTAAAGCACATCTGGCTGG  
AAAAAATATGCAACCGAGTCAGTTAAGCTATCTTCAACAGCTAGTGACAATAACACGCAATCTGTAGC  
AAAAGGATCAACTAGCAAGCCAGCAAATAAATCTGAAAATCTCCAGAGTCTTTTGAAGGAAGCTCTATGA  
TTCACCTAGCGCCCAACGTTACAGTGAATCAGATGGCCCTGGTCTTTGACCCTGCTAAGATTATCAGTCG  
TACACCAAAATGGAGTTGCGAATCCGCGATGGCGACCATTACCACCTTATTCCTTACAGCAAGCTTCTGCG  
CTTAGAAGAAAAGATTGCCAGAATGGTGCCTATCAGTGGAACTGGTTCTACAGTTTCTACAAATGCAAAA  
ACCTAATGAAGTAGTGTCTAGTCTAGGCAGTCTTTCAAGCAATCCTTCTTCTTTAAGCAAGTAAGGA  
GCTCTCTTCAGCATCTGATGGTTATATTTTAAATCCAAAAGATATCGTTGAAGAAACGGCTACAGCTTA  
TATTGTAAGACATGGTGATCATTTCCATTACATTCCAAAATCAAATCAAATGGGCAACCGACTCTTCC  
AAACAATAGTCTAGCAACACCTTCTCCATCTCTTCCAATCAATCCAGGAAGCTTACATGAGAAACATGA  
AGAAGATGGATACGGATTTGATGCTAATCGTATTATCGCTGAAGATGAATCAGGTTTTGTCTAGTCA  
CGGAGACCACAATCATTATTTCTTCAAGAAG

**SP103 amino acid (SEQ ID NO:182)**

LNQHRSEQENKDNRRVSYVDGSQSSQKSENLPDQVSQKEGIAEQIVIKITDQGYVTSBGHDHYHYNGK  
VPYDALFSEELLMKDPNYQLKDADIVNEVKGYYIIKVDGKYVYVLKDAHADNVRTKDEINRQKQEHVK  
DNEKVSNNVAVARSQGRYTTNDGYVFNPAIDTGNAYIVPHGGHYHYIPKSDLSASELAAAKAHLAG  
KNMQPSQLSYSSSTASDNNQSVAKGSTSKPANKSENLSLLKELYDSPAQRYSESDDLVDPAKIIISR  
TPNGVAIPHGDHYHFIPYSKLSALEEKIARMVPISGTGSTVSTNAKPNEVVSSLGSLSSNPSSLTTSKE  
LSSASDGYIFNPKDIVEETATAYIVRHGDHFHYIPKSNQIQPTLPNNSLATPSPSLPINPGTSHEKHE  
EDGYGFDANRIIAEDES GFVMSHGDHNYHFFKK

**SP105 nucleotide (SEQ ID NO:183)**

TGACTACCTTGAAATCCCACTTTACAGCTATCTTGGTGGATTCAACACTAAAGTTCTTCCAACCTCCAAT  
GATGAACATCATCAACGGTGGTTCTCACTCTGACGCTCCAATCGCTTTCCAAGAGTTTCATGATCTTGCC  
AGTTGGTGCGCCAACATTTAAAGAAGCCCTTCGTTACGGTGCTGAAATCTTCCACGCTCTTAAGAAAAT  
CCTTAAATCACGTGGTTTGAAAAGTGGCGTAGGTGACGAAGGTGGATTGCTCCTCGTTTTCGAAGGAAC  
TGAAGATGGTGTGAAACTATCCTTGCTGCGATTGAAGCTGCTGGATATGTACCAGGTAAAGACGTATT  
TATCGGATTTGACTGTGCTTCATCAGAAATCTACGATAAAGAACGTAAAGTTTACGACTACACTAAATT  
TGAAGGTGAAGGTGCTGCTGTTTCGTACATCTGCAGAACAAATCGACTACCTTGAAGAATTGGTTAACAA  
ATACCCAATCATCACTATTGAAGATGGTATGGATGAAAACGACTGGGATGGTTGGAAGCTCTTACTGA  
ACGCTCTTGTAAGAAAGTACAACCTTGTGGTGACGACTTCTTCGTAACAAACACTGACTACCTTGCACG

Table 1

TGGTATCCAAGAAGGTGCTGCTAACTCAATCCTTATCAAAGTTAACCAAATCGGTACTCTTACTGAAAC  
TTTTGAAGCTATCGAAATGGCTAAAGAAGCTGGTTACACTGCTGTTGTATCACACCGTTCAGGTGAAAC  
TGAAGATTCAACAATCGCTGATATTGCAGTTGCAACTAACGCAGGACAAATCAAGACTGGTTCACCTTTC  
ACGTACAGACCGCATCGCTAAATACAACCAATTGCTTCGTATCGAAGACCAACTTGGTGAAGTAGCTGA  
ATATCGTGGATTGAAATCATTCTACAACCTTAAAAAA

**SP105 amino acid (SEQ ID NO:184)**

DYLEIPLYSYLGGFNTKVLPTPMMNIINGGSHSDAPIAFQEFMILPVGAPTFKEALRYGAEIFHALKKI  
LKSRGLETAVGDEGGFAPRFEGTEDGVETILAAIEAAGYVPGKDVFIGFDCASSEFYDKERKVYDYTKF  
EGEGAARTSAEQIDYLEELVNKYPIITIEDGMDENDWDGKALTERLGKKVQLVGDDFFVTNTDYLAR  
GIQEGAANSILIKVNQIGTLTETFEAIEMAKEAGYTAVVSHRSGETEDSTIADIATNAGQIKTGSLS  
RTDRIAKYNQLLRIEDQLGEVAEYRGLKSFYNLKK

**SP106 nucleotide (SEQ ID NO:185)**

TCGTATCTTTTTTGGAGCAATGTTTCGCGTAGAAGGACATTCCATGGATCCGACCCCTAGCGGATGGCGA  
AATTCCTCTCGTTGTAAACACCTTCCTATTGACCGTTTTGATATCGTGGTGGCCCATGAGGAAGATGG  
CAATAAGGACATCGTCAAGCGCGTGATTGGAATGCCTGGCGACACCATTCGTTACGAAAATGATAAACT  
CTACATCAATGACAAAGAAACGGACGAGCCTTATCTAGCAGACTATATCAAACGCTTCAAGGATGACAA  
ACTCCAAAGCACTTACTCAGGCAAGGGCTTTGAAGGAAATAAAGGAACCTTCTTTAGAAGTATCGCTCA  
AAAAGCTCAAGCCTTCACAGTTGATGTCAACTACAACACCAACTTTAGCTTTACTGTTCCAGAAGGAGA  
ATACCTTCTCCTCGGAGATGACCGCTTGGTTTCGAGCGACAGCCGCCACGTAGGTACCTTCAAAGCAAA  
AGATATCACAGGGGAAGCTAAATTCCGCTTATGGCCAATCACCCGTATCGGAACATTT

**SP106 amino acid (SEQ ID NO:186)**

RIFWFSNVREHGSMDPTLADGEILFVVKHLPIDRFDIVVAHEEDGNKDIVKRVIGMPGDTIRYENDKL  
YINDKETDEPYLADYIKRFKDDKLQSTYSKGFEKNKGTFFRSIAQKAQFTVDVNYNTNFSFTVPEGE  
YLLGLDDRLLVSSDSRHVGTFAKADITGEAKFRLWPITRIGTF

**SP107 nucleotide (SEQ ID NO:187)**

GGACTCTCTCAAAGATGTGAAAGCAAATGCTAGCGACAGCAAGCCTGCACAGGACAAGAAGGATGCAAAA  
ACAAGGAACGGAAGATAGTAAGGATTCAGATAAGATGACTGAAACAAACTCAGTTCCGGCAGGAGTGAT  
TGTGGTCAGTCTACTTGCCCTCCTAGGCGTGATTGCCCTCTGGCTGATTCGCCGTAAGAAAGAGTCAGA  
AATCCAGCAATTAAGCACGGAATTGATCAAGGTTCTAGGACAGCTAGATGCAGAAAAAGCGGATAAAAA  
AGTCCTTGCCAAAGCCCCAAACCTTCTCCAAGAAACCCTTGATTTCTGTGAAGAAGAAAATGGCTCAGC  
AGAGACAGAACTAACTAGTAGAGGAGCTTAAAGCAATCCTTGACAACTCAAG

**SP107 amino acid (SEQ ID NO:188)**

DSLKDVKANASDSKPAQDKKDAKQGTEDSKDSDKMTETNSVPAGVIVVSLALLGVIAFWLIRRKKESE  
IQQLSTELIKVLGQLDAEKADKKVLAKAQNLLQETLDFVKEENGSAETETKLVEELKAILDKLK

**SP108 nucleotide (SEQ ID NO:189)**

CAAGAAATCCTATCATCTCTTCCAGAAGCAAACAGAGACGAGGGGAATTCAGACTCAGTTGATTGAAGA  
ATCGCTTAGTCAGCAGACTATAATCCAGTCCCTTCAATGCTCAAACAGAATTTATCCAAAGATTGCGTGA  
GGCTCATGACAACTACTCAGGCTATTCTCAGTCAGCCATCTTTTATTCTTCAACGGTCAATCCTTCGAC  
TCGCTTTGTAAATGCACTCATTTATGCCCTTTTAGCTGGAGTAGGAGCTTATCGTATCATGATGGGTTC  
AGCCTTGACCGTCGGTCGTTTAGTGACTTTTTTGAAGTATGTTAGCAATACACCAAGCCCTTTAACGA  
TATTTCTTCAAGTGCTAGCTGAGTTGCAAAGTGCTCTGGCTTGCGTAGAGCGTATCTATGGAGTCTTAGA  
TAGCCCTGAAGTGGCTGAAACAGGTAAGGAAGTCTTGACGACAGTGACCAAGTTAAGGGAGCTATTTT  
CTTTAAACATGTCTCTTTTGGCTACCATCTGAAAAATTTTGATTAAGGACTTGCTATCGATATTCC  
AGCTGGTAGTAAGGTAGCCATCGTTGGTCCGACAGGTGCTGGAAAATCAACTCTTATCAATCTCCTTAT  
GCGTTTTTATCCATTAGCTCGGGAGATATCTTGCTGGATGGGCAATCCATTTATGATTATACACGAGT  
ATCATTGAGACAGCAGTTTGGTATGGTGCTTCAAGAAACCTGGCTCACACAAGGGACCATTCATGATAA  
TATTGCCCTTTGGCAATCCTGAAGCCAGTCGAGAGCAAGTAATTGCTGCTGCCAAAGCAGCTAATGCAGA  
CTTTTTCATCCAACAGTTGCCACAGGGATACGATACCAAGTTGGAAAATGCTGGAGAATCTCTCTCTGT  
CGGCCAAGCTCAGCTCTTGACCATAGCCCGAGTCTTTCTGGCTATTCCAAAGATTCTTATCTTAGACGA  
GGCAACTTCTTCCATTGATACACGGACAGAAGTGCTGGTACAGGATGCCTTTGCAAACTCATGAAGGG  
CCGCACAAGTTTTCATATTGCTCACCGTTTGTCAACCATTACAGGATGCGGATTTAATTCTTGTCTTAGT



Table 1

AGATGGTGATATTGTTGAATATGGTAACCATCAAGAACTCATGGATAGAAAGGGTAAGTATTACCAAAT  
GCAAAAAGCTGCGGCTTTTAGTTCTGA

A

**SP108 amino acid (SEQ ID NO:190)**

KKSYHLFQKQETETRGITQLIEESLSQQTIIQSFNAQTEFIQRLREAHDNYSQYSQSAIFYSSVNPST  
RFVNALIIYALLAGVGAYRIMMGSALTVGRLVTFNLNYVQQYTKPFNDISSVLAEQSLACVERIYGVLD  
SPEVAETGKEVLTTSDQVKGAISFKHVSFGYHPEKILIKDLSIDIPAGSKVAIVGPTGAGKSTLINLLM  
RFYPISSGDILLDQGSYDYTRVSLRQQFGMVLTQETWLTQGTIHDNIAFGNPEASREQVIAAAKAAANAD  
FFIQQLPQGYDTKLENAGESLSVGQAQLLTIARVFLAIPKILILDEATSSIDTRTEVLVQDAFAKLMKG  
RTSFIIAHLSTIQDADLILVLVDGDIVVEYGNHQLMDRKGKYYQMOKAAAFSSSE

**SP109 nucleotide (SEQ ID NO:191)**

ACGAAATGCAGGGCAGACAGATGCCTCGCAAATTGAAAAGGCGGCAGTTAGCCAAGGAGGAAAAGCAGT  
GAAAAAACAGAAATTAGTAAAGACGCAGACTTGCACGAAATTTATCTAGCTGGAGGTTGTTTCTGGGG  
AGTGGAGGAATATTTCTCACGTGTTCCCGGGGTGACGGATGCCGTTTCAGGCTATGCAAAATGGTAGAGG  
AGAAACAACCAAGTACGAATTGATTAACCAACAGGTCATGCAGAAACCGTCCATGTCACCTATGATGC  
CAAGCAAATTTCTCTCAAGGAAATCCTGCTTCACTATTTCCGCATTATCAATCCAACCAGCAAAAATAA  
ACAAGGAAATGATGTGGGGACCCAGTACCGTACTGGTGTATTACACAGATGACAAGGATTTGGAAGT  
GATTAACCAAGTCTTTGATGAGGTGGCTAAGAAATACGATCAACCTCTAGCAGTTGAAAAGGAAAACCTT  
GAAGAATTTTGTGGTGGCTGAGGATTACCATCAAGACTATCTCAAGAAAAATCCAAATGGCTACTGCCA  
TATCAATGTTAATCAGGCGCCTATCCTGTCATTGATGCCAGCAAATATCCAAAACCAAGTATGAGGA  
ATTGAAAAGACCCTGTCACCTGAGGAGTATGCAGTTACCCAGGAAAATCAAACAGAACGAGCTTTCTC  
AAACCGTTACTGGGATAAATTTGAATCCGGTATCTATGTGGATATAGCAACTGGGGAACTCTCTTTTC  
ATCAAAAGACAAATTTGAGTCTGGTTGTGGCTGGCCTAGTTTACCCAACCCATCAGTCCAGATGTTGT  
CACCTACAAGGAAGATAAGTCTTACAATATGACGCGTATGGAAGTGCGGAGCCGAGTAGGAGATTCTCA  
CCTTGGGCATGTCTTTACGGATGGTCCACAGGACAAGGGCGGCTTACGTTACTGTATCAATAGCCTCTC  
TATCCGCTTTATTCCCAAAGACCAAATGGAAGAAAAGGCTACGCTTATTTACTAGATTATGTTGAT

**SP109 amino acid (SEQ ID NO:192)**

RNAGQTDASQIEKAAVSQGGKAVKKTEISKDADLHEIYLAGGCFWGVVEEYFSRVPGVTDVSGYANGRG  
ETTKYELINQTHAETVHVYDAKQISLKEILLHYFRIINPTS SKNQGNVDVGTQYRTGVYYTDDKDLEV  
INQVFDEVAKKYDQPLAVEKENLKNFVVAEDYHQDYLLKNPNGYCHINVNQAAYPVIDASKYPKPSDEE  
LKKTLSPPEYAVTQENQTERAFSNRYWDFESGIYVDIATGEPLFSSKDKFESGCGWPSFTQPI SPDVV  
TYKEDKSYNMTRMEVRSRVGDSHLGHVFTDGPQDKGGLRYCINSLSIRFIPKQMEEEKGYAYLLDYVD

**SP110 nucleotide (SEQ ID NO:193)**

TGTATAGTTTTTAGCGCTTGTCTTCTAATCTGNTAAAAATGAAGAAAATACTTCTAAAGAGCATGCC  
CCTGATAAAATAGTTTTAGATCATGCTTTCGGTCAAACCTATATTAGATAAAAAACCTGAAAGAGTTGCA  
ACTATTGCTTGGGGAAATCATGATGTAGCATTAGCTTTAGGAATAGTTCCTGTTGGATTTTCAAAAGCA  
AATTACCGTGTAAGTGTGATAAAGGAGTTTTACCATGGACAGAAGAAAAAATCAAAGAACTAAATGGT  
AAAGCTAACCTATTTGACGATTGGATGGACTTAACCTTTGAAGCAATATCAAATCTAAACCAGATGTT  
ATCTTAGCAGGTTATTCTGGTATAACTAAAGAAGATTATGACACTCTATCA

**SP110 amino acid (SEQ ID NO:194)**

CIVFSACSSNSXKNEENTSKEHAPDKIVLDHAFQGTILDKKPERVATIAWGNHDVALALGIVPVGFASKA  
NYGVSADKGVLPWTEEKIKELNGKANLFDLDGLNFEAISNSKPDVILAGYSGITKEDYDTLS

**SP111 nucleotide (SEQ ID NO:195)**

GTGTGTCGAGCATATTCTGAAGCAAACCTATCAAATATAGAAATTATTTTAGTTGATGACGGTTCTAC  
GGATAATTCTGGGGAAATTTGTGATGCTTTTATGATGCAAGATAATCGTGTGCGAGTATTGCATCAAGA  
AAATAAGGGGGGGCAGCACAAAGCTAAAAATATGGGGATTAGTGTAGCTAAGGGAGAGTACATCACGAT  
TGTTGATTACAGATGATATCGTAAAAGAAAATATGATTGAAACTCTTTATCAGCAAGTCCAAGAAAAGGA  
TGCAGATGTTGTTATAGGGAATTACTATAATTATGACGAAAGTGACGGGAATTTTTATTTTATGTAAC  
AGGGCAAGATTTTTCGCTCGAAGAATTAGCTATACAAGAAATTATGAACCGTCAAGCAGGAGATTGGAA  
ATTCAATAGCTCGGCCTTTATATTGCCGACATTTAAGTTGATTAAAAAGAATTATTCAATGAAGTTCA  
CTTTTCAAATGGTCGCCGCTTTGATGATGAAGCAACTATGCATCGCTTTTATCTCTTCTTAAAT  
CGTCTTTATAAACGATAATCTCTATCTGTATAGAAGACGTTTCAGGAAGCATCATGAGAACGGAATTGA

Table 1

TCTTTCCTGGGCAAGAGATATTGTTGAAGTGTTCCTAAGAAAATATCGGATTGTGCTTGGCTGGTTT  
GGATGTCTCCGTTCTGCGTATTTCGATTTGTCAATCTTTTAAAAGATTATAAGCAAACCTTTAGAATACCA  
TCAATTAACAGATACTGAGGAATATAAAGATATTTGTTTCAGATTAAAGTTGTTTTTGTATGCAGAACA  
AAGAAATGGTAAAGT

**SP111 amino acid (SEQ ID NO:196)**

CVEHILKQTYQNIEIILVDDGSTDNSGEICDAFMMQDNRRVRLHQENKGGAAQAKNMGISVAKGEYITI  
VDSDDIVKENMIETLYQQVQEKDADVIGNYNYNDESDGNFYFYVTGQDFCVEELAIQEIIMNRQAGDWK  
FNSSAFILPTFKLIKELFNEVHFSNGRRFDDEATMHRFYLLASKIVFINDNLYLYRRRSGSIMRTEFD  
LSWARDIVEVFSKKISDCVLAGLDVSVLRIRFVNLLKDYKQTLFYHQLTDTEEYKDICFRLKLFDAEQ  
RNGKS

**SP0112 nucleotide (SEQ ID NO:197)**

GTGTTTGGATAGCATTCAGAATCAGACGTATCAAAATTTTGAGTGTATTATTAATCAATGATGGCTCTCC  
AGATCATTCATCCAAAATATGTGAAGAATTTGTAGAGAAAGATTCTCGTTTCAAATATTTTGAAGAAAGC  
AAACGGCGGTCTTTTCATCAGCTCGTAACCTAGGTATTGAATGTTTCGGGGGGGCGTACATTACTTTTGT  
AGACTCTGATGATTGGTTGGAACATGATGCTTTAGACCGATTATATGGTGCTTTGAAAAAGGAAAACGC  
AGATATTAGTATCGGGCGTTATAATTCTTTATGATGAAACACGCTATGTGTATATGACTTATGTTACGGA  
TCCAGATGATTCTCTAGAAAGTGATAGAAGGTAAAGCAATTATGGATAGGGAAGGTGTGCAAGAAGTCAG  
AAATGGGAAGTGGACTGTAGCTGTCTTGAAGTTATTCAAGAGAGAGTTACTACAAGATTTACCATTTCC  
TATAGGAAAAATTCAGAGGATACCTTACTGGACATGGAAGGTACTTCTAAGAGCTTCGAGGATAGTCTA  
TTTGAATCGTTGTGTTTACTGGTACCGTGTGGTTTATCTGATACCTTATCGAATACATGGAGTGAAAA  
GCGTATGTATGATGAAATTTGGGCTAGGGAAGAAAAGATAGCTATTTTAGCAAGTTCAGACTATGACTT  
GACCAATCATATTTTGATTATAAAAATAGATTACAAAGAGTGATAGCAAAATTAGAAGAACAAAATAT  
GCAGTTCACAGAGATTACAGAAGAATGATGGAATAATTTGCTTTACTTCCG

**SP0112 amino acid (SEQ ID NO:198)**

CLDSIQNQTYQNFECCLINDGSPDHSSKICEEFVEKDSRFKYFEKANGGLSSARNLGIIECSGGAYITFV  
DSDDWLEHDALDRLYGALKKENADISIGRYNSYDETRYVYMTYVTDPPDSLEVIIEGKAIMDREGVEEVR  
NGNWTVAVLKLFKRELLQDLPPFIGKIAEDTYWTWKVLLRASRIVLYLNRVCVYWRVGLSDTSLNTWSEK  
RMYDEIGAREEKIAILASSDYDLTNHILYKYNRLQRVIAKLEEQNMQFTEIYRRMMEKLSLLP

**SP113 nucleotide (SEQ ID NO:199)**

GTGCCCTAGATAGTATTATTACTCAAACATATAAAAAATATTGAGATTGTTGTCGTTAATGATGGTTCTAC  
GGATGCTTCAGGTGAAATTTGTAAAGAATTTTCAGAAATGGATCACCGAATCTCTATATAGAACAAAGA  
AAATGCTGGTCTTTCTGCCGCACGAAACACCGGTCTGAATAATATGTCCGGAATTTATGTGACCTTTGT  
GGACTCGGATGATTGGATTGAGCAAGATTATGTAGAACTCTATATAAAAAAATAGTAGAGTATCAGGC  
TGATATTGCACTGGTAATTATTATCTTTCAACGAAAGTGAAGGAATGTTCTACTTTTCATATATTGGG  
AGACTCCTATTATGAGAAAGTATATGATAATGTTTCTATCTTTGAGAACTTGATGAAACTCAAGAAAT  
GAAGAGTTTGTCTTTGATATCTGCTTGGGGTAACTCTATAAGGCAAGATTGTTTGTAGCAGTTGCGCTT  
TGACATAGGTAAATTAGGAGAAGATGGTTACCTCAATCAAAAGGTATATTTATTATCAGAAAAGGTAAT  
TTATTTAAATAAAAGTCTTTATGCTTATCGGATTAGAAAAGGTAGTTTATCAAGAGTTTGGACAGAAAA  
GTGGATGCACGCTTTAGTTGATGCTATGCTGAACGTATTACGCTACTAGCTAATATAGGTTATCCTCT  
ATCTGACACAGCAACGTATAAAGAGTTTGAAATGAAACAAAGGCTTTTAAATCAGCTATCGAGACAAGA  
GGAAAGTGAAAAGAAAGCCATTGTCTCGCAGCAAACCTATGGCTATGTAGACCAAGTTTAAACGACAAT  
CAAGTCTATTGTATTATCATAATCGTTTCGATTCTGTTTATCTGATTATAGCGATTTTCCAAATGAATG  
GATTAAGCAATTAAATAAGCGCTTAGAGAAGTTGACTCAGAAATTATTAATTGTCCGGTAACCTCTGA  
GCAAAATTCATGTTATAAATCGGATATTAGTTACACAGTCTTTTACGCTATTTTCATAGCTGATTTCTG  
GCAAGAAGACAAGGCCCTCTACTTGGACTGTGATCTAGTTGTAACGAAAAATCTGGATGACTTGTTTGC  
TACAGACTTACAAGATTATCCTTTGGCTGCTGTTAGAGATTTTGGGGGCAGAGCTTATTTTGGTCAAGA  
AATCTTTAATGCCGGTGTTCTCTTGGTAAACAATGCTTTTGGAAAAAAGAGAATATGACCCAAAAATT  
AATTGATGTAACCAATGAATGGCATGATAAGGTGGATCAGGCAGATCAGAGCATCTTGAATATGCTTTT  
TGAACATAAATGGTTGGAATTGGACTTTGATTATAATCATATTGTCAATTCATAAACAGTTTGTGTGATTA  
TCAATTGCCGTGAGGTCAGGATTATCCTGCTATTATCACTATCTTTCTCATCGGAAACCGTGGAAGA  
TTTGGCGGCCCAACCTATCGTGAAGTTTGGTGGTACTATCATGGGCTTGAATGGACAGAATTGGGACA  
AAACCATCATTTACATCCATTACAAAGATCTCACATCTATCCAATAAAGGAACCTTTCACTTGTCTAAT  
CTATACTGCCTCAGACCATATTGAACAAATGAGACATTGGTTCAATCCTTGCTGATATTACAGTTTAA

Table 1

89

GATAGCAGCTAGAGTAATAGTTAGTGATCGATTGGCTCAGATGACAATTTATCCAAACGTGACTATATT  
TAACGGAATTCACATTTTGGTAGATGTCGATAATGAATTGGTAGAAACCAGTCAAGTACTTTTATAGATAT  
TAATCATGGCGAAAAGACAGAAGAAATCTCGATCAATTTGCTAATCTTGGCAAGCCTATCTTATCCTT  
TGAAAATACTAAAACCTATGAAGTAGGTCAGGAGGCATATGCTGTTGACCAAGTTCAAGCAATGATTGA  
AAAATTGAGAGAAAATAAGCAAA

**SP113 amino acid (SEQ ID NO:200)**

CLDSIITQTYKNIEIVVNDGSTDASGEICKEFSEMDHRILYIEQENAGLSAARNTGLNNMSGNYVTFV  
DSDDWIEQDYVETLYKKIVEYQADIAVGNYSFNESEGMFYFHILGDSYIEKVYDNVSIFENLYETQEM  
KSFALISAWGKLYKARLFEQLRFDIGKLGEDGYLNQKVYLLSEKVIYLNKSLYAIRKGSLSRVWTEK  
WMHALVDAMSERITLLANMGYPLEKHLAVYRQMLEVSLANGQASGLSDTATYKEFEMKQRLNQLSRQE  
ESEKKAIVLAANYGYVDQVLTTIKSICYHNRSIRFYLIHSDFPNEWIKQLNKRLEKFDSEIINCRVTSE  
QISCYKSDISYTVFLRYFIADFVQEDKALYLDCLDVVTKNLDDLFDLQDYPLAAVRDFGGRAYFGQE  
IFNAGVLLVNNAFWKENMTQKLI DVTNEWHDKVDQADQSILNMLFEHKWLELDFDYNHIVHVKQFADY  
QLPEGQDYPATIIHYLSHRKPWKDLAAQTYREVWYHYHGLEWTELGQNHHLHPLQRSHIYPIKEPFTCLI  
YTASDHIEQIETLVQSLPDIQFKIAARVIVSDRLAQMITYPNVTIFNGIHYLVVDVDNELVETSQVLLDI  
NHGEXTEEILDQFANLGKPILSFENTKTYEVGQEAAYVDQVQAMIEKLEISK

**SP114 nucleotide (SEQ ID NO:201)**

CATTCAGAAGCAGACCTATCAAAATCTGGAAATTATTCTTGTGATGATGGTGCAACAGATGAAAGTGG  
TCGCTTGTGTGATTCAATCGCTGAACAAGATGACAGGGTGTGAGTGCCTTCATAAAAAGAACGAAGGATT  
GTCCGAAGCAGCAATGATGGGATGAAGCAGGCTCACGGGGATTATCTGATTTTTATTGACTCAGATGA  
TTATATCCATCCAGAAATGATTCAGAGCTTATATGAGCAATTAGTTCAAGAAGATGCGGATGTTTTGAG  
CTGTGGTGTCTGATGATGTCTATGCTAATGATGAAAGCCACAGTCAGCCAATCAGGATGACTATTTTGT  
CTGTGATTCTCAAACATTTCTAAAGGAATACCTCATAGGTGAAAAATACCTGGGACGATTTGCAATAA  
GCTAATCAAGAGACAGATTGCAACTGCCCTATCCTTTCTTAAGGGGTGATTTACGAAGATGCCTATTA  
CCATTTTGATTTAATCAAGTTGGCCAAGAAGTATGTGGTTAATACTAAACCCCTATTATTACTATTTCCA  
TAGAGGGGATAGTATTACGACCAAAACCCCTATGCAGAGAAGGATTTAGCCTATATTGATATCTACCAAAA  
GTTTTATAATGAAGTTGTGAAAACTATCCTGACTTGAAAGAGGTCGCTTTTTTTCAGATTGGCCTATGC  
CCACTTCTTTTATTCTGGATAAGATGTTGCTAGATGATCAGTATAAACAGTTTGAAGCCTATTCTCAGAT  
TCATCGTTTTTTTAAAGGCCATGCCTTTGCTATTCTAGGAATCCAATTTTCCGTAAGGGGAGAAGAAT  
TAGTGCTTTGGCCCTATTTCATAAATATTTCTTATATCGATTCTTATTACTGAAAAATATTGAAAAATC  
TAAAAAATTACAT

**SP114 amino acid (SEQ ID NO:202)**

IQKQTYQNLEIILVDDGATDESGRLCDSIAEQDDRVSVLHKKNEGLSQARNDBGMKQAHGJYLIFIDSDD  
YIHPMIQSLYEQLVQEDADVSSCGVMNVYANDESPQSANQDDYFVCDSTFLKEYLIGEKIPGTICNK  
LIKQRIATALSFPKGLIYEDAYYHFDLIKLAKKVVNTKPYYYYFHRGDSITTKPYAEKDLAYIDIYQK  
FYNEVVKNYPDLKEVAFFRLAYAHFFILDKMLLDDQYKQFEAYSQIHRFLKGHAFASRNPIFRKGRRI  
SALALFINISLYRFLLLKNIEKSKLH

**SP115 nucleotide (SEQ ID NO:203)**

TAAGGCTGATAATCGTGTTCAAATGAGAACGACGATTAATAATGAATCGCCATTGTGCTTTCTCCGTT  
GTATGGCAATGATAATGGTAACGGATTATGGTGGGGGAACACATTGAAGGGAGCATGGGAAGCTATTCC  
TGAAGATGTAAAGCCATATGCAGCGATTGAACCTTCATCCTGCAAAAGTCTGTAAACCAACAAGTTGTAT  
TCCACGAGATACGAAAGAATTGAGAGAATGGTATGTCAAGATGTTGGAGGAAGCTCAAAGTCTAAACAT  
TCCAGTTTTCTTGGTTATTATGTCGGCTGGAGAGCGTAATACAGTTCTCCTCAGAGTGGTTAGATGAACA  
ATTCCAAAAGTATAGTGTGTTAAAAGGTGTTTAAAATATTGAGAATTATTGGATTTACAATAACCAGTT  
AGCTCCGCATAGTGCTAAATATTTGGAAGTTTGTGCCAAATATGGAGCGCATTTTATCTGGCATGATCA  
TGAAAAATGGTCTGGGAACTATTATGAATGATCCGACATTCTTTGAAGCGAGTCAAAAATATCATAA  
AAATTTGGTGTGGCAACTAAAAATACGCCAATAAGAGATGATCGGGGTACAGATTCTATCGTTAGTGG  
ATTTTGGTTGAGTGGCTTATGTGATAACTGGGCTCATCAACAGATACATGGAAATGGTGGGAAAAACA  
TTATACAAACACATTTGAAACTGGAAGAGCTAGGGATATGAGATCCTATGCATCGGAACCAGAATCAAT  
GATTGCTATGGAAATGATGAATGTATATACTGGGGAGGCACAGTTTATAATTTGGAATGTGCCCGGTA  
TACATTTATGACAAATGATGTACCAACTCCAGCATTTACTAAAGGTATTATTCTTTCTTTAGACATGC  
TATACAAAATCCAGCTCCAAGTAAGGAAGAAGTTGTAAATAGAACAAAAGCTGTATTTTGAATGGAGA  
AGGTAGGATTAGTTTCATTAAACGGATTTTATCAAGGACTTTATTTCGAATGATGAAACAATGCCTTTATA  
TAATAATGGGAGATATCATATCTTCTGTAATACATGAGAAAATTGATAAGGAAAAGATTTTCATCTAT

Table 1

ATCCCTAATGCAAAAATTTTACTAAAAATAGTGAGGAATTGTCTAGTAAAGTCAACTATTTAAACTC  
GCTTTATCCAAAACCTTTATGAAGGAGATGGGTATGCTCAGCGTGTAGGTAATTCCTGGTATATTTATAA  
TAGTAATGCTAATATCAATAAAAAATCAGCAAGTAATGTTGCCTATGTATACTAATAATACAAAGTCGTT  
ATCGTTAGATTTGACGCCACATACTTACGCTGTTGTTAAAGAAAATCCAAATAATTTACATATTTTATT  
GAATAATTACAGGACAGATAAGACAGCTATGTGGGCATTATCAGGAAATTTTGATGCATCAAAAAGTTG  
GAAGAAAGAAGAATTAGAGTTAGCGAAGTGGATAAGCAAAAATTTATCCATCAATCCTGTAGATAATGA  
CTTTAGGACAACAACACTTACATTAAAAGGGCATACTGGTCATAAACCTCAGATAAATATAAGTGGCGA  
TAAAAATCATTATACTTATACAGAAAATTGGGATGAGAATACCCATGTTTATACCATTACGGTTAATCA  
TAATGGAATGGTAGAGATGTCTATAAATACTGAGGGGACAGGTCCAGTCTCTTTCCCAACACCAGATAA  
ATTTAATGATGGTAATTTGAATATAGCATATGCAAAACCAACAACACAAAGTTCTGTAGATTACAATGG  
AGACCTTAATAGAGCTGTGGATGGTAACAGAAATGGTAATTTTAACTCTGGTTCGGTAACACACACTAG  
GGCAGATAATCCCTCTTGGTGGGAAGTCGATTTGAAAAAATGGATAAAGTTGGGCTTGTAAAATTTA  
TAATCGCACAGATGCTGAGACTCAACGTCTATCTAATTTT

**SP115 amino acid (SEQ ID NO:204)**

KADNRVQMRTTINNESPLLSPLYGNDNGNGLWGNLKGAWAIPEDVKPYAAIELHPAKVCKPTSCI  
PRDTKELREWYVKMLEEAQSLNIPVFLVIMSAGERNTVPPEWLDEQFQKYSVLKGVNLNIENYWIYNQL  
APHSKYLEVCAKYGAHFIIWDHEKWFETIMNDPTFFEASQKYHKNLVLATKNTPIRDDAGTDSIVSG  
FWLSGLCDNWGSSTDWVWEKHNTTFFETGRARDMRSYASEPESMIAMEMMNVTGGGTVYNFECAAY  
TFMTNDVPTPAFTKGIIPFRHAIQNPAPSKEEVNRTKAVFVWNGEGRISLNGFYQGLYSNDETMPLY  
NNGRYHLPVIHEKIDKEKISSIFPNAKILTKNSEELSSKVNLYNSLYPKLYEGDGYAQRVGNNSWYIYN  
SNANINKNQVMLPMYTNNTKSLSLDLTPHTYAVVKENPNNLHILLNNYRTDKTAMWALSGNFDASKSW  
KKEELELANWISKYNSINPVDNDFRTTTLTKGHTGHKPQINISGDKNHYTYTENWDENTHVTITVNH  
NGMVEMSIINTEGTGPVSFPTPDKFNNDGNLNIAYAKPTTQSSVDYNGDPNRAVDGNRNGNFNSGVSHTHR  
ADNPSWWEVDLKKMDKVGLVKIYNRTDAETQRLSNF

**SP117 nucleotide (SEQ ID NO:205)**

CTGTGGCAATCAGTCAGCTGCTTCCAAACAGTCAGCTTCAGGAACGATTGAGGTGATTTACGAGAAAA  
TGGCTCTGGGACACGGGTGCTTCACAGAAATCAGGGGATTCTCAAAAAAGACGGTGATAAAAAAAT  
TGACAACACTGCCAAAACAGCTGTGATTCAAAATAGTACAGAAGGTGTTCTCTCAGCAGTTCAAGGGAA  
TGCTAATGCTATCGGCTACATCTCCTTGGGATCTTTAACGAAATCTGTCAAGGCTTTAGAGATTGATGG  
TGTCAGGCTAGTCCGAGACACAGTTTTAGATGGTGAATACCCCTCTTCAACGTCCTTCAACATTTGTTG  
GTCTTCTAATCTTTCCAAGCTAGGTCAAGATTTTATCAGCTTTATCCACTCCAAACAAGGTCAACAAGT  
GGTCACAGATAATAAATTTATTGAAGCTAAACCGAAACACGGAATATACAAGCCAACACTTATCAGG  
CAAGTTGTCTGTTGTAGGTTCCACTTCAGTATCTTCTTAAATGGAATAATAGCAGAAGCTTATAAAAA  
AGAAAATCCAGAAGTTACGATTGATATTACCTCTAATGGGTCTTCAGCAGGTATTACCGCTGTTAAGGA  
GAAAACCGCTGATATTGGTATGGTTCTAGGGAATTAACCTCTGAAGAAGGTAAGAGTCTCACCCATGA  
TGCTATTGCTTTAGACGGTATTGCTGTTGTGGTCAATAATGACAATAAGGCAAGCCAAGTCAGTATGGC  
TGAACCTGCAGACGTTTTTAGTGGCAAATTAACCACCTGGGACAAGATTAA

**SP117 amino acid (SEQ ID NO:206)**

CGNQSAASKQSASGTIEVISRENGSGTRGAFTEITGILKKGDKIDNTAKTAVIQNSTEGVLSAVQGN  
ANAIGYISLGSITKSVKALEIDGVKASRDVLDGEYPLQRPFNIVWSSNLSKLGQDFISFIHSKQGQOV  
VTDNKFIEAKTETTEYTSQHLSGKLSVVGSTSVSSLMEKLAELAYKKENPEVTIDITSNGSSAGITAVKE  
KTADIGMVSRELTPPEGKSLTHDAIALDGIADVNNNDNKASQVSMALADVFSGLKTTWDKIK

**SP118 nucleotide (SEQ ID NO:207)**

TTGTCAACAACAACATGCTACTTCTGAGGGGACGAATCAAAGGCAAAGCAGTTTCAGCGAAAGTTCCATG  
GAAAGCTTCATACCAACCTAAACAACAGGTAAGTACAGAAGAGGTCAAATCTCTCTTATCAGCTCA  
CTTGGATCCAAATAGTGTGATGCATTTTTTAATCTCGTTAATGACTATAATACCATTGTCTGGCTCAAC  
TGGCTTATCAGGAGATTTCACTTCCTTACTCACACCGAATACGATGTTGAGAAAATCAGTCATCTCTG  
GAATCAAAAGAAGGGCGATTTTGTGGGACCAACTGCCGTATCAATAGTTATTGTCTTTTGAAAAATTC  
AGTCACCATTCCAAAGCTGAAAAGATGACCAGTTGCTTTTCTAGATAATGATGCGATTGATAAAGG  
AAAGGTCTTTGATTCACAAGATAAGGAAGAGTTTGATATCTATTTTCGAGAGTTCCAAGTGAAGTCAAC  
TACAGATGTCAAGGTTACGCTGAAAAGATGGAAGCATCTCTCACAATTTCAATTCAATGAAAAGC  
TCGAATGCTGTCTGTAGTCTTGACGACAATTTGGATGGCGAGTATCTGTTGTAGGCCACGTTGGGGT  
CTTAGTACCTGCTGATGACGGTTTCTTATTTGTAGAGAAATTGACTTTCGAAGAGCCCTACCAAGCGAT

Table 1

TAAATTTGCTAGTAAGGAAGATTGCTACAAGTATTTGGGCACCAAGTATGCGGATTATACAGGCGAGGG  
ACTGGCTAAGCCTTTTATCATGGATAATGATAAGTGGGTAAACTT

**SP118 amino acid (SEQ ID NO:208)**

CQQQHATSEGTNQRQSSSAKVPWKASYTNLNNQVSTEEVKSLLSAHLDPNSVDAFFNLVNDYNTIVGST  
GLSGDFTSFTHTEYDVEKISHLWNQKKGDFVGTNCRINSYCLLKNSVTIPKLEKNDQLFLDNDIDAIDKG  
KVFDSQDKEFDILFSRVPTESSTDVKVHAEKMEAFFSQFQFNEKARMLSVVLHDNLDGEYLFVGHVGV  
LVPADDGFLFVEKLTFEOPYQAIKFASKEDCYKYLGTKYADYTGEGLAKPFI MDNDKWVKL

**SP119 nucleotide (SEQ ID NO:209)**

TTGTTCAGCAAGTCCGTGACTAGTGAACACCAAACGAAAGATGAAATGAAGACGGAGCAGACAGCTAG  
TAAACAACGCGCAGCTAAAGGGAAGAGGTGGCTGATTTTGAATTGATGGGAGTAGATGGCAAGACCTA  
CCGTTTATCTGATTACAAGGGCAAGAAAGTCTATCTCAAATCTTGGGCTTCTTGGTGTTCATCTGTCT  
GGCTAGTCTTCCAGATACGGATGAGATTGCTAAAGAAGCTGGTGATGACTATGTGGTCTTGACAGTAGT  
GTCACCAGGACATAAGGGAGAGCAATCTGAAGCGGACTTTAAGAATTGGTATAAGGGATTGGATTATAA  
AAATCTCCAGTCCTAGTTGACCCATCAGGCAAACTTTTGGAACTTATGGTGTCCGTTCTTACCCAAC  
CCAAGCCTTTATAGACAAAGAAGGCAAGCTGGTCAAAACACATCCAGGATTCTGGAAGAAAGATGCAAT  
TTTGCAAACTTTGAAGGAATTAGCC

**SP119 amino acid (SEQ ID NO:210)**

CSGKSVTSEHQTKDEMKEQTASKTSAKKGKEVADFELMGVDGKTYRLSDYKGGKVVYKFWASWCSICL  
ASLPDTDEIAKEAGDDYVVLTVVSPGHKGEQSEADFKNWKYGLDYKNLPVLVDPGSKLLETYGVRSYPT  
QAFIDKEGKLVKTHPGFMEKDAILQTLKELA

**SP120 nucleotide (SEQ ID NO:211)**

CTCGCAAAATTGAAAAGGCGGCAGTTAGCCAAGGAGGAAAAGCACTGAAAAAACAGAAATTAGTAAAGA  
CGCAGACTTGCACGAAATTTATCTAGCTGGAGGTTGTTTCTGGGGAGTGGAGGAATATTTCTCACGTGT  
TCCCGGGGTGACGGATGCCGTTTCAGGCTATGCAAAATGGTAGAGGAGAAACAACCAAGTACGAATTGAT  
TAACCAAAACAGGTCATGCAGAAACCGTCCATGTACCTATGATGCCAAGCAAATTTCTCTCAAGGAAAT  
CCTGCTTCACTATTTCCGCATTATCAATCCAACGCAAAAAATAACAAGGAAATGATGTGGGGACCCA  
GTACCGTACTGGTGTTTATTACACAGATGACAAGGATTTGGAACTGATTAACCAAGTCTTTGATGAGGT  
GGCTAAGAAAATACGATCAACCTCTAGCAGTTGAAAAGGAAAACCTTGAAGAATTTTGTGGTGGCTGAGGA  
TTACCATCAAGACTATCTCAAGAAAAATCCAAATGGCTACTGCCATATCAATGTTAATCAGGCGGCCCTA  
TCCTGTCAATTGATGCCAGCAAATATCCAAAACCAAGTGATGAGGAATTGAAAAAGACCCTGTACCTGA  
GGAGTATGCAGTTACCCAGGAAAATCAAACAGAACGAGCTTTCTCAAACCGTTACTGGGATAAATTTGA  
ATCCGGTATCTATGTGGATATAGCAACTGGGGAACCTCTCTTTTCATCAAAGACAAATTTGAGTCTGG  
TTGTGGCTGGCCTAGTTTTACCCAACCCATCAGTCCAGATGTTGTACCTACAAGGAAGATAAGTCTTA  
CAATATGACGCGTATGGAAGTGCGGAGCCGAGTAGGAGATTCTCACCTTGGGCATGTCTTTACGGATGG  
TCCACAGGACAAGGGCGGCTTACGTTACTGTATCAATAGCCTCTCTATCCGCTTTATTCCCAAAGACCA  
AATGGAAGAAAAAGGTACGCTTATTTAC

**SP120 amino acid (SEQ ID NO:212)**

SQIEKAAVSQGGKAVKKEISKDADLHEIYLAGGCFWGVVEEYFSRVPGVTDVSGYANGRGETTKYELI  
NQTGHAETVHVTYDAKQISLKEILLHYFRIINPTSKNKQGNVGTQYRTGVVYTDKDLVINQVFDEV  
AKKYDQPLAVEKENLKNFVVAEDYHQDYLLKPNNGYCHINVNQAAYPVIDASKYPKPSDEELKKTLSPE  
EYAVTQENQTERAFSNRYWDFESGIYVDIATGEPLFSSKDKFESGCGWPSFTQPI SPDVVITYKEDKSY  
NMTRMEVRSRVGDSHLGHVFTDGPQDKGGLRYCINLSIRFIPKDMEEKGTLIY

**SP121 nucleotide (SEQ ID NO:213)**

TTGTCACTCAGGTTCTAATGGTTCTCAGTCTGCTGTGGATGCTATCAAACAAAAAGGGAAATTAGTTGT  
GGCAACCACTCCTGACTATGCACCCTTTGAATTTCAATCATTTGTTGATGGAAAGAACCAGGTAGTCGG  
TGCAGACATCGACATGGCTCAGGCTATCGCTGATGAACCTGGGGTTAAGTTGGAATCTCAAGCATGAG  
TTTTGACAATGTTTTGACCAGTCTTCAAACCTGGTAAGGCTGACCTAGCAGTTGCAGGAATTAGTGCTAC  
TGACGAGAGAAAAAGAAGTCTTTGATTTTCAATCCCATACTATGAAAACAAGATTAGTTTCTTGGTTTCG  
TAAGGCTGATGTGGAAAAATACAAGGATTTAACTAGCCTAGAAAAGTGCTAATATTGCAGCCCCAAAAGG  
GACTGTTCCAGAATCAATGGTCAAGGAACAATTGCCAAAAGTTCAATTAACCTCCCTAACTAATATGGG  
TGAAGCAGTCAATGAATTGCAGGCTGGAAAAATAGATGCTGTTTATATGGATGAGCCTGTTGCACTTAG

Table 1

TTATGCTGCTAAAAACGCTGGCTTAGCTGTGCGCAACTGTCAGCTTGAAGATGAAGGACGGCGACGCCAA  
TGCC

**SP121 amino acid (SEQ ID NO:214)**

CQSGSNGSQSAVDAIKQKGLVATSPDYAPFEFQSLVDGKNQVVGADIDMAQAIADELGVKLEISSMS  
FDNVLTSLQTKADLAVAGISATDERKEVFDFSIPYYENKISFLVRKADVEKYKDLTSLESANIAAQKG  
TVPEMVKELPKVQLTSLTNMGEAVNELQAGKIDAVHMDPEVALSYAAKNAGLAVATVSLKMKDGDAN  
A

**SP122 nucleotide (SEQ ID NO:215)**

GGAAACTTCACAGGATTTTAAAGAGAAGAAAACAGCAGTCATTAAGGAAAAAGAAGTTGTTAGTAAAAA  
TCCTGTGATAGACAATAACACTAGCAATGAAGAAGCAAAAATCAAAGAAGAAAATCCAATAAATCCCA  
AGGAGATTATACGGACTCATTTGTGAATAAAAAACACAGAAAATCCCAAAAAAGAAGATAAAGTTGTCTA  
TATTGCTGAATTTAAAGATAAAGAATCTGGAGAAAAAGCAATCAAGGAACTATCCAGTCTTAAGAATAC  
AAAAGTTTTATATACTTATGATAGAAATTTTAACGGTAGTGCCATAGAAAACAACTCCAGATAACTTGGGA  
CAAAATTAAACAAAATAGAAGGTATTTTCATCGGTTGAAAGGGGCACAAAAAGTCCAACCCATGATGAATCA  
TGCCAGAAAGGAAATTTGAGATTGAGGAAGCTATTGATTACCTAAAGTCTATCAATGCTCCGTTTGGGAA  
AAATTTTGATGGTAGAGGTATGGTCATTTCAAATATCGATACTGGAACAGATTATAGACATAAGGCTAT  
GAGAATCGATGATGATGCCAAAGCCTCAATGAGATTTAAAAAGAAGACTTAAAGGCACTGATAAAAA  
TTATTGGTTGAGTGATAAAATCCCTCATGCGTTCAATTATTATAATGGTGGCAAAATCACTGTAGAAAA  
ATATGATGATGGAAGGGATTATTTTGACCCACATGGGATGCATATTGCAGGGATTCTTGCTGGAATGA  
TACTGAACAAGACATCAAAAACCTTTAACGCGATAGATGGAAATGACACCTAATGCACAAATTTTCTCTTA  
CAAAATGTATTCTGACCGAGGATCTGGGTTTGCGGGTGATGAAACAATGTTTCATGCTATTGAAGATTCT  
TATCAAAACACAACGTTGATGTTGTTTCGGTATCATCTGGTTTACAGGAACAGGCTCTGTAGGTGAGAA  
ATATTGGCAAGCTATTCGGGCATTAAGAAAAGCAGGCATTCCAATGGTTGTCGCTACGGGTAACTATGC  
GACTTCTGCTTCAAGTCTTCATGGGATTTAGTAGCAAATAATCATCTGAAAATGACCGACACTGGAAA  
TGTAACACGAACTGCAGCACATGAAGATGCGATAGCGGTGCTTCTGCTAAAAATCAAACAGTTGAGTT  
TGATAAAGTTAACATAGGTGGAGAAAAGTTTAAATACAGAAATATAGGGGCCTTTTTCGATAAGAGTAA  
AATCACAACAAATGAAGATGGAACAAAAGCTCCTAGTAAATTTAAATTTGTATATATAGGCAAGGGGCA  
AGACCAAGATTTGATAGGTTTGGATCTTAGGGGCAAAATTCAGTAATGGATAGAATTTATACAAAGGA  
TTTAAAAAATGCTTTTAAAAAAGCTATGGATAAGGGTGACGCGCCATTATGGTTGTAATACTGTAA  
TTACTACAATAGAGATAATTGGACAGAGCTTCAGCTATGGGATATGAAGCGGATGAAGGTACTAAAAG  
TCAAGTGTTTTCAATTTCAAGGATGATGGTGTAAAGCTATGGAACATGATTAATCCTGATAAAAAAAC  
TGAAGTCAAAAGAAATAATAAAGAAGATTTTAAAGATAAAATGGAGCAATACTATCCAATTTGATATGGA  
AAGTTTTTAATTCACAAACCGAATGTAGGTGACGAAAAAGAGATTGACTTTAAGTTTGCACCTGACAC  
AGACAAAGAACTCTATAAAGAAGATATCATCGTTCCAGCAGGATCTACATCTTGGGGGCCAAGAATAGA  
TTTACTTTTAAAAACCGATGTTTCAGCACCTGGTAAAAATATTAAATCCAGCTTAATGTTATTAATGG  
CAAATCAACTTATGGCTATATGTCAGGAACAGTATGGCGACTCCAATCGTGGCAGCTTCTACTGTTTT  
GATTAGACCGAAATTAAGGAAATGCTTGAAAGACCTGTATTGAAAAATCTTAAGGGAGATGACAAAAT  
AGATCTTACAAGTCTTACAAAAATTGCCCTACAAAATACTGCGCGACCTATGATGGATGCAACTTCTTG  
GAAAGAAAAAGTCAATACCTTGCATCACCTAGACAACAGGGAGCAGGCCTAATTAATGTGGCCAATGC  
TTTGAGAAATGAAGTTGTAGCAACTTTCAAAAACACTGATTCTAAAGGTTTGGTAAATCATATGGTTC  
CATTTCTCTTAAAGAAATAAAAGGTGATAAAAAATACTTTACAATCAAGCTTCACAATACATCAAACAG  
ACCTTTGACTTTTAAAGTTTCAGCATCAGCGATAACTACAGATTCTCTAACTGACAGATTAAAACTTGA  
TGAAACATATAAAGATGAAAAATCTCCAGATGGTAAGCAAATTGTTCCAGAAATTCACCCAGAAAAAGT  
CAAAGGAGCAAAATATCACATTTGAGCATGATACTTTCACTATAGGCGCAAATCTAGCTTTGATTGAA  
TGCGGTTATAAATGTTGGAGAGGCCAAAAACAAAAATAAATTTGTAGAAATCATTATTTCATTTTGAGTC  
AGTGGAAGCGATGGAAGCTCTAAACTCCAGCGGAAGAAATAAACTTCCAACCTTTTGTGCTGATGCC  
TCTAATGGGATTTGCTGGGAATTGGAACCACGAACCAATCCTTGATAAATGGGCTTGGGAAGAAGGGTC  
AAGTCAAAAAACACTGGGAGGTTATGATGATGATGGTAAACCGAAAAATTCAGGAACCTTAAATAAGGG  
AATTGGTGGAGAACATGGTATAGATAAATTTAATCCAGCAGGAGTTATACAAAATAGAAAAGATAAAAA  
TACAACATCCCTGGATCAAAATCCAGAATTATTTGCTTTCAATAACGAAGGGATCAACGCTCCATCATC  
AAGTGGTTCTAAGATTGCTAACATTTATCCTTTAGATTCAAATGGAAATCCTCAAGATGCTCAACTTGA  
AAGAGGATTAAACACCTTCTCCACTTGTATTAAGAAGTGCAGAAGAAGGATTGATT

**SP122 amino acid (SEQ ID NO:216)**

ETSQDFKEKKTAVIKEKEVSKNPVIDNNTSNEEAKIKEENSNSQGDYTDTSFVNKNTENPKKEDKVY  
IAEFKDKESGEKAIKELSSLKNTKVLYTYDRIFNGSAIETTPDNLDKIKQIEGISSVERAQKVQPMNH

Table 1

93

ARKEIGVEEAIDYLSINAPFGKNFDGRGMVISNIDTGTDIRHKAMRIDDDAKASMRFKKEDLKGTDKN  
YWLSDKIPHAFNYNGGKITVEKYDDGRDYFDPHGMHIAGILAGNDTEQDIKNFNGIDGIAPNAQIFSY  
KMYSDAGSGFAGDETMFHAIEDSIKHNVDVVSVSSGFTGTGLVGEKYWQAIRALRKAGIPMVVATGNYA  
TSASSSSWDLVANNHLKMTDTGNVTRTAAHEDAIIVASAKNQTVEFDKVNIGGESFKYRNIGAFFDKSK  
ITTNEGDGTPKPSKLFVYIGKGQDQDLIGLDLRGKIAVMDRIYTKDLKNAFKKAMDKGARAIMVVNTVN  
YYNRDNWTELPAWGYEADGEGTKSQVFSISGDDGVKLWNMINPDKKTEVVRNNKEDFKDKLEQYYPIDME  
SFNSNKNPNVGDEKEIDFKFAPDTEKELYKEDIIVPAGSTSWGPRIDLKLLKPDVSAPGKNKSTLNIVING  
KSTYGYMSGTSMATPIVAASTVLIRPKLKEMLERPVLKLNKGDDKIDLTSLTKIALQNTARPMMDATSW  
KEKSQYFASPROQGAGLINVANALRNEVVATFKNNTDSKGLVNSYGSISLKEIKGDKKYFTIKLHNTSNR  
PLTFKVSASAITTDSLTDRLKLDETYKDEKSPDGKQIVPEIHPEKVKGANITFEHDTFTIGANSSFDLN  
AVINVGEAKNKNKFVESFIHFESVEAMEALNSSGKKINFQPSLSMPLMGFAGNWNHEPILDKWAWEEGS  
RSKTLGGYDDDGKPKIPGTLNKGIGGEHGIDKFNPAQVIQNRKDKNTTSLDQNPFLFAFNNEG INAPSS  
SGSKIANIYPLDSNGNPQDAQLERGLTPSPLVLRSAEEGLI

**SP123 nucleotide (SEQ ID NO:217)**

TGTGGTTCGAAGTTGAGACTCCTCAATCAATAACAAATCAGGAGCAAGCTAGGACAGAAAACCAAGTAGT  
AGAGACAGAGGAAGCTCCAAAAGAAGAAGCACCTAAAACAGAGAAAGTCCAAAGGAAGAACCAAAATC  
GGAGGTAAAACCTACTGACGACACCCTTCTTAAAGTAGAAGAGGGGAAAGAAGATTACAGCAGAACCCAGC  
TCCAGTTGAAGAAGTAGGTGGAGAAGTTGAGTCAAAACAGAGGAAAGATAGCAGTTAAGCCAGAAAAG  
TCAACCATCAGACAAACAGCTGAGGAATCAAAAAGTTGAACAAGCAGGTGAACCCAGTCGCGCCAAGAGA  
AGACGAAAAGGCACCAGTCGAGCCAGAAAAGCAACCAGAGCTCCTGAAGAAGAGAAGGCTGTAGAGGA  
AACACCGAAACAAGAAGAGTCAACTCCAGATACCAAGGCTGAAGAACTGTAGAACCAAAAGAGGAGAC  
TGTTAATCAATCTATTGAACAACCAAAAGTTGAAACGCCTGCTGTAGAAAACAAACAGAACCAACAGA  
GGAACCAAAAGTTGAACAAGCAGGTGAACCCAGTCGCGCCAAGAGAAGACGAACAGGCACCAACGGCACC  
AGTTGAGCCAGAAAAGCAACCAGAGTTCTTGAAGAAGAGAAGGCTGTAGAGGAAACACCGAAACCAGA  
AGATAAAATAAAGGGTATTGGTACTAAAGAACCAGTTGATAAAAGTGAGTTAAATAATCAAATTGATAA  
AGCTAGTTCACTTCTCTACTGATTATTCTACAGCAAGTTACAATGCTCTTGGACCTGTTTTAGAAAC  
TGCAAAAGGTGCTATGCTTCAGAGCCTGTAAAACAGCCTGAGGTAAATAGCGAGACAAATAAACTTAA  
AACGGCTATTGACGCTCTAAACGTTGATAAACTGAATTAACAATACGATTGCAGATGCAAAAACAAA  
GGTAAAAGAACATTACAGTGATAGAAGTTGGCAAAACCTCCAAACTGAAGTTACAAAGGCTGAAAAAGT  
TGCAGCTAATACAGATGCTAAACAAGTGAAGTTAACGAAGCTGTTGAAAAATTAAGTGAACCTATTGA  
AAAATTGGTTGAATTATCTGAAAAGCCAATATTAAACATTGACTAGTACCGATAAGAAAAATATTGGAACG  
TGAAGCTGTTGCTAAGTATACTCTAGAAAATCAAAACAAAACAAAATCAAATCAATACAGCTGAATT  
GAAAAAAGGAGAAGAAGTTATTAATACTGTAGTCTTACAGATGACAAGGTAACAACAGAACTATAAG  
CGCTGCATTTAAGAACCTAGAGTACTACAAGAATACACCCTATCTACAACATGATTTACGACAGAGG  
TAACGGTGAAGAACTGAACTCTAGAAAATCAAATATTCAATTAGATCTTAAAAAAGTTGAGCTTAA  
AAATATTAAACGTACAGATTTAATCAAATACGAAAATGGAAGAAAGAACTAATGAATCACTGATAACAAC  
TATTCCTGATGATAAGAGCAATTATTATTTAAAAATAACTTCAAATAATCAGAAAACCTACATTACTAGC  
TGTTAAAAATATAGAAGAACTACGGTTAACGGAACACCTGTATATAAAGTTACAGCAATCGCAGACAA  
TTTAGTCTCTAGAACTGCTGATAATAAATTTGAAGAAGAA

**SP123 amino acid (SEQ ID NO:218)**

VVEVETPQSI TNQEQARTENQVVETEEAPKEEAPKTEESPKEEPKSEVKPTDDTL PKVEEGKEDSAEPA  
PVEEVGGEVESKPEEKVAVKPESQPSDKPAEESKVEQAGEPVAPREDEKAPVEPEKQPEAPEEEKAVEE  
TPKQEESTPDTKAEETVEPKEETVNQSI EQPKVETPAVEKQTEPTTEPKVEQAGEPVAPREDEQAPTAP  
VEPEKQPEVPPEEEKAVEETPKPEDKIKGIGTKEPVDKSELNNQIDKASSVSPTDYSTASYNALGPVLET  
AKGVYASEPVKQPEVNSETNKLKTAIDALNVDKTELNNIADAKTKVKEHYSRWSQNLQTEVTKAKEV  
AANTDAKQSEVNEAVEKL TATIEKLVELSEKPI LTLTSTDKKILEREAVAKYTLENQNKTKIKSITAE  
LKGEVINTVVLTDKVTETETISA AFKNLEYKEYTLSTMTIYDRNGEETETLENQNIQLDLKKVELK  
NIKRTDLIKYENGKETNESLITTI PDDKSNYYLKITSNNQKTLLAVKNIEETTVNGTPVYKVTAIADN  
LVSRTADNKFEEE

**SP124 amino acid (SEQ ID NO:219)**

AACACCTGTATATAAAGTTACAGCAATCGCAGACAATTTAGTCTCTAGAACTGCTGATAATAAATTTGA  
AGAAGAAACAGTTCACTATATTGAAAAACCTAAAGTCCACGAAGATAATGTATATTATAATTTCAAAGA  
ATTAGTGGAAGCTATTCAAACGATCCTTCAAAGAATATCGTCTGGGACAATCAATGAGCGCTAGAAA  
TGTTGTTCTTAATGGAATAATCATATATCACTAAAGAATTCACAGGAAACTTTTAAGTTCTGAAGGAAA  
ACAATTTGCTATTACTGAATTGGAACATCCATTATTTAATGTGATAACAAACGCAACGATAAATAATGT

Table 1

GAATTTTGGAAATGTAGAGATAGAAGCTTCTGGTCAAGATAATATTGCATCATTAGCCAATACTATGAA  
AGGTTCTTCAGTTATTACAAATGTCAAAATTACAGGCACACTTTCAGGTCGTAATAATGTTGCTGGATT  
TGTAATAATATGAATGATGGAACCTCGTATTGAAAAATGTTGCTTTCTTTGGCAAACCTACACTCTACAAG  
TGGAAATGGCTCTCATACAGGGGGAATTGCAGGTACAAACTATAGAGGAATTGTTAGAAAAGCATATGT  
TGATGCTACTATTACAGGAAACAAACACGCGCCAGCTTGTAGTTCCTAAAGTAGATTATGGATTAAAC  
TCTAGACCATCTTATTGGTACAAAAGCTCTCCTAACTGAGTCGGTTGTAAAAGGTAAAAAGATGTTTC  
AAATCCAGTAGAAGTTGGAGCAATAGCAAGTAAGACTTGGCCTGTAGGTACGGTAAGTAATTCGTGACG  
CTATGCTAAGATTATCCGTGGAGAGGAGTTATTCGGCTCTAACGACGTTGATGATTCTGATTATGCTAG  
TGCTCATATAAAAGATTTATATGCGGTAGAGGGATATTTCGTCAGGTAATAGATCATTAGGAAATCTAA  
AACATTTACTAAATTAATAAGAACAAAGCTGATGCTAAAGTTACTACTTTCAATATTACTGCTGATAA  
ATTAGAAAGTGATCTATCTCTCTTGCAAACTTAATGAAGAAAAGCCTATTCTAGTATTCAAGATTA  
TAACGCTGAATATAACCAAGCCTATAAAAACTTTGAAAAATTAATACCATTCTACAATAAGATTATAT  
TGTATATCAAGGTAATAAATTAATAAGAACACCATCTAAATACTAAAGAAGTTCTTTCTGTTACCGC  
GATGAACAACAATGAGTTTATCACAACCTAGATGAAGCTAATAAAATTATTGTTCACTATGCGGACGG  
TACAAAAGATTACTTTAACTTGTCTTCTAGCAGTGAAGGTTTAAAGTAATGTAAAAGAATATACTATAAC  
TGACTTAGGAATTAATATACCTAATATCGTTCAAAAAGATAACACTACTCTTGTAAATGATATAAA  
ATCTATTTTAGAATCAGTAGAGCTTCAGTCTCAACGATGTATCAGCATCTAAATCGATTAGGTGACTA  
TAGAGTTAATGCAATCAAGATTTATATTTAGAAGAAAGCTTCACAGATGTTAAAGAAAACCTTAACAAA  
CCTAATCACAAAATTAGTTCAAAACGAAGAACATCAACTAAATGATTCTCCAGCTGCTCGTCAAATGAT  
TCGTGATAAAGTCGAGAAAAACAAAGCAGCTTTATTACTAGGTTTAACTTACCTAAATCGTTACTATGG  
AGTTAAATTTGGTGATGTTAATATTAAAGAATTAAATGCTATTCAAACCAGATTTCTATGGTGAAGAAAGT  
TAGCGTATTAGACAGATTAATTGAAATCGGTTCTAAAGAGAACAACATTAAAGGTTACGTTACATTCTGA  
CGCATTCGGTCAAGTA

**SP124 amino acid (SEQ ID NO:220)**

TPVYKVTAIADNLVSRTADNKFEEYVHYIEKPKVHEDNVYYNFKELVEAIQNDPSKEYRLGQSMSARN  
VVPNGKSYITKEFTGKLLSSEKQFAITELEHPLFNVTNATINNUNFENVEIERSGQDNILASLANTMK  
GSSVITNVKITGTLSGRNNVAGFVNMNDGTRIENVAFFGKLHSTSGNGSHTGGIAGTNYRGIVRKAYV  
DATITGNKTRASLLVPKVDYGLTDLHLIGTKALLTESVVKGKIDVSNPVEVGAIASKTWPVGTVSNVS  
YAKIIRGEELFGSNDVDDSDYASAHIKDLYAVEGYSSGNRSFRKSKFTFKLTKEQADAKVTFNITADK  
LES DLSPLAKLNEEKAYSSIQDYNAEYNQAYKNLEKLI PFYNKDYIVYQGNKLNKEHHLNTKEVLSVTA  
MNNNEFITNLDEANKIIVHYADGTDYFNLSSESSEGLSNVKEYTITDLGIKYTPNIVQKDNTTLVNDIK  
SILESVELQSQTMVQHLNRLGDYRVNAIKDLYLEESFTDVKENLTNLITKLVQNEEHQLNDS PAARQMI  
RDKVEKNKAALLLGLTYLNRYGVKFGDVNIKELMLFKPDFYGEKVSVDRLIEIGSKENNIKGSRTFD  
AFGQV

**SP125 nucleotide (SEQ ID NO:221)**

ATTAGACAGATTAATTGAAATCGGTTCTAAAGAGAACAACATTAAAGGTTACGTACATTTCGACGCATT  
CGGTCAAGTATTGGCTAAATATACTAAATCAGGTAATTTAGATGCATTTTAAATTTATAATAGACAATT  
GTTCACAAATATAGACAATATGAACGATTGGTTTATTGATGCTACAGAAGACCATTGTCTACATCGCAGA  
ACGCGCTTCTGAGGTCGAAGAAATTAATAATCTAAACATCGTGCATTTCGATAATTTAAACGAAGTCA  
CCTTAGAAATACTATACTCCCACTACTGAATATTGATAAAGCACATCTTTATTTAATTTCAAATTATAA  
TGCAATTGCCTTTGGTAGTGCAGAGCGATTAGGTAATAAATCATTAGAAGATATTAAAGATATCGTTAA  
CAAAGCTGCAGATGGTTATAGAACTATTATGATTTCTGGTATCGTCTAGCGTCTGATAACGTTAAACA  
ACGACTACTAAGAGATGCTGTTATTCCTATTGGGAAGGTTATAACGCTCCTGGTGGATGGGTTGAAAA  
ATATGGCCGCTATAATACCGACAAAGTATATACTCTCTTAGAGAATTCTTTGGTCTATGGATAAGTA  
TTATAATTATAATGGAACAGGAGCTTATGCTGCTATATATCCTAACTCTGATGATATTAGAAGTATGAT  
AAAATATTGTTCAATTAGAAATGGTTGGTGAATACGGTATTTAGTTTACACACATGAAACAACACACGT  
CAACGACCGTGCGATTTACTTAGGTGGCTTTGGACACCGTGAAGGTACTGATGCTGAAGCATATGCTCA  
GGGTATGCTACAACTCCTGTTACTGGTAGTGGATTGATGAGTTTGGTTCTTTAGGTATTAATATGGT  
ATTTAAACGCAAAAATGATGGGAATCAGTGGTATATTACAGATCCAAAACCTCTAAAACACGAGAAGA  
TATTAATAGATATATGAAGGGTTATAATGACACTTTAACTCTTCTTGATGAAATTGAGGCTGAATCTGT  
GATTTCTCAACAAAATAAGATTTAAATAGTGCATGGTTCAAAAAATAGATAGAGAATACCGTGATAA  
CAATAAATTAATCAATGGGATAAAAATCGAAATCTAAGTCAAGAAGAGAAAAATGAATTAAATATTCA  
ATCTGTTAATGATTTAGTTGATCAACAATTAATGACTAATCGCAATCCAGGTAATGGTATCTATAAACC  
CGAAGCAATTAGCTATAACGATCAATCACCATTATGTAGGTGTTAGAATGATGACCGGTATCTACGGAGG  
TAATACTAGTAAAGGTGCTCCTGGAGCTGTTTCATTCAAACATAATGCTTTTAGATTATGGGGTTACTA  
CGGATACGAAAATGGGTTCTTAGGTTATGCTTCAAAATAAATAAACAACAATCTAAAACAGATGGTGA



Table 1

95

GTCTGTTCTAAGTGATGAATATATTATCAAGAAAATATCTAACAATACATTTAATACTATTGAAGAATT  
TAAAAAGCTTACTTCAAAGAAGTTAAAGATAAAGCAACGAAAGGATTAACAACATTGCAAGTAAATGG  
TTCTTCCGTTTCATCATACGATGATTTACTGACATTGTTTAAAGAAGCTGTTAAAAAGATGCCGAAAC  
TCTTAAACAAGAAGCAAACGGTAATAAAACAGTATCTATGAATAATACAGTTAAATTAAAAGAAGCTGT  
TTATAAGAACTTCTTCAACAAACAAATAGCTTTAAACCTCAATCTTTAAA

**SP125 amino acid (SEQ ID NO:222)**

LDRLIEIGSKENNIKGSRTFADFQVLAKYTKSGNLDAFLNYNRQLFTNIDNMNDWFDATEDHVYIAE  
RASEVEEIKNSKHRAFDNLKRSHLRNTILPLLNDKAHLYLISYNAIAFGSAERLGKKSLEDIKDIVN  
KAADGYRNYDFWYRLASDNVQRLRLRAVIPIWEGYNAPGGWVEKYGRYNTDKVYTPLREFFGPMCKY  
YNYNGTGAYAAIYPNSDDIRTDVKYVHLEMVGEYGISVYTHETTHVNDRAIYLGGFGHREGTDAEAYAQ  
GMLQTPVTGSGFDEFGSLGINMVFKRKNDGNQWYITDPKTLKTREDINRYMKGYNDTLTLLEIEAESV  
ISQONKDLNSAWFKIDREYRDNNKLNQWDKIRNLSQEEKNELNIQSVNDLVDQQLMTNRNPGNGIYKP  
EAI SYNDQSPYVGVRMMTGIIYGGNTSKGAPGAVSFKHNAFRLWGYGYENGFLGYASNKYKQSKTDGE  
SVLSDEYIIKKISNNTFNTIEEFKKAYFKEVKDKATKGLTTFEVNGSSVSSYDDLTLTFKEAVKKAET  
LKQEANGNKTVMNNTVKLKEAVYKLLQQTNSFKTSIFK

**SP126 nucleotide (SEQ ID NO:223)**

TAAGACAGATGAACGGAGCAAGGTGTTGACTTTTCCATTCCCTACTATACTGCAAAAAATAAATCAT  
TGTCAAAAAATCTGACTTGACTACTTATCAGTCTGTAAACGACTTGGCGCAGAAAAAGGTTGGAGCGCA  
GAAAGGTTTCGATTCAAGAGACGATGGCGAAAGATTTGCTACAAAATCTTCCCTCGTATCTCTGCCTAA  
AAATGGGAATTTAATCACAGATTTAAAAATCAGGACAAGTGGATGCCGTTATCTTTGAAGAACCCTGTTTC  
CAAGGGATTTGTGGAAAATAATCCTGATTTAGCAATCGCAGACCTCAATTTTGAAAAAGAGCAAGATGA  
TTCTTACGCGGTAGCCATGAAAAAGATAGCAAGAAATTGAAGAGGCAGTTCGATAAAACCATTCAAAA  
GTTGAAGGAGTCTGGGGAATTAGACAAACTCATTGAGGAAGCCTTA

**SP126 amino acid (SEQ ID NO:224)**

KTDERSKVDFDSIPYYTAKNKLIVKKSLLTTYQSVNDLAQKKVGAQKGSIQETMAKDLLQNSSLVSLPK  
NGNLITDLKSGQVDAVIFEEPVSCKGFVENNPDLAIADLNFEKEQDDSYAVAMKKDSKKLKRQFDKTIQK  
LKESGELDKLIEEAL

**SP127 nucleotide (SEQ ID NO:225)**

CTGTGAGAATCAAGCTACACCCAAAGAGACTAGCGCTCAAAAGACAATCGTCCTTGCTACAGCTGGCGA  
CGTGCCACCATTGACTACGAAGACAAGGGCAATCTGACAGGCTTTGATATCGAAGTTTAAAGGCAGT  
AGATGAAAAACTCAGCGACTACGAGATTCAATTCCAAAGAACCGCTGGGAGAGCATCTTCCCAGGACT  
TGATTCTGGTCACTATCAGGCTGCGGCAATAACTTGAGTTACACAAAAGAGCGTGCTGAAAAATACCT  
TTACTCGCTTCCAATTTCCAACAATCCCTCGTCCTTGTCAGCAACAAGAAAAATCCTTTGACTTCTCT  
TGACCAGATCGCTGGTAAAACAACACAAGAGGATACCGGAATTCTAACGCTCAATTATCAATAACTG  
GAATCAGAAACACACTGATAATCCCCTACAATTAATTTTCTGGTGAGGATATTGGTAAACGAATCCT  
AGACCTTGCTAACGAGAGTTTGATTTCTAGTTTGTGACAAGGTATCCGTTCAAAAGATTATCAAGGA  
CCGTGGTTTAGACCTCTCAGTCGTTGATTTACCTTCTGCAGATAGCCCCAGCAATTATATCATTTTCTC  
AAGCGACCAAAAAGAGTTTAAAGAGCAATTTGATAAAGCGCTCAAAGAACTCTATCAAGACGGAACCTT  
TGAAAAACTCAGCAATACCTATCTAGGTGGTTCTTACCTCCCAGATCAATCTCAGTTACAA

**SP127 amino acid (SEQ ID NO:226)**

CENQATPKETSAQKTIVLATAGDVPPFDYEDKGNLTGFDIEVLKAVDEKLSDYEIQFQRTAWESIFPGL  
DSGHYQAAANNLSYTKERAKEYLYSLPISNNPLVLVSNKKNPLTSLDQIAGKTTQEDTGTSNAQFINNW  
NQKHTDNPATINFSGEDIGKRILDLANGEFDLFLVFDKVSQKIIKDRGLDLSVVDLP SADSPSNYIIFS  
SDQKEFKEQFDKALKELYQDGTLEKLSNTYLGGSYLPDQSQLO

Table 2  
*S. pneumoniae* Antigenic Epitopes

**SP001**

Lys-1 to Ile-10; Leu-13 to Lys-32; Arg-41 to Ile-51; Ser-85 to Glu-97; Ala-159 to His-168; Val-309 to Thr-318; Val-341 to Asn-352; Asn-415 to Met-430; Phe-454 to Asn-464; Ser-573 to Gly-591; Asn-597 to Thr-641; and Asn-644 to Ala-664.

**SP004**

Thr-9 to Thr-24; Ile-29 to Ala-48; Thr-49 to Val-56; Val-286 to Val-312; Pro-316 to Glu-344; Val-345 to Ile-367; Gln-368 to Val-399; Ser-400 to Glu-431; Asn-436 to Ala-457; Ile-467 to Ala-498; and Thr-499 to Glu-540.

**SP006**

Glu-1 to Lys-13; Pro-24 to Gly-36; Val-104 to Thr-112; Ala-118 to Asn-130; Trp-137 to Ala-146; Ser-151 to Ile-159; Ile-181 to Leu-188; and Pro-194 to Tyr-202.

**SP007**

Gly-1 to Asn-7; Tyr-24 to Gln-34; His-47 to Phe-55; Ser-60 to Ala-67; Ala-122 to Leu-129; Leu-221 to Lys-230; Val-236 to Phe-256; and Asp-271 to Gly-283; and Leu-291 to Asp-297.

**SP008**

Leu-4 to Lys-17; Gln-24 to Leu-32; Asp-60 to Ser-66; Ser-70 to Asp-76; Ala-276 to Lys-283; Asn-304 to Lys-311; and Thr-429 to Pro-437.

**SP009**

Thr-4 to Glu-11; Leu-50 to Asp-60; Ile-102 to Trp-123; and Ser-138 to Ile-157.

**SP010**

Phe-34 to Gly-41; Asp-44 to Lys-50; Leu-172 to Val-186; Leu-191 to Val-198; Ser-202 to Ile-209; and Val-213 to Leu-221.

**SP011**

Asn-2 to Thr-10; Asp-87 to Ala-102; Tyr-125 to Glu-132; Thr-181 to Tyr-189; Arg-217 to Thr-232; Asn-257 to Lys-264; Pro-271 to Ser-278; Tyr-317 to Ala-325; Glu-327 to Pro-337; and Thr-374 to Val-381.

**SP012**

Gly-1 to Lys-19; Phe-34 to Tyr-41; Leu-109 to Lys-126; and Leu-231 to Glu-247.

**SP013**

Ala-1 to Lys-12; Ile-42 to Pro-53; Leu-138 to Lys-146; Ile-205 to Lys-217; Ser-235 to Ile-251; and Ser-261 to Tyr-272.

**SP014**

Gly-1 to Val-16; Leu-35 to Leu-44; Asp-73 to Asp-81; Ile-83 to Asp-92; Glu-145 to Ile-153; Phe-188 to Asn-196; Ser-208 to Phe-215; Ile-224 to Leu-231; and Asn-235 to Ala-243.

**SP015**

Ser-1 to Pro-16; Asn-78 to Glu-88; Ala-100 to Val-108; Ala-122 to Thr-129; Thr-131 to Ser-137; Leu-201 to Ser-220; and Gly-242 to Val-251.

Table 2  
*S. pneumoniae* Antigenic Epitopes

**SP016**

Gly-1 to Glu-20; Thr-30 to Val-38; Gln-94 to Asn-105; Lys-173 to Pro-182; Gly-189 to Arg-197; Ser-207 to Val-224; Pro-288 to Leu-298; Ala-327 to Ala-342; and Ser-391 to Ala-402.

**SP017**

Ser-1 to Thr-12; Ala-36 to Tyr-45; Gln-48 to Ile-54; Lys-59 to Lys-76; Tyr-113 to Leu-138; and Phe-212 to Asp-219.

**SP019**

Val-97 to Glu-117; Asp-163 to Leu-169; Thr-182 to Thr-191; and Lys-241 to Ser-250.

**SP020**

Asn-18 to Lys-25; Thr-47 to Glu-60; Trp-75 to Val-84; Gly-102 to Val-110; Pro-122 to Ala-131; and Glu-250 to Pro-258.

**SP021**

Ser-1 to Asp-8; Val-44 to Asp-54; Ala-117 to Val-125; Thr-165 to Thr-173; and Glu-180 to Pro-189.

**SP022**

Phe-5 to Lys-13; Thr-20 to Ser-36; Glu-59 to Lys-81; Tyr-85 to Gly-93; Trp-94 to Trp-101; and Thr-195 to Trp-208.

**SP023**

Gln-45 to Glu-59; Asp-69 to Pro-85; Lys-111 to Asn-121; Pro-218 to Ala-228; and Glu-250 to Asn-281.

**SP025**

Gln-14 to Thr-20; Gly-27 to Phe-33; Gly-63 to Glu-71; and Ile-93 to Phe-102.

**SP028**

Asp-171 to Pro-179; Tyr-340 to Glu-350; Pro-455 to Tyr-463; and Asp-474 to Pro-480.

**SP030**

Leu-22 to Leu-37; Trp-81 to Ala-90; Phe-101 to Ala-106; Thr-124 to Tyr-130; and Asn-138 to Glu-144.

**SP031**

Asp-8 to Val-16; Gly-27 to Thr-35; Gly-178 to Asp-195; Thr-200 to Asp-209; Trp-218 to Leu-224; and Lys-226 to Asp-241.

**SP032**

Ser-9 to Asp-28; Phe-31 to Val-40; Gly-42 to Arg-50; Ile-52 to Leu-60; Asp-174 to Phe-186; Leu-324 to Met-333; and Thr-340 to Asn-347.

**SP033**

Gln-2 to Ile-13; Phe-46 to Ile-53; and Asp-104 to Thr-121.

**SP034**

Glu-36 to Gly-43; Ala-188 to Asp-196; Trp-313 to Gly-320; and Leu-323 to Leu-329.

Table 2  
*S. pneumoniae* Antigenic Epitopes

**SP035**

Arg-19 to Asp-36; Asp-47 to Val-57; Asn-134 to Thr-143; Asp-187 to Arg-196; and Glu-222 to Ser-230.

**SP036**

Arg-10 to Arg-17; Lys-29 to Ser-39; Ser-140 to Ala-153; Arg-158 to Tyr-169; Asp-175 to Ala-183; Gly-216 to Asn-236; Ala-261 to Leu-270; Arg-282 to Phe-291; and Thr-297 to Ala-305; Pro-342 to Gln-362; Phe-455 to Asp-463; His-497 to Thr-511; Ala-521 to Gly-529; Ile-537 to Val-546; Ile-556 to Ala-568; Pro-581 to Ser-595; Glu-670 to Ala-685; Ser-696 to Ala-705 and Leu-782 to Ser-791.

**SP038**

Glu-61 to Pro-69; Phe-107 to Ala-115; Leu-130 to Tyr-141; Ala-229 to Glu-237; Ser-282 to Asn-287; Ala-330 to Glu-338; and Tyr-387 to Glu-393.

**SP039**

Ser-28 to Asp-35; Pro-88 to Pro-96; Leu-125 to Arg-135; Phe-149 to Leu-157; Gln-246 to Val-254; Ala-357 to Thr-362; Gly-402 to Lys-411; and Leu-440 to Pro-448.

**SP040**

Thr-21 to Ile-30; His-54 to Gln-68; Arg-103 to Leu-117; and Thr-127 to Leu-136.

**SP041**

Gly-36 to Asp-49; Leu-121 to Val-128; and Ala-186 to Ile-196.

**SP042**

Gly-11 to Arg-19; Ile-23 to Lys-31; His-145 to Asn-151; Gln-159 to Asp-166; Ile-175 to Asp-181; Gly-213 to Tyr-225; Ile-283 to Val-291; Pro-329 to Glu-364; Arg-372 to Ser-386; Thr-421 to Phe-430; Leu-445 to Val-453; Ile-486 to Ala-497; Asp-524 to Ala-535; His-662 to Gly-674; and His-679 to Gln-702.

**SP043**

Lys-2 to Asp-12; Val-58 to Asn-68; Ser-87 to Asp-95; and Asp-102 to Lys-117.

**SP044**

Gln-3 to Lys-11; Asp-37 to Tyr-52; Glu-171 to Leu-191; His-234 to Asn-247; and Asn-283 to Ala-291.

**SP045**

Tyr-52 to Ile-63; Asp-212 to Gln-227; Ser-315 to Thr-332; Leu-345 to Phe-354; Asp-362 to Val-370; Thr-518 to Asn-539; Ala-545 to Lys-559; and Val-601 to Pro-610.

**SP046**

Gln-9 to Ala-18; Glu-179 to Lys-186; Lys-264 to Glu-271; Gly-304 to Glu-17; Ser-503 to Asn-511; Asn-546 to Thr-553; and Asn-584 to Asp-591.

**SP048**

**Table 2**  
***S. pneumoniae* Antigenic Epitopes**

Tyr-4 to Asp-25; Lys-33 to Val-70; Asp-151 to Thr-170; Asp-222 to Val-257; Thr-290 to Phe-301; and Gly-357 to Val-367.

**SP049**

Ala-23 to Arg-37; Tyr-85 to Gln-95; Glu-106 to Ile-118; Arg-131 to Ile-144; Gly-150 to Ser-162; and Ala-209 to Asp-218.

**SP050**

Asp-95 to Glu-113; Gly-220 to Gly-228; Asn-284 to Glu-295; Thr-298 to Val-315.

**SP051**

Lys-16 to Glu-50; Lys-57 to Asn-104; Ser-158 to Trp-173; Asp-265 to Pro-279; Val-368 to Tyr-386; Glu-420 to Ile-454; Pro-476 to Ile-516; Phe-561 to Gly-581; Thr-606 to Gly-664; and Glu-676 to Val-696.

**SP052**

Asn-41 to Tyr-60; Phe-80 to Glu-103; Ala-117 to Val-139; Ile-142 to Leu-155; Val-190 to Lys-212; Glu-276 to Phe-283; Arg-290 to Ser-299; Leu-328 to Val-351; Gly-358 to Thr-388; Glu-472 to Ala-483; Val-533 to Asn-561; Asp-595 to Val-606; Glu-609 to Val-620; Glu-672 to Ser-691.

**SP053**

Ala-62 to Val-101; Thr-147 to Leu-174; Lys-204 to Val-216; Gln-228 to Val-262; Ser-277 to Gly-297; Thr-341 to Gly-368; Thr-385 to Ala-409; Thr-414 to Ser-453; Asn-461 to Leu-490; Glu-576 to Thr-625; Gly-630 to Arg-639; and Asp-720 to Leu-740.

**SP054**

Glu-7 to Val-28; and Tyr-33 to Glu-44.

**SP055**

Pro-3 to Val-18; Thr-21 to Lys-53; Val-84 to Lys-99; Ile-162 to Val-172; and Val-204 to Ser-241.

**SP056**

Val-34 to Tyr-41; Leu-47 to Glu-55; and Pro-57 to Gln-66.

**SP057**

Asp-1 to Val-25; Pro-29 to Ile-80; Asn-96 to Val-145; and Pro-150 to Glu-172.

**SP058**

Ala-64 to Thr-70; Leu-82 to His-138; and Val-228 to Asn-236.

**SP059**

Val-10 to Thr-24; Ser-76 to Pro-102; Ser-109 to Ile-119; Ser-124 to Val-130; Thr-186 to Ile-194; and Asn-234 to Ser-243.

**SP060**

Leu-70 to Arg-76; and Val-79 to Ile-88.

**SP062**

Glu-14 to Lys-28; Ser-32 to Lys-46; and Glu-66 to Thr-74.

Table 2  
*S. pneumoniae* Antigenic Epitopes

**SP063**

Ile-10 to Val-25; Val-30 to Thr-40; Asp-44 to Pro-54; Asn-57 to Val-63; Pro-71 to Val-100; and Thr-105 to Thr-116.

**SP064**

Pro-12 to Leu-32; Val-40 to Leu-68; Asp-95 to Ala-125; Ser-164 to Glu-184; Ser-314 to Glu-346; Asn-382 to Val-393; Leu-463 to Gln-498; Asn-534 to Lys-548; and Lys-557 to Gly-605.

**SP065**

Asn-2 to Ile-12; Ala-39 to Thr-61; and His-135 to Ala-155.

**SP067**

Gly-1 to Thr-13; Asp-203 to Asn-218; and Gly-240 to Asp-253.

**SP068**

Ser-2 to Ser-12; Val-17 to Gln-26; and Lys-54 to Cys-67.

**SP069**

Ser-32 to Thr-41; Pro-66 to Glu-80; Thr-110 to Val-122; and Val-147 to Thr-180.

**SP070**

Lys-6 to Tyr-16; Gln-19 to Ile-27; Arg-50 to Ala-58; Leu-112 to Val-128; Ile-151 to Asn-167; Leu-305 to Phe-321.

**SP071**

Gln-92 to Asn-158; Gln-171 to Gln-188; Val-204 to Val-240; Thr-247 to Ala-273; Glu-279 to Thr-338; Pro-345 to Glu-368; Asn-483 to Lys-539; Val-552 to Ala-568; Glu-575 to Ser-591; Ser-621 to Gly-640; Gln-742 to Gly-758.

**SP072**

Val-68 to Tyr-81; Tyr-86 to Val-121; Leu-127 to Gly-140; Gly-144 to Ala-155; Gln-168 to Val-185; Asp-210 to Tyr-241; Glu-246 to Thr-269; Lys-275 to Tyr-295; Gly-303 to Pro-320; Arg-327 to Ile-335; Thr-338 to Thr-364; Tyr-478 to Phe-495; and Tyr-499 to Arg-521.

**SP073**

Glu-37 to Val-45; Glu-55 to Val-68; Thr-104 to Thr-119; Ile-127 to Tyr-135; Asn-220 to Ile-232; Thr-237 to Ala-250; Ser-253 to Ala-263; Glu-284 to Ile-297; and Met-438 to Asn-455.

**SP074**

Gly-2 to Ala-12; Gly-96 to Ile-110; and Thr-220 to Phe-239.

**SP075**

Phe-33 to Tyr-42; Gln-93 to Gly-102; and Val-196 to Asp-211.

**SP076**

Ser-64 to Leu-76; and Phe-81 to Ala-101.

**SP077**

Asp-1 to Glu-12; Tyr-26 to Val-36; and Val-51 to Tyr-62.

Table 2  
*S. pneumoniae* Antigenic Epitopes

**SP078**

Ala-193 to Ile-208; Tyr-266 to Asn-275; Glu-356 to Leu-369; Ala-411 to Gly-422; Ser-437 to Pro-464; Thr-492 to Glu-534; and Glu-571 to Gln-508.

**SP079**

Gly-11 to Leu-20; Lys-39 to Leu-48; Leu-72 to Val-85; Asn-147 to Ser-158; Ile-178 to Asp-187; Tyr-189 to Gln-201; and Leu-203 to Ala-216

**SP080**

Ser-2 to Glu-12; Gln-42 to Ala-51; Ala-116 to Ser-127; Phe-131 to Asp-143; and Ile-159 to Ile-171.

**SP081**

Gln-2 to Leu-9; Gln-49 to Cys-57; Ile-108 to Val-131; Gly-134 to Leu-145; and Trp-154 to Cys-162.

**SP082**

Ile-101 to Ser-187; Gly-191 to Asn-221; Arg-225 to Arg-236; Tyr-239 to Leu-255; and Gly-259 to Arg-268.

**SP083**

Ser-28 to Asp-70.

**SP084**

Leu-42 to Gln-66; Thr-69 to Lys-81; Glu-83 to Arg-92; and Gly-98 to Asn-110.

**SP085**

Gln-2 to Val-22; and Ser-45 to Glu-51.

**SP086**

Leu-18 to Gln-65; and Lys-72 to Val-83.

**SP087**

Ser-45 to Leu-53; and Thr-55 to Gln-63

**SP088**

Pro-8 to Ile-16; Leu-25 to Trp-33; Tyr-35 to Gln-43; Leu-51 to Val-59; Val-59 to Arg-67; Thr-55 to Tyr-63; Asn-85 to Gly-93; Thr-107 to Leu-115;  
Leu-115 to Trp-123; Ala-121 to Thr-129; Tyr-153 to Ala-161; His-176 to Gly-184; Tyr-194 to Ala-202; Ala-217 to Gly-225; and Asn-85 to Gly-93.

**SP089**

Trp-43 to Ala-51; Gln-68 to Phe-76; Val-93 to Gln-101; Phe-106 to Phe-114; Lys-117 to Lys-125; Trp-148 to Phe-156; Glu-168 to Gln-176; Ile-193 to Tyr-201; Lys-203 to Lys-211; Glu-212 to Gln-220; Ile-237 to Tyr-245; Lys-247 to Lys-255; Glu-256 to Gln-264; Met-275 to Gly-283; Lys-286 to Gly-294; Trp-292 to Glu-300; Asp-289 to Thr-297; Tyr-315 to Ser-323; Asp-334 to Lys-342; Pro-371 to Arg-379; Arg-485 to Asn-493; Lys-527 to Arg-535; Phe-537 to Met-545; and Tyr-549 to Glu-557.

**SP090**

Table 2  
*S. pneumoniae* Antigenic Epitopes

Phe-2 to Gln-10; Gln-13 to Lys-21; Tyr-19 to Glu-27; Tyr-39 to Met-47; Pro-65 to Leu-73; Tyr-121 to His-129; Lys-147 to Ile-155; Gly-161 to Lys-169; Gly-218 to Trp-226; Asp-230 to Thr-238; Tyr-249 to Ala-257; and Ala-272 to Gly-280.

**SP091**

Ser-19 to Ser-27; Asn-25 to Thr-33; Val-51 to Gln-59; Asn-75 to Asn-83; Ile-103 to Trp-111; Tyr-113 to Ala-121; Leu-175 to Asn-183; Glu-185 to Trp-193; Ala-203 to Tyr-211; Val-250 to Phe-258; Asn-260 to Thr-268; Ser-278 to Asp-286; Tyr-305 to Leu-313; Asn-316 to Gly-324; Asn-374 to Asp-382; Asn-441 to Gly-449; and Ser-454 to Gln-462.

**SP092**

Arg-95 to Glu-103; Ala-216 to Val-224; Leu-338 to Glu-346; Pro-350 to Ala-358; Pro-359 to Ala-367; Pro-368 to Ala-376; Pro-377 to Ala-385; Pro-386 to Ala-394; Pro-395 to Ala-403; Pro-350 to Ala-358; Gln-414 to Lys-422; Pro-421 to Asn-429; Trp-465 to Tyr-473; Phe-487 to Tyr-495; Asn-517 to Gly-525; Trp-586 to Tyr-594; Phe-608 to Tyr-616; and Asp-630 to Gly-638.

**SP093**

Gln-30 to Ile-38; Gln-52 to Val-60; Ala-108 to His-116; Tyr-133 to Glu-141; Tyr-192 to Ala-200; and Phe-207 to Ser-215.

**SP094**

Ala-87 to Val-95; Leu-110 to Cys-118; Gln-133 to Leu-141; Ser-185 to Leu-193; Ile-195 to Gly-203; Asp-206 to Gln-214; Ser-211 to Gly-219; Ile-241 to Thr-249.

**SP095**

Arg-1 to Gln-9; Phe-7 to Asn-15; Thr-21 to Asn-30; Leu-46 to Phe-54; and Ser-72 to Met-80.

**SP096**

Gly-29 to Ile-37; Glu-52 to Ser-60; and Leu-64 to Gly-72.

**SP097**

Ala-11 to Thr-19; Glu-53 to Glu-61; Ser-91 to Lys-99; Thr-123 to Gln-131; and Gly-209 to Lys-217.

**SP098**

Thr-3 to Ser-11; Gly-38 to Phe-46; Tyr-175 to Asn-183; Met-187 to Cys-195; Gln-197 to Leu-205; Tyr-307 to Gln-315; Gly-318 to Tyr-326; Asn-348 to Val-356; Lys-377 to Pro-385; and Leu-415 to Val-423.

**SP099**

Arg-19 to Gly-27; Asp-76 to Ser-84; Val-90 to Lys-98; Phe-165 to Val-173; Leu-237 to Pro-245.

**SP100**

His-111 to Gln-119; Ser-141 to His-149; Asp-154 to Ser-162; Gln-158 to Gln-166; Asp-154 to Gln-166; Lys-180 to Gln-188; and Ser-206 to Gln-214.

**SP101**



Table 2  
*S. pneumoniae* Antigenic Epitopes

Glu-23 to Glu-31; Glu-40 to Val-48; Gln-50 to Ser-58; Thr-61 to Ile-69; Leu-82 to Ile-90; Ala-108 to Leu-116; Gln-121 to Pro-129; and Leu-130 to Thr-138.

**SP102**

Asp-32 to His-40; Arg-48 to Lys-56; and Asp-102 to Thr-110.

**SP103**

Arg-5 to Gln-13; Gln-22 to Leu-30; Arg-151 to Gln-159; Arg-167 to Gln-175; Pro-189 to Glu-197; Gly-207 to Leu-215; Ser-219 to Gln-227; Ser-233 to Ser-241; Pro-255 to Asp-264; Lys-272 to Gly-280; Ser-318 to Val-326; Thr-341 to Asp-351; Asn-356 to Thr-364; Val-370 to Tyr-378; Ile-379 to Gln-387; and Met-435 to Tyr-443.

**SP105**

Asn-28 to Pro-36; Thr-77 to Phe-85; Arg-88 to Val-96; Gly-107 to Phe-115; Asp-169 to Asp-177; His-248 to Ser-256; and Ser-274 to Ala-282.

**SP106**

Val-10 to Thr-18; Ile-62 to Tyr-70; Ile-71 to Pro-79; Lys-86 to Gln-94; Lys-100 to Thr-108; Phe-132 to Leu-140; and Asp-145 to Arg-153.

**SP107**

Asp-33 to Val-41; and Arg-63 to Gln-71.

**SP108**

Lys-9 to Gln-17; Leu-44 to Ser-52; Ser-63 to Phe-71; Tyr-109 to Ser-117; Ile-183 to Ile-191; Pro-194 to Leu-202; Gly-257 to Gln-265; Ala-323 to Thr-331; and Leu-381 to Tyr-389.

**SP109**

Asn-2 to Gln-10; Ala-65 to Lys-73; Leu-76 to Glu-84; Thr-111 to Asp-119; Gln-116 to Tyr-124; Tyr-130 to Val-138; Asp-173 to Gly-181; Asp-196 to Ser-204; Asn-231 to Ser-239; Phe-252 to Ser-260; Phe-270 to Tyr-278; Val-291 to His-299; Asp-306 to Leu-314; and Pro-327 to Gly-335.

**SP110**

Ser-8 to Glu-16; Ile-37 to Val-45; Ala-107 to Val-115; and Gly-122 to Thr-130.

**SP111**

Asp-19 to Glu-28; Leu-43 to Ala-51; Asn-102 to Phe-110; Gln-133 to Ser-141; Phe-162 to Asp-170; Tyr-194 to Met-202; and Asp-273 to Ser-281.

Table 2  
*S. pneumoniae* Antigenic Epitopes

**SP112**

Asp-3 to Gln-11; Gly-21 to Ile-29; Ala-46 to Arg-54; Arg-98 to Arg-106; Thr-114 to Val-122; Gln-133 to Asn-141; and Leu-223 to Thr-231.

**SP113**

Asn-19 to Gly-27; Arg-54 to Ser-62; Val-69 to Gln-77; Ser-117 to Asn-125; Gly-164 to Leu-172; Tyr-193 to Ser-201; Cys-303 to Phe-311; His-315 to Ile-323; Arg-341 to Cys-349; Ile-347 to Ser-355; Arg-403 to Phe-411; Gln-484 to Pro-492; Ser-499 to Leu-507; Ile-541 to Thr-549  
Asn-622 to Ile-630; and Glu-645 to Gly-653.

**SP114**

Gly-17 to Leu-25; His-40 to Gln-48; Arg-49 to Arg-57; Ile-65 to Pro-73;  
Asn-101 to Asp-111; Gly-128 to Cys-136; Phe-183 to Thr-191; and Pro-268 to Ile-276.

**SP115**

Met-8 to Ser-16; Tyr-24 to Leu-32; Cys-68 to Leu-76; Ser-100 to Pro-108; Thr-193 to Thr-201; Gly-238 to Pro-250; Thr-280 to Phe-288; Pro-303 to Asn-312; Trp-319 to Leu-328; Leu-335 to Leu-344; Lys-395 to Ala-403; Asn-416 to Gln-424; Tyr-430 to Ser-438; Val-448 to Leu-456; Leu-460 to Thr-468; Pro-502 to Thr-510; Lys-515 to Ile-524; Gln-523 to His-532; Tyr-535 to Thr-543; Ser-559 to Pro-567; Thr-572 to Asn-580;  
Val-594 to Arg-602; Arg-603 to Asn-611; Thr-620 to Trp-628; and Tyr-644 to Arg-653.

**SP117**

Ala-6 to Gly-14; Ile-19 to Thr-27; Thr-99 to Leu-107; Ser-117 to Asp-125; His-131 to Val-139; Ile-193 to Gly-201; and Val-241 to Gln-249.

**SP118**

Ser-8 to Trp-23; His-46 to Ala-54; Asn-93 to Gly-101; Val-100 to Ser-108; Arg-155 to Asp-163; and His-192 to Leu-200.

**SP119**

Tyr-46 to Lys-54; Ser-93 to Ser-101; Trp-108 to Asn-116; Val-121 to Glu-129; and Tyr-131 to Gln-139.

**SP120**

Ala-57 to Lys-65; Leu-68 to Glu-76; Thr-103 to Tyr-116; Tyr-122 to Val-130; His-163 to Gly-173; Asp-188 to Ser-196; Ser-222 to Ser-231; Phe-244 to Ser-252; Pro-262 to Tyr-270; Val-283 to His-291; and Asp-298 to Leu-306.

**SP121**

Ser-3 to Ala-11; Asp-13 to Leu-21; Ser-36 to Val-44; and Gln-136 to Met-144.

**SP122**

Asn-28 to Lys-36; Glu-39 to Thr-50; Val-54 to Lys-62; Asn-106 to Leu-114; Phe-159 to Gly-167; Asn-172 to Arg-180; Glu-199 to Asn-207;

Table 2  
*S. pneumoniae* Antigenic Epitopes

Lys-230 to His-241; Asn-252 to Gly-263; Met-278 to Ala-287; Thr-346 to Asp-354; Lys-362 to Thr-370; Asp-392 to Asn-405; Asp-411 to Ala-424; Gly-434 to Gly-443; Tyr-484 to Glu-492; Ile-511 to Leu-519; Asn-524 to Asp-538; Glu-552 to Ile-567; Val-605 to Lys-613; Phe-697 to Ala-705; Phe-722 to Leu-730; Leu-753 to Leu-761; Asp-787 to Gln-795; Leu-858 to Asn-866; Ala-892 to Thr-901; Gly-903 to Ile-913; Ile-921 to Asn-931; Asn-938 to Pro-951; Gly-960 to Lys-970; Leu-977 to Asp-985; and Leu-988 to Pro-996.

**SP123**

Val-4 to Asn-12; Glu-47 to Leu-55; Lys-89 to Glu-100; Ser-165 to Thr-173; Lys-234 to Val-242; Ser-258 to Ser-266; Glu-284 to Asn-292; Tyr-327 to Leu-335; Tyr-457 to Thr-465; Tyr-493 to Glu-501; Thr-506 to Tyr-514; Lys-517 to Thr-525; Asn-532 to Gly-540; and Arg-556 to Glu-564.

**SP124**

Arg-16 to Glu-24; Gln-52 to Arg-60; Asn-69 to Tyr-77; Glu-121 to Asn-129; Ala-134 to Val-142; Thr-151 to Ala-159; Asn-164 to Glu-172; His-181 to His-189; Thr-210 to Ala-218; Ser-244 to Val-252; Phe-287 to Tyr-297; Ser-312 to Thr-323; His-433 to Tyr-441; Ser-445 to Asn-453; Asn-469 to Thr-477; Asn-501 to Asn-509; Gln-536 to Ala-547; and Gln-608 to Asp-621.

**SP125**

Ser-9 to Asp-21; Ala-28 to Leu-36; Asn-49 to Phe-57; Val-137 to Arg-145; Asn-155 to Leu-163; Glu-183 to Asp-191; Gly-202 to Tyr-210; Pro-221 to Asp-229; Phe-263 to Ala-271; Phe-300 to Gln-308; Asp-313 to Glu-321; Asn-324 to Asp-332; Ile-346 to Asn-354; Asp-362 to Lys-370; Met-402 to Gly-410; Gly-437 to Gly-445; Ser-471 to Glu-483; Gly-529 to Asp-537; Gln-555 to Val-563; and Leu-579 to Lys-587.

**SP126**

Leu-22 to Thr-30; Val-65 to Leu-73; and Thr-75 to Asp-83.

**SP127**

Glu-2 to Ala-12; Asp-28 to Thr-36; Val-105 to Thr-113; Lys-121 to Thr-129; Trp-138 to Pro-146; Ser-152 to Ile-160; Lys-180 to Asp-188; Leu-194 to Asn-202; and Gly-228 to Thr-236.

Table 3  
*S. pneumoniae* ORF Cloning Primers

Primer Name	SEQ ID	Sequence	RE
SP001A	NO:227	GACTGGATCCTAAAAATCTACGACAATAAAAAATC	Bam HI
SP001B	NO:228	CTGAGTCGACTGGTTGTGCTGGTTGAG	Sal I
SP004A	NO:229	GTCAGGATCCAAATTACAATACGGACTATG	Bam HI
SP004B	NO:230	CAGTGTGCGACTAAGCTTAGGTTCGGAAAC	Sal I
SP006A	NO:231	GACTGGATCCTGAGAATCAAGCTACACCCAAAGAG	Bam HI
SP006B	NO:232	AGTCAAGCTTTTGTAACTGAGATTGATCTGG	Hind III
SP007A	NO:233	GACTGGATCCTGGTAACCGCTCTTCTCGTAACGCAGC	Bam HI
SP007B	NO:234	AGTCAAGCTTTTTTCAGGAACTTTTACGCTTCC	Hind III
SP008A	NO:235	AGTCAGATCTTGTGGAATTTTGACAGGTAACAGCAAAAAAGCTGC	Bgl II
SP008B	NO:236	ACTGAAGCTTTTTTGTCTTTTCAAGAAATTCATCG	Hind III
SP009A	NO:237	GACTGGATCCTGGTCAAGGAAGTCTTCTAAAGAC	Bam HI
SP009B	NO:238	AGTCAAGCTTTCACAAATTCGTTGGTGAAGCC	Hind III
SP010A	NO:239	GACTGGATCCTAGGTCAGGTGGAACGCTGGTTCATCC	Bam HI
SP010B	NO:240	AGTCAAGCTTATCAACTTTTCCACCTTCAACAACC	Hind III
SP011A	NO:241	GTCAAGATCTCTCCAATATGGTAAATCTGCGGATGG	Bgl II
SP011B	NO:242	AGTCCTGCAGATCCACATCCGCTTTTCATCGGGTTAAAGAAGG	Pst I
SP012A	NO:243	GACTGGATCCTGGGAAAAAATCTAGCGAAACTAGTGG	Bam HI
SP012B	NO:244	GTCAGTGCAGCTGTCTTCTTTTACTTCTTTGGTTGC	Pst I
SP013A	NO:245	GACTGGATCCTGCTAGCGGAAAAAAGATACAACCTTCTGG	Bam HI
SP013B	NO:246	CTGAAAGCTTTTTTGGCAATCCTTCAGCAATCTTGTC	Hind III
SP014A	NO:247	GACTAGATCTTGGCTCAAAAAATACAGCTTCAAGTCC	Bgl II
SP014B	NO:248	AGTCCTGCAGGTTTTTGTGTTGCTTGGTATTGGTCG	Pst I
SP015A	NO:249	GACTGGATCCTAGTACAAACTCAAGCACTAGTCAGACAGAG	Bam HI
SP015B	NO:250	CAGTCTGCAGTTTTCAAAGCTTTTTGTATGTCTTC	Pst I
SP016A	NO:251	GACTGGATCCTGGCAATCTGGCGGAAGTAAAGATGC	Bam HI
SP016B	NO:252	AGTCAAGCTTGTTCATAGCTTTTTTGATTGTTTCG	Hind III
SP017A	NO:253	GACTGGATCCTTCACAAGAAAAAACAATAAAGATGG	Bam HI
SP017B	NO:254	AGTCAAGCTTATCGAGCTAGTCTCCGCCTTC	Hind III
SP019A	NO:255	GACTGGATCCGAAAGCTGTGTGGTCAAATAATCTTACC	Bam HI
SP019B	NO:256	AGTCAAGCTTAGAGTTAATCATGGTGTGCTTGCCAAATAGG	Hind III
SP020A	NO:257	GACTGGATCCAAACTCAGAAAAGAAAGCAGACAATGC	Bam HI
SP020B	NO:258	AGTCAAGCTTCCAAACTGGTTGATCCAAACCATCTG	Hind III
SP021A	NO:259	GACTGGATCCTTCGAAAGGGTCAGAAGGTGCAGACC	Bam HI
SP021B	NO:260	AGTCAAGCTTCTGTAGGCTTGGTGTGCCCCAGTTGC	Hind III
SP022A	NO:261	CTGAGGATCCGGGGATGGCAGCTTTTAAAAATC	Bam HI
SP022B	NO:262	CAGTAAGCTTGTTTACCCATTACCATTTACC	Hind III
SP023A	NO:263	CAGTGGATCCAGACGAGCAAAAAATTAAG	Bam HI
SP023B	NO:264	TCAGAAAGCTTGTTTACCCATTACCATTT	Hind III
SP025A	NO:265	GACTGGATCCCTGTGGTGAGGAAGAACTAAAAAG	Bam HI
SP025B	NO:266	CTGAGTCGACAATATTCTGTAGGAATGCTTCGAATTTG	Sal I
SP028A	NO:267	CTGAGGATCCGACTTTTAAACAATAAACTATTGAAGAG	Bam HI
SP028B	NO:268	GTCAGTGCAGGTTGTCACTTCAAAAAATCACGG	Pst I
SP030A	NO:269	GACTGGATCCCTTTACAGGTTAAACAACACACAGTCGG	Bam HI
SP030B	NO:270	CAGTAAGCTTTTTCGAAGTTTGGCTCAGAATTG	Hind III
SP031A	NO:271	GACTGGATCCCCAGGCTGATACAAGTATCGCA	Bam HI
SP031B	NO:272	CAGTAAGCTTATCTGCAGTATGGCTAGATGG	Hind III
SP032A	NO:273	GACTGGATCCGTCTGTATCATTTGAAAACAAAGAAAC	Bam HI
SP032B	NO:274	CAGTCTGCAGTTTTACTGTTGCTGTGCTTGTG	Pst I
SP033A	NO:275	ACTGAGATCTTGGTCAAAAGGAAAGTCAGACAGGAAAGG	Bgl II
SP033B	NO:276	CAGTAAGCTTATTCCTGAGCTTTTTTGTATAAGGTTGCGCA	Hind III
SP034A	NO:277	ACTGGGATCCGAAGGATAGATATATTTTAGCATTTGAGAC	Bam HI
SP034B	NO:278	AGTCAAGCTTCCATGGTATCAAAGGCAAGACTTGG	Hind III
SP035A	NO:279	GTCAGGATCCGGTAGTTAAAGTTGGTATTAACGG	Bam HI
SP035B	NO:280	AGTCAAGCTTGCAATTTTTCGGAAGTATTCGAAGAG	Hind III
SP036A	NO:281	AGTCGGATCCTTCTTACGAGTTGGGACTGTATCAAGC	Bam HI

Table 3  
*S. pneumoniae* ORF Cloning Primers

Primer		Sequence	RE
Name	SEQ ID		
SP036B	NO:282	AGTCAAGCTTGTTTATTTTTTCCTTACTTACAGATGAAGG	Hind III
SP038A	NO:283	AGTCGGATCCTACTGAGATGCATCATAATCTAGGAGC	Bam HI
SP038B	NO:284	TCAGCTCGAGTCTTTTGACATCTCCATCATAAGTCGC	Xho I
SP039A	NO:285	GACTGGATCCGGTTTTTGAGAAAGTATTTGCAGGGG	Bam HI
SP039B	NO:286	CAGTAAGCTTGGAATTTTTTCATGGATGCAATTTTTTTGG	Hind III
SP040A	NO:287	GACTGGATCCGACAACATTTACTATCCATACAGTAGAGTCAGC	Bam HI
SP040B	NO:288	GACTAAGCTTGGCATAAGGTGCAATTCTGGATTAATTGG	Hind III
SP041A	NO:289	GACTGGATCCGGCTAAGGAAAGAGTGGATG	Bam HI
SP041B	NO:290	GACTAAGCTTTTCATTTTTTAAATTGACTATGCGCCCG	Hind III
SP042A	NO:291	GACTGGATCCTTGTTCCCTATGAACCTGGTCGTCACC	Bam HI
SP042B	NO:292	CATGAAGCTTATCCTGGATTTTCCAAGTAAATCT	Hind III
SP043A	NO:293	GACTGGATCCTTATAAGGGTGAATTAGAAAAAGG	Bam HI
SP043B	NO:294	GACTAAGCTTCTTATTAGGATGTGTAGTAGTTG	Hind III
SP044A	NO:295	GACTGGATCCGAATGTTTCAGGCTCAAGAAAGTTCAGG	Bam HI
SP044B	NO:296	GACTAAGCTTTTCCCCTGATGGAGCAAAGTAATACC	Hind III
SP045A	NO:297	GACTGGATCCCTTGGGTGTAACCCATATCCAGCTCCTTCC	Bam HI
SP045B	NO:298	GACTGTCGACTTCAGCTTGTTTATCTGGGGTTGC	Sal I
SP046A	NO:299	GACTGGATCCTAGTAGGTACTTGGCAAGGAAAACAG	Bam HI
SP046B	NO:300	ACTGCTGCAGATCTTTGCCACCTAGCTTCTCATTTG	Pst I
SP048A	NO:301	GTCAGGATCCTGGGATTCAATATGTCAGAGATGATACTAG	Bam HI
SP048B	NO:302	CTAGAAGCTTACGCACCCATTACCATTTATCATTG	Hind III
SP049A	NO:303	GTCAGGATCCGGATAATAGAGAAGCATTAATAAAC	Bam HI
SP049B	NO:304	AGTCAAGCTTGACAAAATCTGAAACTCCTCTGGTC	Hind III
SP050A	NO:305	GTCAGGATCCAGATTTTGTGCGAGGAGTGTCAATACC	Bam HI
SP050B	NO:306	AGTCAAGCTTTCCCTTTTACCCTTACGAATCCAGG	Hind III
SP051A	NO:307	GACTGGATCCATCTGTAGTTTATGCGGATGAAACACTTATTAC	Bam HI
SP051B	NO:308	GACTGTCGACGCTTTGGTAGAGATAGAAGTCATG	Sal I
SP052A	NO:309	GACTGGATCCTTACTTTGGTATCGTAGATACAGCCGGC	Bam HI
SP052B	NO:310	AGTCAAGCTTTGTTAATTGCGTACCTTCTAAGCGACC	Hind III
SP053A	NO:311	GACTGGATCCAGCTAAGTTGCATGGGATGCGATTGC	Bam HI
SP053B	NO:312	GACTGTCGACCTGGGCTTTATTAGTTTGACTAGC	Sal I
SP054A	NO:313	CAGTGGATCCCTATCACTATGTAAATAAAGAGA	Bam HI
SP054B	NO:314	ACTGAAGCTTTTCTGTCCCTGTTTGAGGCA	Hind III
SP055A	NO:315	CAGTGGATCCTGAGACTCCTCAATCAATAACAAA	Bam HI
SP055B	NO:316	ACGTAAGCTTATAATCAGTAGGAGAACTGAACT	Hind III
SP056A	NO:317	CAGTGGATCCGGATGCTCAAGAACTGCGG	Bam HI
SP056B	NO:318	GACTAAGCTTTTGCCCTCTCATTCTTGCTTCC	Hind III
SP057A	NO:319	CAGTGGATCCCGACAAAGGTGAGACTGAG	Bam HI
SP057B	NO:320	ACGTAAGCTTATTTCTTAATTCAAGTGTTTCTCTG	Hind III
SP058A	NO:321	GACTGGATCCAAATCAATTGGTAGCACAGATCC	Bam HI
SP058B	NO:322	CAGTGTGACATTAGGAGCCACTGGTCTC	Sal I
SP059A	NO:323	CAGTGGATCCCAAACAGTCAGCTTCAGGAAC	Bam HI
SP059B	NO:324	GACTCTGCAGTTTAATCTTGTCCCAGGTGG	Pst I
SP060A	NO:325	GACTGGATCCATTTCGATGATGCGGATGAAAAG	Bam HI
SP060B	NO:326	GACTAAGCTTTCATTTGCTTTGGGTATTTCGCA	Hind III
SP062A	NO:327	CAGTGGATCCGGAGAGTCGATCAAAAAGTAG	Bam HI
SP062B	NO:328	GTCAGTGCAGTTGCTCGTCTCGAGGTTT	Pst I
SP063A	NO:329	CAGTGGATCCATGGACAACAGGAACTGGGAC	Bam HI
SP063B	NO:330	CAGTAAGCTTATTAGCTTCTGTACCTGTGTTTG	Hind III
SP064A	NO:331	GACTGGATCCCGATGGGCTCAATCCAACCCAGGTCAAGTC	Bam HI
SP064B	NO:332	GACTCTGCAGCATAGCTTTATCCTCTGACATCATCGTATC	Pst I
SP065A	NO:333	GACTGGATCCTTCCAATCAAAAACAGGCAGATGG	Bam HI
SP065B	NO:334	GACTAAGCTTGAGTCCCATAGTCCAAGGCA	Hind III
SP067A	NO:335	AGTCGGATCCTATCACAGGATCGAACGTAAGACAACC	Bam HI
SP067B	NO:336	ACTGGTGCAGCTTCTTTTAACTCCGCTACTGTGTC	Sal I

Table 3  
*S. pneumoniae* ORF Cloning Primers

Primer			
Name	SEQ ID	Sequence	RE
SP068A	NO: 337	CAGTGGATCCAAGTTCATCGAAGATGGTTGGGAAGTCC	Bam HI
SP068B	NO: 338	GATCGTCGACCCGCTCCCACATGCTCAACCTT	Sal I
SP069A	NO: 339	TGACGGATCCATCGCTAGCTAGTGAAATGCAAGAAAG	Bam HI
SP069B	NO: 340	TGACAAGCTTATTTCGTTTTTGAAGTGTGCTTTTCGT	Hind III
SP070A	NO: 341	GACTGGATCCGCACCAGATGGGGCACAAGGTTCAAGG	Bam HI
SP070B	NO: 342	TGACAAGCTTAAGTTGTAACGAACAGTTCAATCTG	Hind III
SP071A	NO: 343	GACTAGATCTTTTAAACCAACTGTTGGTACTTTCC	Bgl II
SP071B	NO: 344	TGACAAGCTTGTTAGGTGTTACATTTTGACCGTC	Hind III
SP072A	NO: 345	ACTGAGATCTTTTAAACCAACTGTTGGTACTTTTC	Bgl II
SP072B	NO: 346	GACTAAGCTTTCTACGATAACGATCATTTTCTTTACC	Hind III
SP073A	NO: 347	GACTGTGACTCGTAGATATTTAAGTCTAAGTGAAGCG	Sal I
SP073B	NO: 348	AGTCAAGCTTGTTAGGTGTTACATTTTGCAAGTC	Hind III
SP074A	NO: 349	GACTGGATCCCTTTGGTTTTGAAGGAAGTAAG	Bam HI
SP074B	NO: 350	TGACCTGCAGACGATTTTTGAAAAATGGAGGTGTATC	Pst I
SP075A	NO: 351	CAGTGGATCCCTACTACCTCTCGAGAGAAAG	Bam HI
SP075B	NO: 352	ACTGAAGCTTTTCGCTTTTACTCGTTTGACA	Hind III
SP076A	NO: 353	CAGTGGATCCTAAGGTCAAAAGTCAGACCGCTAAGAAAGTGC	Bam HI
SP076B	NO: 354	CAGTAAGCTTTAGGGTATCCAAATACTGGTTGTTGATG	Hind III
SP077A	NO: 355	TGACAGATCTTGACGGGTCTCAGGATCAGACTCAGG	Bgl II
SP077B	NO: 356	TGACAAGCTTCAAAGACATCCACCTCTTGACCTTTG	Hind III
SP078A	NO: 357	GACTGGATCCTAGAGGCTTTGCCAAATGGTGGGAAGGG	Bam HI
SP078B	NO: 358	GTCAGTCGACTTGTTGTAACACTTTTCGAGGTTTGGTACC	Sal I
SP079A	NO: 359	CAGTGGATCCTCAAAAAGAGAAGGAAAACCTGG	Bam HI
SP079B	NO: 360	CAGTCTGCAGTTTCTTCAACAAACCTTGTTCTTG	Pst I
SP080A	NO: 361	CAGTGGATCCACGTTCTATTGAGGACCACTT	Bam HI
SP080B	NO: 362	CAGTAAGCTTTTCCTTCTCAGTCAATTCTTTTCC	Hind III
SP081A	NO: 363	GACTGGATCCCGCTCAAAATACCAGAGGTGTTTCAG	Bam HI
SP081B	NO: 364	GACTAAGCTTAGTACCATTGGGTGTGACAGGTTTGAA	Hind III
SP082A	NO: 365	CTGAGGATCCAATTGTACAATTAGAAAAAGATAGC	Bam HI
SP082B	NO: 366	TGACAAGCTTGCGTTGACTAGGTTCTGCAATGCC	Hind III
SP083A	NO: 367	GACTGGATCCTCTGACCAAGCAAAAAGAAGCAGTCAATGA	Bam HI
SP083B	NO: 368	TCAGCAGCTGATCATTGACTTTACGATTTGCTCC	Bgl II
SP084A	NO: 369	GACTGGATCCGTCGGGCTCTGTCCAGTCCACTTTTTACGG	Bam HI
SP084B	NO: 370	TCAGAAGCTTATTTTTTGTTCCTTAATGCGTT	Hind III
SP085A	NO: 371	GACTGGATCCGGGACAAATTCAAAAAATAGGCAAGAGG	Bam HI
SP085B	NO: 372	GTCAAAGCTTTGGCTCTTTGATTGCCAACAACCTG	Hind III
SP086A	NO: 373	GACTGGATCCTCGCTACCAGCAACAAAGCGAGCAAAAGG	Bam HI
SP086B	NO: 374	GACTAAGCTTACTTTTTTCTTTTCCACACGA	Hind III
SP087A	NO: 375	CAGTGGATCCGAACCGACAAGTCGCCCCTATCAAGACT	Bam HI
SP087B	NO: 376	CTGAAAGCTTTGAATTCTCTTTCTTTTCAGGCT	Hind III
SP088A	NO: 377	TCGAGGATCCGGTTGTGCGGCTGGCAATATATCCCGT	Bam HI
SP088B	NO: 378	CAGTAAGCTTCCGAACCCATTGCGCATTATAGTTGAC	Hind III
SP089A	NO: 379	AGTCGGATCCGGCCAAATCAGAAATGGGTAGAAGAC	Bam HI
SP089B	NO: 380	TGACCTGCAGCTTCTCATTGATTTTCATCATCAC	Pst I
SP090A	NO: 381	GACTGGATCCATTGTCAGATGATTCTGAAGGATGG	Bam HI
SP090B	NO: 382	TCAGCTGCAGCTTAACCCATTACCATTTAGTTTAAG	Pst I
SP091A	NO: 383	GACTGGATCCTGTCGCTGCAAAATGAACTGAAGTAGC	Bam HI
SP091B	NO: 384	GACTAAGCTTATACCAACGCTGACATCTACGCG	Hind III
SP092A	NO: 385	AGTCAGATCTTACGTCTCAGCCTACTTTTGTAAGAGC	Bgl II
SP092B	NO: 386	GACTAAGCTTAACCCATTACCATTTGGCATTGAC	Hind III
SP093A	NO: 387	CAGTGGATCCTGGACAGGTGAAAGGTCATGCTACATTTGTG	Bam HI
SP093B	NO: 388	GACTAAGCTTCAACCATTTAGACCTTGCAACAC	Hind III
SP094A	NO: 389	GTCAGGATCCGATTGCTCCTTTGAAGGATTTGAGAGAAACC	Bam HI
SP094B	NO: 390	GACTAAGCTTCGATCAAAGATAAGATAAATATATAAAGT	Hind III
SP095A	NO: 391	GACTGGATCCTAGGTCATATGGGACTTTTTTCTACAACAAATAGG	Bam HI

Table 3  
*S. pneumoniae* ORF Cloning Primers

Primer Name	SEQ ID	Sequence	RE
SP095B	NO: 392	TGACAAGCTTATCTATCAGCTCATTTAATCGTTTTTG	Hind III
SP096A	NO: 393	CTGAGGATCCCAACGTTGAGAATTATTTGCGAATG	Bam HI
SP096B	NO: 394	TGACAAGCTTGAGTCTACAAAAGTAATGTAC	Hind III
SP097A	NO: 395	GTCAGGATCCCTACTATCAATCAAGTTCTTCAGCC	Bam HI
SP097B	NO: 396	TGACAAGCTTGACTGAGGCTTGGACCAGATTGAAAAG	Hind III
SP098A	NO: 397	GACTGGATCCGACAAAACATTAAAACGTCCTGAGG	Bam HI
SP098B	NO: 398	GACTAAGCTTAGCACGAAGTGTGACGCTGGTTCC	Hind III
SP099A	NO: 399	GACTGGATCCTTCTCAGGAGACCTTTAAAAATATC	Bam HI
SP099B	NO: 400	GACTAAGCTTGTTGGCCATCTTGTACATACC	Hind III
SP100A	NO: 401	GACTGGATCCAGTAAATGCGCAATCAAATTC	Bam HI
SP100B	NO: 402	AGTCCTGCAGGTATTTAGCCCAATAATCTATAAAGCT	Pst I
SP101A	NO: 403	CAGTGGATCCTTACCGCGTTTCATCAAGATGTC	Bam HI
SP101B	NO: 404	GACTAAGCTTGCCAGATGTTGAAAAGAGAGTG	Hind III
SP102A	NO: 405	GACTGGATCCGTGGATGGGCTTTAACTATCTTCGTATTCG	Bam HI
SP102B	NO: 406	AGTCAAGCTTGCTAGTCTTCACTTTCCCTTTCC	Hind III
SP103A	NO: 407	GACTGTCGACACTAAACCAGCATCGTTTCGAGGA	Sal I
SP103B	NO: 408	CTGACTGCAGCTTCTTGAAGAAATAATGATTGTGG	Pst I
SP105A	NO: 409	CAGTGGATCCTGACTACCTTGAATCCCCTT	Bam HI
SP105B	NO: 410	CAGTAAGCTTTTTTTTAAAGTTGTAGAATGATTTCAATC	Hind III
SP106A	NO: 411	CAGTGTGACTCGTATCTTTTTTTGGAGCAATGTT	Sal I
SP106B	NO: 412	GACTAAGCTTAAATGTTCCGATACGGGTGATTG	Hind III
SP107A	NO: 413	CAGTGGATCCGACTCTCTCAAAGATGTGAAAG	Bam HI
SP107B	NO: 414	GACTAAGCTTCTTGAGTTTGTCAAGGATTGCTTT	Hind III
SP108A	NO: 415	CAGTGGATCCCAAGAAATCCTATCATCTCTTCCAGAAG	Bam HI
SP108B	NO: 416	GACTAAGCTTTTCAGAACTAAAAGCCGCAGCTT	Hind III
SP109A	NO: 417	GACTGGATCCACGAAATGCAGGGCAGACAG	Bam HI
SP109B	NO: 418	CAGTAAGCTTATCAACATAATCTAGTAAATAAGCGT	Hind III
SP110A	NO: 419	CAGTGGATCCTGTATAGTTTTTAGCGCTTGTTCTTC	Bam HI
SP110B	NO: 420	GTCAAAGCTTTGATAGAGTGTCAATAATCTTCTTTAG	Hind III
SP111A	NO: 421	GACTGGATCCGTGTGTCGAGCATATTCTGAAG	Bam HI
SP111B	NO: 422	CAGTAAGCTTACTTTTACCATTCTTTGTTCTGCATC	Hind III
SP112A	NO: 423	GACTGTGACGTGTTTGGATAGCATTGAGAATCAGACG	Sal I
SP112B	NO: 424	CAGTAAGCTTCGGAAGTAAAGACAATTTTTCC	Hind III
SP113A	NO: 425	CAGTGGATCCGTGCCTAGATAGTATTATTACTCAAAC	Bam HI
SP113B	NO: 426	GACTAAGCTTTTGTCTTATTTCTCTCAATTTTTTC	Hind III
SP114A	NO: 427	CAGTGGATCCCATTCAGAAGCAGACCTATCAAATC	Bam HI
SP114B	NO: 428	ACTGAAGCTTATGTAATTTTTTAGATTTTTCAATATTTTCAG	Hind III
SP115A	NO: 429	AGTCGGATCCCTAAGGCTGATAATCGTGTTCAAATG	Bam HI
SP115B	NO: 430	GACTAAGCTTAAAATTAGATAGACGTTGAGT	Hind III
SP117A	NO: 431	AGTCGGATCCCTGTGGCAATCAGTCAGCTGCTTCC	Bam HI
SP117B	NO: 432	GACTGTGACTTTAATCTTGTCCCAGGTGGTTAATTTGCC	Sal I
SP118A	NO: 433	ACTGGTGCAGTTGTCAACAACAACATGCTACTTCTGAG	Sal I
SP118B	NO: 434	GACTCTGCAGAAGTTTAACCCACTTATCATTATCC	Pst I
SP119A	NO: 435	ACTGGGATCCTTGTTCAGGCAAGTCCGTGACTAGTGAAC	Bam HI
SP119B	NO: 436	GACTAAGCTTGGCTAATTCCTTCAAAGTTTGCA	Hind III
SP120A	NO: 437	AGTCGGATCCCTCGCAAATTGAAAAGGCGGCAGTTAGCC	Bam HI
SP120B	NO: 438	GACTAAGCTTGTAATAAGCGTACCTTTTTCTTCC	Hind III
SP121A	NO: 439	TCAGGGATCCTTGTGTCAGTCAGGTTCTAATGGTTCTCAG	Bam HI
SP121B	NO: 440	AGTCAAGCTTGGCATTGGCGTCGCGCTCCTTC	Hind III
SP122A	NO: 441	GACTGGATCCGAACTTCACAGGATTTTAAAGAGAAG	Bam HI
SP122B	NO: 442	GACTGTGACAATCAATCCTTCTTCTGCACTTCT	Sal I
SP123A	NO: 443	CAGTGGATCCTGTGGTCAAGTTGAGACTCCTCAATC	Bam HI
SP123B	NO: 444	GACTAAGCTTTTCTTCAAATTTATTATCAGC	Hind III
SP124A	NO: 445	AGTCGGATCCAACACCTGTATATAAAGTTACAGCAATCG	Bam HI
SP124B	NO: 446	GACTGTGCACTACTTGACCGAATGCGTCAATGTACG	Sal I

Table 3  
*S. pneumoniae* ORF Cloning Primers


Primer			
<u>Name</u>	<u>SEQ ID</u>	<u>Sequence</u>	<u>RE</u>
SP125A	NO:447	CTGAGGATCCATTAGACAGATTAATTGAAATCGG	Bam HI
SP125B	NO:448	GACTGTCGACTTTAAAGATTGAAGTTTAAAGCT	Sal I
SP126A	NO:449	TGACGGATCCTAAGACAGATGAACGGAGCAAGGTG	Bam HI
SP126B	NO:450	CTGAAAGCTTTAAGGCTTCCTCAATGAGTTTGTCT	Hind III
SP127A	NO:451	GACTGGATCCCCTGTGAGAATCAAGCTACACCCA	Bam HI
SP127B	NO:452	CTGAAAGCTTTTGTAAGTGAAGATTGATCTGGGAG	Hind III



## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>9</u> , line <u>12</u>	
B. IDENTIFICATION OF DEPOSIT <span style="float: right;">Further deposits are identified on an additional sheet <input type="checkbox"/></span>	
Name of depositary institution <b>American Type Culture Collection</b>	
Address of depositary institution (including postal code and country) <b>12301 Parklawn Drive Rockville, Maryland 20852 United States of America</b>	
Date of deposit <b>October 10, 1996</b>	Accession Number <b>55840</b>
C. ADDITIONAL INDICATIONS (leave blank if not applicable) <span style="float: right;">This information is continued on an additional sheet <input checked="" type="checkbox"/></span>	
In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	

For receiving Office use only
<input checked="" type="checkbox"/> This sheet was received with the international application
 Authorized officer
<b>12 DECEMBER 1997</b>

For International Bureau use only
<input type="checkbox"/> This sheet was received by the International Bureau on:
Authorized officer

**SINGAPORE**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for international publication of the application.

**NORWAY**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegians Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Registration), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**ICELAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Icelandic Patent Office), or has been finally decided upon by the Icelandic Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected in the art.

Page 2

**DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person approved by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PUT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant, any request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by the applicant in the individual case.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the International publication of the application.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapse, the microorganism shall be made available as provided in Rule 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever two dates occurs earlier.

*What Is Claimed Is:*

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- 5 (a) a nucleotide sequence encoding any of the amino acid sequences of the polypeptides shown in Table 1; or
- (b) a nucleotide sequence complementary to any of the nucleotide sequences in (a).
- 10 2. An isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent hybridization conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a) or (b) of claim 1 wherein said polynucleotide which hybridizes does not hybridize under
- 15 stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A residues or of only T residues.
3. An isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence of an epitope-bearing portion of a polypeptide having an amino acid sequence in (a) of claim 1.
- 20 4. The isolated nucleic acid molecule of claim 3, wherein said epitope-bearing portion of a polypeptide has an amino acid sequence listed in Table 2.
- 25 5. A method for making a recombinant vector comprising inserting an isolated nucleic acid molecule of claim 1 into a vector.
6. A recombinant vector produced by the method of claim 5.
- 30 7. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 6 into a host cell.
8. A recombinant host cell produced by the method of claim 7.
- 35 9. A method of producing a polypeptide encoded by the nucleic acid molecule of claim 1 comprising culturing the host cell of claim 8 under conditions favoring expressing the heterologous polypeptide.

10. A polypeptide produced according to the method of claim 9.
11. An isolated polypeptide comprising an amino acid sequence at  
5 least 70% identical to a sequence selected from the group consisting of an amino acid sequence of any of the polypeptides described in Table 1.
12. An isolated polypeptide antigen comprising an amino acid  
10 sequence of an *S. pneumoniae* epitope shown in Table 2.
13. An isolated nucleic acid molecule comprising a polynucleotide  
with a nucleotide sequence encoding a polypeptide of claim 9.
14. An isolated antibody that binds specifically to a polypeptide of  
15 claim 11.
15. A hybridoma which produces an antibody according to claim 14.
16. A vaccine, comprising:  
20 (1) one of more *S. pneumoniae* polypeptides selected from the group consisting of a polypeptide comprising an amino acid sequence identified in Table 1, or a fragment thereof; and  
(2) a pharmaceutically acceptable diluent, carrier, or excipient;  
wherein said polypeptide is present, in an amount effective to elicit protective  
25 antibodies in an animal to a member of the *Streptococcus* genus.
17. A method of preventing or attenuating an infection caused by a  
member of the *Streptococcus* genus in an animal, comprising administering to  
said animal a polypeptide of claim 11, wherein said polypeptide is administered  
30 in an amount effective to prevent or attenuate said infection.
18. A method of detecting *Streptococcus* nucleic acids in a biological  
sample obtained from an animal involving assaying for one or more nucleic acid  
sequences encoding *Streptococcus* polypeptides in a sample comprising:  
35 (a) contacting the sample with one or more of the above-described nucleic acid probes, under conditions such that hybridization occurs, and  
(b) detecting hybridization of said one or more probes to the one or  
more *Streptococcus* nucleic acid sequences present in the biological sample.

19. A method of detecting *Streptococcus* nucleic acids in a biological sample obtained from an animal, comprising:

- 5 (a) amplifying one or more *Streptococcus* nucleic acid sequences in said sample using polymerase chain reaction, and  
(b) detecting said amplified *Streptococcus* nucleic acid.

20. A kit for detecting *Streptococcus* antibodies in a biological sample obtained from an animal, comprising

- 10 (a) a polypeptide of claim 12 attached to a solid support; and  
(b) detecting means.

21. A method of detecting *Streptococcus* antibodies in a biological sample obtained from an animal, comprising

- 15 (a) contacting the sample with a polypeptide of claim 12; and  
(b) detecting antibody-antigen complexes.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/31, 5/18, 1/21, C07K 14/315,</b> <b>C12Q 1/68, A61K 39/09, G01N 33/569,</b> <b>33/68</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 98/18930</b> <b>(43) International Publication Date:</b> 7 May 1998 (07.05.98)
<b>(21) International Application Number:</b> PCT/US97/19422 <b>(22) International Filing Date:</b> 30 October 1997 (30.10.97)  <b>(30) Priority Data:</b> 60/029,960                      31 October 1996 (31.10.96)                      US  <b>(71) Applicant (for all designated States except US):</b> HUMAN GENOME SCIENCES, INC. [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> KUNSCH, Charles, A. [US/US]; 2398B Dunwoody Crossing, Atlanta, GA 30338 (US). CHOI, Gil, H. [KR/US]; 11429 Potomac Oaks Drive, Rockville, MD 20850 (US). JOHNSON, L., Sydnor [US/US]; 13545 Ambassador Drive, Germantown, MD 20874 (US). HROMOCKYJ, Alex [US/US]; 10003 Sidney Road, Silver Spring, MD 20901 (US).  <b>(74) Agents:</b> BROOKES, A., Anders et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims</i> <i>and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 8 October 1998 (08.10.98)	
<b>(54) Title:</b> <i>STREPTOCOCCUS PNEUMONIAE</i> ANTIGENS AND VACCINES		
<b>(57) Abstract</b> <p>The present invention relates to novel vaccines for the prevention or attenuation of infection by <i>Streptococcus pneumoniae</i>. The invention further relates to isolated nucleic acid molecules encoding antigenic polypeptides of <i>Streptococcus pneumoniae</i>. Antigenic polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention additionally relates to diagnostic methods for detecting <i>Streptococcus</i> nucleic acids, polypeptides and antibodies in a biological sample.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



# INTERNATIONAL SEARCH REPORT

Intern: )al Application No  
PCT/US 97/19422

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/31 C12N5/18 C12N1/21 C07K14/315 C12Q1/68  
A61K39/09 G01N33/569 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 06732 A (UNIV ROCKEFELLER ;MASURE H ROBERT (US); PEARCE BARBARA J (US); TUO) 9 March 1995 SEQ ID nos. 3 and 4 see claims 1-52	1-21
X	--- C. MARTIN ET AL.: "Relateness of penicillin-binding protein 1a genes from different clones of penicillin-resistant Streptococcus pneumoniae isolated in South Africa and Spain" EMBO J., vol. 11, no. 11, November 1992, OXFORD UNIVERSITY PRESS,GB;; pages 3831-3836, XP002060148 see the whole document --- -/-	1-15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

6 May 1998

Date of mailing of the international search report

18. 08. 1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

HORNIG H.

## INTERNATIONAL SEARCH REPORT

Intern: )al Application No  
PCT/US 97/19422

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 16082 A (ASTRA AB ;BALGANESH TANJORE SOUNDARARAJA (IN); TOWN CHRISTINE MARY) 30 May 1996 SEQ ID nos. 5 and 6 see claims 1-26 ---	1-15
A	WO 95 31548 A (UAB RESEARCH FOUNDATION ;YOTHER JANET (US); DILLARD JOSEPH P (US)) 23 November 1995 see the whole document ---	1-21
A	WO 95 14712 A (RES CORP TECHNOLOGIES INC) 1 June 1995 see the whole document ---	1-21
A	WO 96 05859 A (AMERICAN CYANAMID CO) 29 February 1996 see abstract ---	1-21
A	WO 93 10238 A (US HEALTH) 27 May 1993 see the whole document ---	1-21
A	EP 0 687 688 A (UNIV OVIEDO ;UNIV LEICESTER (GB)) 20 December 1995 see abstract ---	1-21
A	EP 0 622 081 A (UAB RESEARCH FOUNDATION) 2 November 1994 see the whole document ---	1-21
A	B.J. PEARCE ET AL.: "Genetic identification of exported proteins in Streptococcus pneumoniae" MOLECULAR MICROBIOL., vol. 9, no. 5, 1993, BLACKWELL, OXFORD, GB, pages 1037-1050, XP002060149 see the whole document -----	1-21

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 97/ 19422

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim 17 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see continuation-sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-21 partially (subject 1. on continuation-sheet)

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 1. Claims: (1-21) partially

An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence from the group consisting of of: (a) a nucleotide sequence SEQ ID no.1 encoding the amino acid sequence of the polypeptide SEQ ID no.2 shown in Table 1; or (b) a nucleotide sequence complementary to said nucleotide sequence in (a); an isolated nucleic acid molecule comprising a polynucleotide which hybridizes under stringent conditions to a polynucleotide having a nucleotide sequence identical to a nucleotide sequence in (a) or (b), wherein said polynucleotide which hybridizes does not hybridize under stringent hybridization conditions to a polynucleotide having a nucleotide sequence consisting of only A or of only T residues; an isolated nucleic acid molecule comprising a polynucleotide which encodes the amino acid sequence or an epitope-bearing portion of a polypeptide having an amino acid sequence of SEQ ID no.2 in (a); said epitope-bearing portion of a said polypeptide has an amino acid sequence listed in Table 2; a method of making a vector using said isolated nucleic acid molecule; said recombinant vector; a method of making a recombinant host cell using said vector; said recombinant host cell; a method of producing said polypeptide; said polypeptide; an isolated antibody that binds to said polypeptide; a hybridoma which produces said antibody; a vaccine comprising said polypeptide selected from SEQ ID no.2 in Table 1, or a fragment thereof; a method of preventing or attenuating an infection caused by a member of Streptococcus genus in animal using said polypeptide; a method for detecting Streptococcus nucleic acid sequences using the above-described nucleic acid probe; a kit for detecting Streptococcus antibodies in a biological sample using said polypeptide sequence;

## 2-113. Claims: (1-21) partially

-Idem as subject 1 but limited to the sequences having SEQ ID nos. 3 to 226. (Invention 2 is limited to SEQ ID nos. 3 and 4; Invention 3 is limited to SEQ ID nos. 5 and 6; ..... Invention 113 is limited to SEQ ID nos. 225 and 226).

For the sake of conciseness, the first group is explicitly defined, the other groups are defined by analogy hereto.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern Application No

PCT/US 97/19422

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9506732 A	09-03-95	AU 7680994 A CA 2170726 A EP 0721506 A FI 960977 A JP 9504686 T NO 960839 A	22-03-95 09-03-95 17-07-96 30-04-96 13-05-97 19-04-96
WO 9616082 A	30-05-96	AU 693537 B AU 2045895 A AU 3088795 A CA 2150532 A CN 1173182 A EP 0792284 A FI 972215 A GB 2290792 A HU 77487 A IE 950412 A NO 972353 A NZ 272242 A	02-07-98 18-01-96 17-06-96 02-01-96 11-02-98 03-09-97 26-05-97 10-01-96 28-05-98 10-01-96 01-07-97 26-03-96
WO 9531548 A	23-11-95	AU 2638595 A EP 0804582 A	05-12-95 05-11-97
WO 9514712 A	01-06-95	US 5474905 A	12-12-95
WO 9605859 A	29-02-96	US 5565204 A AU 3363695 A CA 2198251 A EP 0778781 A JP 10504717 T	15-10-96 14-03-96 29-02-96 18-06-97 12-05-98
WO 9310238 A	27-05-93	AU 3065892 A	15-06-93
EP 0687688 A	20-12-95	ES 2075803 A ES 2088820 A WO 9516711 A	01-10-95 16-09-96 22-06-95
EP 0622081 A	02-11-94	AU 682018 B AU 5769694 A CA 2116261 A	18-09-97 27-10-94 21-10-94

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/19422

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0622081 A		FI 941695 A	21-10-94
		JP 7126291 A	16-05-95
		NO 941420 A	21-10-94
		US 5679768 A	21-10-97
		ZA 9401584 A	12-10-94
-----			